|
|
·|û¡GCliff10135274 µoªí®É¶¡:2017/5/7 ¤U¤È 11:02:30
|
¡u¤ß®®¥ÍÂå¥H¯f±wªº»Ýn¬°Àu¥ý¦Ò量¡A±Mª`©ó¤¤¼Ï¯«¸g¯e¯f»â°ì¡AÂåÀø»Ý¨D©|¥¼³Qº¡¨¬ªº³¡¥÷¶i¦æ·sÃĬãµo¡C¡v ´Á³\ª©¤W½Ñ½å¡A¥H¤ß®®²£«~ªº°ò¥»±¡B¥«³õÄvª§¹ï¤â°ÊºAµ¥°T®§´£¨Ñ±´°Q¡A»P¥t¤@Ó¡u¤ß®®¥ÍÂåÄw½X°lÂÜ©«¡vª©°µ¥X°Ï¹j¡A¤]Åwªï¥t¶}¡u§Þ³N¤ÀªRª©¡v»P¡u²á¤Ñª©¡v¡AÅý¦Uª©Äݩʧó©ú½T¡A¥H«Kª©¤ÍŪ¨ú¡C Ų©ó¥i¯à¹ï¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^¹B§@·P¨ì¯¥Í¡A«Øij¥ý¨ã³Æ¬ÛÃö°ò¥»»{ÃÑ«á¸û¯àº¥¤J¨Î¹Ò¡C ¥Bê©ó¥»ª©µLªkÅã¥Ü¹Ï«¬¸Ñ»¡¡A«Øij¥ý°Ñ¦Ò¥H¤U¸ê®Æ¡C ¡uliaw6575¡v¡G¡uhttp://liawbf.pixnet.net/blog¡v¡C·PÁ»·¦b«n¥xÆWµoÁnªº¹ù¤j¤j¨¯¶Ôªº¯Ñ¯Ð¡C ¡uSNOOPYÁ¿¥j¡v¡G¡]ì§}¤wÃö³¬¡F¦ýºô§}«O¯d¦b¦¹¤£§R°£¡A¬O¬°¤F·PÁ¦ѥv¤j¤j´¿¸gµL¨pªº¥I¥X¡C¡^¡umychannel.pchome.com.tw/channels/s/n/snoopychiang/content.htm?page=1&ord=v&vol=100¡v |
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/4/26 ¤U¤È 07:15:59²Ä 549 ½g¦^À³
|
¤ß®®©P¤G(4/23)Àò±o³æ¹ç»Ä(Compositions containing tannic acids and uses thereof )ªº¬ü°ê±M§Q®É(10,265,336) Åý¤H·Q°_¹ù¥S¦~ªìªº¤@½g±M¤å [ 108¦~·s¦~·s§Æ±æ: §Ú¹ï SND-7ªº´Á«Ý ] liawbf.pixnet.net/blog/post/48772971 ±M¤å½Í¤Î ²{¦æ§Üºë¯«ÃĪ«ªº°Æ§@¥Î---¥NÁ¯gÔ¸s(MetS) SND-7°£¤F°w¹ï§Üºë¯«ªvÀø , ÁÙ¦³®ø°£©Î´î»´²{¦æÃĪ«¥NÁ¯gÔ¸sªºÂù«§@¥Î 2018/9 Àò±oªº±M§Q Compositions containing benzoate compound and tannic acid for treating central nervous system disorders (10,064,833) ·|¤£·|SND-7¤]¬O³oÓ²Õ¦X , ¥u¤£¹L°t¤è¤ñ¨Ò¤£¦P¦Ó¤w? 1.³æ¹ç»Ä (TA)°§C¦å¿}¤ô¥ , §í¨îªÎDªº½×¤å ³æ¹ç»Ä (TA)¨ë¿E¸²µå¿}Âà¹B¨Ã§í¨î3T3-L1²ÓM¤¤ªº¯×ªÕ²ÓM¤À¤Æ academic.oup.com/jn/article/135/2/165/4663627 ªÎD¬OXºî¦X¼x©MII«¬¿}§¿¯f¡]T2D¡^ªº¥Dn¦MÀI¦]¯À¡CµM¦Ó¡A¤j¦h¼Æ°¿}ÃĪº§Ü¿}§¿¯fÃĪ«¤]¥i«P¶iÅ髼W¥[¡A±q¦Ó´î»´T2Dªº¤@ºØ¯gª¬¡A¦P®É¥[«¾ÉPT2Dªº¥Dn¦MÀI¦]¯À¡C¯×ªÕ²ÓMªº¤À¤Æ©M¼W´Þ¯×ªÕ¥Í¦¨¬O¾ÉPÅ髼W¥[©MªÎDªº¥Dn¾÷¨î¡C«D±`§Æ±æ¶}µo¥Î©ó°§C¦å¿}¤ô¥¦Ó¤£»¤¾É±wªÌ¯×ªÕ§Î¦¨ªºT2DªºÃĪ«©MªvÀø¡C §Ú̶i¤@¨BÀË´ú¨ìTA»¤¾É¯Ø®q¯À¨üÅé¡]IR¡^©MAktªºÁC»Ä¤Æ¡A¥H¤Î¸²µå¿}Âà¹B³J¥Õ4¡]GLUT4¡^ªºÂà¹B¡A¸²µå¿}Âà¹B³J¥Õ4¬O°Ñ»P¯Ø®q¯À¤¶¾Éªº¸²µå¿}Âà¹Bªº«H¸¹¶Ç¾É³~®|ªº³J¥Õ½è¦]¤l¡C§ÚÌÁÙÃÒ©úTA§í¨î¯×ªÕ¥Í¦¨ªºÃöÁä°ò¦]ªºªí¹F¡CP <0.05¡^¡C³o¨Çµ²ªGªí©úTA¥i¥Î©ó¹w¨¾©MªvÀøT2D¤Î¨ä¬ÛÃöªºªÎD¯g¡CTA¥i¯à¦³¥i¯à¦¨¬°¶}µo·s«¬§Ü¿}§¿¯fÃĪ«ªº¥ý¾É¤Æ¦Xª«¡A³o¨ÇÃĪ«¯à°÷¦b¤£¼W¥[ªÎDªº±¡ªp¤U°§C¦å¿}¤ô¥¡C TAªº2ºØ¬¡©Êªº²Õ¦X¨Ï¨ä«D±`¾A¦X§@¬°ì«¬¤Æ¦Xª«¥Î©ó¶i¤@¨Bªºµ²ºc©M¥\¯à¬ã¨s¡A¥H¶}µoªvÀøX©MT2Dºî¦X¼x¯gª¬ªº·s«¬ÃĪ«¡A¦p°ª¦å¿}¡A°ª¯Ø®q¯À¦å¯g©M°ª¥Ìªo¤Tà¦å¯g¡A¦Ó¤£¦ñÀHÅ髼W¥[¬Æ¦Ü´îªÎ¡C¹ï©ó±w¦³¿}§¿¯f¬ÛÃöÅé«°ÝÃDªº°ª¹F90¢HªºT2D±wªÌ¡A¨ã¦³³oºØ©Ê½è²Õ¦XªºÃĪ«À³¸Ó¬O§ó¦nªº¿ï¾Ü¡C 2.³æ¹ç»Ä(TA) ¦P®É¹w¨¾°ª¦åÀ£©M°ª¯×¦å¯gªº½×¤å ³æ¹ç»Ä(TA)¬O¤j¹«¥D°Ê¯ß¦åºÞ¥·Æ¦Ù©M¨x¤W¥Ö²ÓM¤¤¦åºÞºò±i¯À1«¬¨üÅé©M§C±K«×¯×³J¥Õ¨üÅ骺²Õ´¯S²§©ÊÂù«½Õ¸`¾¯¡G¬}¹î¡§ªk°ê®¯½×¡¨ www.fasebj.org/doi/abs/10.1096/fasebj.31.1_supplement.1005.10 ¡§ªk°ê®¯½×(French Paradox)¡¨ªí©ú¬õ¸²µå°s¤¤¦s¦bªº¦UºØ¦h×ô¹ï¤ß¦åºÞ¯e¯fªº«OÅ@§@¥Î¡C³æ¹ç»Ä¡]TA¡^¡A¤@ºØ¥i¤ô¸Ñ¦h×ô¡A¨ã¦³¤£¦PªºÃIJz§@¥Î¡A¦ý¨ä¤ßŦ«OÅ@¾÷¨î©|¤£²M·¡¡C¦b³o¶µ¬ã¨s¤¤¡A§Ú̬ã¨s¤F³æ¹ç»Ä¹ï¦åºÞºò±i¯À1«¬¨üÅé¡]AT1R¡^©M§C±K«×¯×³J¥Õ¨üÅé¡]LDLR¡^ªº¼vÅT¡A³o¨âºØ¥Dn¦]¯À»P°ª¦åÀ£©M°ª¯×¦å¯gµ¥¤ß¦åºÞ¯e¯f¦³Ãö¡C Á`¤§¡A¥»¬ã¨sº¦¸ªí©úTA¤¶¾É³q¹LEGFR¿E¬¡MAP¿E酶¹ïRASMCs©MWB²ÓM¤¤AT1R©MLDLRªº½Õ¸`¦ÜÃö«n¡A¥i³q¹L©ú½T¹v¦VAT1R©MLDLR¦P®É¹w¨¾°ª¦åÀ£©M°ª¯×¦å¯g¡A¦]¦¹¡A´£¨Ñ¹ï¡§ªk°ê®¯½×¡¨ªº¾÷¨î¬}¹î¤O¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/4/24 ¤W¤È 08:40:46²Ä 548 ½g¦^À³
|
¿D¬w¾ÇªÌ¤]¦³¬ã¨sTA¹ïADªº§@¥Î ªüº¸¯ý®üÀq¯f¤¤³æ¹ç»Äªº¤À¤l¹vÂI www.eurekaselect.com/node/149819/article/molecular-targets-of-tannic-acid-in-alzheimers-disease TAªº´XºØÅé¥~©MÅ餺¼Ò«¬¤wÅã¥ÜTA¹ïADªº¯«¸g«OÅ@§@¥Î¡C°£¤F¨ä±j¤jªº§Ü®ñ¤Æ©M§Üª¢§@¥Î¥~¡A¦³ÃÒ¾Úªí©úTA¤]¬O£]-¤Àªc酶¡]BACE1¡^¬¡©Ê©M³J¥Õ½èªí¹Fªº¤ÑµM§í»s¾¯¡CBACE1¬Ot³dA£]肽²£¥Í©M¨H¿nªº¥Dn酶¡CTAÁÙ¦bÅé¥~¨Ï¯«¸g¬r©Ê¾ý¯»¼Ë³J¥Õ£]¡]A£]¡^ìÅÖºû¤£Ã©w¡C°£¤F¹ïA£]¯ÅÁpªº¼vÅT¥~¡ATAÁÙ¥i¥H§í¨îtau肽ªºÅé¥~»E¶°¡Atau肽¬O²ÓM¤º¯«¸gìÅÖºûÄñµ²¡]NFT¡^ªº®Ö¤ß²Õ¤À¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/4/23 ¤U¤È 04:20:51²Ä 547 ½g¦^À³
|
¤µ¤éSND-5Àò±o²Õ¦Xª«©M¥Î³~ªº¬ü°ê±M§Q ¹ù¥S°¨¤WÀ°§Ṳ́W¤F¤@°óTAªº½Ò TA §í¨î¥|ºØ酶 ¦³§U©ó§Ü AD »P¿}§¿¯f liawbf.pixnet.net/blog/post/48895644 ¤å¤¤z¤Î TA ¤ñ²{¦æªvÀøAD »P¿}§¿¯fªºÃĪ« , ¦³§ó¨Îªº[¥b§í¨î¿@«×IC50] ©M [§í¨î±`¼ÆKi] ¸Ô±¡½Ð°Ñ¹ù¥S¤Wz±M¤å ³Ì«á , ¤pªº ¤]n¸òµÛ¹ù¥S³Û [¤ß®®ªºSND-1 , SND-5 , SND-7 ¥[ªo! ] ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/4/23 ¤U¤È 12:55:56²Ä 546 ½g¦^À³
|
¹ï¤£°_! ¦A«×§ó¥¿ ³oÓ±M§Q À³¸Ó¥]¬A SND-5 ªº²Õ¦Xª«±M§Q ÁÙ¦³¥¦ªº¥Î³~±M§Q ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/4/23 ¤U¤È 12:39:22²Ä 545 ½g¦^À³
|
¹ï¤£°_! §ó¥¿³¡¤À¼Æ¦r Google½Ķªº [ Claims ][ Åv§Qn¨D] ¡G 1.¤@ºØ²Õ¦Xª«¡A¥]§t¡]i¡^³æ¹ç»Ä©Î¨äÃľǤW¥i±µ¨üªºÆQªº²V¦Xª«¡A©M¡]ii¡^¸üÅé¡A¨ä¤¤¸Ó²Õ¦Xª«§t¦³¨ã¦³¤Ö©ó¥|ÓÙ«³æ¹çªº³¡¤À®ò°ò»Ä¤p©ó5¢H ¡A¨ä¤¤¸üÅé¥]¬A¤G®ñ¤Æª¿©Mf¥Ò»Ä¡C 2.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥ 98¢H ªº³æ¹ç»Ä¨ã¦³4-12Ó¨S¹¤l酰°ò³¡¤À¡C 3.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥ 97¢H ªº³æ¹ç»Ä¨ã¦³5-12Ó¨S¹¤l酰°ò³¡¤À¡C 4.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥ 90¢H ªº³æ¹ç»Ä¨ã¦³6-12Ó¨S¹¤l酰°ò³¡¤À¡C 5.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥ 60¢H ªº³æ¹ç»Ä¨ã¦³8-12Ó¨S¹¤l酰°ò³¡¤À¡C 6.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤¦b²Õ¦Xª«¤¤¡A¬ù 10-20¢H ªº³æ¹ç»Ä¨ã¦³5Ó¨S¹¤l酰°ò³¡¤À¡A¬ù 15-25¢H ªº³æ¹ç»Ä¨ã¦³6-7Ó¨S¹¤l酰°ò³¡¤À¡A©M¬ù 55-65¢H ªº³æ¹ç»Ä¡C³æ¹ç»Ä¨ã¦³8-12Ó¨S¹¤l酰°ò³¡¤À¡C 7.¦pÅv§Qn¨D1©Òzªº²Õ¦Xª«¡A¨ä¤¤©Òz²Õ¦Xª«¬OÃĪ«²Õ¦Xª«¡AÀç¾iÃĪ«²Õ¦Xª«¡A«O°·¹«~©ÎÂåÀø¹«~¡C 8.Åv§Qn¨D7ªº²Õ¦Xª«¡A¨ä¤¤©Òz²Õ¦Xª«¬O¤ù¾¯¡A½¦Ån¡A³n©CÄZª«©Î¾®½¦¡C 9.¤@ºØ§í¨î¨ü¸ÕªÌ¤¤D-®ò°ò»Ä®ñ¤Æ酶¡]DAAO¡^ªº¤èªk¡A¥]¬A¦V¦³¦¹»Ýnªº¨ü¸ÕªÌ¬I¥Î¦³®Ä¶qªºÅv§Qn¨D1ªº²Õ¦Xª«¡C 10.®Ú¾ÚÅv§Qn¨D9©Òzªº¤èªk¡A¨ä¤¤©Òz¨ü¸ÕªÌ¬O±w¦³¡AÃhºÃ±w¦³¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^¯f¯g©Î»PªÎD¬ÛÃöªº¯f¯g©Î³B©ó¨ä¤¤·ÀIªº¤HÃþ±wªÌ¡C 11.Åv§Qn¨D10ªº¤èªk¡A¨ä¤¤©Òz¤HÃþ±wªÌѦ³¡AÃhºÃ±w¦³CNS¯e¯f©Î³B©ó±w¦³CNS¯e¯fªº·ÀI¤¤¡A©Òz±wªÌ¿ï¦Ûºë¯«¤Àµõ¯g¡Aºë¯«»Ùê¡Aªüº¸¯ý®üÀq¯f¡AÃBù®¸Ã¨§b¡A¦åºÞ©Êè§b¡Aè§b¡C¸ô©öÅé¡A¦Ñ¦~©Êè§b¡A»´«×»{ª¾»Ùê¡A¨}©Ê¿ò§Ñ¡A³¬¦X©ÊÀY³¡·l¶Ë¡A¦Û³¬¯gÃШt»Ùê¡Aªü´µ§B®æºî¦X¯g¡A¯Ü©ÊXºî¦X¼x¡Aª`·N¤O¯Ê³´¦h°Ê»Ùê¡Aª`·N¤O¯Ê³´»Ùê¡A±j¢¯g¡A©â°Ê»Ùê¡A¨àµ£¾Ç²ß»Ùê¡A¸g«e´Áºî¦X¼x¡A§íÆ{¯g¡A««×§íÆ{¯g¡A§Ö·P¯Ê¥F¯g¡A¦Û±þ·N©À©M/©Î¦æ¬°¡AÂù¬Û±¡·P»Ùê¡AµJ¼{¯g¡A®£·W¯g¡A³Ð¶Ë«áÀ³¿E»Ùê¡AºC©Ê»´«×©M¤£¥i¹w´úªºÀ£¤O¡A¶¼¹¥¢½Õ¡A¦¨Å}¯g¡A¤H®æ»Ùê¡A©¬ª÷´Ë¯f¡A¦ë§Ê¹y¯f¡A¦hµo©Êµw¤Æ¯g¡A¦ÙµäÁY°¼¯Áµw¤Æ¯g¡A¹Ï¹p¯Sºî¦X¼x¡A©]¶¡¿ò§¿¯g¡A«DÅöíwµo§@¡A²´Â¥µjÅË¡A§ù¤ó¦ÙÀç¾i¤£¨}¯g¡A¤¤·¡AºC©Ê¯kµh¡A¥]¬Aµhı¹L±Ó©M²§±`©Ê¯kµh¦b¤ºªº¯«¸g©Ê¯kµh¡A¿}§¿¯f©Ê¦hµo©Ê¯«¸g¯f©MºC©Ê¯kµhºî¦X¼x¡C 12.Åv§Qn¨D10ªº¤èªk¡A¨ä¤¤©Òz¤HÃþ±wªÌѦ³¡AÃhºÃ±w¦³©Î¦³±w¦³»PªÎD¦³Ãöªº¯e¯fªº·ÀI¡A©Òz¯e¯f¿ï¦Û¶i¹»Ùê¡A¯«¸g©Ê¹½¹¯g¡A¯«¸g©Ê³g¹¯g¡A¤¤·¡A«a¤ß¯f¡C ¡A¤ßż¯fµo§@¡A¥R¦å©Ê¤ß¤O°IºÜ¡A¥ý¤Ñ©Ê¤ßż¯f¡A°ª¦åÀ£¡A«D°sºë©Ê¯×ªÕ©Ê¨xª¢¡A¯Ø®q¯À©è§Ü¡A°ª§¿»Ä¦å¯g¡A¥Òª¬¸¢¥\¯à´î°h¯g¡A°©Ãö¸`ª¢¡AÁxµ²¥Û¡A¤£¥¥¯g¡AªÎD³q®ð¤£¨¬ºî¦X¼x¡Aªý¶ë©ÊºÎ¯v©I§l¼È°±¡AºC©Êªý¶ë©ÊªÍ¯f©Mý³Ý¡C 13.¦pÅv§Qn¨D10©Òzªº¤èªk¡A¨ä¤¤©Òz¤HÃþ±wªÌѦ³¡AÃhºÃ±w¦³»PªÎD¬ÛÃöªº¯e¯f©Î³B©ó±w¦³¸Ó¯e¯fªº·ÀI¤¤¡A©ÒzªÎD¯g¬O¿ï¦Û¿}§¿¯f¡A°ª¦å¿}¯g¡A°ª¯×¦å¯g©M°ªÁx©T¾J¦å¯gªºªÎD¯g¡C 14.Åv§Qn¨D9ªº¤èªk¡A¨ä¤¤©Òz¨ü¸ÕªÌ¥H¨C¤Ñ¤T¦¸¦Ü¨C¨âÓ¤ë¤@¦¸ªºÀW²v¬I¥Î©Òz²Õ¦Xª«¡C 15.Åv§Qn¨D10ªº¤èªk¡A¨ä¤¤©Òz¨ü¸ÕªÌ»P¤@ºØ©Î¦hºØ¥t¥~ªºÃľ¯¦P®É¡A¤§«e©Î¤§«á¥Î©óªvÀøCNS¯f¯g©Î»PªÎD¬ÛÃöªº¯f¯g¡C 16.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤©Òz²Õ¦Xª«§t¦³¤Ö©ó1¢Hªº¨ã¦³¤Ö©ó¥|Ó¨S¹¤l酰°ò³¡¤Àªº³æ¹ç»Ä¡C 17.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤³æ¹ç»Äªº²V¦Xª«³q¹L¥]¬A±q´Óª«¨Ó·½´£¨ú³æ¹ç»Ä©M°£¥h¨ã¦³¤Ö©ó¥|Ó¨S¹¤l酰°ò³¡¤Àªº³æ¹ç»Äªº¤èªk»s³Æ¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/4/23 ¤U¤È 12:33:09²Ä 544 ½g¦^À³
|
Google½Ķªº [ Claims ][ Åv§Qn¨D] ¡G 1.¤@ºØ²Õ¦Xª«¡A¥]§t¡]i¡^³æ¹ç»Ä©Î¨äÃľǤW¥i±µ¨üªºÆQªº²V¦Xª«¡A©M¡]ii¡^¸üÅé¡A¨ä¤¤¸Ó²Õ¦Xª«§t¦³¨ã¦³¤Ö©ó¥|ÓÙ«³æ¹çªº³¡¤À®ò°ò»Ä¤p©ó5¢H ¡A¨ä¤¤¸üÅé¥]¬A¤G®ñ¤Æª¿©Mf¥Ò»Ä¡C 2.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥9.8¢Hªº³æ¹ç»Ä¨ã¦³4-12Ó¨S¹¤l酰°ò³¡¤À¡C 3.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥9.7¢Hªº³æ¹ç»Ä¨ã¦³5-12Ó¨S¹¤l酰°ò³¡¤À¡C 4.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥90¢Hªº³æ¹ç»Ä¨ã¦³6-12Ó¨S¹¤l酰°ò³¡¤À¡C 5.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤²Õ¦Xª«¤¤≥60¢Hªº³æ¹ç»Ä¨ã¦³8-12Ó¨S¹¤l酰°ò³¡¤À¡C 6.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤¦b²Õ¦Xª«¤¤¡A¬ù10-20¢Hªº³æ¹ç»Ä¨ã¦³5Ó¨S¹¤l酰°ò³¡¤À¡A¬ù15-25¢Hªº³æ¹ç»Ä¨ã¦³6-7Ó¨S¹¤l酰°ò³¡¤À¡A©M¬ù55-65¢Hªº³æ¹ç»Ä¡C³æ¹ç»Ä¨ã¦³8-12Ó¨S¹¤l酰°ò³¡¤À¡C 7.¦pÅv§Qn¨D1©Òzªº²Õ¦Xª«¡A¨ä¤¤©Òz²Õ¦Xª«¬OÃĪ«²Õ¦Xª«¡AÀç¾iÃĪ«²Õ¦Xª«¡A«O°·¹«~©ÎÂåÀø¹«~¡C 8.Åv§Qn¨D7ªº²Õ¦Xª«¡A¨ä¤¤©Òz²Õ¦Xª«¬O¤ù¾¯¡A½¦Ån¡A³n©CÄZª«©Î¾®½¦¡C 9.¤@ºØ§í¨î¨ü¸ÕªÌ¤¤D-®ò°ò»Ä®ñ¤Æ酶¡]DAAO¡^ªº¤èªk¡A¥]¬A¦V¦³¦¹»Ýnªº¨ü¸ÕªÌ¬I¥Î¦³®Ä¶qªºÅv§Qn¨D1ªº²Õ¦Xª«¡C 10.®Ú¾ÚÅv§Qn¨D9©Òzªº¤èªk¡A¨ä¤¤©Òz¨ü¸ÕªÌ¬O±w¦³¡AÃhºÃ±w¦³¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^¯f¯g©Î»PªÎD¬ÛÃöªº¯f¯g©Î³B©ó¨ä¤¤·ÀIªº¤HÃþ±wªÌ¡C 11.Åv§Qn¨D10ªº¤èªk¡A¨ä¤¤©Òz¤HÃþ±wªÌѦ³¡AÃhºÃ±w¦³CNS¯e¯f©Î³B©ó±w¦³CNS¯e¯fªº·ÀI¤¤¡A©Òz±wªÌ¿ï¦Ûºë¯«¤Àµõ¯g¡Aºë¯«»Ùê¡Aªüº¸¯ý®üÀq¯f¡AÃBù®¸Ã¨§b¡A¦åºÞ©Êè§b¡Aè§b¡C¸ô©öÅé¡A¦Ñ¦~©Êè§b¡A»´«×»{ª¾»Ùê¡A¨}©Ê¿ò§Ñ¡A³¬¦X©ÊÀY³¡·l¶Ë¡A¦Û³¬¯gÃШt»Ùê¡Aªü´µ§B®æºî¦X¯g¡A¯Ü©ÊXºî¦X¼x¡Aª`·N¤O¯Ê³´¦h°Ê»Ùê¡Aª`·N¤O¯Ê³´»Ùê¡A±j¢¯g¡A©â°Ê»Ùê¡A¨àµ£¾Ç²ß»Ùê¡A¸g«e´Áºî¦X¼x¡A§íÆ{¯g¡A««×§íÆ{¯g¡A§Ö·P¯Ê¥F¯g¡A¦Û±þ·N©À©M/©Î¦æ¬°¡AÂù¬Û±¡·P»Ùê¡AµJ¼{¯g¡A®£·W¯g¡A³Ð¶Ë«áÀ³¿E»Ùê¡AºC©Ê»´«×©M¤£¥i¹w´úªºÀ£¤O¡A¶¼¹¥¢½Õ¡A¦¨Å}¯g¡A¤H®æ»Ùê¡A©¬ª÷´Ë¯f¡A¦ë§Ê¹y¯f¡A¦hµo©Êµw¤Æ¯g¡A¦ÙµäÁY°¼¯Áµw¤Æ¯g¡A¹Ï¹p¯Sºî¦X¼x¡A©]¶¡¿ò§¿¯g¡A«DÅöíwµo§@¡A²´Â¥µjÅË¡A§ù¤ó¦ÙÀç¾i¤£¨}¯g¡A¤¤·¡AºC©Ê¯kµh¡A¥]¬Aµhı¹L±Ó©M²§±`©Ê¯kµh¦b¤ºªº¯«¸g©Ê¯kµh¡A¿}§¿¯f©Ê¦hµo©Ê¯«¸g¯f©MºC©Ê¯kµhºî¦X¼x¡C 12.Åv§Qn¨D10ªº¤èªk¡A¨ä¤¤©Òz¤HÃþ±wªÌѦ³¡AÃhºÃ±w¦³©Î¦³±w¦³»PªÎD¦³Ãöªº¯e¯fªº·ÀI¡A©Òz¯e¯f¿ï¦Û¶i¹»Ùê¡A¯«¸g©Ê¹½¹¯g¡A¯«¸g©Ê³g¹¯g¡A¤¤·¡A«a¤ß¯f¡C ¡A¤ßż¯fµo§@¡A¥R¦å©Ê¤ß¤O°IºÜ¡A¥ý¤Ñ©Ê¤ßż¯f¡A°ª¦åÀ£¡A«D°sºë©Ê¯×ªÕ©Ê¨xª¢¡A¯Ø®q¯À©è§Ü¡A°ª§¿»Ä¦å¯g¡A¥Òª¬¸¢¥\¯à´î°h¯g¡A°©Ãö¸`ª¢¡AÁxµ²¥Û¡A¤£¥¥¯g¡AªÎD³q®ð¤£¨¬ºî¦X¼x¡Aªý¶ë©ÊºÎ¯v©I§l¼È°±¡AºC©Êªý¶ë©ÊªÍ¯f©Mý³Ý¡C 13.¦pÅv§Qn¨D10©Òzªº¤èªk¡A¨ä¤¤©Òz¤HÃþ±wªÌѦ³¡AÃhºÃ±w¦³»PªÎD¬ÛÃöªº¯e¯f©Î³B©ó±w¦³¸Ó¯e¯fªº·ÀI¤¤¡A©ÒzªÎD¯g¬O¿ï¦Û¿}§¿¯f¡A°ª¦å¿}¯g¡A°ª¯×¦å¯g©M°ªÁx©T¾J¦å¯gªºªÎD¯g¡C 14.Åv§Qn¨D9ªº¤èªk¡A¨ä¤¤©Òz¨ü¸ÕªÌ¥H¨C¤Ñ¤T¦¸¦Ü¨C¨âÓ¤ë¤@¦¸ªºÀW²v¬I¥Î©Òz²Õ¦Xª«¡C 15.Åv§Qn¨D10ªº¤èªk¡A¨ä¤¤©Òz¨ü¸ÕªÌ»P¤@ºØ©Î¦hºØ¥t¥~ªºÃľ¯¦P®É¡A¤§«e©Î¤§«á¥Î©óªvÀøCNS¯f¯g©Î»PªÎD¬ÛÃöªº¯f¯g¡C 16.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤©Òz²Õ¦Xª«§t¦³¤Ö©ó1¢Hªº¨ã¦³¤Ö©ó¥|Ó¨S¹¤l酰°ò³¡¤Àªº³æ¹ç»Ä¡C 17.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤³æ¹ç»Äªº²V¦Xª«³q¹L¥]¬A±q´Óª«¨Ó·½´£¨ú³æ¹ç»Ä©M°£¥h¨ã¦³¤Ö©ó¥|Ó¨S¹¤l酰°ò³¡¤Àªº³æ¹ç»Äªº¤èªk»s³Æ¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/4/23 ¤U¤È 12:15:46²Ä 543 ½g¦^À³
|
SND-5 «nªº¥Î³~±M§Q ®¥³ß¤ß®®èèÀò±oUSPTO±Â»Pªº SND-5 ¥Î³~±M§Q Compositions containing tannic acids and uses thereof United States Patent 10,265,336 April 23, 2019 patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=%22Tsai%3B+Guochuan+Emil%22.INNM.&OS=IN/%22Tsai;+Guochuan+Emil%22&RS=IN/%22Tsai;+Guochuan+Emil%22 1. A composition, comprising (i) a mixture of tannic acids or a pharmaceutically acceptable salt thereof, and (ii) a carrier, wherein the composition contains less than 5% of tannic acids having less than four galloyl moieties, wherein the carrier comprises silicon dioxide and benzoic acid. ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/4/4 ¤U¤È 04:03:25²Ä 542 ½g¦^À³
|
¿}§¿¯fÀøªk©Î¯à¦³®Ä§í¨îªüº¸¯÷®üÀq¯f¶i®i ¨Ó·½¡G ¥Íª«¨¦ ¡@2019-04-04 med.sina.com/article_detail_103_1_63942.html ªñ¤é¡A¤@¶µ¥Zµn¦b°ê»ÚÂø»xDiabetes Care¤Wªº¬ã¨s³ø§i¤¤¡A¨Ó¦Û«n¥[¦{¤j¾Çªº¬ì¾Ç®a̳q¹L¬ã¨sµo²{¡A±µ¨ü2«¬¿}§¿¯fÃĪ«ªvÀøªº±wªÌ©Î³\·|¦³®Ä»·Â÷ªüº¸¯÷®üÀq¯f¡C¤å³¹¤¤¬ã¨sªÌªí¥Ü¡A¬Û¤ñ¥¼±w¿}§¿¯fªºÓÅé¦Ó¨¥¡A¥¼±µ¨üªvÀøªº¿}§¿¯f±wªÌ¥X²{ªüº¸¯÷®üÀq¯fªº¸ñ¹³¬O«eªÌªº1.6¿¡C ¬ã¨sªÌDaniel A. Nationªí¥Ü¡A§Ú̪º¬ã¨sµ²ªG±j½Õ¤FºÉ¥i¯à¦¦a¦b¦¨¦~¤H¤¤µo²{¿}§¿¯f©M¨ä¥¦¥NÁ©ʯe¯fªº«n©Ê¡A¦b¿}§¿¯f±wªÌ¤¤¡Aè§b¯g©Mªüº¸¯÷®üÀq¯fªºµo¯f²v®t²§ÅãµM»P±wªÌ¬O§_ªAÃĪ½±µ¬ÛÃö¡C ¬ã¨sªÌNation»¡¹D¡AªvÀø¿}§¿¯fªºÃĪ«©Î³\¦bªýÂ_¤j¸£°h¤Æªº¶i®i¤Wªí²{¥X¤@©w¼vÅT ªþµù: ³æ¹ç»Äªº¥Î³~±M§Q¤º¤å´£¨ì [¥»¤½¶}¤º®e°ò©ó¥H¤Uµo²{¡G³æ¹ç»Ä¡A¯S§O¬O¨ã¦³¦h©ó¤TÓ¨S¹¤l酰°ò³¡¤Àªº¨º¨Ç¡A¦³®Ä¦a§í¨îDAAOªº¬¡©Ê¡C¦]¦¹¡A§t¦³³oºØ³æ¹ç»Äªº²Õ¦Xª«±N¦³¯q©óªvÀø»PDAAO©M/©Î¨¦®ò»Ä¯à¯«¸g¶Ç»¼¬ÛÃöªº¯e¯f©M¯f¯g¡A¨Ò¦pªÎD¯g¡A¿}§¿¯f¡A°ª¯×¦å¯g©MCNS¯f¯g¡C] [¥»¤½¶}¤º®eªº¤@Ӥ豯A¤Î²Õ¦Xª«...©M¥]§t¤@ºØ©Î¦hºØ³æ¹ç»Ä©M¸üÅ骺ÂåÀø¹«~¡A¨Ò¦pÃľǤW¥i±µ¨üªº¸üÅé©M/©Î¥i¹¥Îªº¸üÅé¡C³o¨Ç¤ÑµM¦s¦bªº©Î«D¤ÑµM¦s¦bªº¡]¦X¦¨ªº¡^¸üÅé¥i½á¤©²Õ¦Xª«¤¤ªº³æ¹ç»Ä¦UºØ¯q³B¡A¨Ò¦p¡A§ïµ½³æ¹ç»ÄªºÅé¥~©M/©ÎÅ餺éw©Ê¡A´£°ª³æ¹ç»Äªº¥Íª«§Q¥Î«× ¡A¼W¥[³æ¹ç»Äªº¥Íª«¬¡©Ê¡A©M/©Î´î¤Ö°Æ§@¥Î¡C¦X¾Aªº¸üÅé¥]¬A¦ý¤£©ó...©Î¨ä²Õ¦X¡C¦b¤@¨Ç¹ê¨Ò¤¤¡A¸üÅé¥i¥]§tf¥Ò»ÄÆQ¡A¨Ò¦pf¥Ò»Ä¶u¡C ] ¤S «e½g(541)ªº³ø¾É ¤]´¦¥Ü [¦×®Û¤£¶È¯à§ïµ½2«¬¿}§¿¯f¦å¿}¡A§ó¦³§U©ó½Õ¸`Áx©T¾J¤ô¥¡A¦P®É¤]¯à°§C¿}§¿¯f±wªÌ¿©±w¤ß¦åºÞ¯e¯f¡BµÇŦ°ÝÃD¡B¯«¸g·l¶Ë¡B¤ßŦ¯f¤Î¤¤·µ¥¬ÛÃö¨Öµo¯g·ÀI¡C] SND-1¤]¥H³æ¹ç»Ä¬°½á§Î¾¯ ¡A³£¬O f¥Ò»Ä¶u + ³æ¹ç»Äªº²Õ¦X ¡A¨âªÌ³£¦³§ïµ½2«¬¿}§¿¯fªº§@¥Î ¡A¤µ¨ä¬Û¥[©Î³£¼W²KÃĮĪº¥i¬Ý©Ê ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/28 ¤U¤È 07:06:50²Ä 541 ½g¦^À³
|
³o»®Æ¼F®`¡I¬ã¨s¡G¦³§U½Õ¸`¦å¿}¤ÎÁx©T¾J 10:442019/03/28 ¤¤®É¹q¤l³ø ³¯·×²» www.chinatimes.com/realtimenews/20190328003448-260405?chdtv ¿}§¿¯f±wªÌ»Ý§Ò¤f°ª¿}¡B°ªªo¯×¹ª«¡C¥~´C³ø¾É¡A¬ã¨sµo²{¡A¦×®Û¯à´î§C¿}§¿¯f±wªÌ¦Y¿}ªº¼¤±æ¡A§ó¦³§U©ó¦å¿}½Õ¸`¡A¼W¥[¤HÅ骺¯Ø®q¯À±Ó·P©Ê¡A¤]¦³§U©ó½Õ¸`Áx©T¾J¤ô¥¡A´î¤Ö¤ß¦åºÞ¯e¯fªº¾÷²v¡C ®Ú¾Ú¡mDaily Express¡n³ø¾É¡A¦×®Û«Ü¥i¯à¬O±wªÌ¥Î¨Ó´À¥N°ª¿}¹«~ªº¨}¤è¡A¬ã¨sµo²{¡A¦×®Û¯à´î§C±wªÌ¦Y¿}ªº¼¤±æ¡A§ïµ½¦å¿}¤ô¥¡A¨Ã¼W¥[¯Ø®q¯À±Ó·P©Ê¡A¼W¥[¿E¯Àªº¤Àªc¡AÁ{§É¹êÅç¤]Åã¥Ü¡AªA¥Î¦×®Û90¤Ñªº2«¬¿}§¿¯f±wªÌ¡AªÅ¸¡¦å¿}È¥§¡¤U°¤F10.3¢H¦Ü29¢H¡C ³ø¾É«ü¥X¡A¦×®Û¤£¶È¯à§ïµ½2«¬¿}§¿¯f¦å¿}¡A§ó¦³§U©ó½Õ¸`Áx©T¾J¤ô¥¡A¦P®É¤]¯à°§C¿}§¿¯f±wªÌ¿©±w¤ß¦åºÞ¯e¯f¡BµÇŦ°ÝÃD¡B¯«¸g·l¶Ë¡B¤ßŦ¯f¤Î¤¤·µ¥¬ÛÃö¨Öµo¯g·ÀI¡C ¦×®Ûªº¥NÁª« f¥Ò»Ä¶u , ¬OSND-1ªº¥D¦¨¥÷ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/28 ¤U¤È 12:31:28²Ä 540 ½g¦^À³
|
««×§íÆ{¯g·sÃÄÀòFDA¬ð¯}©ÊÀøªk»{©w ¨Ó·½¡GÃÄ©ú±d¼w¡@2019-03-28 med.sina.com/article_detail_103_2_63440.html AXS-05¬O¤@ºØ³Ð·s¤fªANMDA¨üÅé«ú§Ü¾¯¡C¥¦¥Ñ¥k¬ü¨Fªâ¡]dextromethorphan¡^©M¦w«D¥Lଡ]bupropion¡^ºc¦¨¡A¨Ã¥B¨Ï¥Î¤FAxsome¤½¥qªº¥NÁ§í¨î§Þ³N¡C¥k¬ü¨Fªâ¬O¤@ºØ«DÄvª§©ÊNMDA¨üÅé«ú§Ü¾¯¡A¥¦¦P®É¤]¬Osigma-1¨üÅé¿E°Ê¾¯¡AµÒÆP«¬¤A酰ÁxÆP¨üÅé«ú§Ü¾¯¡A©M5-ßm¦âÓi©M¥h¥ÒµÇ¤W¸¢¯ÀÂà¹B³J¥Õªº§í»s¾¯¡C¦w«D¥Lଯà°÷´£°ª¥k¬ü¨Fªâªº¥Íª«§Q¥Î«×¡A¦P®É¤]¬O¥h¥ÒµÇ¤W¸¢¯À©M¦h¤ÚÓi¦AÄá¨ú§í»s¾¯¡A©MµÒÆP«¬¤A酰ÁxÆP¨üÅé«ú§Ü¾¯¡C ªþµù: ¥k¬ü¨Fªâ zh.wikipedia.org/wiki/%E5%8F%B3%E7%BE%8E%E6%B2%99%E8%8A%AC ¥k¬ü¨FªâÀò§åªº¬ü°ê±M§Q 2,676,177¤w©¡º¡¡A¦b1958¦~³Q§å㬰¥i¤£»Ý³B¤è°â½æªºÂí«yÃÄ¡C ÃĪ«ÀݥΠ¥k¬ü¨Fªâ¦³ÃĪ«ÀݥΪº¦MÀI¡AÀݥΪ̱`±`±NÃĪ«¾ãªO§]¤U©Î¾ã²~¤@¶¼¦ÓºÉ¨Ã°t¤W¥i¼Ö©Î¨ä¥L§t¦³©@°Ø¦]ªº¶¼®Æ¥H¨D¿³¾Ä®ÄªG[3]¡C¤¤°ê¤j³°¤@¨Ç´CÅéºÙ¨ä¬°¡u¥i«Ý¦]²Ä¤G¡v[4]¡C ªø´Á¤j¾¯¶qªºªA¥Î¥i¯à¾ÉP¤ò²Ó¦åºÞ¯Ü¤Æ¡A²Õ´©ö¥X¦å¡A¼W¥[³Ð¶Ëªºµ{«×¡C ¦w«D¥LପºÀݥΠread01.com/zh-tw/oQaRg6.html#.XJxME1Uzapo |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/23 ¤U¤È 05:35:20²Ä 539 ½g¦^À³
|
¹ù¥Sªº´_¥j· SND-1¹ïCNS¯e¯f¤§Àø®Ä¾÷Âà liawbf.pixnet.net/blog/post/48856380 ¹ù¥S§i¶D§ÚÌSND-1(NABEN)ªº¤@Ó¯µ¤è ¦P®É¤]½Ð¹ù¥S¥´¶}¶W³sµ² , ¦nÅý¤j®a¤è«K½Æ²ß ÁÂÁ¹ù¥Sªº¤À¨É ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/22 ¤W¤È 08:49:45²Ä 538 ½g¦^À³
|
£]¾ý¯»¼Ë³J¥Õ¡]Beta-amyloid¡^¤S¥¢±Ñ Biogen°±¤îªüº¸¯ý®üÀq¯gÃĪ«±ß´Á¹êÅçªÑ»ù¼É¶^ªñ30% 2019¦~03¤ë22¤é05:39 ·s®ö°]¸gºî¦X finance.sina.com.cn/stock/usstock/c/2019-03-22/doc-ihsxncvh4530697.shtml 3¤ë21¤é¬O¥O¥þ²yÃöª`ªüº¸¯ý®üÀq¤ó¯g¬ã¨sªº¤HÌ¿·Pµh¤ßªº¤@¤Ñ¡C ¡@¡@¬üªÑ½L«eªº¡§Ãz¬µ¯Å¡¨·s»DºÙ¡A¬ü°ê¥Íª«§Þ³N¤½¥qBiogen©M¤é¥»»sÃĤ½¥qEisaiªí¥Ü¡A±N°±¤î¨â¶µªüº¸¯ý®üÀq¤ó¯gªº±ß´ÁÃĪ«¸ÕÅç¡]late-stage trail¡A¤]ºÙ¬°¤T´ÁÁ{§É¸ÕÅç¡^¡A¦P®É°±¤îªºÁÙ¦³¤@¶µ¤G´ÁÁ{§É¸ÕÅ窺¦w¥þ©Ê¬ã¨s¡A¥H¤Î¤@¶µ1b´ÁÁ{§É¸ÕÅ窺¦A«×®i´Á¡C Biogenªí¥Ü¡A¨â®a¤½¥q°±¤î¸ÕÅç¨Ã«D¦]¬°¦w¥þì¦]¡C°±¤î¸ÕÅ窺¨M©w¬O°ò©ó¿W¥ß¼Æ¾ÚºÊ´ú©eû·|¶i¦æªºµL®Ä¤ÀªRªºµ²ªG¡A¸Ó©eû·|»{¬°¡A¸ÕÅç¦b§¹¦¨«á¤£¤Ó¥i¯àº¡¨¬¨ä¥DnÀø®Ä¡C |
|
|
·|û¡G¤pÀs¤k10146282 µoªí®É¶¡:2019/3/20 ¤U¤È 03:37:10²Ä 537 ½g¦^À³
|
ªÑ»ù¤w¤½uªÈµ²¡A¤£ª¾¦ó®ÉªÑ»ùÃzµo°µ¬ð¯} |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/20 ¤W¤È 11:10:47²Ä 536 ½g¦^À³
|
SAGE¤½¥q¶}µoº´Ú²£«á§íÆ{¯g·sÃĤµ¤éÀò§å ¨Ó·½¡GÃÄ©ú±d¼w¡@2019-03-20 med.sina.com/article_detail_103_2_62968.html ¤ë20¤é¡AFDA«Å¥¬¡A§åãSAGE Therapeutics¤½¥q¶}µoªºZulresso¡]brexanolone¡^¤W¥«¡A¥Î©óªvÀø²£«á§íÆ{¯g¡]PPD¡^±wªÌ¡C³o¤@Àøªk±N¦b¸g¹L·ÀIµû¦ô©M½w¸Ñµ¦²¤»{ÃÒ¡]REMS¡^ªºÂåÀø¾÷ºc¤¤¥Ñ¦X®æªºÂåÅ@¤Hûª`®g(ÀR¯ßª`®g60¤p®É)¡CZulresso¦¨¬°²Ä¤@´Ú°w¹ïPPDªºÀò§åÀøªk¡A¥¦¤]¬OSAGE¤½¥q²Ä¤@´ÚÀò±oFDA§å㪺Àøªk¡C Zulresso¬O¤@ºØGABAA¨üÅ骺§Oºc½Õ¸`¾¯¡A¥¦¥i¥H½Õ¸`¯«¸g¬ðIJ¤º©M¬ðIJ¥~GABAA¨üÅ骺¥\¯à¡C¹ï¯«¸g»¼½è¨üÅ骺§Oºc½Õ¸`¯à°÷±N¨üÅ鬡©Ê½Õ¸`¨ì¤£¦P¤ô¥¡A¦Ó¤£¬O§¹¥þ¿E¬¡©ÎªÌ§í¨î¨üÅé¡CGABAA¨üÅé©MNMDA¨üÅé¤À§O°_¨ì§í¨î©M¨ë¿E¤j¸£¯«¸g¤¸²£¥Í¯«¸g½Ä°Êªº§@¥Î¡C³o¨âºØ¨üÅ鬡©Ê¤§¶¡ªº¥¢¿Å¬O¾ÉP§íÆ{¯gµ¥¦hºØºë¯«¯e¯fªºì¦]¡CZulresso¯à°÷¦³®Ä©M¦w¥þ¦a«ì´_GABAA¨üÅé©MNMDA¨üÅ鬡©Ê¤§¶¡ªº¥¿Å¡CZulresso´¿¸gÀò±oFDA±Â¤©ªº¬ð¯}©ÊÀøªk»{©w©MEMA±Â¤©ªºPRIMEÃÄ«~»{©w¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/18 ¤W¤È 08:47:16²Ä 535 ½g¦^À³
|
¹ù¥Sªº½×¤å¯Å¤j§@ SND-1 for BDNF , BDNF for SCZ liawbf.pixnet.net/blog/post/48848142 ¹ù¥S¤Þz¾ÇªÌ¬ã¨s , »¡©úºë¯«¤Àµõ¯g(SCZ)¯f¤HªºBDNF¤ô·Ç , ©úÅã¤ñ¥¿±`¤H§C¸¨ ¥BBDNFªº§C¸¨ , ©úÅã¦ñÀHSCZªº¯fµ{´c¤Æ , ¸g¹L§Üºë¯«¯fÃĪ«ªvÀø , ¤]¥i©úÅã´£¤ÉBDNF ¤Sf¥Ò»Ä¯Ç¦b°Êª«¹êÅç¥ç¥i´£¤ÉBDNF , ±N¥i¦¨¬° SND-1 ¦b¤HÅé¸ÕÅç¤W¦³®Ä§ïµ½¸g®É¯f¯gª¬ªºÀø®Ä¤§¤@ ¥t¤p§Ì»{¬° , SND-13¬OÄÝ©ó1+1ªºªþ¥[ªvÀø¤è¦¡ , 2a´Áªº¤HÅéÁ{§É¤wÃÒ©ú¦bµØ¤H¦³ÅãµÛ®ÄªG ¦Ü©ó¦b¦è¤è¤H¬O§_¦³¦P¼ËÀø®Ä , ´NÅý2b+3´Áªº¦¨®Ä¨ÓÃÒ©ú ÁÂÁ¹ù¥Sªº¶Ô©ó¬ã¨s½×¤å©M¤À¨É , Åý¤j®a¹ï¤ß®®·sÃĪº¬ãµo¦³§ó²`¨èªº»{ÃÑ©M¤F¸Ñ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/17 ¤U¤È 04:39:36²Ä 534 ½g¦^À³
|
ÁÂÁ Cliff ¤j®¦¼w µeÀsÂI·úªº¸Ñ»¡ ¸g¹L Cliff ¤j®¦¼wªº»¡©ú ¤pªº¤~²VµM²M¿ô¦a¤F¸Ñ---[ ³oÓLi-Sarcosine¦n¹³¨ã¦³¶W¥éÃÄ¡]Supergenerics¡^ªº·§©À ] ±M§Q[ Claims ] ¦³»¡ ³oÓLi-SarcosineªºªvÀø¥\¯à 6.¤@ºØ¥Î©ó´î»´¯«¸gºë¯«¯f¯gª¬ªº¤èªk¡A¥]¬A¦V¦³»Ýnªº¨ü¸ÕªÌ¬I¥Î¦³®Ä¶qªºN-¥Ò°ò¥Ì®ò»Ä¾YÆQ©Î¥]§t¾YÆQªº²Õ¦Xª«¡C 7.¦pÅv§Qn¨D6©Òzªº¤èªk¡A¨ä¤¤©Òz¯«¸gºë¯«¯f¯g¬O¨ã¦³¬¡°Ê¹L«×¯gª¬ªº¯«¸gºë¯«¯f¯g¡C 9.Åv§Qn¨D6ªº¤èªk¡A¨ä¤¤¯«¸gºë¯«¯f¯g¬O¨ã¦³·Pı¹B°Ê¯Ê³´ªº¯«¸gºë¯«¯f¯g¡C 11.®Ú¾ÚÅv§Qn¨D6©Òzªº¤èªk¡A¨ä¤¤©Òz¯«¸gºë¯«¯f¯g¬O¨ã¦³¾Ç²ß©M°O¾Ð¯Ê³´ªº¯«¸gºë¯«¯f¯g¡C 13.Åv§Qn¨D6ªº¤èªk¡A¨ä¤¤©Òz¨ü¸ÕªÌ¥Î¥t¥~ªº¯«¸gºë¯«¯f¯gÃľ¯ªvÀø¡C 14.Åv§Qn¨D13ªº¤èªk¡A¨ä¤¤©Òz¥t¥~ªºÃľ¯¿ï¦Û§Üºë¯«¯fÃÄ¡A§Ü§íÆ{ÃÄ¡A±¡ºüéw¾¯¡A§ÜµJ¼{Ãĩκ믫¿³¾Ä¾¯¡C 15.Åv§Qn¨D14ªº¤èªk¡A¨ä¤¤©Òz¥t¥~ªºÃľ¯¬O¿ï¦Û¤U²Õªº§Üºë¯«¯fÃÄ¡G¤B酰f¡A§h噻嗪¡A¬t¾Ä¤DÀR¡A¾Ä¤DÀR¡A¤þ´â©Ô嗪¡A¥Ò²¸èý嗪¡A¤T¬t©Ô嗪¡A¬ü¯Á¹F嗪¡A¤þ嗪¡A¤T¬t¤þ嗪¡A¥ª±Û¤þ嗪¡A²§¤þ嗪¡A噻¾·¡A´â噻嗪¡A flupentixol¡Athiothixene¡Azuclopenthixol¡Aclozapine¡Aolanzapine¡Arisperidone¡Aquetiapine¡Aziprasidone¡Aamisulpride¡Aasenapine¡Apaliperidone¡Aaripiprazole¡Acannabidiol¡ALY2140023¡Adperperidol¡Apimozide¡Abutaperazine¡Acarphenazine¡Aremoxipride¡Apiperacetazine¡Asulpiride¡Aacamprosate¡Atannic acid¡Aand tetenenazine¡C 16.Åv§Qn¨D14ªº¤èªk¡A¨ä¤¤©Òz¥t¥~ªºÃľ¯¬O¿ï¦Û¤U²Õªº§Ü§íÆ{ÃÄ¡G³æÓi®ñ¤Æ酶§í»s¾¯¡]MAOI¡^¡A¤TÀô§Ü§íÆ{ÃÄ¡]TCAs¡^¡A¥|Àô§Ü§íÆ{ÃÄ¡]TeCAs¡^¡A¿ï¾Ü©Ê5-ßm¦âÓi¦AÄá¨ú§í»s¾¯¡]SSRIs¡^¡A¥h¥ÒµÇ¤W¸¢¯À¯àÃÄ¡C©M¯S²§©Ê5-ßm¦âÓi¯à§Ü§íÆ{ÃÄ¡]NASSAs¡^¡A¥h¥ÒµÇ¤W¸¢¯À¡]¥h¥ÒµÇ¤W¸¢¯À¡^¦AÄá¨ú§í»s¾¯¡A¥h¥ÒµÇ¤W¸¢¯À - ¦h¤ÚÓi¦AÄá¨ú§í»s¾¯©M5-ßm¦âÓi - ¥h¥ÒµÇ¤W¸¢¯À¦AÄá¨ú§í»s¾¯¡]SNRIs¡^¡C 17.Åv§Qn¨D14ªº¤èªk¡A¨ä¤¤©Òz¥t¥~ªºÃľ¯¬O¿ï¦Û¤U²Õªº§Ü§íÆ{ÃÄ¡G¬t¦è¥Å¡A©¬Ã¹¦è¥Å¡A¨Ì¥L´¶±[¡A¦è酞´¶Äõ¡AªÙ¦±ªL¡A¬t¥ñ¨F©ú¡A¤å©Ôªk¨¯¡A¦Ì¨º´¶±[¡A«×¬¥¦è¥Å¡A¦Ì´á¥¡A¦Ì¦w¦âªL¡A·çªi¦è¥Å¡A¦w«D¥LଡAªü¦Ì´ÀªL¡A¥h¥Ò´ÀªL¡A´¶Ã¹´ÀªL¡A¦a©õ©¬©ú¡A¦±¦Ì©¬©ú¡Aªü²ö¨F¥¡A¦w«D¥LଡA´â¦Ì©¬©ú¡A¦a©õ©¬©ú¡A¦h¦è¥¡A²§¥dªi肼¡A¤ÏfÀô¤þÓi¡A¦±ÐüଡA©`ªkÐüଡAf¤A肼¡A©Ô°¨µß¯À¡A¾Y¡A¦«ýmà¡A¥[¤Ú¼Q¤B¡A¥d°¨¦è¥¡A¶ø¥d¦è¥¡A¤þ¥³»ÄÆQ¡A°¨´¶´ÀªL¡A·Íªkù©ú¡A¦Ným¶©¡A¶Ü´â¨©Ói¡A²§·Ï肼©M²§¤þ嗪¡C 18.Åv§Qn¨D14ªº¤èªk¡A¨ä¤¤©Òz¥t¥~ªºÃľ¯¬O¿ï¦Û¤U²Õªººë¯«¿³¾Ä¾¯¡G哌¥Òà¡A¥k±Û噻§h¥Òà¡A²§¤þ°ò哌Ôr¡A¥i¥d¦]¡Af¤þÓi¡A¥Ò°òf¤þÓi¡A¥kf¤þÓi¡A3,4-¨È¥Ò¤G®ñ°ò¥Ò°òf¤þÓi¡A¤Ç²öªL¡Af¥Ò嗪¡A¤G¤A°ò¤þ»Ä¡A´âf¤BÓi¡Aým«£ÖJ¡A¹ïßm°ò³Â¶ÀÆP¡Aªâ¬t©Ô©ú¡A1-¡]2,5-¤G¥Ò®ñ°ò-4-¥Ò°òf°ò¡^-2-®ò°ò¤þÖJ¡A¦w«D¥LଡA¥L¥ÅÃþ¡A²ö¹F«D¥§¡AÂb·}ÆP¡A¥k¬ü¨Fªâ¡Alisdexamfetamine dimesylate¡A²V¦XÆQ¦w«D¥L©ú¡A¦«²ö¦è¥Å¡A¥i¼Ö©wÆQ»ÄÆQ¡AÆQ»ÄÐgªk¨¯©MÂb·}ÆP¡C 19.Åv§Qn¨D14ªº¤èªk¡A¨ä¤¤©Òz¥t¥~ªºÃľ¯¬O±¡ºüéw¾¯¡A¨ä¿ï¦Û¾Y¡A©Ô²ö¤T嗪¡A¥d°¨¦è¥¡A¦«ýmà¡AÐüým©Z¡A¥d°¨¦è¥©M¤þ¥³»ÄÆQ¡C 20.Åv§Qn¨D14ªº¤èªk¡A¨ä¤¤©Òz¥t¥~ªºÃľ¯¬O¿ï¦Û¤U²Õªº§ÜµJ¼{ÃÄ¡G¦a¦èÌñ¡Aªü´¶Ðü¨Ú¡A¤TÐü¨Ú¡Aindiplon¡A¤ã¨Ó´¶¶©¡A·Í¦èÌñ¡A¶ø¨F¦èÌñ¡A¤BÁ³ÀôଡAßm嗪¡A¥Ò´â喹ଡA¬ü¦««}©w¡A¨Ì¦««}à¡Aªü¥ßÐü¨Ú¡A´â´á¡A clobenzepam¡Aflurazepam¡Alorazepam¡Aclonazepam¡Aloprazolam¡A«}¹FÐü¨Ú¡Aalpidem¡Aalseroxlon¡Aamphenidone¡Aazacyclonol¡Abromisovalum¡Achlorazepate¡A¶tN-carboamoylaspartate¡Acaptodiamine¡Acapuride¡Acarbcloral¡Acarbromal¡Achloral betaine¡Aenciprazine¡Aflesinoxan¡Aipsapiraone¡Aipsapirone¡Alesopitron¡A¬¥¨F¥¡A¥Ò喹ଡAmethprylon¡Apropanolol¡Atandospirone¡Atrazadone¡Azopiclone©Mzolpidem¡C 21.Åv§Qn¨D13ªº¤èªk¡A¨ä¤¤©Òz¯e¯f¬Oªüº¸¯ý®üÀq¤ó¯f¡]AD¡^¡A¨Ã¥B©Òz¥t¥~ªºÃľ¯¿ï¦Û¦h©`哌»ô¡A¥d¤Ú©Ô¥Å¡A¥[Äõ¥L±Ó¡A¬üª÷è¡A¦Û¨¾J¡Amidafotel¡A¥L§JªL¡A¥q¨Ó¦NÄõ©Mºû¥Í¯ÀE. ³o´N¦n¤ñ¤½¥q©Òµo¥¬¶W¯Å¾Ç¦WÃıM§Qªº·s»D½Z www.syneurx.com/2018/09/10/article13/ ³oÓ±M§Q [ Claims ] ¤¤¤]¦³ 2.Åv§Qn¨D1ªº²Õ¦Xª«¡A¨ä¤¤f¥Ò»Äà¤Æ¦Xª«¬Of¥Ò»Ä¶u¤Æ¦Xª«©Îf¥Ò»Ä¾Y¤Æ¦Xª«¡C 7.Åv§Qn¨D1ªº²Õ¦Xª«¡AÁÙ¥]§t¥Î©ó¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^¯f¯gªº¥t¥~ªºªvÀø¾¯¡C 8.Åv§Qn¨D7ªº²Õ¦Xª«¡A¨ä¤¤©ÒzCNS¯e¯fªº¥t¥~ªvÀø¾¯¿ï¦Û¥Ñ¥d§Q©Ô嗪¡A¥¬哌嗪¡A¤B酰f¡A§h噻嗪¡A¬t¾Ä¤DÀR¡A¾Ä¤DÀR¡A¤þ´â©Ô嗪¡A²¸§Q嗪¡A¤T¬t©Ô嗪¡A¬ü¯Á¹F嗪¡A¤þ嗪¡A¤T¬t¤þ嗪¡A²§¤þ嗪¡A thioxanthene¡Achlorprothixene¡Aflupenthixol¡Athiothixene¡Aclozapine¡Aolanzapine¡Arisperidone¡Aquetiapine¡Aziprasidone¡Aamisulpride¡Aasenapine¡Apaliperidone¡Aaripiprazole¡Alamotrigine¡Adperperidol¡Apimozide¡Abutaperazine¡Acarphenazine¡Aeemoxipride¡Apiperacetazine¡Asulpiride¡Aacamprosate¡Atetrabenazine¡Avilazodone¡Alevomilnacipran¡A¬t¦è¥Å¡A©¬Ã¹¦è¥Å¡A¨Ì¥L´¶±[¡A¦è酞´¶Äõ¡AªÙ¦±ªL¡A¬t¥ñ¨F©ú¡A¤å©Ôªk¨¯¡A¦Ì¨º´¶±[¡A«×¬¥¦è¥Å¡A¦Ì´á¥¡A¦Ì¦w¦âªL¡A·çªi¦è¥Å¡A¦w«D¥LଡAªü¦Ì´ÀªL¡A¥h¥ÒµÇ¤W¸¢¯À¡A¦a©Ô¨ºªL¡A¦a©õ©¬©ú¡A¦±¦Ì©¬©ú¡Aªü²ö¨F¥¡A´â¦Ì©¬©ú¡A¦h¼{¥¡A¤ÏfÀô¤þÓi¡A¥q¨Ó¦NÄõ¡A¦±ÐüଡA©`ªkÐüଡAf¤A肼¡A©Ô°¨¦a¥Ì嗪¡A¾YÆQ¡A¦«ýmà¡A¥[¤Ú¼Q¤B¡A¥d°¨¦è¥¡A¶ø¥d¦è¥¡Aõé¨F©Z¡A°¨´¶´ÀªL¡A¦Ì´á¥¡A·ÍªkÓi¡A¶Ü´â¨©Ói¡A²§·Ï肼¡A²§¤þ嗪¡A¦w«D¥L©ú¡A²V¦XÆQf¤þÓi¡A²ö¹F«D¥§¡Adesoxyn¡A¥Ò°òf¤þÓi¡A¥i¥d¦]¡AÂb·}ÆP¡A¥k±Û哌¥ÒÓi¡A¥k±Û¦w«D¥L©ú¡A哌¥Òà¡Alisdexamfetamine dimesylate¡A¦«²ö¦è¥Å¡A¥i¼Ö©w¡AÐgªk¨¯¡AÂb·}ÆP¡A¤Ç²öªL¡A¦h©`哌»ô¡A¥L§JªL¡A¥d¤Ú©Ô¥Å¡A¬üª÷è¡A¬r«ó¨§ÆP¡AÂb·}ÆP¡A¥q¨Ó¦NÄõ¡A§Q¾|Ðü¡A³æ¹ç»Ä©M»È§ö¸´£¨úª«¡C¥d°¨¦è¥¡Aoxacarbazepine¡Avalporate¡Amaprotiline¡Amirtazapine¡Abrofaromine¡Amoclobemide¡A²§·Ï肼¡Aiproniazid¡A¦w«D¥L©ú¡A²V¦XÆQf¤þÓi¡A²ö¹F«D¥§¡Adesoxyn¡A¥Ò°òf¤þÓi¡A¥i¥d¦]¡AÂb·}ÆP¡Adexmethylphenidate¡A¥k±Û¦w«D¥L©ú¡A哌¥Òà¡Alisdexamfetamine dimesylate¡Aatomoxetine¡A¥i¼Ö©w¡Aguanfacine¡Aarecoline ¡A¤Ç²öªL¡A¦h©`哌»ô¡A¥L§JªL¡A§Q¤Z´µªº©ú¡A¬üª÷è¡A¬r«ó¨§ÆP¡AÂb·}ÆP¡A¥q¨Ó¦NÄõ¡A§Q¾|Ðü¡A³æ¹ç»Ä©M»È§ö¸´£¨úª«¡C¥d°¨¦è¥¡Aoxacarbazepine¡Avalporate¡Amaprotiline¡Amirtazapine¡Abrofaromine¡Amoclobemide¡A²§·Ï肼¡Aiproniazid¡A¦w«D¥L©ú¡A²V¦XÆQf¤þÓi¡A²ö¹F«D¥§¡Adesoxyn¡A¥Ò°òf¤þÓi¡A¥i¥d¦]¡AÂb·}ÆP¡Adexmethylphenidate¡A¥k±Û¦w«D¥L©ú¡A哌¥Òà¡Alisdexamfetamine dimesylate¡Aatomoxetine¡A¥i¼Ö©w¡Aguanfacine¡Aarecoline ¡A¤Ç²öªL¡A¦h©`哌»ô¡A¥L§JªL¡A§Q¤Z´µªº©ú¡A¬üª÷è¡A¬r«ó¨§ÆP¡AÂb·}ÆP¡A¥q¨Ó¦NÄõ¡A§Q¾|Ðü¡A³æ¹ç»Ä©M»È§ö¸´£¨úª«¡C¥L§JªL¡A§Q¤Z´µªº©ú¡A¬üª÷è¡A¬r«ó¨§ÆP¡AÂb·}ÆP¡A¥q¨Ó¦NÄõ¡A§Q¾|Ðü¡AÂý»Ä©M»È§ö¸´£¨úª«¡C¥L§JªL¡A§Q¤Z´µªº©ú¡A¬üª÷è¡A¬r«ó¨§ÆP¡AÂb·}ÆP¡A¥q¨Ó¦NÄõ¡A§Q¾|Ðü¡AÂý»Ä©M»È§ö¸´£¨úª«¡C ©Ò¥HLi-SarcosineÀ³¸Ó¤]¬O¶W¥éÃÄ¡]Supergenerics¡^ªº·§©À²Õ¦X ¦A¦¸ÁÂÁ Cliff ¤j®¦¼w ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2019/3/17 ¤W¤È 11:13:51²Ä 533 ½g¦^À³
|
Äò²q·Q¤j2019/3/12²Ä 531 ½g¦^À³ªº¤º®e¡G¤½¥q·s¨ú±oªº¬ü°ê±M§Q 2019 Mar12 US Patent Pub. No.:2019/0008813 A1 ¡uLithium salts of N-substituted glycine compounds and uses thereof ¡v ³o¬Ý°_¨Ó¹³¬O¡uSarcosineªº¾YÆQ¡v¡A¾Ú»¡¬O¦b¬ãµo¹Lµ{¤¤µL·Nµo²{¥¦¨ã¦³½w¸Ñºë¯«¤Àµõ¯gªº¥¿©Ê¡Bt©Ê¯gª¬¤Î§ïµ½»{ª¾¥\¯à¯Ê·lªº¥\¯à¡CY«ö·Ó³o¦¸2/27½²¸³·|«á©Ò´£¨ìªº¼W±jÃĪ«®ÄªGªº¤èªk¡G°µ¦¨ÆQÃþ©Î¥[¤W»²ÃĪº¤èªk¨Ó¬Ý¡A³oÓLi-Sarcosine¦n¹³¨ã¦³¶W¥éÃÄ¡]Supergenerics¡^ªº·§©À¡]°µ¦¨ÆQÃþ¡^¡C ±M§Q¤º¤åÁÙ´£¨ì¡A©Ò¦³§t¦³Li-Sarcosine¦¨¤ÀªºÃÄÁÙ¥i¥H¦A¶i¤@¨B¥[¤WTannic acid°µ¬°²Ä¤GºØ»s¾¯¨Ó©µ¦ùLi-Sarcosine¦¨¤ÀªºªvÀø¥\¯à¡]§Y¥[¤W»²ÃÄ¡^¡C ¦^·QLiBen¬ONaBenªº¾YÆQ¡]°µ¦¨ÆQÃþ¡^¡FY§âNaBen¥[¤WTannic acid¡]¥[¤W»²ÃÄ¡^´N¦¨¤F¬ü°ê±M§QUS Patent Pub. No.:20180036267¡]2018/02/08¨ú±o±M§Q¡^¡A¬O§_¤]¨ã¦³¶W¥éÃĪº·§©À¡H ¹ï·Ó³o¤@¥÷ªº·s»D½Z¨Ó¬Ý¦ü¥G§ó²M·¡¡G¡uwww.syneurx.com/2018/09/10/article13/¡v ¤£¹LNaBen¡BSarcosine¤´µM¤£¬O¤W¥«ÃĪ«¡A¤W±Ó¤H©Òz¦ü¥G¦³»y¯f¡A©Ò¥HÀ³¸Ó¬O§â²{¦³¥«±¤Wªº¤W¥«ÃĪ«°µ×¹¢¡B±j¤Æ¦¨¬°¶W¥éÃÄ¡A¨Ò¦pClozapine¡]´â´á¥¡^+Tannic acid¬O¤£¬O¤ñ¸û¦X²z¡H ê©óÓ¤H°¾¨£¡A¥i¯à¦bÅÞ¿è©Î®É§Ç¥ý«á¤W¦³©ÒÂÕ»~¡A¶È¨Ñ°Ñ¦Ò¡C |
|
|
·|û¡G¤p¨È10135608 µoªí®É¶¡:2019/3/12 ¤U¤È 01:39:22²Ä 532 ½g¦^À³
|
¬ãµo¦¨ªG¦n®ø®§¤@¥ó¤S¤@¥ó¡A½Ð¤j®a@¤ßµ¥«Ý®É¶¡¨ì¨Ó¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/12 ¤U¤È 01:27:52²Ä 531 ½g¦^À³
|
¤ß®®èè¤SÀò±o¬ü°ê±M§Q United States Patent 10,226,442 March 12, 2019 Lithium salts of N-substituted glycine compounds and uses thereof Abstract The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I): ##STR00001## in which R.sup.1, R.sup.2, and R.sup.3 each are independently hydrogen, alkyl, alkenyl, alkynyl, aralkyl, carbocyclyl, aryl, or heteroaryl, or one of R.sup.1, R.sup.2, and R.sup.3 is absent. Also provided in the present invention is a method of mitigating at least one symptom of a neuropsychiatric disorder, comprising administering to a subject in need thereof the lithium salt of an N-substituted glycine compound of Formula (I). ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/10 ¤U¤È 12:27:33²Ä 530 ½g¦^À³
|
¹ï¤£°_! ²Ä529½g§ó¥¿¬° ¦V¤j®a²`²`¤@Áù°`¹Dºp ¥»ª©¤p§Ì©Ò¶K ²Ä514½g ²Ä517½g ²Ä527½gªºªþµù , ÁÙ¦³¤Íª©²Ä1128½gªº¶K¤å§@¼o ¤p§Ì¬Q¤ÑµL·N¤¤§ä¨ì¤F¤@½g¥Ñ¥_¥d¤j¾Ç(UNC)Rachel Kloss Silverman¥ý¥Í©Ò¼gªº METHODS FOR THE SEQUENTIAL PARALLEL COMPARISON DESIGN ( SPCD ) cdr.lib.unc.edu/indexablecontent/uuid:035047ed-5f26-4cba-884d-b100959ab00d ¸Ô²Ó»¡©ú¤FSPCD ¤Î¨äÀ³¥Î CHAPTER 1: LITERATURE REVIEW ÄÄz²z½× CHAPTER 2: SAMPLE SIZE RE-ESTIMATION AND OTHER MIDCOURSE ADJUSTMENTS WITH SEQUENTIAL PARALLEL COMPARISON DESIGN »¡©ú´Á¤¤¤ÀªR¼Ë¥»¼Æªº«¦ô CHAPTER 3: SEQUENTIAL PARALLEL COMPARISON DESIGN WITH BINARY AND TIME-TO-EVENT OUTCOMES ¨Æ¥ó®É¶¡¤ÀªRªºÀ³¥Î CHAPTER 4: PERMUTATION-BASED INFERENCE FOR SEQUENTIAL PARALLEL COMPARISON DESIGN APPENDIX 1: FIGURES AND TABLES.................................................................50 REFERENCES.........................................................................64 ¹ï§Ú³oÓ²Îpªù¥~º~¨Ó»¡ ¦nÃø ©Ò¥H¶K¥X¨ÓÅý¤j®a¨Ó¦@¦P§V¤O¬ã¨s §ó´Á«Ý²Îp°ª¤â̪º«ü¾É©M±Ð¾Ç ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/10 ¤W¤È 10:38:06²Ä 529 ½g¦^À³
|
¦V¤j®a²`²`¤@Áù°`¹Dºp ¥»ª©¤p§Ì©Ò¶K ²Ä514½g ²Ä517½g ²Ä527½gªºªþµù , ÁÙ¦³¤Íª©²Ä1128½gªº¶K¤å§@¼o [ ¤½¦¡¤¤ªºÅv«w=0ªº¸Ü(´N¬O¤£±Ä¥Îrun-in ¶¥¬qªº¼Æ¾Ú) , ·|¤ñ¸û¶Kªñ¼ÒÀÀ , ¦ý§Ṳ́£ª¾¹D½²±Ð±Â¬O¥Î 0.5 , 0.25 ©Î¬O 0 ? ] ¤p§Ì¬Q¤ÑµL·N¤¤§ä¨ì¤F¤@½g¥Ñ¥_¥d¤j¾Ç(UNC)Rachel Kloss Silverman¥ý¥Í©Ò¼gªº METHODS FOR THE SEQUENTIAL PARALLEL COMPARISON DESIGN ( SPCD ) cdr.lib.unc.edu/indexablecontent/uuid:035047ed-5f26-4cba-884d-b100959ab00d ¸Ô²Ó»¡©ú¤FSPCD ¤Î¨äÀ³¥Î CHAPTER 1: LITERATURE REVIEW ÄÄz²z½× CHAPTER 2: SAMPLE SIZE RE-ESTIMATION AND OTHER MIDCOURSE ADJUSTMENTS WITH SEQUENTIAL PARALLEL COMPARISON DESIGN »¡©ú´Á¤¤¤ÀªR¼Ë¥»¼Æªº«¦ô CHAPTER 3: SEQUENTIAL PARALLEL COMPARISON DESIGN WITH BINARY AND TIME-TO-EVENT OUTCOMES ¨Æ¥ó®É¶¡¤ÀªRªºÀ³¥Î CHAPTER 4: PERMUTATION-BASED INFERENCE FOR SEQUENTIAL PARALLEL COMPARISON DESIGN APPENDIX 1: FIGURES AND TABLES.............................................................................50 REFERENCES.........................................................................64 ¹ï§Ú³oÓ²Îpªù¥~º~¨Ó»¡ ¦nÃø ©Ò¥H¶K¥X¨ÓÅý¤j®a¨Ó¦@¦P§V¤O¬ã¨s §ó´Á«Ý²Îp°ª¤â̪º«ü¾É©M±Ð¾Ç ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/8 ¤U¤È 07:59:17²Ä 528 ½g¦^À³
|
§Ü§íÆ{ÃľԳõ¤ÓºG¯P¡I¦ãº¸«Ø5.6»õ¶RªºÃÄ¥|¶µ¬ã¨s§¡¥¢±Ñ ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2019-03-08 med.sina.com/article_detail_103_2_62137.html º¸«Ø¡]Allergan ¡^¥H5.6»õ¬ü¤¸¦¬ÁÊNaurex¤½¥qÀò±oªº§Ü§íÆ{¯gÃĪ«rapastinel³Ìªñ¤½§G¤F³Ì·s¬ã¨sµ²ªG¡A¤£©¯ªº¬O¡A¸ÓÃĪ«¤T¶µÃöÁä©Ê¸ÕÅ秡¥¼¯à¹F¨ì¨ä¥Dn²×ÂI¡C§óÁV¿|ªº¬O¡A²Ä¥|¶µ¬ã¨sªº¤¤´Á¤ÀªR¤]Åã¥Ü¥X¡A¥Dn©MÃöÁ䪺¦¸nÁ{§É²×ÂI±NµLªk¹ê²{¡C±µ³sªº¸ÕÅ祢±Ñ¾ÉP rapastinelªº¥¼¨Ó¤@¤ù´ù¯í¡C ¬Û¤ñ¤§¤U¡A´N¦b¦ãº¸«Ø«Å¥¬ÃĪ«¸ÕÅ祢±Ñªº«e¤@¤Ñ¡A¦³¦PÃþ§@¥Î¾÷¨îªºNMDA¨üÅé«ú§Ü¾¯¡X¡X±j¥ÍºX¤U·¨´Ë»sÃÄSpravato¡]esketamine¡^CIII»ó¼QÃú¾¯Àò±o¤F¬ü°êFDA§åã¡AÁp¦X¤fªA§Ü§íÆ{ÃĥΩóÃøªv©Ê§íÆ{¦¨¤H±wªÌªºªvÀø¡C¦¹¦¸§åã¤]¨Ï±oSpravato¦¨¬°¹L¥h30¦h¦~¨ÓºÓ¨ã¦³·s§@¥Î¾÷¨îªº§Ü§íÆ{ÃĪ«¡C¡]¸Ô¨£¡G30¦~ºÓ·s¾÷¨î§Ü§íÆ{ÃÄÀò§å¡I±j¥ÍSpravato±N¥Î©óÃøªv§íÆ{¡^ Rapastinel¬O¤@ºØÀR¯ßª`®g¥ÎN-¥Ò°ò-D¤Ñ¥V®ò»Ä¡]NMDA¡^¨üÅ骺¥|肽½Õ¸`ÃÄ¡A¦ãº¸«Ø¦¹¦¸¶i¦æªºÁ{§É¸ÕÅç¬O´ú¸Õ¸ÓNMDA¨üÅé½Õ¸`¾¯§@¬°««×§íÆ{¯g¡] MDD¡^±wªÌªº»²§UªvÀø®ÄªG¡C¤T¶µ3´Á¬ã¨sÁ`¦@¯Ç¤J¤F1,510¨Ò««×§íÆ{¯g±wªÌ¡C°Ñ»P¤T¶µrapastinel¬ã¨sªº±wªÌ¦~ÄÖ¦b18-65·³¤§¶¡¡A²Å¦X««×§íÆ{¯g¼Ð·Ç¡A°Ñ»PªÌ¥²¶·¦³¦Ü¤Ö¤K¶g¥B«ùÄò®É¶¡¤£¶W¹L18Ӥ몺««×§íÆ{µo§@¡C¦¹¥~¡A²Å¦X±ø¥óªº±wªÌ¥²¶·¹ï§Ü§íÆ{ªvÀø«ùÄòªvÀø¦s¦b³¡¤À°_®Ä¤ÏÀ³¡A¦b¾ãÓ¬ã¨s¤¤¥Héw¾¯¶qÄ~Äò¤fªAªvÀø¡C ¦ãº¸«Ø¦b¬ü°ê·í¦a®É¶¡¶g¤T¡]3¤ë6¤é¡^¤U¤Èªº¤@¥÷Án©ú¤¤ªí¥Ü¡A¦b¨ä¤¤¨â¶µ¸ÕÅ礤¡A±wªÌ¨C¶g¦b¤fªA§Ü§íÆ{ÃÄ°ò¦¤W¤À§Oª`®g¦w¼¢¾¯©ÎRapastinel¡C²Ä¤T¶µ¬ã¨s¦b³]p¤WÃþ¦ü¡A¥u¬O¥¦ÁÙµû¦ô¤F¸û§C¾¯¶qrapastinelªºªvÀø®ÄªG¡C¦b©Ò¦³¤T¶µ¬ã¨s¡]RAP-MD-01¡BRAP-MD-02¡BRAP-MD-03¡^¤¤¡A¸ÓÃĪ«ªº@¨ü©Ê¨}¦n¡A¨S¦³¥ô¦óÀÀºë¯«¯f°Æ§@¥Îªº«H¸¹¡C¦ýÁV¿|ªº¬O¡A¤T¶µ¬ã¨s¤¤rapastinelªvÀø²Õ¦b¥Dn©MÃöÁ䦸n²×ÂI¤W§¡»P¦w¼¢¾¯²ÕµL²Îp¾Ç¤WªºÅãµÛ®t§O¡A§Y¸ÓÃĪ«ªºªvÀø®ÄªG¥i¥H©¿²¤¤£p¡C¦¹¥~¡A²Ä¥|¶µ¬ã¨srapastinel´_µo¹w¨¾¬ã¨sRAP-MD-04ªº¤¤´Á¤ÀªRµ²ªGªí©ú¡A¸ÓÃĪ«µLªk¹F¨ì¥Dn©MÃöÁ䦸n²×ÂI¡C ¦ãº¸«Ø¬ãµo¥DºÞDavid Nicholsonªí¥Ü¡A¦ãº¸«Ø±N¤ÀªR³o¨Ç¼Æ¾Ú¹ï¨ä¥Lrapastinel¸ÕÅçp¹ºªº¼vÅT¡A¨Ã¦b2019¦~¤¤°µ¥X¶i¤@¨Bªº¨M©w¡C ¦bII´ÁÁ{§É¸ÕÅ礤Åã¥Ü¡A¹ï¨ä¥L§Ü§íÆ{ÃĤÏÀ³¤£¨¬ªº««×§íÆ{¯g±wªÌ¡Arapastinel³æÃĪvÀø«á¤@¤Ñ¡A±wªÌ§Ü§íÆ{ÃĮIJv¨³³t±o¨ì´£°ª¡C¦ýÁp¦X¥ÎÃĬã¨s®ÄªG¨Ã¤£¦p¹w´Á¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/8 ¤U¤È 07:48:43²Ä 527 ½g¦^À³
|
¦ãº¸°· ( Allergan ) §Ü§íÆ{ÃĪ«rapastinel¤TÓ¤T´ÁÁ{§É¥¢±Ñ ¨Ó·½¡G¬ü¤¤ÃÄ·½¡@2019-03-08 med.sina.com/article_detail_103_1_62114.html Rapastinel¤£¶È¶¶§Q³q¹LÁ{§É«eªº««Ãö¥d¡B¦b¤G´ÁÁ{§É¤]Åã¥Ü¸û¦nÀø®Ä¡C³o±o·PÁ§ܧíÆ{ÃĪ«¬ãµoªº¥t¤@Ó¤j§|¡A§Y¦w¼¢¾¯®ÄÀ³¡C«Ü¦h§íÆ{±wªÌµo¯f®ÉªA¥Î¤°»ò³£¯à½w¸Ñ¯gª¬¡B¤×¨ä¬O¦bÂå°|Àô¹Ò¤U¡A©Ò¥H§Y¨Ï¦³®ÄÃĪ«¦b¹ï·Ó¸ÕÅ礤¤]¥u¦³«Ü¤pªºµ¡¤f¯àÅã¥Ü°Ï¤À¡A¶§©Êµ²ªG«D±`Ãø¥H±o¨ì¡C³Q»{¬°ÄAÂФF§íÆ{ªvÀøªº¦Ê¼~¸Ñ¤ñ¦w¼¢¾¯§ïµ½¤]«D±`¦³¡A·í¦~NEJM¥D½sMarcia Angell¨º¥»¡m»sÃĬɯu¬Û¡n¤@®Ñ¤¤±Mªù´£¨ì³oÓÃĪ«ªº·L¤pÁ{§É§ïµ½ ¹ù¥Sªº¤j¤å SNG-12 PK Rapastinel (GLYX-13 ) liawbf.pixnet.net/blog/post/47551911 Á{§Éºôªº´yz This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 milligrams (mg) compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT. ºû°ò¦Ê¬ì en.wikipedia.org/wiki/Rapastinel Rapastinel (INN) (former developmental code names GLYX-13, BV-102) is a novel antidepressant that is under development by Allergan (previously Naurex) as an adjunctive therapy for the treatment of treatment-resistant major depressive disorder. It is a centrally active, intravenously administered (non-orally active) amidated tetrapeptide (Thr-Pro-Pro-Thr-NH2) that acts as a selective, weak partial agonist (mixed antagonist/agonist) of an allosteric site of the glycine site of the NMDA receptor complex (Emax ≈ 25%). rapastinel is technically an allosteric modulator of the glycine site of the NMDA receptor, and hence is more accurately described as a functional glycine site weak partial agonist. Allosteric modulator In biochemistry and pharmacology, an allosteric modulator (allo- from the Greek meaning other) is a substance which indirectly influences (modulates) the effects of a primary ligand that directly activates or deactivates the function of a target protein. Targets may be metabotropic, ionotropic and nuclear receptors, enzymes and transporters[. Pure modulators have no direct effect on the function of the protein target. Allosteric agonists are to be distinguished from pure allosteric modulators. They are defined as ligands able to directly activate a receptor by binding to an allosteric agonist binding site distinct from the primary (orthosteric) site. ªþµù : Ãø¨ì³o¤S¬O°ª¦w¼¢¾¯®ÄÀ³·Sªºº×? ¶Ç²ÎªºÀH¾÷¤À²Õ·|¦³°ª¦w¼¢¾¯®ÄÀ³ , ¦³ÀuÂI , ¤]¦³¯ÊÂI ÀuÂI¬O : ¨â²Õªº[ÃÄ®Ä]ªí²{ , ³£«Ü¦n¬Ý ¯ÊÂI¬O : ¥´²V¾Ôªºµ²ªG , ¨â²Õ®t²§·|§_¨S¦³¹F¨ì²Îp·N¸q? °²¦p¥Î¤ß®®ªºSPCD , Àu¯ÊÂIè¦n¬Û¤Ï °§C°ª¦w¼¢¾¯®ÄÀ³ , ·|Åý¤ÏÀ³²v°§C , [ÃÄ®Ä]Åã±o¨S¦³¶Ç²Î¤èªk¤À²Õªº¦n¬Ý , ¦ý¬O®t²§¸û®e©ö¹F¨ìÅãµÛ (¦p½²±Ð±ÂÁ|¨Òªº¨â²Õ¤ÏÀ³²v¤ñ ¥Ñ50%/30% ¼W¬° 30%/10% ) ¦A¨Ó Allergan ªº Apimostinel¡]NRX-1074¡^¬O Rapastinel ªºÃþ¦üª«¡A¨ã¦³¬Û¦Pªº§@¥Î¾÷¨î »Papimostinel¤@¼Ë³£¦b§@¬°rapastinelªº¤fªA«áÄò¤Æ¦Xª«ªºAGN-241751 , ·|¤£·|¨ü¨ì¼vÅT , ©Î«ÝÆ[¹î ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2019/3/7 ¤W¤È 11:14:47²Ä 526 ½g¦^À³
|
SpravatoÁp¦X¤fªA§Ü§íÆ{ÃĪº°Æ§@¥Î¤£¤Ö..¦ý¤´¹LÃö..¥NªíCNS»â°ì·sÃĪº«æ¢©Ê... ¥i¹w´Á«áÄòCNS·s¾÷¨îªºÃÄ«~±N³°Äò©ó¥«³õ¤W¥X²{...¤ß®®·s¾÷Âà·sÃÄȱoµ¥«Ý! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/6 ¤U¤È 06:20:25²Ä 525 ½g¦^À³
|
30¦~ºÓ·s¾÷¨î§Ü§íÆ{ÃÄÀò§å¡I±j¥ÍSpravato ( esketamine¡^±N¥Î©óÃøªv§íÆ{ ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2019-03-06 med.sina.com/article_detail_103_2_61962.html ¾Ú¦ôp¡A¦b¬ü°ê¡A¤j¬ù¤T¤À¤§¤@ªºÄY«§íÆ{¯g¦¨¤H±wªÌ¬°TRD¡C¦¹¦¸§åã¡A¨ÏSpravato¦¨¬°¹L¥h30¦h¦~¨ÓºÓ¨ã¦³·s§@¥Î¾÷¨îªº§Ü§íÆ{ÃĪ«¡C¦b¬ü°ê¡AFDA¤§«e¤w±Â¤©SpravatoªvÀøTRD©MªvÀø¦ñ¦³ºò¢¦Û±þ·ÀIªºÄY«§íÆ{¯g¬ð¯}©ÊÃĪ«¸ê®æ¡C»P¼Ð·Çªº¤fªAªvÀøÃĪ«¬Û¤ñ¡ASpravato³q¹L»óµÄ¤ºµ¹ÃĪº¤è¦¡¥i´£¨Ñ§Ö³t°_®ÄªºÀu¶Õ¡C»Ýn«ü¥Xªº¬O¡ASpravatoÃĪ«¼ÐÅÒ¤¤ªþ±a¦³¤@«h¶Â®Øĵ§i¡A´£¥Ü·ÀIµû¦ô©M´î¨a¾Ô²¤¡]REMS¡^¥H¤Î¦b¨à¬ì±wªÌ©M¦~»´¦¨¤H¤¤¦Û±þ·Qªk©M¦æ¬°ªº·ÀI¡C(SPRAVATO™ carries a Boxed WARNING regarding a Risk Evaluation and Mitigation Strategy (REMS) and the risk of suicidal thoughts and behaviors in pediatric patients and young adults.) ¬ã¨s¤¤¡ASpravatoÁp¦X¤fªA§Ü§íÆ{Ãij̱`¨£ªº°Æ§@¥Î¥]¬A¡G¸ÑÂ÷¡BÀY·w¡Bäú¤ß¡BÂíÀR¡B¯t·w·P¡BIJı©M·Pı´î®z¡BµJ¼{¡Bºë¤O¤£¨¬¡B¦åÀ£¤É°ª¡B¹Ã¦R©M°s¾K·P¡C ¤@¥¹Spravato³Q½T©w¬°¦X¾AªºªvÀø¤è®×¡A®Ú¾ÚREMS¡A±wªÌ±N¦b¸g»{ÃÒªºªvÀø¤¤¤ß±µ¨üªvÀø¡CSpravato¤£·|ª½±µ³B¤èµ¹±wªÌ¦b®a¨Ï¥Î¡A¸ÓÃıN¥Ñ±wªÌ¦bÂåÀø«O°·´£¨ÑªÌªºª½±µÆ[¹î¤U¶i¦æ¦Û§ÚªAÃÄ¡A¨ÃÆ[¹îÂíÀR¡B¸ÑÂ÷©M¦åÀ£ÅܤƦܤÖ2Ó¤p®É¡Aª½¨ì±wªÌ³Q½T»{¦w¥þ«á¤è¥iÂ÷¶}¡C¦¹¥~¡A±wªÌ¦b±o¨ì¨}¦nªººÎ¯v«á¡Aª½¨ì²Ä¤G¤Ñ¤~¯à¾r¾p©Î¾Þ§@««¬¾÷±ñ¡C©Ò¦³±wªÌ³£±Nµn°O¦bSpravato REMSµù¥U¤¤¤ß¡A¥H¶i¤@¨B´yzÂíÀR¡B¸ÑÂ÷¡BÀݥΩM»~¥Î³y¦¨ÄY«¤£¨}«áªGªº·ÀI¡A¨Ã¤ä«ù¦w¥þ¦a¨Ï¥Î¸ÓÃĪ«¡C¦¹¥~¡A·¨´ËCarePath±N´£¨Ñ¥þ±ªº¤ä«ùp¹º¡AÀ°§U±wªÌ±Ò°ÊSpravatoªvÀø¨Ã«O«ù¸ò踪¡C¡]·s®öÂåÃĽsĶ/newborn¡^ |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2019/3/6 ¤U¤È 01:55:47²Ä 524 ½g¦^À³
|
¦pªG¥H¤½¥q¯ó³Ð´Á...¥¼¤W¥««eªº¨ÆÂÝ...(¨º®É¥¼¤W¥«ªÑ»ù´N¤w¦³200¤¸¥H¤W)... ¦Ó§Ú¥ý«e´£¨ìªºÆ[ÂI¬O..3¦~«e¤ß®®¤W¿³Âd®ÉªºªÑ¥»¤Î©Ó¾P»ùªºq©w..¬O¨Ì·Ó°ê»Ú·sÃÄ»ùÈrNPVµû¦ôªk¥h©w»ù168¤¸.. ----------------------------------------------------------------------------------------------- ¤½¥q¦Û¤W¿³Âd¥H«á¨Ã¥¼¦³¥ô¦ó¼W¸ê...3¦~«e©Ó¾P»ù168¤¸¤W¿³Âd«á...ªÑ¥»¨Ã¥¼¿±µÈ.... ¦pªGn»¡¤jªÑªFÁÈ¿ú...¨º¤£³X·Q·Q¤j¥ß¥úªºì©lªÑªF¨ì²{¦bÁȦh¤Ö? ·sÃĤ½¥q³Ìì©lªºªÑªF©Ó¾áªº¬OÁ{§É©|¥¼¦³¥ô¦ó¹êÁZªº§ë¸ê...·ÀI«Y¼Æ³Ì¤j...¦³¦h¤j©Ó¾á·ÀI¦ÛµM¦³¦h¤j³ø¹S.. ¦Ó²{¦bªº¤ß®®¤w¤£Â_§V¤O±N¦U·sÃıÀ¦Ü2-3´ÁÁ{§É...·ÀI¨t¼Æ»·§C©ó¤½¥q¯ó³Ð´Á...¨ä¹ê¬Ý¤jªÑªFÁȦh¤Ö·N¸q¤£¤j.. ¤j®a§ë¸êªÑ²¼¬Ýªº¬O¤½¥q¸gÀçªÌ¸Û«H¥H¤Î¤½¥q¥¼¨Óªº»ùȦ³¦h¤Ö..¥Ø«eȤ£È±o§ë¸ê... ----------------------------------------------------------------------------------------------- ¤ß®®·sÃĶi«×»·¤ñ¤T¦~«e¤j¦³¶i®i..³o¤T¦~ªÑ¥»¥¼¿±µÈ...ªÑ»ù³Ñ¤U©Ó¾P»ùªº1/3»ù...¬Oȱoªø´Á§ë¸ê... §ë¸êªÌ¦pı±o¤ß®®ªº·sÃĨS¦³¥ô¦ó»ùÈ...©Î°ê»Úµû¦ô·sÃĤ½¥q»ùȪº¤è¦¡¨S¥ô¦ó·N¸q... ¨º«Øij´N§O§ë¸ê·sÃĤ½¥q..¥i¥H¥h§ë¸ê¦³¹ê»ÚEPSªº¤½¥q..¶O¤ß¦b¤ß®®ª©¤W..¥u¬O¦h®ö¶O®É¶¡½}¤F... ----------------------------------------------------------------------------------------------- ¥H¤W...¶È¨Ñªø´Á§ë¸êªº¾Ô¤Ḭ́ѦÒ...¨CÓ§ë¸êªÌ¥i©Ó¾áªº·ÀI¤£¦P...¤Å·í§@Ó¤H§ë¸ê¨Ì¾Ú... |
|
|
·|û¡Gº©¹CªÌ10144096 µoªí®É¶¡:2019/3/6 ¤U¤È 01:14:53²Ä 523 ½g¦^À³
|
¤p´²¤á §A¦n¡A ³o½g¤µ©P¥Zªº¤å³¹¡A¤½¥q¤w¸gµo¹L«°T¼á²M¹L ¡u¸`¿ý¥»¤½¥qµo¨¥¥þ¬°§ù¼¶¡v ¥þ¤å¦p¤U¡G ========= ²Ä¤T¤Q¥|±ø¡@²Ä26´Ú 1.¶Ç¼½´CÅé¦WºÙ:1001´Á¤µ©P¥Z¤Î¨ä¥L´CÅé³ø¾É 2.³ø¾É¤é´Á:105/02/24 3.³ø¾É¤º®e: ¡u¤ß®®¥ÍÂåªí¥Ü¡A¡u³o»ò°µ¬O§Æ±æ¦h¶Ò¨ì¤@ÂI²{ª÷¡C¡v·í®É¤ß®®¬O¥¼¤½¶}µo¦æ¤½¥q¡A ¨Ì·Ó¡m¤½¥qªk¡n¡A¥un²Å¦Xn¥ó¡A¤½¥q¥i¥H³o»ò°µ¡A¦ý¬O¤½¶}µo¦æ¤§«á¡A¡u§Ṳ́£·| ¦A¥Î¸ê¥»¤½¿nÂà¼W¸ê¡C¡v 4.§ë¸ê¤H´£¨Ñ°T®§·§n:¤£¾A¥Î 5.¤½¥q¹ï¸Óµ¥³ø¾É©Î´£¨Ñ°T®§¤§»¡©ú: ¥»¤½¥q»ùȬ°¦U¶¥¬q§ë¸êªÌ©Ò»{¥i¡A©Ò¦³¸ê¥»§Î¦¨¤ÎªÑÅv¤À°t¡A §¹¥þ¦X©óªk¥O³W³¹¡A¸`¿ý¥»¤½¥qµo¨¥¥þ¬°§ù¼¶¡C 6.¦]À³±¹¬I:µL 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê ±Á{·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C |
|
|
·|û¡G¤p´²¤á10147972 µoªí®É¶¡:2019/3/6 ¤U¤È 12:36:01²Ä 522 ½g¦^À³
|
¤ß®®¨S¦³¼W¸ê¡A¦ý¬O¦³®³¸ê¥»¤½¿n°tªÑ¡A¾ÉPªÑ¥»Åܤj°Ú¡CGoogle¤@¤U´N§ä¨ì¤F ¤jªÑªF̪º¦¨¥»¬O²{¦bªÑ»ùªº¤Q¤À¤§¤@¡A·íªì§ëªº¿ú³£ÁȦ^¨Ó¤F¡C ³Ñ¤U¤pªÑªFè誺µ¥«Ý·sÃĪº®ø®§¡A¤@¦~¤S¤@¦~¹L¥h.... *********************************************************************************************** ¦¨¥ß©ó¤@¤T¦~ªº¤ß®®¥ÍÂå¡A§â±b¤Wªº¸ê¥»¤½¿n·í§@ªÑ§Q®³¨Ó°tªÑµ¹ªÑªF¡A§Ö³t¿±µÈªÑ¥»¡A¡u´X®ÉÅ¥¹L¤½¥q¥Î¸ê¥»¤½¿n¨Ó°tªÑªº¡H¡v¥L½èºÃ¡C ¤@¤»¦~¤@¤ë¡A³o®a¤½¥qªº¥«È¤w½Ä¤W¤G¤¤»õ¤¸¡A¬Û¤ñ¤§¤U¡A¦¨¥ß¤»¤Q¥|¦~ªº¥Ã«HÃÄ«~¡A¦P¼Ë¿n·¥µo®i·sÃÄ¡A¨¯¶Ô¯Ñ¯Ð»sÃIJ£·~¡A¥«È³ºµM¥u¦³¤ß®®¥ÍÂ媺¤T¤À¤§¤G¡C ¤ß®®¥ÍÂ媺§@ªk¬O¡A²Ä¤@¦¸°tªÑ¡AÅý¨C¦ìì©lªÑªF°t¤G¡D¤T¤@±iªÑ²¼¡A¤]´N¬O¤@±iªÑ²¼Åܦ¨¤T¡D¤T¤@±i¡F²Ä¤G¦¸¤S¦A°tµoªÑªF¡³¡D¤¤±iªÑ²¼¡AªÑ¥»¦]¦¹¨³³t¿±µÈ¡A쥻¤ß®®¥ÍÂ媺ªÑªF¤â¤W«ùªÑ¡A´N±q¤@±iÅܦ¨¤±i¡A¦]¦¹·í¤½¥q¥H¤@¤»¤K¤¸¦b¿³Âd¥æ©ö¡AªÑ²¼»ùȤ£¨ì¤T¦~¡A´N¿±µÈ¤K¤Q¿¡C ¤ß®®¥ÍÂåµo¨¥¤H½²¥É´@ªí¥Ü¡A¡u³o»ò°µ¬O§Æ±æ¦h¶Ò¨ì¤@ÂI²{ª÷¡C¡v¥h¦~¤K¤ë¤ß®®¥ÍÂå¶Ò¸ê¤Q¤À§xÃø¡A¬°¤FÅý§ë¸ê¤H¹ïªÑ»ù¡u¦³·P¡v¡A¼W¥[§ë¸ê»ùȤ~³o»ò°µ¡A¡u§Ṳ́]µLªk¹w®Æ«á¨Ó¥Í§ÞªÑ¤jº¦¡C¡v¦o¸ÑÄÀ¡A·í®É¤ß®®¬O¥¼¤½¶}µo¦æ¤½¥q¡A¨Ì·Ó¡m¤½¥qªk¡n¡A¥un²Å¦Xn¥ó¡A¤½¥q¥i¥H³o»ò°µ¡A¦ý¬O¤½¶}µo¦æ¤§«á¡A¡u§Ṳ́£·|¦A¥Î¸ê¥»¤½¿nÂà¼W¸ê¡C¡v |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2019/3/4 ¤U¤È 08:54:09²Ä 521 ½g¦^À³
|
¤T¦~«eªÑ»ù°ªÂI265¤¸©Î³\¬O·í®É¥Í§Þ¥¿¼ö¦Ó¶Wº¦... ¦ý·í®É¤½¥q¤W¿³Âd©Ó¾P»ù168¤¸ªºq©w¬O¸g¹LrNPV¨Óq»ù... °Ñ¦Ò°ê»Ú¤W¹ï©ó·sÃĤ½¥qµû¦ôªº¤è¦¡...¬O¦³¨ä¥«³õµû¦ô²z½×°ò¦ªº... --------------------------------------------------------------------------------- ·íµM¼vÅTªÑ»ùªºì¦]²³¦h..¨Ò¦p..·sÃĤ½¥qªº¼W¸êª½±µ³y¦¨ªÑ¥»¿±µÈ¦Ó¼vÅT¤FªÑ»ù... ¦ý¤ß®®³o¤T¦~¨«¨Ó...¨Ã¥¼¦³¥ô¦ó¼W¸ê...ªÑ¥»¨Ã¥¼¿±µÈ... ªÑ»ù¥Ñ©Ó¾P»ù168¤¸¦Ü¤µ³Ñ¤U¬ù1/3»ù... --------------------------------------------------------------------------------- ¦b¤½¥q·sÃÄÁ{§É¶i«×«ùÄò¶i®i¤U...¤½¥q»ùȤ£Â_´£¤É...¬O«Üȱoªø´Á§ë¸êªº... ©Î³\¥Ø«e¥«³õ¤Wªº§ë¸ê¤H¤£Ä@·N¶R¥Í§Þ·sÃĪÑ... ¦ýÓ¤Hªº¬Ýªk¥¿¦n¬Û¤Ï...·í¤j®a¨S«H¤ß®É¥¿¬O¥xÆW¥Í§Þ·sÃĪѱNn¸Uµo»ô©ñªº¶}©l... ¹ï©ó»ùȶW¶^ªº·sÃĤ½¥q¥¿¬O·¥¦nªº§ë¸ê®É¾÷... ¥H¤W...¶È¨Ñªø´Á§ë¸êªº¾Ô¤Ḭ́ѦÒ...¨CÓ§ë¸êªÌ¥i©Ó¾áªº·ÀI¤£¦P...¤Å·í§@Ó¤H§ë¸ê¨Ì¾Ú... |
|
|
·|û¡G¤p´²¤á10147972 µoªí®É¶¡:2019/3/4 ¤U¤È 06:36:37²Ä 520 ½g¦^À³
|
¤T¦~«e©Ò¦³¥Í§ÞªÑ³£ª£¤W¤Ñ¡A¤ß®®·íµM¥i¥H½Ä¨ì200¦h¡C²{¦bªº¥Í§ÞÃþªÑ¡A´X¥G³£¬O¬Û¹ï§CÀɪº¦ì¸m¡A¥Dn§ë¸ê¤H¤£Ä@·N¶R¥Í§ÞªÑ²¼¡C§ë¸ê¥Í§ÞªÑ¯uªº¬O¤@±øº©º©ªø¸ô¡A¤£¤@©w¦³©Ò¦^³ø¡C²¦³º¨S¦³°tªÑ°t®§¡A¸Ñª¼¥¢±Ñ´N¤@³õªÅ¡C |
|
|
·|û¡G¤p¨È10135608 µoªí®É¶¡:2019/3/4 ¤U¤È 01:26:01²Ä 519 ½g¦^À³
|
¤p©¯¹B¤j¡G§ë¸ê¤H±¹ïªÑ»ù²{ªp©Ò°µªº¤ß²z¤ÏÀ³µÛ¹ê½ÆÂø¡A¤@»y¹D¯}´N¬O°l°ª±þ§C¡A¹J§Q¦h²r°l¡A¬Æ©Î¤Û·Q¥¼¨ÓªÑ»ù¸¤W¤Ñ»Ú¡A¹J§QªÅ©Î¤£©`¤[½L«h¦Û³]°±·l¥X³õ¡AÓ¤H¦³20¾l¦~ªÑÄÖ¡A¤@¨Ó¸g¾ú¸gÅç±Ð°V»á¦h¡A²`¿Ú´²¤á¤ß²z©M¤j¤á¤âªk¡A¤WӤ뤤¦¯¡A¤ß®®ªÑ»ù¦³¤@ªi¤U±þ¡A§Ú¦b¤¤Â_®É©ß´²¤á¤ßºA¡A¥ý¥X¤â©Ó±µ¤@¨Ç¡A¦ý¥¼´ú±o©³³¡»ù¡AÀH«á´X¤Ñ¦A«×±a¶q¤U±þ¡A§Ú«i´±¥X¤â¦A¶R¶i¤@¦¸¡A²×©ó´ú±oªi¬q©³»ù¡C¤ß®®ªÑ»ù¬O¥Ñ²³¦h§ë¸ê¤HÁp¦X¦æ¬°©Òq©wªº¡A§ÚµL±q¹wª¾°ª§C¡A¦ý¬O§Ú¦Û»{¶R¶iªº»ù¦ì«Üȱo¡A°_½X¤w¬O¤W¿³Âd»ù®æªº1/3»ù¡Aªp¥B¤½¥q¥¿©¹©Z³~µo®i¡A¦³¦ó¤£¥i¡C |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2019/3/4 ¤U¤È 12:18:55²Ä 518 ½g¦^À³
|
3¦~«e¤ß®®±aµÛ¬ð¯}©ÊÀøªkªºÀu²§·sÃÄÅD¤W¿³Âd¥H©Ó¾P»ù168¤¸ª½¤W265¤¸... 3¦~«á¤ß®®¦U¶µ·sÃĬҦ³¶i®i...¤½¥q𷪺¨B¥ï¤@¨B¤@¨B¦V«e...ªÑ»ù«o¥u³Ñ·íªìªº1/3... §ë¸ê¤ß²z¾Ç¯uªº¬O¬Û·í²`¶ø.... ----------------------------------------------------------------------------------- ·PÁ²q·Q¤j¤À¨ÉÁ{®ÉªÑªF·|ªº¸ê°T¥H¤ÎÄ_¶Qªº¨£¸Ñ... ¤]·PÁ¤j¤á¤jªºÆ[ÂI>>¦]¬°¦¬®×ªº«~½è¦Ó¹ïÁ{§É¹ï¶Hªº¿z¿ï«D±`ÄY®æ¦Ó³y¦¨¦¬®×ªº½wºC... Ó¤H»{¬°...¬°½T«O·sÃĦ¨¥\...ÄY®æ¿z¿ïÁ{§É¹ï¶H¬O¥²¶·ªº... ------------------------------------------------------------------------------------ ȱo´Á«ÝªºQ2-Q3 ´Á¤¤¼Æ¾Ú..¥H¤Î«áÄò±ÂÅv/IPOµ¥µ¥ªº¶i®i... ¥H¤W~~¨Ñªø´Á§ë¸ê¾Ô¤Ḭ́ѦÒ~~~¤Å·í§@§ë¸ê¨Ì¾Ú~~·P®¦~~~~~~ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/4 ¤W¤È 11:45:38²Ä 517 ½g¦^À³
|
¤j¤á¤j ±zªºÆ[ÂI¤]¬O¤@ºØ¥i¯à ¤ß®®107 H1ªº¬y°Ê¸ê²£©|¾l 4.38»õ¥x¹ô ¨Ì·Ó¤ß®®ªá¿úªº³t«× ¨C¥b¦~ 0.9»õ¥x¹ô À³¥i¼µ¨ì109 ¤W¥b¦~µ²§ô ¦ý¬O½²±Ð±Â¦b106ªÑªF±`·| ´N¹w§i106¦~©³n¼W¸ê µM¦Ó¨ì²{¦b³£ÁÙ¨S±Ò°Êªº·N«ä ²{ª÷¬y¶qªº¬y¤J¬y¥X³Wµe Á`n¦³¤@Ó¦w¥þªº¾l¸Î °²¦p¬O§ÚÌ¥D¬F ¨Ì§Ú̲{¦b©Ò¨£ªº±¡ªp ¦´N¸Ó¶i¦æ¼W¸ê¤F ¤£¹L§Ṳ́£¬O½²±Ð±Â §Ú̬ݤ£¨ì½²±Ð±Â©Ò¬Ý¨ì¤½¥qªº±ÂÅv½Í§P¶i«× ¤£ª¾¹DÁ{§Éªº¼Æ¾Ú (´N¦p¤p§Ì¬Q¤é©Ò»¡ªº---¨â²Õ¦XpªºÁ`¤ÏÀ³²v ) ³o¨Ç©Î³\³£¼vÅTµÛ½²±Ð±Âªº¨Mµ¦ »¡¤£©w ±ÂÅv½Í§P¶i«×¤wªñ¦¨¼ô ©Ò¥H¤£¼W¸ê ¤S®³¬Q¤Ñ¼ÒÀÀªº¼Æ¾Ú TRR(%)¡KER (%) ¡KCR (%) ¡KER/CR ¡K¹LÃö©Ò»ÝÁ`¼Ë¥»¼Æ (PÈ < 0.05 ) ¡K..12.5¡K...15¡K¡K.10¡K¡K¡K¡K1.5¡K¡K¡K¡K. > 1374 ¡K..15¡K¡K...20¡K¡K.10¡K¡K¡K¡K..2¡K¡K¡K¡K..450 ¡K..20¡K¡K...30¡K¡K.10¡K¡K¡K¡K..3¡K¡K¡K¡K..150 ¡K..25¡K¡K...40¡K¡K.10¡K¡K¡K¡K..4¡K¡K¡K¡K..90 ¡K..30¡K¡K...50¡K¡K.10¡K¡K¡K¡K..5¡K¡K¡K¡K..60 ¹ï·Ó²Õªº¤ÏÀ³²v¦b10%ªþªñ¬O«Ü¦³¥i¯àªº ©Ò¥HÁ`¤ÏÀ³²v¦b20% , 25% , 30% ¨ä¹LÃöªº³Ì§CÁ`¼Ë¥»¼Æ ¤À§O¬° 150 , 90 , 60 ½²±Ð±Â©Ò¬Ý¨ìªºÁ`¤ÏÀ³²v »¡¤£©wÅý½²±Ð±Â§PÂ_²{¦bªº¦¬®×¤H¼Æ¤w¸g°÷¤F? ·íÁ`¤ÏÀ³²v¶V°ª ¶V¦³¥¿±´£¦¦¬¤uªº¥i¯à©Ê «e¨Ç®ÉÔ ¤p§Ì¤]¦³¼ÒÀÀ»¡ ¦w¥þ«Y¼Æ > 6 ³o´NÁô§tµÛ ¥¿±´£¦¦¬¤uªº¥i¯à ³o©Î³\©M±ÂÅv¤S¦³¥¿¬ÛÃö ¤p§Ìªº¤ÀªRÁö¦³ÅÞ¿è©Ê ¦ý²×¨s¤´¬O²q´ú °²¦pÅý§Ú̪¾¹DÁ`¤ÏÀ³²v ¬Û«H¤ÀªR·|§ó¶Kªñ¨Æ¹ê ÁÙ¬O¦Ñ¸Ü¤@¥y ¥H¤W»¡ªk¤Á¤Å§@¬°±z§ë¸êªº¨Ì¾Ú ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2019/3/4 ¤W¤È 10:22:02²Ä 516 ½g¦^À³
|
¦¬®×¶i«×¬O½²±Ð±Â¦b¥D±± , ÀHµÛ¸êª÷°µ¾ãÅé¦Ò¶q½Õ¾ã¡¦ ²q·Q¤j±zªº·N«ä¬O²{¦b¦]¬°¸êª÷¤£°÷,©Ò¥H¦¬®×©ñºC? §ÚÓ¤H¬Oı±o¦]¬°½²±Ð±Â¦]¬°¦¬®×ªº«~½è¦Ó¹ïÁ{§É¹ï¶Hªº¿z¿ï«D±`ÄY®æ¦Ó³y¦¨¦¬®×ªº½wºC¡D |
|
|
·|û¡G¤p¨È10135608 µoªí®É¶¡:2019/3/3 ¤U¤È 08:13:02²Ä 515 ½g¦^À³
|
²q·Q¤j¡G¯u¨ØªA§AºëÅPªº¤ÀªR¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/3 ¤U¤È 07:53:03²Ä 514 ½g¦^À³
|
¤j¤á¤jªº«äºû , ¶Kªñ¤@¯ë¥«³õªº·Qªk , ©Ò¥H2018ªÑªF±`·|·í¤é¤j¾_Àú , ÀH«á½L¶^ , ¦]¥ý«eº¦´T¹O¿ ³o¦¸2019ªÑÁ{·|·í¤é¤]¬O¤U¶^ , µM«á©O? ¤pªº¦³¤@Ó¤£¦Pªº·Qªk , ©h¥BºÙ¬°---è¤H»¡¹Ú¨g·Q¦± . Ó¤Hı±o ¦¬®×¶i«×¬O½²±Ð±Â¦b¥D±± , ÀHµÛ¸êª÷°µ¾ãÅé¦Ò¶q½Õ¾ã . ¥»¨Ó³oÓ¸ê®Æ¤p§Ì¬O¤£·Q¤½¶}ªº , ¤@¨Ó²Ê²¤ , ¤G¨Ó©È¼vÅTªB¤Í ³oÓ¸ê®Æ¬O¥Î¥d¤èÀËÅç¼ÒÀÀªº : ER : ¹êÅç²Õ¤ÏÀ³²v CR : ¹ï·Ó²Õ¤ÏÀ³²v TRR : ¨â²Õ¦X°_¨ÓªºÁ`¤ÏÀ³²v[=(ER+CR)/2] , Âùª¼¶¥¬qÀ³¤]¬Ý±o¨ìªº¼Æ¾Ú? TRR(%)¡KER (%) ¡KCR (%) ¡KER/CR ¡K¹LÃö©Ò»ÝÁ`¼Ë¥»¼Æ (PÈ < 0.05 ) ¡K..7.5¡K¡K..10¡K¡K..5¡K¡K¡K¡K..2¡K¡K¡K¡K.1000 ¡K..10¡K¡K...15¡K¡K..5¡K¡K¡K¡K..3¡K¡K¡K¡K..348 ¡K..12.5¡K...20¡K¡K..5¡K¡K¡K¡K..4¡K¡K¡K¡K..195 ¡K..15¡K¡K...25¡K¡K..5¡K¡K¡K¡K..5¡K¡K¡K¡K..130 ¡K..17.5¡K...30¡K¡K..5¡K¡K¡K¡K..6¡K¡K¡K¡K..110 ¡K..22.5¡K...40¡K¡K..5¡K¡K¡K¡K..8¡K¡K¡K¡K..50 ¡K..12.5¡K...15¡K¡K.10¡K¡K¡K¡K1.5¡K¡K¡K¡K. > 1374 ¡K..15¡K¡K...20¡K¡K.10¡K¡K¡K¡K..2¡K¡K¡K¡K..450 ¡K..20¡K¡K...30¡K¡K.10¡K¡K¡K¡K..3¡K¡K¡K¡K..150 ¡K..25¡K¡K...40¡K¡K.10¡K¡K¡K¡K..4¡K¡K¡K¡K..90 ¡K..30¡K¡K...50¡K¡K.10¡K¡K¡K¡K..5¡K¡K¡K¡K..60 ¡K..17.5¡K...20¡K¡K.15¡K¡K¡K¡K..1.33¡K¡K.. > 1374 ¡K..20¡K¡K...25¡K¡K.15¡K¡K¡K¡K..1.67¡K¡K..600 ¡K..22.5¡K...30¡K¡K.15¡K¡K¡K¡K..2¡K¡K¡K¡K..300 ¡K..25¡K¡K...35¡K¡K.15¡K¡K¡K¡K..2.33¡K¡K..190 ¡K..27.5¡K...40¡K¡K.15¡K¡K¡K¡K..2.67¡K¡K..140 ¡K..30¡K¡K...45¡K¡K.15¡K¡K¡K¡K..3¡K¡K¡K¡K..100 ¡K..22.5¡K...25¡K¡K.20¡K¡K¡K¡K..1.25¡K¡K.. > 1374 ¡K..25¡K¡K...30¡K¡K.20¡K¡K¡K¡K..1.50¡K¡K...650 ¡K..27.5¡K...35¡K¡K.20¡K¡K¡K¡K..1.75¡K.¡K..320 ¡K..30¡K¡K...40¡K¡K.20¡K¡K¡K¡K..2.00¡K.¡K..200 ¡K..32.5¡K...45¡K¡K.20¡K¡K¡K¡K..2.25¡K.¡K..130 ¡K..35¡K¡K...50¡K¡K.20¡K¡K¡K¡K..2.50¡K¡K...100 ¡K..40¡K¡K...50¡K¡K.30¡K¡K¡K¡K..1.67¡K¡K...200 Á`¤ÏÀ³²v¦Ü¤Ö¦b´Á¤¤¤ÀªR´N·|ª¾¹D , ©Î³\²{¦b¤]ª¾¹D , ¥u¬O½²±Ð±Â¿ï¾Ü¤£¤½¶} ¬°¤F©ö©ó§PÂ_ , §Ú̱NÁ`¤ÏÀ³²v¬Û¦Pªº©ñ¦b¤@°_¤ñ¸û TRR(%)¡KER (%) ¡KCR (%) ¡KER/CR ¡K¹LÃö©Ò»ÝÁ`¼Ë¥»¼Æ (PÈ < 0.05 ) ¡K..7.5¡K¡K..10¡K¡K..5¡K¡K¡K¡K..2¡K¡K¡K¡K.1000 ¡K..10¡K¡K...15¡K¡K..5¡K¡K¡K¡K..3¡K¡K¡K¡K..348 ¡K..12.5¡K...20¡K¡K..5¡K¡K¡K¡K..4¡K¡K¡K¡K..195 ¡K..12.5¡K...15¡K¡K.10¡K¡K¡K¡K1.5¡K¡K¡K¡K. > 1374 ¡K..15¡K¡K...25¡K¡K..5¡K¡K¡K¡K..5¡K¡K¡K¡K..130 ¡K..15¡K¡K...20¡K¡K.10¡K¡K¡K¡K..2¡K¡K¡K¡K..450 ¡K..17.5¡K...30¡K¡K..5¡K¡K¡K¡K..6¡K¡K¡K¡K..110 ¡K..17.5¡K...20¡K¡K.15¡K¡K¡K¡K..1.33¡K¡K.. > 1374 ¡K..20¡K¡K...30¡K¡K.10¡K¡K¡K¡K..3¡K¡K¡K¡K..150 ¡K..20¡K¡K...25¡K¡K.15¡K¡K¡K¡K..1.67¡K¡K..600 ¡K..22.5¡K...40¡K¡K..5¡K¡K¡K¡K..8¡K¡K¡K¡K..50 ¡K..22.5¡K...30¡K¡K.15¡K¡K¡K¡K..2¡K¡K¡K¡K..300 ¡K..22.5¡K...25¡K¡K.20¡K¡K¡K¡K..1.25¡K¡K.. > 1374 ¡K..25¡K¡K...40¡K¡K.10¡K¡K¡K¡K..4¡K¡K¡K¡K..90 ¡K..25¡K¡K...35¡K¡K.15¡K¡K¡K¡K..2.33¡K¡K..190 ¡K..25¡K¡K...30¡K¡K.20¡K¡K¡K¡K..1.50¡K¡K...650 ¡K..27.5¡K...40¡K¡K.15¡K¡K¡K¡K..2.67¡K¡K..140 ¡K..27.5¡K...35¡K¡K.20¡K¡K¡K¡K..1.75¡K.¡K..320 ¡K..30¡K¡K...50¡K¡K.10¡K¡K¡K¡K..5¡K¡K¡K¡K..60 ¡K..30¡K¡K...45¡K¡K.15¡K¡K¡K¡K..3¡K¡K¡K¡K..100 ¡K..30¡K¡K...40¡K¡K.20¡K¡K¡K¡K..2.00¡K.¡K..200 ¡K..32.5¡K...45¡K¡K.20¡K¡K¡K¡K..2.25¡K.¡K..130 ¡K..35¡K¡K...50¡K¡K.20¡K¡K¡K¡K..2.50¡K¡K...100 ¡K..40¡K¡K...50¡K¡K.30¡K¡K¡K¡K..1.67¡K¡K...200 Ó¤H¹ê¦b¤£§Æ±æ±N¹ï·Ó²Õ¤ÏÀ³²v(CR)>20%®³¨Ó¤ÀªR ½²±Ð±Â¤£¬OÁ|¤F¤@Ó¤£«ç»ò«ê·í¦ý¤S¶K¤Áªº¤ñ³ë¶Ü ¨âÓ¤kªB¤Í , ¤@Ó±`¨£± , ¥t¤@Ó¸ûªø®É¶¡¤~¨£± , ¨Ó»¡©úSPCD¸ÕÅ窺¦w¼¢¾¯®ÄÀ³ ¤]´N¬O»¡ , Âùª¼ÀH¾÷¶¥¬qªº±wªÌ , ³£¬O¨Ó¦Ûrun-in ¶¥¬qªA¥Î¦w¼¢¾¯ªº¤£¤ÏÀ³ªÌ(PANSS§ïµ½´T«×¥¼¹F20%ªÌ) ³o¨Ç¥H«eªA¥Î¦w¼¢¾¯´N¤£¤ÏÀ³ªº±wªÌ , ¦bÂùª¼ÀH¾÷¶¥¬q , Y¦AªA¥Î¦w¼¢¾¯, ·|Åܦ¨¤ÏÀ³ªÌ¶Ü? À³¸Ó¤£°ª§a ¦ý³o¨Ç±wªÌY¦bÂùª¼ÀH¾÷¶¥¬q , §ïªANaBen , °£¤FNaBenªºÃĮĥ~ , ¥i¯àÁÙ·|¦³©M¤§«eªA¥Î¦w¼¢¾¯¤£¤@¼Ëªº·P¨ü²£¥Í? ³oÀ³¬O½²±Ð±Â¨âÓ¤kªB¤ÍªºÂA¬¡¤ñ³ëªººë¯« ©Ò¥H , ¹ï·Ó²Õªº¤ÏÀ³²v20% , ©Î¥i©¿²¤¤£¬Ý °²¦p¹ï·Ó²Õªº¤ÏÀ³²v¤j©óµ¥©ó20%ªº¤£¬Ý , ¨º»ò Á`¤ÏÀ³²vY¦b25%(§t)¥H¤W , «hÁ`¼Ë¥»¼Æ©Î¥i¦b200¥H¤U Ó¤H¬O¶É¦V©ó¥Î¹ï·Ó²Õ¤ÏÀ³²v(CR)=10%¨Ó¤ÀªR ¤]´N¬O³o²Õ¼ÒÀÀ ¡K..12.5¡K...15¡K¡K.10¡K¡K¡K¡K1.5¡K¡K¡K¡K. > 1374 ¡K..15¡K¡K...20¡K¡K.10¡K¡K¡K¡K..2¡K¡K¡K¡K..450 ¡K..20¡K¡K...30¡K¡K.10¡K¡K¡K¡K..3¡K¡K¡K¡K..150 ¡K..25¡K¡K...40¡K¡K.10¡K¡K¡K¡K..4¡K¡K¡K¡K..90 ¡K..30¡K¡K...50¡K¡K.10¡K¡K¡K¡K..5¡K¡K¡K¡K..60 °²Y¬O³o¼Ë ©Î³\¨º¤Ñ¬ð³QDSMB¡]data and safety monitoring board¡F¸ê®Æ¤Î¦w¥þºÊ´ú©eû·|¡^³qª¾¦¬¤u , ´N¦p¦P½÷·çªºCDK 4/6§í¨î¾¯Ibrance ¤@¼Ë , ©Î³\¤]¤£·|ı±o³Y²§? ½²±Ð±Â¦³ÄYÂÔªº¤ÀªR¤èªk §ÚÌ°µ§ë¸ê§PÂ_ªº´N¥u¯à¥Î²Ê²¤ªº¤è¦¡¨Ó¼ÒÀÀ , ¼ÖÆ[©Î«O¦u·íµM¦s¥G±z§ÚÓ¤Hªº®³®º ¤p§Ì¤]¥u¯àÄYµÂªº»¡ , ¥H¤W¼ÒÀÀ±À´ú©ÎÂ÷¨Æ¹ê¬Æ»· , ¤Á¤Å§@¬°±z§ë¸êªº¨Ì¾Ú ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡Gseniorbbs10144999 µoªí®É¶¡:2019/3/3 ¤U¤È 06:05:46²Ä 513 ½g¦^À³
|
¤£·|º¦ªºì¦] 1.¨S¦³ÃD§÷ 2.ÀsÀYªÑ--¤¤¸Îªº¾P°âª¬ªp¤]¤£¦n Y¬O³W¹º¥xÆW¤W¥«ÂdÀ³¸Ó´N¬O¨«IPOÄw¸ê¡An¶Ò±o¤ñ¸û¦hªº¸êª÷ªÑ»ù¶Õ¥²n°ª¡A©Ò¥HÀ³¸Ó·|¦³ÃD§÷ª£§@ªÑ»ù¤~¹ï¡C³Ì±ß©ú¦~À³¸Ó´N·|¬Ý¨ì¤F.... |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2019/3/3 ¤U¤È 01:43:46²Ä 512 ½g¦^À³
|
²{¦bªÑ»ù§C°g¥Dnªºì¦]À³¸Ó¬O ¦¬®×³t«×ªº½wºC. SND-13¦¬®×±µªñ¨â¦~,n¨ì¤µ¦~ªº²Ä¤T©u¤~°µ¨ä¤¤¤ÀªR, ¥Nªín¨ì²Ä¤T©uªº¦¬®×¤~¦³170´X¤H.¦pªG¨ì®É¤Sn¼W¥[¦¬®×¤H¼Æ,¨º½Ð°Ý³o¤£¬On¦Ü¤Ö¦Aµ¥¤T¦~¥H¤W¤~·|¦³µ²ªG¡H |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/3 ¤W¤È 09:30:43²Ä 511 ½g¦^À³
|
¤p¨È¤jªº³o¬q¸Ü [ ¤½¥q¦pªG¥H±ÂÅvÃÄ«~±M§Qªº¤è¦¡¨Ó¨ú±o¥Ø«e©Ò»Ý¸êª÷¡A¬O³Ì§Ö³t¤]¬O³Ì·ÓÅUªÑªFÅv¯qªº³~®| ] Åý¤p§Ì·Q°_½²±Ð±Â·|¤¤¦bÁ¿z±ÂÅv®É¤@¬q@¤H´M¨ýªº¸Ü ±ÂÅvªºÁ`ª÷ÃB«Ü¤j ¦ý¬Oñ¬ùª÷¥u¦³¤@ÂI , ³o¨Ã¤£¯àº¡¨¬·í«e¤½¥q¸êª÷ªº»Ý¨Dª¬ªp ±z¬O§_»{¬° , ³o¬OY¤zÃļt¶}¥Xªº±ø¥ó¦ÓÅý½²±Ð±Â«H¤â©à¨Óªº¤@Ó¨Ò¤l??? ÁÙ¬O§Ú·Q¤Ó¦h , ·Q¨ì¦Û¤vµØ¾v³B³B ¤j®a¦h«Ü²H©wÀRÀq , ½Ðì½Ì¤pªº¤@¦A¤j¼L¤Ú¨¥¤£¤Î¸q ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¤p¨È10135608 µoªí®É¶¡:2019/3/2 ¤U¤È 10:03:26²Ä 510 ½g¦^À³
|
¤ß¤ÍÌ¡G¦h¦~¸gÅ穾§i§Ú¡A³ß®®È±oµ¥«Ý¡A¨I¤£¦í®ð¶]µu缐¡A«Ü¦³¥i¯à¿ù¥¢¨}¾÷¡C |
|
|
·|û¡G¤p¨È10135608 µoªí®É¶¡:2019/3/2 ¤U¤È 09:55:10²Ä 509 ½g¦^À³
|
Ó¤H»{¬°¤½¥q¦³¦h¶µ¤T´Á·sÃÄ¥¿µ¥«Ýµu¡B¤¤¡Bªø´Á°õ¦æÁ{§É¸ÕÅç¡AÄw±¹¸êª÷¬O·í«en°È¡A·sÃĤT´ÁÁ{§É©Ò»Ý¸g¶O¡A¤@¯ë·sÃÄ°_½X±on85»õ¡A©t¨àÃĶȻÝ15»õ°_¡A¦¨¥»¬Û¥h¬Æ»·¡A¤½¥q¦pªG¥H±ÂÅvÃÄ«~±M§Qªº¤è¦¡¨Ó¨ú±o¥Ø«e©Ò»Ý¸êª÷¡A¬O³Ì§Ö³t¤]¬O³Ì·ÓÅUªÑªFÅv¯qªº³~³w¡A¦³³oµ§¸êª÷Ѻª`Á{§É¸ÕÅç©Ò»Ý¡Aµ¥«Ý¶i«×Àò±o¨}¦nµ²ªG¡A¦A±µÄò¥Ó½ÐIPO¤W¥«Âd¡Bµo¦æ¼W¸êªÑ¡AÄw±o¤¤Ä~¸êª÷¡A¦A±µ¦AÀy½Ä¨ë¥¦¶µ¤G¡B¤T´ÁÁ{§É¡A³v³À°ê»Ú·sÃÄ¥«³õ¡C |
|
|
·|û¡Gseniorbbs10144999 µoªí®É¶¡:2019/3/2 ¤U¤È 09:54:37²Ä 508 ½g¦^À³
|
¥u¦³®t¥|Ӥ뤽¥q¬°¤°»ò¨º»ò«æ©O?¦X²zªº§PÂ_À³¸Ó¬O±ÂÅv®×¤w¸g´X¥G¤jP©è©w............ |
|
|
·|û¡G¤p¨È10135608 µoªí®É¶¡:2019/3/2 ¤U¤È 08:49:35²Ä 507 ½g¦^À³
|
²q·Q¤j¡GÁÂÁ§A¶}¤Fª÷¤f¡A¹D¥X¥l¶}Á{®É·|¥Dnªº¥Î·N¡A§Ú¥»¨Æ¤£°÷¡A¤£´±»¥¨¥²q´ú¡A¦ý¤]¦p¦P§A©Ò²q´ú¤@¼Ë¡A¥u¬O´e¦b¤ß𥚃¦Û§Ú·Pı¶}¤ß¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/2 ¤U¤È 07:32:04²Ä 506 ½g¦^À³
|
¬ü¤j ±zªºÅU¼{ , ½²±Ð±Â¤]ª¾¹D³o¨ÇºÞ¨î , ÁÙ»¡©È¸êª÷·|¶×¤£¥X¨Ó ¥L¤]ª¾¹D¥Ø«e¤ß®®ªºª¬ªp , ©|¥¼²Å¦X¬ü°ê»´äªº¤W¥«±ø¥ó ©Ò¥H¥L¤]»¡ , ¥H¦b¥xÆW¤W¥«Âdªº¾÷·|©~«e ·|¤¤¥LÁÙ¤ÀªR , ¥x¬ü´äºªº¥«ªp©M§ë¸êªÌªk¤H¦ÛµM¤H¤Î¸êª÷¨Ó·½ªº¦û¤ñ ¬Û«H½²±Ð±Â·|¦b¦UºØ±ø¥ó¤Î¸êª÷»Ý¨Dªº½w«æùØ°µ¤@Ó¿ï¾Ü Ó¤H·Pı , ¤ß®®¦b¥xÆW¤W¥«Âdªº¾÷·|º¡¤jªº µ¥¸êª÷¨ì¦ì(µL½×±ÂÅv©Î¨ä¥L¤è¦¡ªº¼W¸ê) , §Ú·Q¤ß®®Á{§É´N·|°_¸¤F?! ¤ß®®¦]¸êª÷¦]¯À , ´XÓ3´ÁÁ{§É³£¼È®É¥´¦í ªÑªF±`·|»¡nªº¼W¸ê , ª½¨ì²{¦b³£ÁÙ¥¼¦³°Ê§@ ¤]¦³ªÑªF´£°Ý , ±ÂÅvµ¹ SyneuRx Neuroscience , ¬°¦ó¤£µ¥¨ì2019ªºªÑªF±`·| , ¦Ó´£«e4Ó¤ë¥l¶}ªÑÁ{·|? ¤£¹L½²±Ð±Â¨Sª½±µ¨¥©ú , ¥u»¡·íµM¶V§Ö¶V¦n Ãø¹D¬On§Ú̲q´ú±ÂÅv®×¤wªñ¦¨¼ô¤F??? ²q´úªº¶¢²á ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GªY½à¼Æ¦r¬ü10147157 µoªí®É¶¡:2019/3/2 ¤U¤È 06:41:00²Ä 505 ½g¦^À³
|
¤¤°ê¬OÓÄY®æ¥~¶×ºÞ¨îªº°ê®a 2016¦~«e¦b¦X®æ¹Ò¥~¾÷ºc§ë¸êªÌ¹Ò¤ºÃÒ¨é§ë¸êºÞ²z¼È¦æ¿ìªk¤¤ ¦³©Ò¿×ªº¶×¥X¤ñ¨Ò¨î(¤]´N¬O¥~¶×ºÞ¨î) 2016¦~¦Ü2018¦~¤~ÃP¸j ¨ú®ø¶×¥X¤ñ¨Ò¨î©M¨ú®ø¦³ÃöÂê©w´Án¨D ¦Ü©óÓ¤H¤è± Ó¤HÁʶצ³¹ê¦æ¦~«×Á`ÃBºÞ²z¡A¦~«×Á`ÃB¥Ø«e¤À别¬°¨C¤H¨C¦~µ¥È5¸U¬ü¤¸ ºÞ²z¼h¦pªGn¦bº(¬ì³Ðª©)IPOn¦n¦nªº·Q¤@·Q ³oºØ¥~¶×ºÞ¨îµ{«×¡A¿ú¶i¥h¤F¬O¤£¬O®e©ö¥X±o¨Ó »´ä¥¼¨Ó¤]¥i¯à³Qµø¬°¸êª÷°k¥Xªºº|¬} ¦³¤°»ò¤£§Qªº·s¬Fµ¦¹ê¬I¤]¤£·N¥~ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/2 ¤U¤È 03:23:56²Ä 504 ½g¦^À³
|
¤ÀªR®v¡G¤µ¦~80¦Ü90®a¥ø·~µn³°¬ì³ÐªO 2019-03-02 14:21Áp¦X³ø °OªÌ§õ¥òºû¢¬§Y®É³ø¾É 2¤ë28¤éµ²§ô¼x¨D·N¨£¡A¤j³°ÃҺʷ|¤µ¤Ñâ±á¤õ³tµo¥¬¬ì³ÐªO¸ÕÂIµù¥U¨î³W«h¡AIPO¨ü²z§Y±N±Ò°Ê¡A°êª÷ÃҨ麮uµ¦²¤¤ÀªR®v§õ¥ß®pªí¥Ü¡A«ö·Ó³oÓ³t«×¡A¹wp¬ì³ÐªO³Ì§Ö7¤ë1¤é¹B§@±Ò°Ê¡Aº§å20¦Ü25®a¥ª¥k¡A¤µ¦~¥þ¦~µo¦æ80¦Ü90®a¥ª¥k¡C §õ¥ß®p»{¬°¡Aº§åµo¦æ¥Dn¶°¤¤¦b¤T¤jÃþ¦æ·~¡G°ªºÝ»s³y¡B¥b¾ÉÅé¡BÂåÃÄ¡C«ö·Ó¨C®a¿Ä¸êÃB¤H¥Á¹ô3.5»õ¤¸´úºâ¡A¥þ¦~IPO¿Ä¸êÃB¤H¥Á¹ô300»õ¤¸¥ª¥k¡C ³]¥ß¬ì³ÐªO¨Ã¸ÕÂIµù¥U¨î³W«h www.sse.com.cn/lawandrules/sserules/tib/ ¤W®ü证¨é¥æ©ö©Ò¬ì创ªOªÑ²¼发¦æ¤W¥«审®Ö规则 www.sse.com.cn/lawandrules/sserules/tib/review/a/20190302/a9be0ddb9baed2b57e35f436b4b752d4.pdf |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/3/2 ¤W¤È 11:15:33²Ä 503 ½g¦^À³
|
20190227¤ß®®ªÑªFÁ{®É·|«ÂI . ³q¹L±ÂÅv©M¸Ñ°£Äv·~¸T¤î¨î ¥Ñ½²±Ð±Âªº¤@®u¸Ü , ¥i¥H²`²`ªº»â·| , ½²±Ð±Â¤£¶ÈÂå¾Ç»â°ì±M·~»â¥ý·~¬É(¾Ç¬É»â¥ý·~¬É¤Q¦~) , ¹ï©óÂåÃÄ¥«³õ©M¸ê¥»¥«³õªº¹B§@¤]¦p¼Æ®a¬Ã , ª¾¤§¬Æ¸Ô ¥H¤U¬O½²±Ð±Â·|«á½Í¸Üªº«ÂIºKn : . SND-13¹wpQ3´Á¤¤¤ÀªR , ¤£¹L½²±Ð±Â¤]n¤j®a§O¤Ó°ª¿³ , ´Á¤¤¤ÀªR¨Ã¤£¬O¸Ñª¼ , ¦®¦bµû¦ôn¤£n¼W¥[¦¬®×¤H¼Æ ; Ó¤Hı±o½²±Ð±Â¥i¯à¹îı³o¼Ëªº»¡ªk©Î·|¤Þµo¤j®a¹L«×¼ÖÆ[ªº¹w´Á , ²¦³º¨S¦³¦nªº¼Æ¾Ú , ¸Ñª¼¨º¦³°ª¿³¥i¨¥ , ©Ò¥H¤SÁ¿zÁ{§É«áÄò¥i¯àªºµ{§Ç¥H¬°¥¿Å ªþµù : ²{¦b©Î³\ª¾¹DÁ`¤ÏÀ³²v , ¨º´N¬O½²±Ð±Â¦b¸ÑÄÀSPCDªº¸ÕÅç³]p , ¹êÅç²Õªº¤ÏÀ³²v¥i¯à±q50% °¬°30% , ¹ï·Ó²Õªº¤ÏÀ³²v©Î±q30% °¬°10% , ¨º»ò , ¨â²Õªº¤ÏÀ³²v¤ñȱN¥Ñ¶Ç²ÎPD³]pªº1.67 (50%/30%)¸õ¤É¬°SPCD³]pªº 3 ( 30%/10%) , ¤ÏÀ³²v¤ñȪº©Ô¶}¥NªíµÛ¨â²ÕÀø®Äªº®t¶ZÅܤj ¡C ¤p§Ì¹Á¸Õ¥Î348¤H¨Ó²Ê²¤¼ÒÀÀ¥d¤èÀËÅç , ±o¨ì¶Ç²ÎPD³]pªºPȬù¬°0.000128 (¤ÏÀ³²v¤ñÈ 1.67 , ¼Ë¥»¼Æ 348 ) , Y¬°SPCD³]p , PȬù¬°0.00085 (¤ÏÀ³²v¤ñÈ 3 , ¼Ë¥»¼Æ 182 (=348*3/4*0.7) , ¨âªÌPȬÛY , µM¹ù¥S¦b¥Lªº¤j§@¤¤ (liawbf.pixnet.net/blog/post/47542314 ) ´£¨ì¥L¬Ý¹Lªº¾ÇªÌ¬ã¨s , ¨Ï¥ÎSPCD , ®ÄªG¶q¥i¥H´£¤É 2 ~ 3 ¦¨ , ²Îp¦ÒÅç¤O¥i¥H¼W¥[ 1 ~ 5 ¦¨ . Y±N¼Ë¥»¼Æ¥Î³Ì¤jÈ(1374)¨Ó¼ÒÀÀ®É , ±o¨ì¶Ç²ÎPD³]pªºPȬù¬° 4.5 E -14 (¤ÏÀ³²v¤ñÈ 1.67 , ¼Ë¥»¼Æ 1374 ) , Y¬°SPCD³]p , PȬù¬° 2.16 E -11 (¤ÏÀ³²v¤ñÈ 3 , ¼Ë¥»¼Æ 721 (=1374*3/4*0.7) , ¥i¨£¼Ë¥»¼Æ¹ïPȪº¼vÅT¬Æ²` , ¨âªÌPÈÁö®t¤d¿ , ¦ý¹ï³oºØ¶W¤pPÈ , ¤@¼Ë³£¬O¼g¦¨ p < 0.00001 ( ¼ÒÀÀ©Ò¥Îªº°Ñ¼Æ¥²©w»P¹ê»Úªº¼ÆȦ³©Ò¥X¤J , ¤Á¤Å§@¬°§ë¸ê¨Ì¾Ú ) . SND-5 , SNA-1 pµe Q2 ~ Q3 °e¥ó¥Ó½Ð¤G´ÁÁ{§É , ¨ä¤¤SND-5¬O¤¤¡B¬ü¨â¦a¦P®É°e¥ó . SNG-12 ²Ä¤T´ÁÁ{§É¸ÕÅç±N¼W¥[²Ä¤@Ó¬P´Áªºµû¦ô®ÉÂI . SND-5 ªº°Êª«¼Ò«¬ ¬Ò¤ñ SND-1ªÌ ¦n«Ü¦h . ¶W¯Å¥é»sÃÄSNS¨t¦C¬O«ü°w¹ï¤w¨ì´Áªº¤¤¼Ï¯«¸g¨t²Î¯e¯fÃĪ«ªºAPI (¬¡©ÊÃĪ«¦¨¤À) , ²K¥[¦³À°§Uªº»²®Æ©Ò§Î¦¨ªºÃĪ« , ³z¹L¤ß®®ªº§Þ³N¥¥x , §ïµ½¸Óµ¥ÃĪ«§l¦¬©Î´£°ªÀø®Ä©Î°§C°Æ§@¥Î , ½²±Ð±Â»¡³o¬O«D±`¦³»ùȪº§Þ³N . IPO¤´¦bµû¦ô¤¤ , ¥x¡B¬ü¡B´ä¡Bº (¬ì³Ðª©)¬Ò¦b¦Ò¼{ , ¥xÆWªº¾÷·|©Î¦b«e± . ¶Ò¸ê¥H¦h±¦V¬°¤§ --- ¼W¸ê¡B IPO ©Î±ÂÅv . ±ÂÅv½Í§P¶i¦æ¤¤ , ¥ô¦ó²£«~³£¦³¥i¯à±ÂÅv , Ó¤H¥H¬°Y±ÂÅv©³©w , ¤ß®®ªºÁ{§É¶i«×±N·|¬ð¸²r¶i ¥H¤WºKn , Y¦³²¨º| ¡B»~¶Ç ¡B»~¸ÑªÌ , ¦³½Ð¤j®a¸É¥R«ü¥¿ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/2/28 ¤U¤È 07:02:57²Ä 502 ½g¦^À³
|
½²±Ð±Â¤Ò¤Hªº«¢¦ò³Õ¤h½×¤å healthpolicy.fas.harvard.edu/people/vivian-wu ¾Ç¦ì½×¤åÃD¥Ø¡G ¡§ºÞ²z¦¡ÂåÀø»P20¥@¬ö90¦~¥N¤£Â_ÅܤƪºÂå°|²£·~¡¨ ²Ä¤@³¹±´°Q¤FºÞ²z¦¡ÂåÀøp¹º»PÂå°|¶i¦æ»ù®æ½Í§PªºÃÒ¾Ú¡CºÞ²z¦¡ÂåÀøp¹º¤¤Æ[¹î¨ìªº¸û§C»ù®æ¥i¯à»P¤TÓ°²³]¤@P¡G¡]1¡^¦¨¥»®t²§¡A¦]¬°¤@¨Çp¹º¨Ï¥Î¦¨¥»¸û§CªºÂå°|©Î¨ä±wªÌ¦bÂå°|¤ºÀò±o¤£¦Pµ{«×ªºÂåÀøªA°È; ¡]2¡^»ù®æª[µø¡A¨ã¦³¥«³õ¤O¶qªºÂå°|¹ï»Ý¨D¼u©Ê¸û¤jªºÁʶRªÌ¦¬¨ú¸û§Cªº»ù®æ; ¡]3¡^ºÞ²z¦¡ÂåÀøªA°Èªº»ù®æ½Í§P¡A»ù®æ¦]«OÀI¤½¥q¨ã¦³¤£¦Pµ{«×ªºÄ³»ù¯à¤O¦Ó¦³©Ò¤£¦P¡C¨Ï¥Î1994¦~¦Ü2000¦~´Á¶¡°¨ÂĽѶë¦{¹ê»ÚÂå°|»ù®æªº¿W¯S±ªO¼Æ¾Ú¶°¡A§Úµo²{¾¨ºÞ¦¨¥»®t²§©M»ù®æª[µø°²³]¸ÑÄÀ¤F¤ä¥Xªº¤@¨ÇÅܤơA ²Ä¤G³¹¤ÀªR¤FÂå°|¹ïÂåÀø«OÀI«¤j°]°È·l¥¢ªº©w»ù¦æ¬°¡C²{¦³ªº°²³]¨S¦³©ú½T¹w´ú³oºØ¾Ô²¤¦æ¬°¬O§_·|µo¥Í¡A©ÎªÌ¬O§_¦]©Ò¦³ÅvÃþ«¬¦Ó¤£¦P¡C¥»³¹¨Ï¥Î¤F¤@¶µ¦ÛµM¹êÅç - 1997¦~ªº¥¿Å¹wºâªk®×¡]BBA¡^¡A¨Ãµo²{¦bÄvª§§ó¿E¯Pªºªì©l¥«³õ¤¤ªºÂå°|³q¹L¦V¨p¤H«OÀI¤½¥q´£°ª»ù®æ¨Ó©è®ø¬ü¤¸ªºt¾á¡C¦¹¥~¡A³q¹L´£¨Ñ°Ó¾ã¦XÀò±o°Q»ùÁÙ»ùªºÂå°|¥H¤Î³q¹LºÞ²z¦¡ÂåÀøªA°È©ñ¼e´ë¹Dªº§V¤O¯à°÷¶i¤@¨B´£°ª»ù®æ¡C ²Ä¤T³¹¬ã¨s¤FÂå°|Ãö³¬¹ïÄvª§¹ï¤âªº»ù®æ¼vÅT¡C¦í°|ªA°Èªº»Ý¨D¦b¹L¥h¤G¤Q¦~¤¤¤@ª½¦b¤U°¡A¦P®É¦í°|¯f§É®e¶qµäÁY¬ù14¢H¡C³oºØ¯à¤O¤U°ªº«Ü¤j¤@³¡¤À¬O¥Ñ©óÂå°|Ãö³¬¡CÁöµMÂå°|Ãö³¬¦³§U©ó®ø°£¦h¾lªº³]¬I¡A¦ý¥¦Ì¤]´£°ª¤FƦsÂå°|ªº½Í§P¦a¦ì¡C¥»¤å¤ÀªR¤F1992¦~¦Ü1998¦~´Á¶¡Æ¦sªºÄvª§¹ï¤â¡Aµo²{¾aªñÃö³¬¦aÂIªºÂå°|¤ñ¥«³õ¤Wªº¨ä¥LÂå°|§ó¯à´£°ª¥L̪º½Í§P¦a¦ì¡C¦¹¥~¡A¸g¾ú¦h¦¸Ãö³¬ªº¦a°ÏªºÂå°|¯à°÷¹ê²{§ó¤jªº»ù®æ¼Wªø¡C (Google ½Ķ ) ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/2/28 ¤U¤È 02:28:40²Ä 501 ½g¦^À³
|
¶W¯Å¾Ç¦WÃÄ SNS¨t¦C , «Y³q¹L¤ß®®ªº§Þ³N¥¥x , §ïµ½¸Óµ¥¾Ç¦WÃĪºÃĪ«§l¦¬©Î´£°ªÀø®Ä©Î°§C°Æ§@¥Î ½²±Ð±Â»¡ «D±`¦³»ùÈ ¤w©óSeptember 4, 2018 Àò±o¬ü°ê±M§Q United States Patent 10,064,833 Compositions containing benzoate compound and tannic acid for treating central nervous system disorders ¤µ¤é USPTO¤S¤½¶}¸Ó±M§QªºÂX(¸É)¥Rª© United States Patent Application 20190060263 Kind Code A1 February 28, 2019 COMPOSITIONS CONTAINING BENZOATE COMPOUND AND TANNIC ACID FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS ¦³¿³½ìªºªB¤Í ½Ð¦Û¦æ«e©¹°Ñ¦Ò¤ñ¹ï ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/2/28 ¤W¤È 09:27:49²Ä 500 ½g¦^À³
|
½²±Ð±Â»¡ SND-5 ªº°Êª«¼Ò¦¡ ¤ñ SND-1 ¦n«Ü¦h ©Ò¥H ¤¤¬ü¦L¼Ú ³£¦³¥Ó½Ð WO/2017/167168 COMPOSITIONS CONTAINING TANNIC ACIDS AND USES THEREOF WO International Application No.: PCT/CN2017/078361 Publication Date: 05.10.2017 Compositions Containing Tannic Acids and Uses Thereof US Publication Date: 05.04.2018 COMPOSITIONS CONTAINING TANNIC ACIDS AND USES THEREOF IN Publication Date: 11.01.2019 COMPOSITIONS CONTAINING TANNIC ACIDS AND USES THEREOF EP Publication Date: 06.02.2019 ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G¤p´²¤á10147972 µoªí®É¶¡:2019/2/27 ¤U¤È 01:41:17²Ä 499 ½g¦^À³
|
¥i¯à¦³¨Ç¤Hµ¥¤£¤U¥h´N¥ý»{½ß½æ¥X¤F¡A¿ð¿ð¨S¦³®ø®§©Î¬O¶i«×¡C¤Ï¥¿¥H²{¦bªº»ù®æ¤jªÑªFÀH«K½æ³£ÁÈ¡C |
|
|
·|û¡GYendis10145808 µoªí®É¶¡:2019/2/27 ¤U¤È 12:27:00²Ä 498 ½g¦^À³
|
¥¢±æ©Ê½æÀ£.... |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/2/18 ¤W¤È 10:40:46²Ä 497 ½g¦^À³
|
»s¾¯¹Lµ{¤¤µo¥Í´¹«¬ÂàÅܪº·ÀI¦]¯À¥H¤Î¾÷¨î ¨Ó·½¡GÃÄ´ç ¡@2019-02-18 §@ªÌ¡Gmuzhang med.sina.com/article_detail_103_2_60791.html ¤p¤À¤lÃĪ«¤À¤l±Æ¦C¤è¦¡¤£¦P±q¦Ó¨ã¦³¤£¦Pªº´¹«¬¡C¤£¦Pªº´¹«¬²z¤Æ©Ê½è¨ã¦³®t²§¡A¥]¬A±K«×¡B·»¸Ñ«×¡B¥iÀ£©Ê¡B¬y°Ê©Ê¬Æ¦Ü¤Æ¾Çéw©Êµ¥¡C¤£ºÞ¬O·sÃĶ}µo¡AÁÙ¬O¥é»sÃĶ}µo¹Lµ{¤¤¡A¹ïÃĪ«´¹«¬ªº¦Ò¹î¬O¥²¤£¥i¤ÖªºÀô¸`¡C¬°¤F«OÃÒÃÄ«~¦b¥Í²£©MÀx¦s¹Lµ{¤¤½è¶q¥i±±¡A»Ýn¹ï»s¾¯¹Lµ{¤¤«e«áªºÃĪ«´¹«¬¶i¦æ¦Ò¹î¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/2/11 ¤W¤È 11:37:38²Ä 496 ½g¦^À³
|
ÁÂÁ¹ù¥S¤½¶} [ 108¦~·s¦~·s§Æ±æ : §Ú¹ïSND-7 ªº´Á«Ý ] liawbf.pixnet.net/blog/post/48772971 ªø½g½×¤å¯Åªº¤j§@ ±q¥NÁ¯gÔ¸s( MetS )³sµ² NMDAR , ¦A¨ìSND-7 ½×zÃøÀ´¨SÃö«Y , ¦hŪ´X¹M , ©Î³\´N·|¹³¤pªº¤@¼Ë , ±q©üÀYÂà¦V¨ì©ç¤â¥s¦n ¦A¦¸·PÁ¹ù¥Sªá¶O³o»ò¤j¤ß¤Oªº²±®b¤À¨É¤j®a Cliff¤j®¦¼w¤§«e¤]«Øij¤j®a[ ªÑ¥«¤£º¦½m¤º¥\ , ÃÛ¦n°¨¨Bµ¥®É¾÷ ] ´NÅý§ÚÌÃÛ¦n°¨¨Bµ¥Ô®É¾÷§a ! ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/27 ¤W¤È 11:28:57²Ä 495 ½g¦^À³
|
Àò±o¬ð¯}©ÊÀøªk»{©w¹ï¤@Ó·sÃĪº·N¸q¦³¦h¤j¡H ¨Ó·½¡GÂåÃÄÅ]¤è ¡@2019-01-27 §@ªÌ¡GApril Chen med.sina.com/article_detail_103_2_59892.html |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/25 ¤W¤È 10:50:58²Ä 494 ½g¦^À³
|
¬Ý¬Ý§O¤H«ç»ò»¡? «·Å BTD ¥þ¤è¦ì¸ÑŪ¬ð¯}©ÊÀøªk»{©w¡GÃĪ«§Ö³t¤W¥«¦³±¶®| ¨Ó·½¡GCPhI»sÃĦb½u¡@2019-01-25 §@ªÌ¡G³Vd Àò¬ð¯}©ÊÀøªk»{©w¦³þ¨Ç¦n³B¡H «Ü¦hÃÄ¥ø¤£±¤ªá¶O¤j¶q¦¨¥»©M¤H¤O§Æ±æ¦Û¤vªºÃĪ«Àò±o¬ð¯}©ÊÀøªk»{©w¡A¨º»ò¡AÀò±o¬ð¯}©ÊÀøªk»{©w¬O¬°¤Fþ¨Ç¦n³B©O¡H ±qªø»·¤@ÂI¨Ó»¡¡A³Ì¤jªº¦n³B¬O¼f§å¥[³t¡I¾Ú±x¡AÀò±o¬ð¯}©ÊÃĪ«»{ÃÒªºÃĪ«¶}µo¥i¥H±o¨ì¥]¬AFDA©xû¦b¤ºªº§ó¥[±K¤Áªº«ü¾É¡A¤]´N¬O»¡¬ð¯}©ÊÀøªk»{©w¥i¥HÅý¥ø·~»P¬F©²¤§¶¡ªº·¾³q§ó¬°ºò±K¡A¦]¦¹¥i¥H«O»Ù¦b³Ìµu®É¶¡¤ºÀò±o¬ÛÀ³¼f§å¡C ±qªñ¤@ÂI¨Ó»¡¡A¥Ñ©óÀò±o¬ð¯}©ÊÀøªk»{©w¥i¥H³Q·í§@¬ÛÀ³ÃĪ«¤w¸g¦b¤@©wµ{«×¤WÀò±oFDA»{¥i¡A³o¹ï©óÃĪ«¤Î¥ø·~µLºÃ¬O¤@°w±j¤ß¾¯¡CªÑ²¼¼WÈ¡BÀò±o§ë¸ê¥H¤Î¬Fµ¦¶É¦V³£¬OIJ¤â¥i±oªº¦n³B¡C |
|
|
·|û¡Gyuki10141394 µoªí®É¶¡:2019/1/24 ¤U¤È 09:46:30²Ä 493 ½g¦^À³
|
¦U¦ì¤j¤j±ß¦w¡AÆ[¹î¤W§«ô¤ß®®1ªÑªÑªF¤H¼Æ¼W¥[800¦h¤H¡A½Ð±Ð¦U¦ì¤j¤j¬O¤°»òì¦]¡H ªþ¤W¤W¥«¤WÂd±ø¥ó¡AÀ³¸Ó¤£¬O¬°¤FªÑÅv¤À´²¡A³Â·Ð¤j®a¸Ñ´b¤@¤U¡A·PÁ sh823568.pixnet.net/blog/post/186736545-%E7%94%B3%E8%AB%8B%E4%B8%8A%E5%B8%82%E4%B8%8A%E6%AB%83%E7%9A%84%E6%A2%9D%E4%BB%B6 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/24 ¤U¤È 12:21:12²Ä 492 ½g¦^À³
|
¹ù¥S³Ì·s½×¤å½àªR DAAO¥Dn¸g¥Ñ²£¥ÍROS¦Ó«P¶i²ÓM¦Ñ¤Æ liawbf.pixnet.net/blog/post/48782202 ì¨ÓCinnamon metabolite sodium benzoate (NaB) reduces the production of ROS ¤]¬O³oÓ¹D²z ÁÂÁ¹ù¥S ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/21 ¤U¤È 05:42:00²Ä 491 ½g¦^À³
|
ÁÂÁ Cliff¤j®¦¼wªºÅW®b °ò¥»¬[ºc¦³¤F , ¸£µ¬´N²M·¡¦h¤F °²¦p±z¨SªÅ²âÅ¥³¯³Õ¤hªººtÁ¿ , ¨º²Ä¤@½gªº¤å³¹´N¤w§t¬A¤j³¡¤ÀªººtÁ¿¤º®e ¦³½Ð¤j®a²Ó²Ó«~À| ¨ä¤¤³¯³Õ¤h¦b Q&A ¯S§O±j½Õ §Üª¢©Ê ©M ¸£·½©Ê¯«¸gÀç¾i¦]¤l¡] BDNF ¡^ ¥i³ßªº¬O ¤ß®®ªº NaBen ³£¦³³o¨âºØ¥\¯à Sodium Benzoate, a Metabolite of Cinnamon and a Food Additive, Reduces Microglial and Astroglial Inflammatory Responses www.ncbi.nlm.nih.gov/pmc/articles/PMC2862570/ ¥»¬ã¨s±´°Q¤F¦×®Û¥NÁª«f¥Ò»Ä¶u¡]NaB¡^¦b¤p½¦½è²ÓM©M¬P§Î½¦½è²ÓM¤¤ªº§Üª¢¯S©Ê¡C Up-regulation of neurotrophic factors by cinnamon and its metabolite sodium benzoate: Therapeutic implications for neurodegenerative disorders www.ncbi.nlm.nih.gov/pmc/articles/PMC3663914/ f¥Ò»Ä¶u¡]NaB¡^¡A¤@ºØ¼sªx¨Ï¥Îªº¹«~¨¾»G¾¯©M FDA §å㪺§Ü¤HÃþ§¿¯À´`Àô»ÙꪺÃĪ«¡A¦b CNS ¤¤´£°ª¯«¸gÀç¾i¦]¤lªº¤ô¥[¨Ò¦p¸£·½©Ê¯«¸gÀç¾i¦]¤l¡] BDNF¡^©M¯«¸gÀç¾i¦]¤l-3¡]NT-3¡^]¡CNaB ¾¯¶q¨Ì¿à©Ê¦a»¤¾Éì¥N¤H¯«¸g¤¸( primary human neurons )©M¬P§Î½¦½è²ÓM¤¤ BDNF ©M NT-3 ªºªí¹F¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2019/1/21 ¤W¤È 09:27:33²Ä 490 ½g¦^À³
|
ªÑ¥«¤£º¦½m¤º¥\¡AÃÛ¦n°¨¨Bµ¥®É¾÷¡C µ¹¦³¿³½ìªº¤H¡u¸É¸£¡v¡C ¤¤¬ã°|--¬ã¤§¦³ª« ¡u°O¾ÐÅÜ®t¡B¤ÏÀ³ÅܺC¡A¯«¸g²ÓM¥X¤F¤°»ò°ÝÃD¡H¡v ¡uresearch.sinica.edu.tw/neuron-disease/¡v 2016--¤¤¬ã°|105/11ª¾ÃÑÅW®b¡u¼Ä§ÚÃø®Æ- ¯«¸g°h¤Æ¯e¯f¤¤ªº¬P§Î½¦½è²ÓM¡v ¡uwww.youtube.com/watch?v=Qaz8rKEi3C8&feature=youtu.be¡v 2019/01/17 ¬ð¯}BBB ¡u¸£Àù±wªÌºÖµ¡I¬ð¯}¨¾Å@¸n ¦¨¥\¿é°e©`¦ÌÃĪ« ¶}±Ò¸£ÀùªvÀø¤§Æ_¡v ¡unewsletter.sinica.edu.tw/%E8%85%A6%E7%99%8C%E6%82%A3%E8%80%85%E7%A6%8F%E9%9F%B3%EF%BC%81%E7%AA%81%E7%A0%B4%E9%98%B2%E8%AD%B7%E7%BD%A9-%E6%88%90%E5%8A%9F%E8%BC%B8%E9%80%81%E5%A5%88%E7%B1%B3%E8%97%A5%E7%89%A9-%E9%96%8B%E5%95%9F/¡v |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/19 ¤U¤È 03:09:50²Ä 489 ½g¦^À³
|
¦¤W ¤u°Ó®É³ø ·s¥úÂå°|¼ï¹Å©MÂå®v¼¶¼g¦³Ãöª`·N¤O¯Ê·l¹L°Ê¯g---attention deficit hyperactivity disorder (ADHD) ªº¤¶²Ð Åý¤H¾Ð°_½²±Ð±Â©MÂűбÂ...µ¥ ¦b2016/7 µoªíªº½×¤å Sarcosine treatment for oppositional defiant disorder symptoms of attention deficit hyperactivity disorder children journals.sagepub.com/doi/abs/10.1177/0269881116658986?journalCode=jopa [ ºKn ]ªº²Ä¤@Ó¦r , ´N¬O¼gµÛ¼ï¹Å©MÂå®v©Ò¤¶²ÐªºªvÀøADHDÃĪ«---¤¤¼Ï¯«¸g¿³¾Ä¾¯ Methylphenidate Methylphenidate, a stimulant that activates dopaminergic and noradrenergic function, is an important agent in the treatment of attention deficit hyperactivity disorder (ADHD). ½×¤å½Íªº¬OSarcosine ( ¦Ù®ò»Ä )---¦b¦h°Ê¯gªº±¡ªp¤U¡A¦Ù®ò»Ä¥i¯à¬OªvÀøODD¯gª¬ªº·sÃÄ¡C ¦ý¬O¡A¤pªº«o¹ï³oÀÉ---¤¤¼Ï¯«¸g¿³¾Ä¾¯ Methylphenidate ¦³¿³½ì ¤pªº²q´ú , ³o¥i¯à¬O¹ù¥Sµ§¤U¦³Ãö¤ß®®¶W¯Å¾Ç¦WÃÄ SNS 1 ~ 7 ¤¤ªº¤@Àô ¤]´N¬O NaBen + ³æ¹ç»Ä + Methylphenidate ªº²Õ¦X , ¨ÓªvÀø¦h°Ê¯g¯gª¬ , [ Claims ]²Ä 8 ±ø ¥¿±ªí¦CªºÃĪ«¤¤¤]¦³ Methylphenidate ½×¤åµoªíªº¬O¦Ù®ò»Ä , Àò±o±M§Qªº¬O NaBen + ³æ¹ç»Ä , ¤]®¼¦³·N«äªº ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/19 ¤W¤È 08:15:34²Ä 488 ½g¦^À³
|
¦W¡DÂå¡D°Ý¡D¶E¡Ðª`·N¤O¯Ê·l¹L°Ê¯g À³¤Î¦ªvÀø 2019¦~01¤ë19¤é 04:10 ¤u°Ó®É³ø ¤å¡þ¼ï¹Å©M¡]·s¥úÂå°|¨àµ£ºë¯«¬ì¥DªvÂå®v¡^ www.chinatimes.com/newspapers/20190119000431-260209 ª`·N¤O¯Ê·l¹L°Ê¯g¦b¥@¬É¦U°ê«Ä¤l¤¤´¶¹M¦s¦b¡A°ê¤º¤]°ª¹F20¦h¸U¦W¾ÇÄ֫ĵ£¿©±wª`·N¤O¤£¶°¤¤¹L°Ê¯g¡A¨ä¤¤¬ù¦³25¢H¯fµ£¡A¨ä¯gª¬¥i¯à©µ¦ù¦Ü«C¤Ö¦~©Î¦¨¤H¶¥¬q¡A¦ý¥þ¥x«o¶È¦³1¸U¦Wª`·N¤O¤£¶°¤¤¹L°Ê¯g¯fµ£´M¨D¥¿½TºÞ¹D´NÂåªvÀø¡AY®aªøµo²{«Äµ£¨ã¦³ª`·N¤O¤£¨¬¡B½Ä°Ê¡B¹L°Êµ¥¯gª¬¡AÀ³¥ß§Y«e©¹´NÂåµû¦ô©ÎªvÀø¡C ¬ã¨s«ü¥X¡Aª`·N¤O¤£¶°¤¤¹L°Ê¯g¯fµ£¤¤¬ù¦³11¢H¦P®É±w¦³§´·ç¤ó¯g¡A34¢Hªº¯fµ£§ó¨ã¦³µJ¼{²{¶H¡A³o¨Ç¦@¯f¯gª¬¹ï©ó«Äµ£¥¼¨ÓªºÓ©Ê¾i¦¨¡A¬Ò¦³ªø»·ªºt±¼vÅT¡A®aªø¤Î¾Ç®Õ¦Ñ®vÀ³ªÃ«ù¦P²z¤ß¡A³]¥ß¾A·íªº¦æ¬°ªvÀø¥Ø¼Ð¡A¤~¬O¨ó§U«Äµ£ªvÀøªºÃöÁä¦]¯À¤§¤@¡C ¦bÃĪ«ªvÀø¤è±¡A¥Ø«e¦³«D¤¤¼Ï¯«¸g¿³¾Ä¾¯¡]«ä¾U¡AAtomoxetine¡^§@¥Î¦b©ó´£°ª¸£¤¤¥¿µÇ¤W¸¢¯À¡A¡]¯à§ïµ½¸£¤¤¦h¤ÚÓiªº¿@«×¡^... ¤¤¼Ï¯«¸g¿³¾Ä¾¯¡]§Q¥L¯à¡B±M«ä¹F¡^¡AMethylphenidate«h¬°ªvÀø¸£¤¤¦h¤ÚÓiÃĪ«. ¤ß®®ªº±M§Q 10064833 2018¦~9¤ë4¤é §t¦³f¥Ò»ÄÆQ¤Æ¦Xª«©M³æ¹ç»Äªº²Õ¦Xª«¡A¥Î©óªvÀø¤¤¼Ï¯«¸g¨t²Î¯e¯f [ Claims ] ²Ä 15 , 16 , 17 ±ø 15.¤@ºØ¦b±w¦³©ÎÃhºÃ±w¦³¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^¯f¯gªº¨ü¸ÕªÌ¤¤ , ¥Î¥H´î¤Ö¬¡°Ê¹L«×©Î®¾±Ï·Pı¹B°Ê»Ùꪺ¤èªk¡A©Òz¤èªk¥]¬A¦V©Òz¨ü¸ÕªÌ¬I¥ÎÅv§Qn¨D1ªº²Õ¦Xª« ¡C ( A method for reducing hyperactivity or rescuing sensorimotor deficit in a subject having or suspected of having a central nervous system (CNS) disorder, the method comprising administering to the subject the composition of claim 1. ) 16.Åv§Qn¨D15ªº¤èªk¡A¨ä¤¤¤¤¼Ï¯«¸g¨t²Î¯e¯f¿ï¦Ûª`·N¯Ê³´¦h°Ê»Ùê¡Aºë¯«¤Àµõ¯g¡A««×§íÆ{¯g¡Aªüº¸¯ý®üÀq¯f¡AÂù¬Û±¡·P»Ùê¡A¤H®æ»Ùê¡A©â°Ê»Ùê¡A³Ð¶Ë«áÀ³¿E»Ùê¡A®£·W¯g¡A¦Û³¬¯gÃШt»Ùê¡Aªü´µ§B®æºî¦X¯g¡A¯Ü®zXºî¦X¼x¡A±j¢¯g¡ATouretteºî¦X¼x¡Aè§b¡A©¬ª÷´Ë¯f¡A¦ë§Ê¹y¯f¡A©]¶¡¿ò§¿¯g¡A²´Â¥µjÅË©M«DÅöíwµo§@¡C 17.Åv§Qn¨D16ªº¤èªk¡A¨ä¤¤CNS¯f¯g¬O¨ã¦³¦h°Ê¯g¯gª¬ªºCNS¯f¯g¡A¨ä¿ï¦Ûºë¯«¤Àµõ¯g¡AÂù¬Û±¡·P»Ùê¡Aª`·N¤O¯Ê³´¦h°Ê»Ùê¡A±j¢¯g¡A¹Ï¹p¯Sºî¦X¼x¡A¦Û³¬¯gÃШt»Ùê¡A¯Ü©ÊXºî¦X¼x¡A©¬ª÷´Ë¯f¡A¸ô©öÅéè§b©M¦Ñ¦~©Êè§b¡C ¤pµù : ì¨Óª`·N¤O¯Ê³´¦h°Ê»Ùê¤]¬O¤@ºØCNS¯e¯f , ´¶¤Î²v¤]¤£§C ,,¥ú¬O¦b¥xÆW , ´N¦³ 20´X¸U«Äµ£±w¦³¦¹¯g ¦Ó¨ä¥LCNS¯e¯f¤]¦³¦hºØ¨ã¦³¦h°Ê¯g¯gª¬ , ³o¼Ë¬Ý°_¨Ó¥«³õ¤]¤£¤p Ãø©Ç½²±Ð±Ân¥t¦C¤@±ø³æ¿WªºÅv§Q½Ð¨D¶µ¨Ó«OÅ@ ±q¬Q¤éªº³ø¾É --- reducing brain homocysteine ( ¦P«¬¥b¯ÖÓi»Ä )levels , ªvÀøADªºf¥Ò»Ä¶u ¨ì¤µ¤éª`·N¤O¯Ê·l¹L°Ê¯gªº±MÄæ , ÁÙ¦³¤ß®®±M§QªºÀ³¥Î ÁÙ¦³ , ¦b[ Claims ]17¤¤ , ¤]Åã¥Üºë¯«¤Àµõ±wªÌ¤]¨ã¦³¦h°Ê¯g¯gª¬ , SND-11 ~ 13 À³¤]¥i¥HªvÀø¥¦ ¬Q¤µ³o¨â«h³ø¾É , Åý¤H¤£±o¤£¨ØªA½²±Ð±Âªº±M·~©M§V¤O ÁÂÁ½²±Ð±Â©M¤ß®®¹Î¶¤ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/18 ¤U¤È 07:38:05²Ä 487 ½g¦^À³
|
¶¼¹¤¤´£°ªÁxÆP§t¶q¹ï§ÜÀ»³oºØ¡§¤£ªv¤§¯g¡¨¦³©_®Ä ¨Ó·½¡GCPhI»sÃĦb½u¡@2019-01-18 §@ªÌ¡G¸·¬¬õ med.sina.com/article_detail_103_2_59447.html ÁxÆP( choline ) ·|°§C¦P«¬¥b¯Ö®ò»Ä¡]homocysteine¡^ªº¤ô¥¡C¦P«¬¥b¯Ö®ò»Ä¬O¤@ºØ¥i¥H§@¬°±j®Ä¯«¸g¬r¯Àªº®ò°ò»Ä¡A¦³§U©ó¯«¸g¤¸ÅÜ©Ê¡B¾ý¯»¼Ë³J¥Õ¯f´³ªº§Î¦¨¡C¤w¦³¬ã¨sªí©ú¡A¦Ñ¦~è§b±wªÌªº¦P«¬¥b¯Ö®ò»Ä¤ô¥¤É°ª¡C Maternal choline supplementation ameliorates Alzheimer¡¦s disease pathology by reducing brain homocysteine levels across multiple generations. ³oÓ³ø¾É(ameliorates Alzheimer¡¦s disease pathology by reducing brain homocysteine levels )¤]¥i¥H³s¤W¤ß®®ªº SND-14 , SND-51 °Ñ¦Ò¸ê®Æ1: ¦×®Û¤Î¨ä¥NÁ²£ª«f¥Ò»Ä¶u¦bªüº¸¯ý®üÀq¯f°Êª«¼Ò«¬¤¤´î®zp21racªº¬¡¤Æ¨Ã«OÅ@°O¾Ð©M¾Ç²ß¡C www.ncbi.nlm.nih.gov/pubmed/26102198 [ oral feeding of cinnamon (Cinnamonum verum) powder and NaB suppressed the activation of p21rac and attenuated oxidative stress in the hippocampus of Tg mice as evident by decreased dihydroethidium (DHE) and nitrotyrosine staining, reduced homocysteine level and increased level of reduced glutathione. ] °Ñ¦Ò¸ê®Æ2: °ª¥b¯ÖÓi»Ä¡]^»y¡GHomocysteine¡A©ÎºÙ¬°¦P«¬¥b¯ÖÓi»Ä©Î¦P¥b¯ÖÓi»Ä¡^ ¦å²M¤º°ª¥b¯ÖÓi»Äªº°ª¤ô¥¬O¼ç¦b¤ß¦åºÞ¯e¯fªº¼Ð°O¡A¥¦§Y¬O³oºØ¯e¯f¤Î¤¤·ªº·ÀI¦]¯À¡C °ª¥b¯ÖÓi»Ä¦b°ª¿@«×ªº¦h×ô§Ü®ñ¤Æ¾¯¤U·|½Õ°¡A¦Ó¦h×ô§Ü®ñ¤Æ¾¯³Q»{¬°¬O¹ï¤ß¦åºÞ¨t²Î¤Î§K¬Ì¨t²Î¦³¬Y¨Ç°·±d¯q³B¡C¦h×ô§Ü®ñ¤Æ¾¯¥i¥H½Õ°¤ß¦åºÞ¯e¯fªº«n¤Æ¦Xª«¬¡©Ê®ñªº§Î¦¨¡C³z¹L°ª¥b¯ÖÓi»Äªº¦Û°Ê®ñ¤Æ¦¨¬¡©Ê®ñ·|¾ÉP¥Íª«·l®`¡C zh.wikipedia.org/wiki/%E9%AB%98%E5%8D%8A%E8%83%B1%E6%B0%A8%E9%85%B8 ¦h×ô ºû°ò¦Ê¬ì¡A¦Û¥Ñªº¦Ê¬ì¥þ®Ñ zh.wikipedia.org/wiki/%E5%A4%9A%E9%85%9A |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/14 ¤U¤È 04:04:18²Ä 486 ½g¦^À³
|
¼fµû§¹²¦§Üºë¯«¤Àµõ¯g·sÃľ|©Ô¦èଧY±N³yºÖ°ê¤º±wªÌ ¨Ó·½¡GCPhI»sÃĦb½u¡@2019-01-14 §@ªÌ¡G¤pÃĤY ÆQ»Ä¾|©Ô¦èବO¤é¥»¦í¤Í»sÃĤ½¥q¶}µoªº¤@ºØ¨ã¦³Âù«§@¥Îªº«D¨å«¬§Üºë¯«¯fÃÄ¡A¹ï5-HT2A¨üÅé©M¦h¤ÚÓiD2¨üÅ駡¨ã¦³°ª«×¿Ë©M¤O¡C °ò©ó¤@¶µ¬°´Á6¶gªº¬ã¨sµ²ªG¡AFDA©ó2010¦~10¤ë28¤é§åã¤FÆQ»Ä¾|©Ô¦èତù¦b¬ü°êªº¤W¥«¥Ó½Ð¡A°Ó«~¦W¬°Latuda¡A±wªÌ¨C¤é¤fªA¤@¦¸¡A¥Î©óºë¯«¤Àµõ¯gªº¤@½uªvÀø¡C Ų©óºë¯«¤Àµõ¯gµo¯f¾÷²z©|¥¼§¹¥þÄÄ©ú¡B²{¦³ªvÀøÃĪ«Àø®Äªº§½¤Î¤£¨}¤ÏÀ³¡AÁ{§É»ÝnÀø®Ä§ó¦n¡B¤£¨}¤ÏÀ³§ó¤pªºªvÀøÃĪ«¡C°ê¤ººë¯«¬ìÂåÀø¸ê·½¯Ê¥F¡Aºë¯«ÃĪ«¥«³õ¼ç¤O¥¨¤j¡C ¤p·P·Q : ¬JµM§@ªÌ»{¬°¤¤°ê¤j³°ºë¯«¬ìÂåÀø¸ê·½¯Ê¥F¡Aºë¯«ÃĪ«¥«³õ¼ç¤O¥¨¤j¡C ´NÅý§Ú̦A¦¸¦^ÅU¤ß®®ªº SND-13 SND-13 ¤G(b) +¤T´ÁÁ{§ÉªºPrimary Outcome Measures ¥u¦³¤@¶µ : PANSS¶qªíªº¥§¡ÅÜ¤Æ [Positive and Negative Syndrome Scale (PANSS) [ Time Frame: 8 weeks after randomized treatment ] Mean change from baseline in PANSS total score] ¥i¨£±o PANSS¶qªí¹ïSND-13 ªº«n©Ê PANSS¶qªíªºµ²ºc , ¤À¬°4 Ó¤l¶° . ¥¿©Ê¯gª¬(P) 7 ¶µ . t©Ê¯gª¬(N) 7 ¶µ . ¤@¯ëºë¯«¯f²z(G) 16¶µ . ¨ä¥L(S) 3¶µ ¦@p 33¶µ , ¨C¶µ³Ì°ª7¤À(·¥«×ÄY«) , ³Ì§C1¤À(µL¯gª¬) , Á`¤À231¤À ( ¸Ô²Ó¶µ¥Ø½Ð°Ñ¹ù¥S³ø§i µù1 ) «·Å¹ù¥S2017¦~ºë¤ßªº¤j§@--- SND-13¤G´ÁÁ{§É³ø§i liawbf.pixnet.net/blog/post/47579859 ³o¥÷³ø§iºë±mªº¤£¥u¥u¦³¼Æ¾Ú , PANSS¶qªí¤Î¨ä¥L 3 Ó¤l¶°¤]³£¤À§O¦³¨â²Õªº®t²§¤ñ¸û , Åý§Ṳ́@¥Ø¤FµMªº¬Ý¥X¦U¤l¶°ªºÀø®Ä , ¦n§@¬°µû¦ô2(b)+3´Áªº§Q¾¹ PANSS¶qªí¤Î¨ä¥L 3 Ó¤l¶°ªº®t²§¤ñ¸û , ºKn¦p¤U 1. PANSS¶qªí¨â²ÕÅܤƪº¤ñ¸û . NaBen ²Õ ¥Ñ 90.3 ¤À °¦Ü 71.7 ¤À ´î»´20.6 % . ¹ï·Ó²Õ ¥Ñ 87.3 ¤À °¦Ü 81.4 ¤À ´î»´6.8 % . p < 0.001 . ®ÄªG¶q¬O¶W°ª®Äªº 1.53 2. ¥¿©Ê¯gª¬(P) . NaBen ²Õ ¥Ñ 20.6 ¤À °¦Ü 15.3 ¤À ´î»´25.7 % . ¹ï·Ó²Õ ¥Ñ 20.4 ¤À °¦Ü 18.8 ¤À ´î»´7.8 % . p < 0.001 . ®ÄªG¶q¬O¶W°ª®Äªº 1.69 3. t©Ê¯gª¬(N) 7 ¶µ . NaBen ²Õ ¥Ñ 26.1 ¤À °¦Ü 20.8 ¤À ´î»´20.3 % . ¹ï·Ó²Õ ¥Ñ 24.8 ¤À °¦Ü 23.1 ¤À ´î»´6.9 % . p < 0.001 . ®ÄªG¶q¬O¶W°ª®Äªº 1.19 4. ¤@¯ëºë¯«¯f²z(G) 16¶µ . NaBen ²Õ ¥Ñ 43.6 ¤À °¦Ü 35.7 ¤À ´î»´18.1 % . ¹ï·Ó²Õ ¥Ñ 42.2 ¤À °¦Ü 39.6 ¤À ´î»´6.2 % . p < 0.001 . ®ÄªG¶q¬O¶W°ª®Äªº 1.16 ¶µ2,3,4 ´N¬O²Ä1¶µªºPANSS¶qªíªº¤À©î ¥t¥~t©Ê¯gª¬¶qªíSANS¤À¼Æ . NaBen ²Õ ¥Ñ 59.2 ¤À °¦Ü 42.5 ¤À ´î»´28.2 % . ¹ï·Ó²Õ ¥Ñ 55.0 ¤À °¦Ü 51.3 ¤À ´î»´6.7 % . p < 0.001 . ®ÄªG¶q¬O¶W°ª®Äªº 1.56 ¨ä¥L¶µ¥Ø½Ð°Ñ¹ù¥S³ø§i(¥]§t»{ª¾¶µ¥Ø) §Ú̬ݨìPANSS¶qªí©M 3 Ó¤l¶° , pȳ£¤p©ó0.001 , ÁÙ¦³¶W°ª®ÄªGªº®ÄªG¶q ¤]Ãø©Ç½²±Ð±Â¥Î¥¦¨Ó¥D¥´ , ¦]¬°¥¦³Ì¯à¥Nªíºë¯«¤Àµõ¯g¾ãÅ骺Àø®Ä , ¤] ¬O NaBen ³Ì®³¤âªº ¯¬ºÖ¤ß®®ªº SND-13 ´Á¤¤¤ÀªR ©M 2(b)+3 ´ÁÁ{§É , ³£¯à¦p 2(a ) ´Á¤@¼Ë , ®³¨ìºë±m«GÄRªº¦¨ÁZ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/13 ¤W¤È 09:53:39²Ä 485 ½g¦^À³
|
¹ï SNS1-7 ¶W¯Å¾Ç¦WÃĪºÁp·Q liawbf.pixnet.net/blog/post/48763128 ÁÂÁ¹ù¥S¥H±M·~ªº©³Ä , ¬°§Ú̸ѪR¥h¦~9/10¤½¥q¶W¯Å¾Ç¦WÃÄ·s»D½Zªº¥i¯à·N²[ ¥HÃĪ«³q¹L¦å¸£«Ì»Ù ( BBB ) ªºÆ[ÂI , ¨ÓÁp·QSNS¨t¦C¥i¯àªº¼Ë»ª ¦^¥h«·Å¤½¥q·s»D½Z , ¤]Åý¤pªº´n¼Û ¦P¼Ë¤@½g·s»D½Z , ¦b±M·~©M«D±M·~¤§¶¡ªº²z¸Ñ , ³º¦³¤d¨½¤§§O§r! ¦A¦¸·PÁ¹ù¥Sªº¤À¨É , Åý§Ú̱o¥H¨£ÃÑSNS¥i¯àªº«Â¤O ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/11 ¤U¤È 04:10:55²Ä 484 ½g¦^À³
|
¬ì¾Ç®a´¦¥Ü¤j¸£½Õ¸`©ÊT²ÓM«P¶i¯«¸g¨t²Î«ì´_¾÷¨î ¨Ó·½¡G ¥Íª«¨¦ ¡@2019-01-11 med.sina.com/article_detail_103_1_58974.html ¦b¤@¶µ·sªº¬ã¨s¤¤¡A¨Ó¦Û¤é¥»¼yÀ³¸q¹Ñ¤j¾Ç©Mªñ½B¤j¾Çªº¬ã¨s¤Hûµo²{¦bµo¥Í¯Ê¦å©Ê¤¤·«á¡A¤j¶qªºTreg²ÓM¦b¤p¹«¤j¸£¤¤°ï¿n¡A³o«P¶i¤FºC©Ê¯Ê¦å©Ê¸£·l¶Ë´Á¶¡ªº¯«¸g«ì´_¡C ¬ÛÃö½×¤å Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. www.ncbi.nlm.nih.gov/pubmed/30602786 «n¥[¤jªº¾ÇªÌ Terrence Town ±µµÛ´£¥Xµû½× www.alzforum.org/papers/brain-regulatory-t-cells-suppress-astrogliosis-and-potentiate-neurological-recovery ¥»³ø§i´£¨Ñ¤F¤@Ó´I¦³¬}¹î¤Oªº®Ø¬[¡A¥H¸Ñ¨MTregs§Î¦¡ªº¾AÀ³©Ê§K¬Ì¦p¦ó¦b¯Ê¦å©Ê¸£¤¤¤Þ°_§K¬Ì¥\¯à¡C³oºØ¾÷¨î¬O§_¤]¥i¥H¦bADªºI´º¤U¹B§@¡H«D±`¥i¯à - ¬ã¨sTregs¤§¶¡ªº¬Û¤¬§@¥Î¡A¥H¤Î¥i¯àªº¨ä¥LT²ÓM¨È¸s©M¾ý¯»¼Ë³J¥Õ-£]/ tau¯f²z¾Ç¡AÅãµM¬O¥²nªº¡C ¦Ó§Ú̬ݹLªº¤@½g¦³Ãöf¥Ò»Ä¶uªº½×¤å Sodium Benzoate, a Food Additive and a Metabolite of Cinnamon, Modifies T Cells at Multiple Steps and Inhibits Adoptive Transfer of Experimental Allergic Encephalomyelitis europepmc.org/articles/pmc1976122 ¹êÅç©Ê¹L±Ó©Ê¸£¯áÅ誢¡]EAE¡^¬O¦hµo©Êµw¤Æªº°Êª«¼Ò«¬¡C... NaB³q¹L¥Í²z¤W¥i@¨üªº¶¼¥Î¤ôµ¹ÃÄ¡A§ïµ½¨üÅé¤p¹«¤¤EAEªºÁ{§É¯gª¬©M¯e¯f¶i®i¡A¨Ã§í¨î¨ÑÅé¤p¹«¤¤P¸£ª¢©ÊT²ÓMªº²£¥Í¡C²Õ´¾Ç¬ã¨sªí©ú¡ANaB¦³®Ä§í¨îEAE¤p¹«¯áÅ褤³æ®Ö²ÓMªº®û¼í©M²æÅèÀT¡C ¦]¦¹¡ANaBÁÙ§í¨î«Pª¢¤À¤lªºªí¹F¨Ã¨ÏEAE¤p¹«ªºCNS¤¤ªºÅèÀT°ò¦]ªí¹F¥¿±`¤Æ¡C ¦¹¥~¡A§ÚÌÆ[¹î¨ìNaB±NÅèÀTÆP©Ê³J¥Õ¤ÞµoªºT²ÓM±qTh1ÂàÅܬ°Th2¼Ò¦¡¡A´I¶° ( enriched ) ½Õ¸`©ÊT²ÓM¸s¡A¨Ã¤U½ÕT²ÓM¤¤¦UºØ±µÄ²¤À¤lªºªí¹F¡C Á`¤§¡A§Ú̪ºµ²ªGªí©úNaB¦b¦hÓ¨BÆJ¤¤×¹¢P¸£ª¢T²ÓM¡A¨Ã¥BNaB¥i¯à¦b¦hµo©Êµw¤Æ¤¤¨ã¦³ªvÀø«n©Ê¡C ¤p·P·Q: f¥Ò»Ä¶u¥i¥H´I¶° ( enriched ) ½Õ¸`©ÊT²ÓM ( Treg ) ¨Ì¤é¥»¾ÇªÌªº¬ã¨s µo²{¦b¯Ê¦å©Ê¤¤·«á¡A¤j¶qªºTreg²ÓM¦b¤p¹«¤j¸£¤¤°ï¿n¡A³o«P¶i¤FºC©Ê¯Ê¦å©Ê¸£·l¶Ë´Á¶¡ªº¯«¸g«ì´_¡C ³o·|¤£·|¦p«n¥[¤j¾ÇªÌ©Ò»¡±o©MAD¬ÛÃö---¦bAD±wªÌªº¤j¸£¤¤ , f¥Ò»Ä¶u(SND-14)¤]´I¶° ( enriched ) ½Õ¸`©ÊT²ÓM ( Treg ) , ²£¥Í¯«¸g«OÅ@(©Î«ì´_)ªº§@¥Î ¦b¹ù¥S©Ò»`¶°ªºf¥Ò»Ä¶uªº½Ñ¦h¥\¯à¤¤ ( liawbf.pixnet.net/blog/category/2056459 ) ¤S¼W²K¤@¶µ¾÷Â઺¨ÒÃÒ?! SND-14 ¦h¤è¦ì¦aªvÀøAD , Åý¤H±H¤©«p±æ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2019/1/10 ¤U¤È 11:01:00²Ä 483 ½g¦^À³
|
ÁÂÁ²q·Q¤j...Cliff¤j...¥H¤Îªø´Á´£¨Ñ¬ÛÃö¸ê°Tªº¤j¤jÌ... ±M§Qªñ¤@¦~³°Äòªº³q¹L¤Î¥Ó½Ð§ó·sªº±M§Q...ȱo´Á«Ýªº¥¼¨Ó... |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/10 ¤U¤È 07:55:21²Ä 482 ½g¦^À³
|
¬Ý§¹¤F±M§Q¤å¥ó , ¤´µM§Ô¤£¦í¦V¤j®a³ø§i In the learning phase, high dosage of ¤Æ¦Xª« enhances the learning after MK-801 induced learning deficit. In the memory phase, the high dose of ¤Æ¦Xª« treatment completely ameliorated the memory deficit while ¦Ù®ò»Ä is not effective. Therefore, ¤Æ¦Xª« treatment is much superior as compared with ¦Ù®ò»Ä to recover memory deficit induced by the MK-801 treatment. ªþµù : ¦Ù®ò»Ä ´N¬O¹ï«äı¥¢½Õ¯g¤]¦³Àø®Äªº sarcosine , ²{³Q¤ß®®®³¨Ó¸ÕÅç MDD ªºÁ{§É¤T´Á ¤Æ¦Xª« ©hÁô¨ä¦W ¦Ù®ò»ÄªvÀø«äı¥¢½ÕªºÁ{§É³ø§i 1. ¥Ì®ò»ÄÂà¹B³J¥ÕI§í»s¾¯N-¥Ò°ò¥Ì®ò»Ä¡]¦Ù®ò»Ä¡^¥[¤J§Üºë¯«¯fÃĤ¤¥Î©óªvÀøºë¯«¤Àµõ¯g¡C www.ncbi.nlm.nih.gov/pubmed/15023571 2. ¤@¶µÀH¾÷¡AÂùª¼¡A¦w¼¢¾¯¹ï·Óªº¦Ù®ò»Ä¡]N-¥Ò°ò¥Ì®ò»Ä¡^©MD-µ·®ò»Ä²K¥[ªvÀøºë¯«¤Àµõ¯gªº ¤ñ¸û¬ã¨s academic.oup.com/ijnp/article/13/4/451/712753 ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/10 ¤U¤È 03:11:22²Ä 481 ½g¦^À³
|
¤ß®®¤S¥Ó½Ð±M§Q ¥»¦¸®¤¤£¶K¤º®e ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/9 ¤U¤È 03:54:35²Ä 480 ½g¦^À³
|
SAGE±N¹J«l¼Ä ? AXSOME««×¼~Æ{¯g·sÃĤG´Á¼Æ¾Ú¬°§ë¸ê¤H²K«H¤ß ªÑ»ù¨â¤Ñ¤«¼Q 237 % www.genetinfo.com/investment/featured/item/22718.html Axsome Therapeutics«Å¥¬AXS-05¦b««×§íÆ{¯gªº2´Á¸ÕÅ礤Àò±o¥Dn²×ÂI globenewswire.com/news-release/2019/01/07/1681055/0/en/Axsome-Therapeutics-Announces-AXS-05-Achieves-Primary-Endpoint-in-Phase-2-Trial-in-Major-Depressive-Disorder.html »P¬¡©Ê¹ï·Ó¬Û¤ñ¡AMADRSµû¤ÀÅã¥Ü²Îp¾ÇÅãµÛ©Ê§ïµ½¡]¥Dn²×ÂIp <0.001¡^ §íÆ{¯gª¬ªº§Ö³t§ïµ½¦b²Ä¤@©P¤ºÅã¥Ü¥X¤ñ¬¡©Ê¹ï·Ó²Õ¨ã¦³²Îp¾ÇÅãµÛÀu¶Õ¡]CGI-I¤Wp = 0.045¡^ ¦b¦hÓ¦¸n²×ÂI¤WÆ[¹î¨ìAXS-05»P¬¡©Ê¹ï·Ó²Õªº§ïµ½¡A¥]¬A47¢HªºAXS-05±wªÌ»P16¢Hªº¬¡©Ê¹ï·Ó²Õ±wªÌªº½w¸Ñ²v¡]p = 0.004¡^ ¼Æ¾Ú¤ä«ùAXS-05¦bªvÀø©è§Ü©Ê§íÆ{¯g©MMDD¶i¤@¨Bµo®i¤è±ªº«ùÄòµo®i ¼ç¦bªº¤@¬y¤fªANMDA¨üÅé«ú§Ü¾¯¡A¨ã¦³¦h¼Ò¦¡¬¡©Ê¡A¥Î©óªvÀø§íÆ{¯g ¯Ã¬ù¡A2019¦~1¤ë7¤é¡]¥þ²y·s»D¤¤¤ß¡^ - Axsome Therapeutics¡AInc¡C¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GAXSM¡^¬O¤@®aÁ{§É¶¥¬q¥Íª«»sÃĤ½¥q¡A¶}¾v¥Î©óªvÀø¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^¯e¯fªº·sÀøªk¡A¤µ¤Ñ«Å¥¬AXS -05¡A¨ã¦³¦h¼Ò¦¡¬¡©Êªº·s«¬¤fªA¬ã¨sNMDA¨üÅé«ú§Ü¾¯¡A¦b««×§íÆ{¯g¡]MDD¡^ªºASCEND 2´Á¸ÕÅ礤²Å¦X¹w©wªº¥Dn²×ÂI¨ÃÅãµÛ§ïµ½§íÆ{¯gª¬¡CASCEND¬ã¨s¬O¤@¶µÀH¾÷¡AÂùª¼¡A¥D°Ê±±¨î¡A¦h¤¤¤ßªº¬ü°ê¸ÕÅç¡A¨ä¤¤80¦W½T¶E¬°¤¤«×¦Ü««×MDDªº¦¨¦~±wªÌ±µ¨üAXS-05ªvÀø¡]45 mg¥k¬ü¨Fªâ/ 105 mg¦w«D¥Lଡ^¡A©Î¬¡©Ê¤ñ¸û¾¯¦w«D¥Lଡ]105²@§J¡^¡A¨C¤é¨â¦¸¡A¦@6¶g¡C »P¦w«D¥Lବۤñ¡AAXS-05³q¹LÃÒ©ú»Xô°¨§Q - Åsberg§íÆ{µû©w¶qªí¡]MADRS¡^Á`¤À¦b6©PªvÀø´Á¡]Á`ÅéªvÀø®ÄªG¡^¤¤ªº¥§¡È±o¨ì°ª«×²Îp¾ÇÅãµÛ©Ê°§C¡A¹F¨ì¹w©wªº¥Dn²×ÂI¡]p < 0.001¡^¡C¦b²Ä6¶g¡AAXS-05Åã¥ÜMADRSÁ`¤À´î¤Ö17.2¤À¡A¦Ó¦w«D¥L଴î¤Ö12.1¤À¡]p = 0.013¡^¡CAXS-05¨³³t´î¤Ö§íÆ{¯gª¬¡AÃÒ©ú¦b²Ä1¶gÁ{§ÉÁ`Åé¦L¶H§ïµ½¶qªí¡]CGI-I¡^¤W¦w«D¥Lପº²Îp¾ÇÅãµÛ§ïµ½¡]p = 0.045¡^¡C±q²Ä1¶g¶}©l¡AAXS-05¦bMADRSÁ`¤À¤WÀò±o¤F¶W¹L¦w«D¥Lପº¼ÆÈÀu¶Õ¡A¦b²Ä2©P¹F¨ì²Îp¾ÇÅãµÛ©Ê¡A¨Ã¦b¦¹«áªº©Ò¦³®É¶¡ÂI«O«ù¡C¦b²Ä6¶g¡A ... ªþµù : ¦w«D¥Lଡ]°ê»Ú«D±M§QÃÄ«~¦WºÙ¡GBupropion ) ¬O¤@ºØ¥Dn§@¬°§Ü§íÆ{ÃÄ©M§ÙµÒÃĨϥΪºÃĪ«¡B¤]¥i¥Î§@ªvÀøª`·N¤O¤£¨¬¹L°Ê¯gªº²Ä¤G½uÃÄ«~»P¤¤¼Ï¯«¸g¨ë¿E¾¯¦X¨Ö¨Ï¥Î¡A©Î§@¬°¤¤¼Ï¯«¸g¨ë¿E¾¯ªº´À¥N¤è®×¡C ¦w«D¥Lଦb¬ü°ê¬O³Ì±`¥Îªº§Ü§íÆ{ÃĤ§¤@¡A¦b¨ä¥L³\¦h^»y°ê®a¥ç¬O¦p¦¹¡C ¥k¬ü¨Fªâ¡]Dextromethorphan¡^¡A¤S¦W¥k¥Ò¶Ü³ä¡A^¤å²ºÙDM©ÎDXM¡A¬O¤@ºØÂí«yÃĪ«¡A¥¦ªº²B·Í»ÄÆQ±`¥Î©óÃÄ«~¤¤¡C¦b³¡¤À°ê®a±`³Qª«½èÀݥΡC ¬ü°ê¹«~¤ÎÃĪ«ºÞ²z§½¦b1958¦~§åã¥k¬ü¨Fªâ¥i¤£»ÝÂå¥Í³B¤è¦Ó§@¬°Âí«yÃĵo°â¡C·í®É³Ì¼sªx¨Ï¥Îªº«yÃÄ¥i«Ý¦]¦³³QÀݥΪº¥i¯à©Ê¡A¤]¥i¦¨Å}¡C¥k¬ü¨Fªâ¦b³o¨Ç¤è±Áö¤ñ¥i«Ý¦]¦³©Ò§ïµ½¡A¦ý¤]¦³ª«½è¨Ì¿àªº¥i¯à©Ê¡C ¤pµû : AXS-05 ·|¤£·|¤ñ SAGE-217 ¦n? ±N¨Ó¦A»¡§a ! AXS-05 ¤S¬O¨å«¬ªº ¨âºØÂÂÃĪº²Õ¦X¡]45 mg¥k¬ü¨Fªâ/ 105 mg¦w«D¥Lଡ^¡AÀu©ó³æ¾¯¦w«D¥Lଡ]105²@§J¡^ªº¨Ò¤l ³o©M¤ß®®ªº SND-12 , SND-13 , ¶W¯Å¾Ç¦WÃÄ »á¦³²§¦±¦P¤u¤§§® ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/9 ¤W¤È 11:49:47²Ä 479 ½g¦^À³
|
Alector¥Ó½Ð¯Ç´µ¹F§J¤W¥«±Mª`ªvÀø°h¦æ©Ê¸£³¡¯e¯f ¨Ó·½¡G³ÐŲ¶× ¡@2019-01-09 med.sina.com/article_detail_103_1_58818.html Alector¤@®a±Mª`©óªvÀø°h¦æ©Ê¸£³¡¯e¯f¡]¦pªü¯÷®üÀq¯f¡^ªº¥Íª«§Þ³N¤½¥q¡A¤é«e¤w¦b¯Ç´µ¹F§J»¼¥æIPO¥Ó½Ð¡A¥Ø¼ÐÄw¶°1.5»õ¬ü¤¸¡A¬°¨ä§Y±N¶}®iªº¤HÅé¸ÕÅç´£¨Ñ¸êª÷¡C ¾Ú¸Ó¤½¥qªº©ÛªÑ»¡©ú®Ñ¡AAlector»{¬°¡A³y¦¨¯«¸g°h¦æ©Ê¯e¯fªº®Ú¥»ì¦]¦b©ó¤j¸£¤¤ªº§K¬Ì²ÓM¥X²{°ÝÃD¡C¸ÓÆ[ÂI±N¬D¾Ô¤@¨Çªø´Á¦s¦bªº²z½×¡X¡X§Yªü¯÷®üÀq¯fªº³J¥Õ½è-¾ý¯»¼Ë³J¥Õ£]©Mtau¡A©¬ª÷´Ë¯fªº£\-¬ðIJ®Ö³J¥Õ¡A¥H¤ÎÃBù®¸Ã¨§b¡]FTD¡^©M¦ÙµäÁY°¼¯Áµw¤Æ¯g¡]ALS¡^¤¤ªºTDP-43¡A¬O³y¦¨¯e¯fªº®Ú¥»ì¦]¡C Alector±Mª`©ó¤p½¦½è²ÓM¡A³o¬O¤@ºØ§K¬Ì²ÓM¡A¬°¯«¸g¤¸´£¨ÑÀç¾i¡A¡§¦Y¡¨²ÓM¸H¤ù©M¯f²z³J¥Õ¡C®Ú¾ÚAlectorªº¸ÑÄÀ¡A³o¨Ç²ÓM·|ÀHµÛ¦~ÄÖªº¼Wªø¦Ó´c¤Æ¡A±q¦Ó°§C¤F¥¦Ìµo´§¦³¯q©M«OÅ@§@¥Îªº¯à¤O¡C¸Ó¤½¥qªí¥Ü¡A¨äÃĪ«°w¹ï»P¯«¸gÅܩʬÛÃöªº°ò¦]¬ðÅÜ¡A³o¥i¯à·|´î½w¬Æ¦Ü°fÂà¤j¸£§K¬Ì²ÓMªº´c¤Æ¡C Alector¦b©ÛªÑ»¡©ú®Ñ¤¤ªí¥Ü¡G¡§³q¹L«ì´_¤j¸£¤¤°·±dªº§K¬Ì¥\¯à¡A§Ú̬۫H¥i¥H¦P®É©è®ø¾ÉP¯«¸gÅܩʪº¦hºØ¯f²z¡C¡¨ ... Alectorªºªü¯÷®üÀq¯fÃĪ«AL002©MAL003¡A¬O»P¦ã§Bºû¦X§@¶}µoªº¡C®Ú¾Ú¨óij¡A¦ã§Bºû¹w¥I¤F2.05»õ¬ü¤¸¡A¨Ã¹ïAlector¶i¦æ¤F2000¸U¬ü¤¸ªºªÑÅv§ë¸ê¡C®Ú¾ÚÃĪ«¶}µoªº¶i®i¡AAlector¦³Åv§QÀò±oÀò±o°ª¹F9.85»õ¬ü¤¸ªº¨½µ{¸O¥I´Ú¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/8 ¤W¤È 11:00:06²Ä 478 ½g¦^À³
|
§Ü²£«á§íÆ{¯gÃĪ«Sage-217 ¤@¦p¹w´Á ¹F¨ì3´ÁÁ{§É²×ÂI Sage§Ü§íÆ{ÃĪ«¹F¨ì3´ÁÁ{§É²×ÂI ¨Ó·½¡GÃÄ©ú±d¼w¡@2019-01-08 med.sina.com/article_detail_100_2_58709.html GABA¨t²Î¬O¤j¸£©MCNS¤¤ªº¥Dn§í¨î©Ê«H¸¹³q¸ô¡A¥¦¹ïCNS¥\¯àªº½Õ¸`¨ã¦³«n·N¸q¡CSAGE-217¬O¤@´Ú¿ï¾Ü©Ê°w¹ï¬ðIJ©M¬ðIJ¥~GABA¨üÅ骺¤U¤@¥N¥¿¦V§Oºc½Õ¸`¾¯¡A¦Ó¥B¦³µÛ¾A¦X¤fªAªºÃÄ¥N°Ê¤O¾Ç¯S¼x¡CSAGE-217¦³±æ³q¹L¹ïGABA¨t²Îªº½Õ¸`¡A¬°««×§íÆ{¯g¡]MDD¡^©MPDD±wªÌ±a¨ÓºÖµ¡C Á{§É¼Æ¾ÚºKn ½Ð°Ñì³ø¾É |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/6 ¤U¤È 05:58:48²Ä 477 ½g¦^À³
|
¤ß®®¦b±M§Q±ÂÅvªº«°T¤¤¯S§OÂI¥X ¶W¯Å¾Ç¦WÃÄ (SNS¨t¦C ) , ©w¦³¨ä«nªº·N¸q ªG¤£¨äµM , ¦b¤pªº§V¤O¾ã²z¤@¨Ç¤åÄm«á ÁôÁô¬ù¬ù¥i¥H¬Ý¥X½²±Ð±Â¦b¯«¸g»â°ì¥ÎÃĪº¥þ¤è¦ì§G§½ ¦bÁp¦X¥ÎÃĤW , §Ú̦ü¥G¬Ý¨ì¤FÃĮĥ[¦¨»P´î§C°Æ§@¥ÎªºÂù«¦n³B ¦ÓªvÀø¯e¯f¤£¬O´N¦b¼W¥[Àø®Ä©M´î»´°Æ§@¥Î³o¨âºØ®Ä¥Î¤¤ , °l¨D¥ÎÃĪº¬ü¦n¶Ü ?! ½²±Ð±Âªº®v¥S§ÌDarrick T. Balu ±Ð±Â ¦b¥Lªº¤@½g¤å³¹¤¤ The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment www.ncbi.nlm.nih.gov/pmc/articles/PMC5518924/#R94 In schizophrenia, there are also disturbances to the GABAergic, cholinergic, and dopaminergic neurotransmitter systems (Coyle, Balu, Benneyworth, Basu, & Roseman, 2010; Lisman et al., 2008), as well as disruptions to astrocytes and white matter integrity (Mighdoll, Tao, Kleinman, & Hyde, 2015). Furthermore, there is convincing evidence that the immune system and oxidative stress play key roles in the pathophysiology of schizophrenia (Leza et al., 2015). Thus, schizophrenia likely results from various combinations of environmental disruptions in brain development and numerous genetic vulnerabilities. These etiological complexities imply that no single pharmacological approach will treat all aspects of the illness nor be effective for all patients with schizophrenia. ½Í¤Î NMDAR¦b«äı¥¢½Õªº¨¤¦â . disturbances to the GABAergic, cholinergic, and dopaminergic neurotransmitter systems (Coyle, Balu, Benneyworth, Basu, & Roseman, 2010; Lisman et al., 2008) . disruptions to astrocytes and white matter integrity (Mighdoll, Tao, Kleinman, & Hyde, 2015). . There is convincing evidence that the immune system and oxidative stress play key roles in the pathophysiology of schizophrenia (Leza et al., 2015). ¥t¦³§@ªÌ¤]»¡¨ì NMDA©M¦h¤ÚÓi¡GÀ³¥Î©ó¬Û¤¬§@¥Î¨üÅé¨t²Îªº¦hºØ¾÷¨î www.ncbi.nlm.nih.gov/books/NBK5280/ N-¥Ò°ò-D-¤Ñ¥V®ò»Ä¡]NMDA¡^©M¦h¤ÚÓi¡]DA¡^¨üÅé¤Î¨ä¬Û¤¬§@¥Î±±¨îµÛ§¹¾ã¤j¸£¤¤¥O¤HÃø¥H¸m«Hªº¦hºØ¥\¯à¡A¥B·í¨ä²§±`®É¡A³o¨Ç¬Û¤¬§@¥Î§Î¦¨³\¦h¯e¯fªº°ò¦¡C³o¨Ç¨üÅé¬Û¤¬§@¥Î»P½Ñ¦p¹B°Ê±±¨î¡A»{ª¾©M°O¾Ð¡A¯«¸g°h¦æ©Ê¯e¯f¡Aºë¯«¤Àµõ¯g©M¦¨Å}µ¥¦hºØ¥\¯à¬ÛÃö¡C ¤£¥u«äı¥¢½Õ¯g¦p¦¹ ªü¯÷®üÀq¯g¨üÁxÆP¯à(cholinergic), ¦h¤ÚÓi¯à(dopaminergic) ÁÙ¦³ª¢¯g(immune system) ®ñ¤ÆÀ³¿E(oxidative stress)¼vÅT¥ç¤£«Ý¨¥ ´N³s¼~Æ{¯g¤]¬O¦p¦¹ ¦h¤ÚÓi¦b§íÆ{¯g¯f²z¥Í²z¾Ç¤¤ªº§@¥Î miami.pure.elsevier.com/en/publications/the-role-of-dopamine-in-the-pathophysiology-of-depression ª¢¯g¦b§íÆ{¯g¤¤ªº§@¥Î¡G±q¶i¤Æ©R¥O¨ì²{¥NªvÀø¥Ø¼Ð www.ncbi.nlm.nih.gov/pmc/articles/PMC5542678/ §íÆ{¯g¬O§_»P®ñ¤ÆÀ³¿E¼W¥[¦³Ãö¡H¨t²Îµû»ù©MîPµÑ¤ÀªR www.sciencedirect.com/science/article/pii/S0306453014003655 ³o·íµM²o¯A«Ü¦hªvÀø¾÷Âà¬Û»²¬Û¦¨ªº°ÝÃD ´N¹³½²±Ð±Â¦b±M§Q½Ð¨D¶µ²Ä8±ø©Ò¦CÁ|ªº³\¦hÁp¦XªvÀøªºÃĪ«©M¾AÀ³¯g ¤@ÃĦh¥Îªº±¡ªp·íµM¦b©Ò¦h¦³ . «äı¥¢½Õ¯g : cariprazine, brexpiprazole ¡K «Ü¦h . ¼~Æ{¯g : Fluoxetine , Duloxetine , Trazodone , Mirtazapine , Moclobemide , Bupropion , paroxetine , sertraline , reboxetine ¡K . ªü¯÷®üÀq¯g : Memantine , Donepezil , Rivastigmine ¡K . ¤Úª÷´Ë¤ó¯g : selegiline ¡K . ª`·N¤O¤£¨¬¹L°Ê¯gADHD : dextroamphetamine , clonidine , guanfacine , bupropion ¡K . ¦Û³¬¯g : Methylphenidate , Aripiprazole , Atomoxetine ¡K . Åöíw¯g : Lamotrigine ¡Kµ¥ ¦b±M§Q½Ð¨D¶µ¤¤ , ¤´¥H·§¬Aªº¤è¦¡«O¯dµÛÁp¦X¥ÎÃĪº¼u©Ê¤Î«OÅ@ Compositions containing benzoate compound and tannic acid for treating central nervous system disorders patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=4&f=G&l=50&co1=AND&d=PTXT&s1=%22TSAI,+Guochuan+Emil%3B%22&OS=%22TSAI,+Guochuan+Emil;%22&RS=%22TSAI,+Guochuan+Emil;%22 1. A composition, comprising a benzoate compound and an excipient, wherein the excipient comprises tannic acid, or a pharmaceutically acceptable salt thereof, wherein the benzoate compound and the tannic acid are at a ratio of 100:1 to 1:100 by weight in the composition, and wherein the composition comprises about 100 mg to about 1,200 mg of the benzoate compound and about 2.0 to about 1,200 mg of the tannic acid. 7. The composition of claim 1, further comprising an additional therapeutic agent for a central nervous system (CNS) disorder. 8. The composition of claim 7, wherein the additional therapeutic agent for the CNS disorder is selected from the group consisting of cariprazine, brexpiprazole, butyrophenone, phenothiazine, fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine, mesoridazine, promazine, triflupromazine, promethazine, thioxanthene, chlorprothixene, flupenthixol, thiothixene, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, amisulpride, asenapine, paliperidone, aripiprazole, lamotrigine, droperidol, pimozide, butaperazine, carphenazine, eemoxipride, piperacetazine, sulpiride, acamprosate, tetrabenazine, vilazodone, levomilnacipran, fluoxetine, paroxetine, escitalopram, citalopram, sertraline, fluvoxamine, venlafaxine, milnacipram, duloxetine, mirtazapine, mianserin, reboxetine, bupropion, amitriptyline, nortriptiline, protriptyline, desipramine, trimipramine, amoxapine, clomipramine, doxepin, tranylcypromine, selegiline, trazodone, nefazodone, phenelzine, lamatrogine, lithium salts, topiramate, gabapentin, carbamazepine, oxacarbazepine, valporate, maprotiline, mirtazapine, brofaromine, moclobemide, isoniazid, iproniazid, amphetamine, mixed salts amphetamine, modafinil, desoxyn, methamphetamine, cocaine, arecoline, dexmethylphenidate, dextroamphetamine, methylphenidate, lisdexamfetamine dimesylate, atomoxetine, clonidine, guanfacine, arecoline, pemoline, donepezil, tacrine, rivastigmine, memantine, physostigmine, arecoline, selegiline, riluzole, tannic acid, and Ginkgo Biloba extract. 15. A method for reducing hyperactivity or rescuing sensorimotor deficit in a subject having or suspected of having a central nervous system (CNS) disorder, the method comprising administering to the subject the composition of claim 1. ¥Ñ²Ä¤@±ø¤£»â°ìªºÅn¬A , ¨ì²Ä¤C±øCNS»â°ìªº·§¬A , ¦A¨ì²Ä¤K±øªº¥¿±ªí¦C , ¤T««OÅ@¾AÀ³¯gÁp¦Xªº½d³ò ÁÙ¦³ÃB¥~µo²{ªº , ¦bCNS¯e¯f»â°ì¥Î¥H reduce hyperactivity or rescue sensorimotor deficit ¥\¯àªº±M§Q ¬Ý°_¨Ó , ²Ä15±ø¬O¥t¥~¿W¥ßªº±M§Q½Ð¨D¶µ , ©Î¬°CNS¯e¯f»â°ì±`¨£ªº¯f¼x ,¦]¦¹¯S§O¥t¥ß±M§Q«OÅ@ ³o¨ÇÀ³¥Î ( NaBen + ³æ¹ç»Ä ) ªºÀø®Ä¯S©Ê , ¥]¬A . DAAO §í¨î¾¯ ( NMDAR¼W±j ) . ¼W±j»{ª¾ . ¦h¤ÚÓi¯àªº¨}©Ê¬Û¤¬§@¥Î , ´£¤ÉÃÄ®Ä . §Üµoª¢§@¥Î . §Ü®ñ¤Æ§@¥Î ¥¿²Å¦X³o¨Ç¾AÀ³¯gªº¾÷Âà , ©Î¥i¹F©ó 1 + 1 > 2 ªº®ÄªG±d¯q³B f¥Ò»Ä¶uªº°·±d¯q³B www.selfhacked.com/blog/sodium-benzoate-some-preservatives-block-inflammation-and-autoimmune-disease/ f¥Ò»Ä¶u¡A¹«~²K¥[¾¯©M¦×®Û¥NÁª«¡A¦h¨B×¹¢T²ÓM¡A§í¨î¹êÅç©Ê¹L±Ó©Ê¸£¯áÅ誢ªº¹LÄ~Âಾ www.ncbi.nlm.nih.gov/pmc/articles/PMC1976122/ ¹êÅç©Ê¹L±Ó©Ê¸£¯áÅ誢¡]EAE¡^¬O¦hµo©Êµw¤Æªº°Êª«¼Ò«¬¡C§Ú̪ºµ²ªGªí©úNaB¦b¦hÓ¨BÆJ¤¤×¹¢P¸£ª¢T²ÓM¡A¨Ã¥BNaB¥i¯à¦b¦hµo©Êµw¤Æ¤¤¨ã¦³ªvÀø«n©Ê¡C ³æ¹ç»Äªº§@¥Î¡A¥i±¤ª¾¹Dªº¤H¤Ó¤Ö¤F kknews.cc/zh-tw/health/gzgbz58.html ¥H¤W¬O½Í¨ì¼W¶iÀø®Äªº§@¥Î ¦A¨Ó½Í½Í´î»´²{¦sºë¯«¯e¯fÃĪ«ªº°Æ§@¥Î §ÚÌ¥ý¨Ó¬Ý¬Ý¦¨¤jÂå°|精神¬ì李嵐´@Âå®vªº 精神¬ìÃĪ«¤¶²Ð docsplayer.com/20760589-%E7%B2%BE%E7%A5%9E%E7%A7%91%E8%97%A5%E7%89%A9%E4%BB%8B%E7%B4%B9.html §Ü精神¯f¾¯(antipsychotics) . 歷¥v¤W²Ä¤@Ó§Ü精神¯f¾¯¬OCPZ (chlorpromazine)¡Aµoªí©ó1950年¥N¡A¦Û·í®É°_¦Ü1990年¥N¥H«e¦³³\¦h§Ü精神¯f¾¯³Q¦X¦¨¤Î¤WÉ]¡A³o¨Ç²Ä¤@¥NÃĪ«ªº¥Dnªv療®ÄªG¬°±±¨î¥¿©Ê精神¯f¯g狀¡A¦ý®e易³y¦¨´ÕÅé¥~®|¯gÔ¸s(EPS, extra-pyramidal symptoms)¡C²ÎºÙ¬°¡u¶Ç²Î«¬©Î¨å«¬§Ü精神¯f¾¯¡v(conventional or typical antipsychotics) . 1990年¥N¥H«á¤WÉ]ªÌÄÝ©ó²Ä¤G¥N§Ü精神¯f¾¯¡A³o¨Ç·s«¬©Î²Ä¤G¥NªºÃĪ«³Q²ÎºÙ¬°¡u«D¨å«¬§Ü精神¯f¾¯¡v(atypical antipsychotics)¡A¥¦Ì»P²Ä¤@¥NÃĪ«³Ì¤jªº°Ï§O¦b©óEPS¸û¤Ö¡A¥B°£了¥¿©Ê精神¯f¯g狀¥H¥~¡A¹ï©ó精神¤À裂¯g±wªÌ±`見¤§t©Ê¯g狀¤Î»{ª¾¥\¯à¯Ê³´¥i¯à¦³ªv療®ÄªG¡C ²Ä¤@¥N§Ü精神¯f¾¯ºØ類 . Phenothiazine: chlorpromazine (wintermine¡AÃ¥L¯v), triflupromazine (flurazine¡A´I祿ÀR), fluphenazine (flucan¡A復±d) . Thioxanthenes: thioridazine (melleril¡A¬ü立廉) . Dibenzoxazepines . Dihydroindole . Butyrophenones: haloperidol (haldol¡A¦n度) . Diphenylbutylpiperidine ²Ä¤@¥N§Ü精神¯f¾¯°Æ§@¥Î ¥Ñ¦h¤ÚÓiªýÂ_¤Þ°_ . À@Åé¥~®|¯g狀¸s(EPS): ¥]¬A¦Ù¦×ºò±i異±`¡BÀR§¤不¯à¡B¤Ú金´Ë¤ó¯e¯f(¦Ù¦×»øµw¡B行°Ê½wºC¡B¤â§Ýµ¥²{¶H) ªv療¤è¦¡: °±¥Î©Î降§C§Ü精神¯f¾¯¾¯量¡A¨Ö¥Î§ÜÁxÆP§@¥Î¾¯(¦ptrihexylphenidyl¡Bbiperidin)¡A©Î¥[¤W¦h¤ÚÓi«P¶i¾¯(¦pamentadine)¡C¥t¤]¥i¨Ï¥Îf¤G´á¤G´á¥(benzodiazepine)來µÎ½w¡C . ¿ðµo©Ê不¦Û¥D¹B°Ê: µo¥Í¦b¼L¤Ú¡B¦ÞÀY¡B¤U¤Ú¡B¥|ªÏ¡A¬Æ¦ÜÂß·FÀV³¡ªº°Ê§@¡A¯f¤H不Â_°µ©CÄZ狀¡B¦ÞÀY«½Æ¦R¥X¡B¹ª¼L¡B¯w²´¡B°µ°Áyµ¥¡C©Î«½ÆÁqªÓ¡BÂß·F·nÂ\¡B¤â«ü¸}³k不³W«h©Ê©â°Ê¡C ©|¥¼¦³¦³®Äªv療¤è¦¡¡C ¿ðµo©Ê¹B°Ê»Ùê¡]TD¡^¬O¥Ñ©óªø´ÁªA¥Î¸û¤j¾¯¶q§Üºë¯«¯fÃĪ«¤Þ°_ªº¤@²Õ¦Ù¸s¤£¦Û¥Dªº¸`«ß©Ê«½Æ¹B°Ê¡Aµo¥Í²v¦]ÃĪ«ºØÃþ¡B¾¯¶q¡BªAÃÄ´Á©M¦~ÄÖµ¥¦Ó¤£¦P¡C¸ê®ÆÅã¥Ü¡A¦~ÄÖ¡Ö50·³±wªÌTDµo¥Í²v°ª¹F50%¡C¿ðµo©Ê¹B°Ê»Ùê¦h¬°¤£¥i°f©Ê·l®`¡A¦Ó¥BªvÀø¸û¬°§xÃø¡A¦]¦¹¹w¨¾Åã±o¤Q¤À«n¡C ¿ðµo©Ê¹B°Ê»Ùê¡]TD¡^¤SºÙ¿ðµo©Ê¦h°Ê¯g¡B«ùÄò©Ê¹B°Ê»Ùê¡A¬O¤@ºØ¯S®í¦Ó«ù¤[ªºÀ@Åé¥~¨t¤ÏÀ³¡A¥Dn¨£©óªø´ÁªA¥Î¤j¾¯¶q§Üºë¯«¯fÃĪº±wªÌ¡A°¸¨£©óªø´ÁªA¥Î§Ü§íÆ{ÃÄ¡B§Ü¾_Ÿ³Â·ôÃÄ¡B§ÜÅöíwÃÄ©M§Ü²Õ´ÓiÃĪº±wªÌ¡C ¦UºØ§Üºë¯«¯fÃħ¡¥i¤Þ°_TD¡A¦Ó¥H¬t¾Ä¤DÀR¡]Fluphenazine¡^¡B¤T¬t©Ô嗪¡]Stelazine¡^©M¬t哌¥m¾J¡]Haloperidol¡^µ¥§t¬t¤¸¯Àªº§Üºë¯«¯fÃħó±`¨£¡C§Üºë¯«¯fÃÄ©ÒPªº¿ðµo©Ê¹B°Ê»Ùê¦bºë¯«¬ìÁ{§É¤W¬O¤@Ó¤ñ¸û´Æ¤âªº°ÝÃD¡A¤£¶È¼vÅT±wªÌªº¥Í¬¡½è¶q¡A¬Æ¦Ü¥i¦M¤Î±wªÌ¥Í©R¡C . §Ü²Õ´ÓiªýÂ_§@¥Î: ¤Þ°_Å髼W¥[ ¡K ²Ä¤G¥N§Ü精神¯f¾¯ . ²Ä¤G¥N§Ü精神¯f¾¯ªº¥Dnªv療®ÄªG來¦Û¦å²M¯À¤Î¦h¤ÚÓi§ÜÅ餧«ú§Ü§@¥Î(©Ò¥HºÙ¬°Serotonin-Dopamine Antagonists¡ASDA)¡F¦¹¥~¡Aclozapine¤Î»P¨ä¤Æ¾Çµ²ºc¡AÃÄ理§@¥Î類¦üªºÃĦpolanzapine¡Bquetiapineµ¥²ÎºÙMARTAs(Multiple-Acting Receptor Targeted Anti- psychotics )¡A¦Ó§Ü精神¯f¾¯³Ì·sªº¬ã¨s¬Oµo®idopamine system stabilizers¡C . ¨Ì¾Ú¬ü°ê精神¬ìÂå¾Ç·|¥Xª©¤§¡u精神¤À裂¯gªv療·Ç«h¡v¡Aclozapine ¥i¯à³y¦¨agranulocytosis ¦ý療®Ä³Ì¨Î¡A列¬°²Ä¤G©Î²Ä¤T½uÃÄ¡A¨ä¥Lªº§Ü精神¯f¾¯¬Ò¥i§@¬°精神¤À裂¯gªv療ªº²Ä¤@½uÃĪ«¡C ²Ä¤G¥N§Ü精神¯f¾¯ºØ類 ¤ÀÄÝ©ó¤T¤j類ÃÄ理©Ê½èÂkÄÝ¡G . ¦å²M¯À-¦h¤ÚÓi«ú§Ü¾¯(SDAs)¡G risperidone (理«ä¥²§´¡Arisperdal)¡Aziprasidone (geodon¡Aõ«ä)兩ºØ¡C . 神¸g¦h«¨üÅé§@¥Î¾¯類(MARTAs)¡G clozapine (¥iP律¿õ¡Aclozaril)¡Aolanzepine (zeprexa¡A金µÐÂÄ)¡Aquetiapine (seroquel¡A«ä樂±d)¡A©Mzotepine (lodopine¡Aµ¸¿w¥)µ¥¡C . ¿ï¾Ü©Ê¦h¤ÚÓi²Ä¤G©M²Ä¤T«¬¨üÅé«ú§Ü¾¯: amisulpride (solian¡Aº利¦w) . ³¡¤À©Ê¦h¤ÚÓi¨üÅé«P¶i¾¯¤Î¦å²M¯À1A¨üÅé«P¶i¾¯»P2A¨üÅéªýÂ_¾¯: aripiprazole (abilify¡A¦w立復) ²Ä¤G¥N§Ü精神¯f¾¯°Æ§@¥Î ¦h¤ÚÓi§@¥Î¤Þ°_¤§»Ùê . À@Åé¥~®|¯gÔ¸s¡G risperidone ÀH¾¯量¼W¥[®É¸û©úÅã¡Aziprasidone¡Bolanzepine¦b°ª¾¯量¤U¤~·|¡Aquetiapine¡Bclozapine¡Bzotepine©Mamisulpride·ÀI¸û§C¡C . °£了¦h¤ÚÓi§@¥Î¥~¡AÄÝ©ó¦h«¨üÅé§@¥Î¾¯類ªºÃĪ«¡A¤ñ°_¦å²M¯À- ¦h¤ÚÓi«ú§Ü¾¯ ¡A¦³¸û©úÅ㪺§ÜÁxÆP¤Î§Üªý´Ói§@¥Î¡C . Å髼W¥[¡G¥Hclozapine©Molanzepine¸û©úÅã¡Azotepine¦¸¤§¡Aquetiapine¡Brisperidone¸û»´·L¡Aziprasidone¡Bamisulpride©Maripiprazole´X¥G不·|¡C . ¦å糖¤ÎÅé¯×ªÕ¡]¤T»Ä¥Ìªo¯×¡^½Õ¸`異±`¤Î糖尿¯f§Î¦¨¡G©MÅ髼W¥[¤§¶É¦V¬Û¦ü¡C . ¤ß¹q¾É»Ùê(©µªø): ¦å²M¯À-¦h¤ÚÓi«ú§Ü¾¯¸û©úÅã¡A¤×¨ä¥Hziprasidone¦MÀI©Ê³Ì°ª¡C¥i¯à³y¦¨¤ß律不¾ã¡C ¥Ñ¤W±ªº¤¶²Ð §Ú̪¾¹D¦@¦Pªº°Æ§@¥Î¤j¬ù¦³¤T¶µ . À@Åé¥~®|¯gÔ¸s ( EPS ) . ¿ðµo©Ê不¦Û¥D¹B°Ê (Tardive dyskinesia ) . Å髼W¥[ ¤Î ¦å糖¤ÎÅé¯×ªÕ¡]¤T»Ä¥Ìªo¯×¡^½Õ¸`異±`¤Î糖尿¯f§Î¦¨ ¤£ª¾±M§Q¤å¥ó¤¤reducing hyperactivity or rescuing sensorimotor deficitªº§@¥Î ¬O§_©MÀ@Åé¥~®|¯gÔ¸s¤Î¿ðµo©Ê不¦Û¥D¹B°Êªº°Æ§@¥Î¬ÛÃö? Y¥i¥H´î»´ , ±N¬O¬ü¨Æ¤@¼Î ¥t¥~¹ï©óÅ髼W¥[ ¤Î ¦å糖¤ÎÅé¯×ªÕ¡]¤T»Ä¥Ìªo¯×¡^½Õ¸`異±`¤Î糖尿¯f§Î¦¨ªº°Æ§@¥Î NaBen ©M ³æ¹ç»Ä ³£¥i¥H°§CÁx©T¾J ³æ¹ç»Ä¤]¥i¥Î¥H¹w¨¾©MªvÀøT2D ( II«¬¿}§¿¯f ) ¤Î¨ä¬ÛÃöªºªÎD¯g ³æ¹ç»Ä¨ë¿E¸²µå¿}Âà¹B¨Ã§í¨î3T3-L1²ÓM¤¤ªº¯×ªÕ²ÓM¤À¤Æ academic.oup.com/jn/article/135/2/165/4663627 ªÎD¬OXºî¦X¼x©MII«¬¿}§¿¯f¡]T2D¡^ªº¥Dn¦MÀI¦]¯À¡CµM¦Ó¡A¤j¦h¼Æ°¿}ÃĪº§Ü¿}§¿¯fÃĪ«¤]·|«P¶iÅ髼W¥[¡AÁöµM´î»´T2Dªº¤@ºØ¯gª¬¡A¦ý¦P®É¤S¥[«¾ÉPT2Dªº¥Dn¦MÀI¦]¯À¡C¯×ªÕ²ÓMªº¤À¤Æ©M¼W´Þ¯×ªÕ¥Í¦¨¬O¾ÉPÅ髼W¥[©MªÎDªº¥Dn¾÷¨î¡C ³o¨Çµ²ªGªí©úTA¥i¥Î©ó¹w¨¾©MªvÀøT2D¤Î¨ä¬ÛÃöªºªÎD¯g¡C ¬ï´¡Âø¶Ãªº±Ôz , ¥u¦b»¡©ú ¤ß®®ªº¶W¯Å¾Ç¦WÃĨt¦C , ¬J¥iÁp¦X¨âªÌÀø®Ä , ¤S¥i¬Û¹ï´î»´¥Ø«e¥ÎÃĪº°Æ§@¥Î ½²±Ð±Â¥Ñ±M·~¾ÇÃÑ©Òl¥Íªº³Ð·N , ¤Sµo²{ ( NaBen + ³æ¹ç»Ä ) »P¤§°t¦X ¹ê¦b¬O³Ð·sªº²Õ¦X ¤pªº¤í¯Êª¾ÃÑ°ò¦ªº¬ïÆwªþ·| , ©Î¥¼ªí¹F¤½¥q³Ð·sªºì·N ¦³¥¢·q·N ¬è½Ð¤j®aªº«ü¾É«ü¥¿»P¸É¥R ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/5 ¤U¤È 07:43:57²Ä 476 ½g¦^À³
|
ÁÂÁ¹ù¥S¤À¨É³Ì·s¤å³¹ Âűб¬ã¨s¹Î¶¤¦A¦¸µoªíMDD¤§NMDAR¦³Ãö°ò¦]ªí¹F¤§±Ú¸s¬ã¨s®t²§ liawbf.pixnet.net/blog/post/48753153 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/3 ¤U¤È 06:30:14²Ä 475 ½g¦^À³
|
¨â½g¤å³¹¨Ñ°Ñ 1. ºë¯«¤Àµõ¯g¤¤¨¦®ò»Ä©MGABA¥¢½Õªº¦¬ÀÄ©Ê §@ªÌ¡GSarah A. Monaco¡AAustin A. Coley©MWen-Jun Gao www.intechopen.com/books/schizophrenia-treatment-the-new-facets/the-convergence-of-glutamate-and-gaba-dysregulation-in-schizophrenia µ²»y»¡¨ì ¥¼¨Óªº¬ã¨s¦³¥²n¶i¤@¨B¯}¸ÑNMDA¥\¯à´î°h¬O§_¥ý©óGABA¯à¯Ê³´¡A¤Ï¤§¥çµM 2. The impact of NMDA Receptor hypofunction on GABAergic interneurons in the pathophysiology of schizophrenia Samuel M. Cohen,1 Richard W. Tsien,1 Donald C. Goff,2,3 and Michael M. Halassa1,2,* www.ncbi.nlm.nih.gov/pmc/articles/PMC4724170/ Evidence that hypo-NMDA states and GABA dysfunction contribute to the schizophrenia phenotype at multiple levels. GABA deficits secondary to NMDAR hypofunction |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2019/1/3 ¤U¤È 01:14:24²Ä 474 ½g¦^À³
|
^°ê¾ÇªÌªº½×¤å ºë¯«¤Àµõ¯g¤¤ªº¨¦®ò»Ä©M¦h¤ÚÓi¡G21 ¥@¬öªº³Ì·s¶i®i www.ncbi.nlm.nih.gov/pmc/articles/PMC4902122/ ¤º®eºKn : . ¬ã¨sµo²{¡A»P¹ï·Ó²Õ¬Û¤ñ¡Aºë¯«¤Àµõ¯g±wªÌ¦h¤ÚÓiÄÀ©ñÅãµÛ¼W¥[¡A¦b±wªÌ¤¤©ñ®g©Ê¥Ü踪¾¯ªº§ïÅܵ{«×¤j¬ù¥[¿¡A¨Ã¥B§ïÅܵ{«×»Pºë¯«¯f¯gª¬ªº´c¤Æµ{«×¬ÛÃö¡C . ¸£¤¤ªº¿³¾Ä©Ê¯«¸g¶Ç»¼¥Dn¬O¨¦®ò»Ä¯à¡A¨¦®ò»Ä¯à¯«¸g¤¸§Q¥Î¦ûÁ`¸£¥NÁ¬¡©Êªº60¢H¦Ü80%¡C¨¦®ò»Ä¯à¯«¸g¶Ç»¼³q¹L¥NÁ«¬©MÂ÷¤l«¬¨¦®ò»Ä¨üÅéµo¥Í¡A¾¨ºÞ¤w¯A¤Î³\¦h¨¦®ò»Ä¨üÅé¡A¦ý¥Dnªº°²³]¬ONMDA¨üÅé¥\¯à»Ùꬰ¥Dn°Ñ»PªÌ¡C . ¨ãÅé¦Ó¨¥¡ANMDA¨üÅé«ú§Ü¾¯¤w³QÃÒ©ú°§C¤FGABA¯à¤¤¶¡¯«¸g¤¸¥\¯à , §Î¦¨¥h§í¨î¤Æ , ¾ÉPÀ@Åé²ÓMµo©ñ¼W¥[¡C¦³¤H´£¥X¥¦Ì¥i¯à¹ïGABA¯«¸g¤¸¤Wªí¹FªºNMDA¨üÅé¨ã¦³Àu¥ý§@¥Î¡C¥t¤@ºØ°²³]«h¬ONMDA¨üÅé«ú§Ü¾¯»¤¾Éªº¬¡©Ê®ñ¤ô¥Åܤƥi¯à¬O³oºØ¾÷¨îªº®Ö¤ß²Õ¦¨³¡¤À¡A¦]¬°°§C¶W®ñ¤Æª«¤ô¥·|ªý¤î´âÓi଻¤¾Éªº¤¤¶¡¯«¸g¤¸¬¡°ÊÅܤơC¦¹¥~¡A§í¨î¬¡©Ê®ñª«½è§Î¦¨ªýÂ_¤FNMDA¨üÅé«ú§Ü¾¯¦b°Êª«¤¤ªº¦æ¬°®ÄÀ³¡C( NaBen ¤]¥i´î°ROS (¬¡©Ê®ñ) Cinnamon metabolite sodium benzoate (NaB) reduces the production of ROS and the activation of p21rac in microglia.) . ¦h¤ÚÓi©M¨¦®ò»Ä°²»¡ªº¾ã¦X .. NMDA¥\¯à´î°h©M¬ðIJ«e¦h¤ÚÓi¥\¯à»Ùꪺ²Õ¦X¥i¥H´£¨Ñºë¯«¤Àµõ¯gªº©Ò¦³Á{§É¤è±ªº³Ì¨Î¸ÑÄÀ¡C .. ºë¯«¤Àµõ¯g¤¤©Ò¨£ªº¦h¤ÚÓi¥\¯à¥i¯àÄ~µo©ó§ïÅܪº¨¦®ò»Ä¯à¥\¯à¡]McGuire µ¥¡A2008¡^¨¦®ò»Ä¯à©M¦h¤ÚÓi¯à³q¸ô¤§¶¡ªº¬Û¤¬§@¥Î , ¦p¹Ï©Ò¥Ü www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=4902122_emss-66264-f001.jpg . ¦h¤ÚÓi©M¨¦®ò»Ä°Ñ»Pºë¯«¤Àµõ¯g¦³¨âºØ¥i¯àªº¸ÑÄÀ¡C¤@Ó¬O¥¦Ì¬O³oºØ¯e¯fªº¤£¦P¨È«¬ªº°ò¦¡A»P³ÌªñªºªvÀø@Ãĩʵ²ªG¤@P¡C¥t¤@Óºî¦X°²³]¡A¥¦¥i¥H¸ÑÄÀ¬ðIJ«e¦h¤ÚÓiªº¶§©Ê¯gª¬¡A¥H¤Î¨¦®ò»Äªº³±©Ê©M»{ª¾¯gª¬¡C ¥Ø«e«äı¥¢½Õªº¥ÎÃÄ , ³£¬O°w¹ï¦h¤ÚÓi©M¦å²M¯À¨Ó§@¥Î NaBen «h¬O°w¹ï NMDA ¨Ó¥[±j «e±ªº±Ôz´N¬O¦h¤ÚÓi©M¨¦®ò»Äªº¬Û¤¬§@¥Î , ©Îµo´§¤ôÀ°³½ ³½À°¤ôªº¨}©Ê¼vÅT´`Àô SND-13 ´N¬O½²±Ð±Âªº³Ð·N , §â¨âªÌ¥[¦b¤@°_ªvÀøªº³Ç§@ ®ÄªG¦n¤£¦n©O ? §ÚÌ¥un¬Ý SND-13 ¤G(a)´Áªº¼Æ¾Ú , ¥[¤W¥Î³oӼƾÚÀò±o FDAªº«C·ý , ®³¨ì¤F BTD , ´N¥i²¤ª¾¤@¤G ³o½g½×¤å©Î³\À°§U§Ú̹ï SND-13 { add-on } ªºÁp¦X¾÷¨î¦³¤@Ó°ò¦ªº»{ÃÑ Åý§Ú̦b§ë¸ê¤§¾l , ¤]¦³ª¾ÃѤWªº¦¬Ã¬ Google½Ķ©M·QªkY¦³¿ù , ·q½Ð«ü¾É«ü¥¿ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/12/28 ¤W¤È 12:20:53²Ä 473 ½g¦^À³
|
¤p©¯¹B¤j ¥¿¦n¬ù¦b¤@¦~«e¡A¤]´N¬O2018¦~¤¸¥¹¥»ª©¤]´¿°Q½×¹LRS-D7³o´Ú¬ãµo¤¤·sÃÄ¡C ´N¦b¥»ª©¡upage 2¡v¡G¡u2018/1/1 ¤W¤È 12:49:00²Ä 247 ½g¦^À³¡v 2018¤¸¥¹¤pÂI¤ß¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/12/27 ¤U¤È 08:12:38²Ä 472 ½g¦^À³
|
Janssen ªº¬ãµo¤HûA. Ahnaou, H. Huysmans, T. Van de Casteele, and W. H. I. M. Drinkenburgµ¥¤H ¦b2017/12µoªí¤@½g½×¤å Cortical high gamma network oscillations and connectivity: a translational index for antipsychotics to normalize aberrant neurophysiological activity www.ncbi.nlm.nih.gov/pmc/articles/PMC5802558/ ¥L̥Φh¤ÚÓi¯à¿E°Ê¾¯¡]f¤þÓi¡^©MN-¥Ò°ò-D-¤Ñ¥V®ò»Ä¡]NMDA¡^¨üÅé«ú§Ü¾¯¡]PCP©MMK801¡^¦b¤£¦P¥Ö½è°Ï°ì¼ÒÀÀ¶§©Ê¯gª¬©M»{ª¾¯Ê³´¬ÛÃöÂZ°Êªººôµ¸®¶Àú ¨Ã¥Î«D¨å«¬§Üºë¯«¯fÃÄolanzapine, risperidone, and clozapine ¨Ó¥¿±`¤Æ¥\¯à¥¢½Õªº®¶Àú In the combined treatments, antipsychotics attenuated NMDA antagonist-induced abnormalities in functional network oscillations and connectivity, whose effects on motor behavior is mechanistically related. These results suggest that pharmacologically induced disruption of cortical gamma oscillations and network connectivity in rats is a candidate model to study dysfunctional oscillatory patterns described in positive and negative symptoms of schizophrenia. The efficacy of antipsychotics to rescue cortical network oscillatory patterns is in line with the idea that glutamatergic and dopaminergic systems play a role in maintaining the integrity of cortical circuits. ¤pªº¦n©_ªº¬O ¥L̦³¨S¦³§âf¥Ò»Ä¶u¥[¶i¨Ó , °µ¤@Ó add-on ªº¤è¦¡ , ¨Óµû¦ô¬Ý¬Ý¥LÌ©Ò»¡ªºglutamatergic and dopaminergic systems play a role in ¡K ©Î³\¨S¦³ , ¤]©Î³\¦³ , ¥u¬OÁô¦Ó¤£µo , ¤S©Î¤wµo , ¥u¬O¤pªº¨S§ä¨ì ¦³½Ðª¾±¡ªº¤j¤j¸É¥R«ü¾É«ü¥¿ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2018/12/27 ¤W¤È 10:54:07²Ä 471 ½g¦^À³
|
ªñ¤é¬Ý¨ì»O¤j²£¾Ç¦X§@Á`¤¤¤ß¦bNMDA¨üÅé½Õ¸`¾¯·s¬ã¨s§Þ³N... --------------------------------------------------------------------------------- µo©ú¦WºÙ¡GNMDA¨üÅé½Õ¸`¾¯ µo©ú¤H¡G´¿¦t»ñ±Ð±Â¡B¿à¤å±]±Ð±Â¡B¼B´¼¥ÁÂå®v¡BJ®ü°êÂå®v¡B®]¥ò»Ê±Ð±Â¡B ¼B¥ÉÄR¬ã¨sû ³æ¦ì¡G°ê¥ß»OÆW¤j¾Ç¥ÍÂå¹q¤l»P¸ê°T¾Ç¬ã¨s©Ò¡B¤ß²z¾Ç¨tº[¬ã¨s©Ò¡BÂå¾Ç°|ºë ¯«¬ì¡B°ê¥ß¥æ³q¤j¾ÇÀ³¥Î¤Æ¾Ç©Ò¡B°ê®a½Ã¥Í¬ã¨s°|¯«¸g¤Îºë¯«Âå¾Ç¬ã¨s¤¤¤ß¡C ²¾ú¡Gwww.csie.ntu.edu.tw/~yjtseng/ ¥«³õ¤Î»Ý¨D¡G¥@¬É¤W¦³1%ªº¤H¤f±w¦³«äı¥¢½Õ¯g¡A±wªÌ´¶¹M·|¨ü¥¿©Ê¡Bt©Ê¡B »{ª¾¥\¯à¥¢½Õ¡B»P±¡ºü¥¢½Õµ¥¯gª¬¼vÅT¡C¥Ø«e¥«³õ¤W¥u¦³¥i¥H§ïµ½¥¿©Ê»P±¡ºü¯g ª¬ªºÃĪ«¡At©Ê©M»{ª¾¥\¯à¥¢½Õ¯gª¬¦Ü¤µ¤´µLÃÄ¥iªv¡C §Þ³NºKn:¥Ø«e¹Î¶¤¤w³]p¥X¤@¨t¦C¥iªvÀø«äı¥¢½Õ¯gt©Ê¯gª¬ªº¤p¤À¤lÃĪ«¡A ³z¹L¼W¥[NMDA¨üÅ骺¬¡©Ê¨Ãª½±µªº§ïµ½«äı¥¢½Õ¯g»{ª¾¥\¯à»Pt©Ê¯gª¬¡A¨ä¤¤ ½s¸¹RS-D7¬O§Ú̪º³Ì¨ÎÔ¿ïÃĪ«¡A¥i¥Î©óªvÀø¯«¸g¨t²Î¬ÛÃö¯e¯fªº¾AÀ³¯g¡C Àu¶Õ:ÃĪ«¦w¥þ©Ê°ª¡B¤w²¤Æ¦X¦¨¨BÆJ¡B°Êª«¼Ò«¬ÃĮݪ¡B¤w¦³Á{§ÉÅçÃҩʸê®Æ¡C Ävª§²£«~:SyneuRxªºSodium benzoate¦P¼Ë¬ONMDA¨üÅé½Õ¸`¾¯¥Ø«e¦bPhase II¶¥ ¬q¡C ---------------------------------------------------------------------------- ---------------------------------------------------------------------------- ªñ´X¦~¶V¨Ó¶V¦hªº¥xÆW¬ã¨s¹Î¶¤§ë¤JNMDA¨üÅé½Õ¸`¾¯¤§¬ã¨s... ³o¤]¥Nªí¨«¦b«eÀYªº¤ß®®¹Î¶¤¦¨¥\¾÷²v¶V¨Ó¶V°ª... °Ñ¦Ò¨Ó·½:file:///C:/Users/Administrator/Downloads/%E6%8A%80%E8%A1%93%E6%8E%A8%E5%BB%A3%E8%A1%A8-NMDA%E5%8F%97%E9%AB%94%E8%AA%BF%E7%AF%80%E5%8A%91%20(2).pdf ¥H¤W¸ê°T~~¨Ñªø´Á§ë¸ê¾Ô¤Ḭ́ѦÒ... |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/12/25 ¤W¤È 10:51:30²Ä 470 ½g¦^À³
|
¾ú¨Ó³Ì¤j³W¼Ò¬ã¨s¡G³\¦h±`¨£ÃĪ«¥i¯à¤Þ°_¼~Æ{¯g 2018-12-25 10:44Áp¦X³ø °OªÌ§d¤é§g¢¬§Y®É³ø¾É udn.com/news/story/6813/3556451 ©Ò¦³ÃĪ«³£¦³¼ç¦b¥i¯à¤Þµo¤£¨}°Æ§@¥Î¡A¦Ó¼~Æ{¯g¬O±`¨£°Æ§@¥Î¤§¤@¡C®Ú¾Ú¡m¬ü°êÂå¾Ç·|´Á¥Z¡n6¤ëµoªí¤@¶µ¬ã¨sÅã¥Ü¡A¦³¤T¤À¤§¤@¬ü°ê¤H¥Ø«eªA¥ÎÃĪ«¥i¯à¤Þ°_±¡ºü»Ùê¡C¨ä¥L¬ã¨s¤]¦³Ãþ¦üµo²{¡A¬ü°êÂå¾Ç·|¬ã¨s«h¬O¾ú¨Ó³Ì¤j³W¼Ò¬ã¨s¦¨ªG¡C ¬ã¨s¤Hûµo²{¡A¬ù¦³200ºØ³B¤èÃĪ«¡A¥]¬A¦Ñ¦~¤H±`¥ÎÃĪ«¡A¨Ò¦p¥Î©óªvÀøG»Ä¬ÛÃö¯e¯fªº²BÂ÷¤lÀ°®úªýÂ_¾¯(proton pump inhibitor¡A²ºÙPPI)¡A¥H¤ÎªvÀø°ª¦åÀ£ªº£]¨üÅéªýÂ_ÃÄ(Beta blocker¡^¡A¥i¯à¾ÉP¼~Æ{¯g¡CôÛ¤ñ¨È¤j¾Ç¼Ú¤åÂå¾Ç¤¤¤ßºë¯«¯f¾Çº[¬y¦æ¯f¾Ç±Ð±Â¶ø¶O´Ë(Mark Olfson)ªí¥Ü¡A¦ý³\¦hÂå¥Í¥i¯à¤£ª¾¹D¡A±`¥Î³B·ÃĪ«»P¼W¥[±¡ºü¥¢±±·ÀI¦³Ãö¡C ¬ã¨s«ü¥X¡A¤H̪A¥ÎÃĪ«¶V¦h¡A¼W¥[¼~Æ{·ÀI¶V°ª¡C¹ï©ó¤@¨ÇªA¥Î¦hºØÃĪ«ªº¦Ñ¦~¤H¡A¥i¯à¦³§ó¦h¾÷²v¨ü¨ìÃĪ«°Æ§@¥Î¼vÅT¡C¦ý¶ø¶O´Ë¤]»¡¡A§Y¨ÏªA¥ÎÃĪ«»P¼~Æ{¦³Ãö¡A¤]¤£¤@©w¬O³y¦¨¼~Æ{ì¦]¡A¦]¬°¤j¦h¼ÆªA¥ÎÃþ¦üÃĪ«ªº¤H¡A¨Ã¥¼¿©±w¼~Æ{¯g¡C ¯Ã¬ù¦è©`¤s¨Ì§¢Âå¾Ç°|ºë¯«¾Ç±Ð±Â¸ëªL§J(Igor Galynker)ªí¥Ü¡A¦³®ÉÔ¡A¤H̦b¶}©lªAÃÄ«e´Nµo¥Í¼~Æ{¡A©Î¬O¦UºØ°·±dª¬ªp¾ÉP¼~Æ{¡C¨Ò¦p¥b¼Æ¥H¤W¦³ºC©Ê¯kµhªÌ©ö±w¼~Æ{¡A¦]¬°·Pª¾¯kµhªº¤j¸£³¡¤À¤]·|¼vÅT±¡ºü¡C¥H¤U¬O¥i¯à¾ÉP¼~Æ{ªºÃĪ«¡G 1. £]¨üÅéªýº¢¾¯©M¦åºÞºò±i¯ÀÂà´«酶§í»s¾¯(¦åÀ£ÃĪ«)¡Gmetoprolol¡Batenolol¡Benalapril»Pquinapril¡C 2. §Ü¼~Æ{ÃĪ«¡GªÙ¦±ªL(Zoloft»P¾Ç¦WÃÄ)¡B¦è酞´¶Äõ(Celexa)¡B¤G´á¥(Wellbutrin)¡Bªü¦Ì´ÀªLµ¥¡C 3. §ÜļÆ{ÃÄ¡Galprazolam (Xanax)¡Bclonazepam (Klonopin)¡Bdiazepam (Valium)¡Blorazepam (Ativan )¥H¤Îsedative zolpidem (Ambien )¡C 4. ¾~¤ùÃþÃĪ«¡]Opioid¡^¡G²B¥iଲզXÃĪ«(Lorcet¡BNorco¡BVicodin»P¨ä¥L¾Ç¦WÃÄ)¡Btramadol (ConZip)¡C 5. ¥Ö½èÃþ©T¾J¡Gprednisone»P¨ä¥L¡C 6. Ãĩж}¬[ÃĪ«²BÂ÷¤lÀ°®úªýÂ_¾¯(PPI)G»Ä»s¾¯¡Gomeprazole (Prilosec, Zegerid) ¡Besomeprazole (Nexium)¡Bantacids ranitidine (Zantac and generic)¥H¤Îfamotidine (Pepcid)µ¥¡C 7. ¹L±Ó»P®ð³ÝÃĪ«¡G¶}¬[Zyrtec¥H¤Î³B¤èÃĪ«montelukast (¦pSingulair)¡C 8. §ÜÅöíw¯gÃĪ«(Anticonvulsants)¡Ggabapentin (Neurontin)¡Btopiramate (Topamax)¡C 9. ¶Pº¸»X¡G»Û¿E¯Àestradiol (Delestrogen¡BElestrin¡BEstroGel)¡B¤fªA¶¯©Ê¨rÃĪ«finasteride (Proscar¡BPropecia)¡C ¦P®É¡AªA¥ÎÃĪ«®É¡A¶·¦P®ÉºÊ±±±¡ºü¡BÀˬdªA¥ÎÃĪ«¤º®e¡B±K¤ÁÃöª`ªA¥Îªº·sÃÄ¡B¸ß°Ý¦³Ãö§ó´«ÃĪ«¸ê°T¡A©Î¿Ô¸ßÂå¥Í¡A¦Ò¼{¥Í¬¡¤è¦¡¡A¨Ò¦p§Ö¨B¨«¸ô¥i§ïµ½¤[§¤¤£°ÊªÌªº¼~Æ{±¡ªp¡C ¼~Æ{ÃĪ«ªº¾÷·|? |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/12/24 ¤U¤È 06:54:56²Ä 469 ½g¦^À³
|
½LÂI| 2018¦~10¤jÃĪ«Á{§É¬D¾Ô¡GAD¬ãµo²×¤î²v³Ì°ª ¤å³¹°Ñ¦Ò¨Ó·½¡GDown but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018 ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-12-24 ·s®öÂåÃĽsĶ/newborn med.sina.com/article_detail_103_2_58011.html ¦^ÅU2018¦~¡AÂåÃĦæ·~¨ú±o¤F«Ü¦h¦¨´N¡A¦ý¤]±Á{µÛ«Ü¦h¬D¾Ô¡C¥H¤U¬OBiospaceºô¯¸¦C¥Xªº2018¦~³Ì¤Þ¤Hª`¥Øªº¤Q¤jÃĪ«Á{§É¬D¾Ô¡G 1¡Bpioglitazone 1¤ë25¤é¡AªZ¥Ð»sÃÄ»P¦X§@¹Ù¦ñZinfandel¸g¹L¤¤´Á¤ÀªR«á©ñ±ó¤F¬°´Á5¦~ªºTOMORROWÁ{§ÉIII´Á¬ã¨s¡A¸Ó¬ã¨s¥¿¦bµû¦ôpioglitazoneªvÀøªüº¸¯ý®üÀq¤ó¯g¡]AD¡^¤Þ°_ªº»´«×»{ª¾»Ùê¡C 2.BI-409306 2¤ë9¤é¡A«kªL®æ®ï®æ¿««Å¥¬BI-409306¥¼¯à¹F¨ì¥Dn²×ÂI¡A±N²×¤îII´ÁÁ{§É¶}µo¡C¸ÓÃĬO¤@ºØPDE9§í»s¾¯¡A¥Î©óªvÀøºë¯«¤Àµõ¯g©MAD±wªÌªº»{ª¾·l®`©M°O¾Ð»Ùê¡A¦b¨âÓ³æ¿WªºÁ{§É¬ã¨s¤¤§¡¥¼¯àÅã¥Ü¥XÀu©ó¦w¼¢¾¯ªº»{ª¾Àu¶Õ¡C 3¡Bverubecestat 2¤ë14¤é¡AÀq¨FªF«Å¥¬²×¤îverubecestatªvÀø«eÅX´ÁADªº¤j«¬III´ÁÁ{§É¬ã¨sAPECS¡]protocol 01 9 ¡^¡C¥~³¡¼Æ¾ÚºÊ´ú©eû·|¡]eDMC¡^¦b§¹¦¨¤@¶µÁ{®É¤¤´Á¤ÀªR«á«Øij²×¤î¸Ó¬ã¨s¡AºÙ¨ü¯qªº¥i¯à©Ê¨Ã¤£¤j©ó·ÀI¡C¦Ó¦b2017¦~2¤ë14¤é·í¤Ñ¡A¸Ó¤½¥q«Å¥¬²×¤îverubecestatªvÀø»´¦Ü¤¤«×ADªº¤j«¬III´ÁÁ{§É¬ã¨sEPOCH¡]protocol 017¡^¡C³o¤]·N¨ýµÛ¡AverubecestatªvÀøADªºIII´ÁÁ{§É¶µ¥Ø¤w§¹¥þ²×¤î¡Cverubecestat¬O¤@ºØ£]-¾ý¯»¼Ë³J¥Õ«eÅé³J¥Õµõ¸Ñ酶1¡]BACE1¡^¤p¤À¤l§í»s¾¯¡C 4¡Bozanimod 2¤ë28¤é¡A·s°ò¦hµo©Êµw¤Æ¯g¡]MS¡^¤fªAÃĪ«ozanimod·sÃĥӽС]NDA¡^¦¬¨ì¬ü°êFDAªº©Úµ´¨ü²z³qª¾®Ñ¡]RFL¡^¡A¦ÓFDAµ¹¥Xªº©Úµ´¨ü²z²z¥Ñ©~µM¬O¸ÓÃÄNDA¤¤ªº«DÁ{§É©MÁ{§ÉÃIJz¾Ç³¡¤À¡AÁnºÙ¸Ó³¡¤ÀÃÒ¾Ú¤£¨¬¥HÄ~Äò¹ï¨ä¶i¦æ¼f¬d¡C ¤µ¦~6¤ë¡A·s°ò©Ó»{¿ù»~¡A¦ý±N¿ù»~Âk©S©ó¤l¤½¥qReceptos¡COzanimod¬O·s°ò´Á±æ«Ü°ªªº«á´ÁºÞ½uÃĪ«¡A ¦b2015¦~¥H72»õ¬ü¤¸¦¬ÁÊReceptos«áÀò±o¡C 2017¦~5¤ë²Ä2ÓÃöÁä©ÊIII´ÁRADIANCEªº¿n·¥¼Æ¾Ú¥XÄl¤§«á¡A·s°ò¦b2017¦~©³´£¥æ¤FozanimodªºNDA¡C¤µ¦~10¤ë¡A·s°ò¤½§G¤F¨Ó¦ÛIII´ÁSUNBEAM©MRADIANCE B³¡¤À¬ã¨sªº¨â¶µ¨Æ«á¤ÀªR¿n·¥¼Æ¾Ú¡A¨Ãªí¥Ü±N©ó2019¦~¦A¦¸´£¥æ¥Ó½Ð¡C 5¡Bepacadostat 4¤ë6¤é¡AIncyte¤½¥q©ÜÅS¨äIDO1ÃĪ«epacadostat»PÀq¨FªFPD-1¸~½F§K¬ÌÀøªkKeytrudaÁp¦X¥ÎÃĤè®×¦b¶Â¦â¯À½F III´ÁÁ{§É¬ã¨s¡]ECHO-301/KEYNOTE-252¡^¤¤¥¼¯à¹F¨ì¥Dn²×ÂI¡C 6¡Bazeliragon 4¤ë10¤é¡AvTv Therapeutics¤½¥q«Å¥¬azeliragonªvÀø»´«×ADªºIII´ÁSTEADFASTÁ{§É¬ã¨s¥¼¯à¹F¨ì¦@¦P¥DnÀø®Ä²×ÂI¡C¸Ó¬ã¨s¥Ñ¨âÓ¿W¥ß¦ý¬Û¦PªºÂùª¼¡B¦w¼¢¾¯¹ï·ÓPart A©MPart B²Õ¦¨¡CPart A¼Æ¾ÚÅã¥Ü¡A±µ¨üazeliragonªvÀøªº±wªÌªüº¸¯ý®üÀq¤ó¯gµû¦ô¶qªí-»{ª¾¤l¶qªí¡]ADAS-cog¡^¬Û¹ï°ò½u¤U°4.4¤À¡BÁ{§Éè§bµû©w¶qªí¡]CDR-sb¡^¬Û¹ï°ò½u¤U°1.6¤À¡A¦w¼¢¾¯²Õ¤À§O¤U°3.3©M1.6¡C³o¨ÇÅܤƦbÁ{§É¤W¨Ã¤£ÅãµÛ¡CAzeliragon¬O¤@ºØ·s«¬¤fªARAGE¬¡©Ê¤p¤À¤l§í»s¾¯¡A¬O¤½»{ªºªý¤î¸£¨üÅéRAGE¡]±ß´Á¿}¤Æ²×²£ª«¨üÅé¡^ªº³Ì¥ý¶iÃĪ«¡CvTv¤½¥q»{¬°¡AªýÂ_RAGE¥i¥H3ºØ¤è¦¡§ðÀ»AD¡G¯}ÃaAD¾ý¯»¼Ë³J¥Õ¤ù¬qªº»W¿n¬r©Ê¡F´î½w»P¨ä¬ÛÃöªºtau³J¥Õ¤À¸Ñ¡F´î¤Ö¤j¸£ª¢¯g¡C 7¡Bcobimetinib 4¤ë11¤é¡Aù¤ó©MExelixis¼È°±Âಾ©Êµ²ª½¸zÀù II´ÁÁ{§É¬ã¨sMODUL±wªÌ©Û¶Ò¡Aì¦]¬O¦³4¨Ò±wªÌ±µ¨üù¤óPD-L1¸~½F§K¬ÌTecentriq»PExelixis¤½¥qMEK§í»s¾¯Cotellic¡]cobimetinib¡^Áp¦XªvÀø«á¦º¤`¡C¤µ¦~5¤ë¤¤¦¯¡ATecentriq+Cotellic²Õ¦XÀøªk¦bªvÀø¬J©¹±µ¨ü¦Ü¤Ö¨â½ü¤ÆÀø¥¢±Ñªºµ²ª½¸zÀù±wªÌIII´ÁÁ{§É¬ã¨sIMblaze370¤¤Àø®Ä¤£¼Ä«ô¦Õ¹v¦VÃĪ«Stivarga¡]regorafenib¡^¡CCotellic¬O¤@ºØ¤fªA¤p¤À¤lMEK§í»s¾¯¡AMEK¬O¤@ºØ³J¥Õ¿E酶 8¡Batabacestat 5¤ë18¤é¡A±j¥ÍºX¤U·¨´Ë²×¤îatabacestat¡]¤@ºØBACE§í»s¾¯¡^ªvÀøADªºÁ{§É¶µ¥Ø¡C¦¹¦¸²×¤îì¦]¬O¦w¥þ©Ê°ÝÃD¡A¦Ó¤£¬OÀø®Ä¤è±¡C¦bÁ{§É«eAD±wªÌ¤¤¶}®iªºIIb/III´Á¬ã¨sEARLY¥H¤Î¦b¤@¶µII´Áªø´Á¦w¥þ©Ê¬ã¨s¤¤§¡Åã¥Ü¡A±wªÌ¨x酶¤É°ª¡CEARLY¬ã¨s©ó2015¦~±Ò°Ê¡Aìp¹º¦b2024¦~µ²§ô¡C 9¡BExondys 51 9¤ë21¤é¡ASarepta Therapeutics¤½¥q§ù¤ó¦ÙÀç¾i¤£¨}¯g¡]DMD¡^ªvÀøÃĪ«Exondys 51¤W¥«¥Ó½Ð³Q¼Ú¬wÃÄ«~ºÞ²z§½¡]EMA¡^»é¦^¡Cȱoª`·Nªº¬O¡A¦b¬ü°êºÊºÞ¤è±¡AFDA¦b¯A¤Î¸Ó¾÷ºc¤º³¡½Ä¬ð¡B´CÅé³ø¾É¡B°ê·|ijû¥H¤ÎDMD±M®a¤p²Õµo¥X¤½¶}«H¥ó´°«P§å㪺¿E¯Pª§°«¤§«á¡A©ó2016¦~9¤ë§åã¤FExondys 51¡C´£¥æµ¹EMAªº¥Ó½Ð¬O°ò©ó¹ï12¨Ò7-13·³DMD¨k«Ä¶}®iªº¨â¶µÁ{§É¬ã¨s¡C ¦b¬ü°ê¡AExondys 51ªº»ù®æ¼ÐÅÒ°ò©ó±wªÌÅé«¡A¤j¬ù¬°¨C¦~30¸U¬ü¤¸¡C 10¡BALKS5461 11¤ë2¤é¡AFDAªº¨âÓÅU°Ý©eû·|§ë²¼§_¨M¤FAlkermes¤½¥qªº§íÆ{¯gÃĪ«ALKS5461¡C¨ãÅé¦Ó¨¥¡A©eû·|¥H21:2ªº§ë²¼µ²ªG¤Ï¹ï§åã¸ÓÃÄ¡A¦P®É¥H20:3ªº§ë²¼µ²ªG»{¬°Alkermes¤½¥q¨S¦³´£¨Ñ¤ä«ùALKS5461Àø®Äªº¹ê½è©ÊÃÒ¾Ú¡C ¤µ¦~4¤ë¡A¸ÓÃÄNDA¦¬¨ìFDAªº©Úµ´¨ü²z³qª¾®Ñ¡A¸Ó¾÷ºc»{¬°NDA¤¤©Ò¯Ç¤JªºÁ`ÅéÀø®ÄÃÒ¾Ú¤£¨¬¡An¨D¶}®i§ó¦hªºÁ{§É¸ÕÅç¥H¤ä«ù«·s´£¥æ¡C¤§«áAlkermes¤½¥q´£¥X¤W¶D¡A¦ÓÀH«áFDA¤]§ïÅܤF¥D·N¡A«·s¨ü²z¤FALKS5461ªºNDA¡APDUFA¥Ø¼Ð¤é´Á¬°2019¦~1¤ë31¤é¡CÁöµM¨âӿԸߩeû·|³£±j¯P¤Ï¹ï¡A¦ý¨ä·N¨£¹ïFDA¨Ã¨S¦³ªk«ß¬ù§ô¤O¡A¤]´N¬O»¡¸Ó¾÷ºc¦b°µ¥X³Ì²×¼f¬d¨M©w®É¨S¦³¥²n¿í´`¿Ô¸ß©eû·|ªº«Øij¡A¦ý¦pªGFDA§åã¤F¸ÓÃĪ«¡A±N¥O¤H·P¨ìÅå³Y¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/12/24 ¤U¤È 06:34:35²Ä 468 ½g¦^À³
|
©¬ª÷´Ë·sÃÄ¡I¥ª±Û¦h¤Ú§l¤J¯»INBRIJAÀòFDA§åã ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-12-24 med.sina.com/article_detail_103_2_58020.html ¤é«e¡AAcorda »sÃÄ«Å¥¬¡A¬ü°ê¹«~©MÃĪ«ºÞ²z§½¡]FDA¡^§åãINBRIJA¥Î©ó±µ¨ü¥d¤ñ¦h¤Ú/¥ª±Û¦h¤ÚªvÀøªº©¬ª÷´Ë¯fÃö³¬´Á¡] OFF ¡^¶¡·²©ÊªvÀø¡C INBRIJA¬O¤@´Ú«K©ó±wªÌ¦Û¤v¾Þ§@ªº§l¤J¦¡¥ª±Û¦h¤Ú¡A¥Î©óªvÀø¥Ø«e¦b¨Ï¥Î¥d¤ñ¦h¤Ú/¥ª±Û¦h¤Úªº©¬ª÷´Ë¯f±wªÌÃö³¬´Á¯gª¬¡CINBRIJA§Q¥ÎAcordaªºARCUS¥¥x¶}µo¡A¦®¦b¦VªÍ³¡´£¨Ñºë½T¾¯¶qªº¥ª±Û¦h¤Ú°®¯»»s¾¯¡C¤fªAÃĪ«»Ýn¥ý³q¹L¸zG§l¦¬¦A¨ì¹F¤j¸£¡A©Ò¥H°_®Ä¹Lµ{·|¦³ÅܤơC¦Ó§l¤J¦¡ªvÀø¥i¥H³q¹LªÍ³¡¶i¤J¨Åé¡Aª½¹F¤j¸£¡A¶¹L¤F®ø¤Æ¨t²Î¡C ©¬ª÷´Ë¯f¬O¥Ñ©ó¬Y¨Çt³d²£¥Í¦h¤ÚÓiªº¯«¸g¤¸³vº¥³à¥¢¦Ó¤Þ°_ªº¶i¦æ©Ê¯«¸g°h¦æ©Ê¯e¯f¡A·|¾ÉP¤@¨t¦C¯gª¬¡A¥]¬A¹B°Ê¨ü·l¡B¦Ù¦×»øµw©M¾_Ÿ¡C¥Ø«e¡A¥d¤ñ¦h¤Ú/¥ª±Û¦h¤Ú¾¯¶q¬O©¬ª÷´Ë¤ó¯g¤fªAªvÀø¼Ð·ÇÃĪ«¡C¡§¶}-Ãö²{¶H¡¨¡]ON-OFF¡^¬O©¬ª÷´Ë¯f¤HÃĪ«ªvÀø«á´Áªº¨Ãµo¯g¡C¡§¶}¡¨¬O«üÃĪ«ªvÀø¹ï¯f¤H°_¨ì©úÅ㪺ªvÀø®ÄªG¡A¯f¤H¯à¹B°Ê¡F ¡§Ãö¡¨¬O«ü¯f¤H¦b±µ¨üªvÀø¤@¬q®É¶¡«á¹B°Ê¯à¤O³à¥¢¡A³o¬O¥Ñ©ó¤fªA¤§¶¡ªº§C¤ô¥¦h¤ÚÓi¤Þ°_ªº¡C³oºØÅܤƳt«×¥i¥H«D±`§Ö¡A¨Ã¥B¬O¤£¥i¹w´úªº¡C¯f¤H§Î®e¯f±¡ªºÅܤƴN¹³¬O¹q·½ªº¶}¡BÃö¤@¼Ë¡A©Ò¥HÁ{§É¤W§Î¹³¦aºÙ³oºØ²{¶H¬°¶}-Ãö²{¶H¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/12/24 ¤U¤È 06:30:08²Ä 467 ½g¦^À³
|
ÆF¥_ºë¯«¤Àµõ¯g·sÃÄRexulti¤J¼Ú¬w¥«³õ ¨Ó·½¡G ¥Íª«¨¦ ¡@2018-12-24 med.sina.com/article_detail_100_1_58033.html ¤¦³ÁÃÄ¥øÆF¥_¡]H.Lundbeck¡^ªñ¤é«Å¥¬¡A±N©ó2019¦~1¤ë1¤é¦b·ç¤h±À¥XRexulti¡]brexiprazole¡^¡A¥Î©óªvÀøºë¯«¤Àµõ¯g¦¨¤H±wªÌ¡C¸Ó¤½¥q±N¦b2019-2020¦~´Á¶¡³°Äò¦b¨ä¥L¼Ú¬w°ê®a±À¥X¸ÓÃÄ¡C brexpiprazole¬O¤@ºØ¨C¤é¤@¦¸ªº²Ä¤G¥N¡]«D¨å«¬¡^¤fªA§Üºë¯«¯fÃĪ«¡A¥Ñ¤j¶ïµo²{¡A¥ÑÆF¥_©M¤j¶ïÁp¦X¶}µo¡C¦b¬ü°ê¥«³õ¡Abrexpiprazole¡]«~µP¦WRexulti¡^©ó2015¦~7¤ëÀò§å¡A»²§UªvÀø««×§íÆ{¯g¡]MDD¡^¦¨¤H±wªÌ¥H¤ÎªvÀøºë¯«¤Àµõ¯g¦¨¤H±wªÌ¡C¦b¼Ú·ù¡Abrexpiprazole©ó2018¦~7¤ë©³Àò§å¡AªvÀøºë¯«¤Àµõ¯g¦¨¤H±wªÌ¡C ºë¯«¤Àµõ¯g¡]schizophrenia¡^¬O¤@ºØºC©Ê¡BÄY«ªººë¯«°·±d»Ùê¡A©¹©¹P´Ý¡F±wªÌ¥i¯à¥X²{»{ª¾¡B±¡ºü¡B¦æ¬°¤è±ªº§ïÅÜ¡A¨ä¤¤¦k·Q©M¤Ûı¬O³Ì±`¨£ªº¯gª¬¡Cºë¯«¤Àµõ¯gªº¯fµ{¤@¯ë¾E©µ¡A§e¤Ï´_µo§@¡B¥[«©Î´c¤Æ¡A³¡¤À±wªÌ³Ì²×¥X²{°I°h©Mºë¯«´Ý¯e¡A¦ý¦³ªº±wªÌ¸g¹LªvÀø«á¥i«O«ù²¬Â¡©Î°ò¥»²¬Â¡ª¬ºA¡C ¥Ø«e¡ARexultiªvÀø««×§íÆ{¯g¡]MDD¡^©Mºë¯«¤Àµõ¯gªº½T¤Á§@¥Î¾÷¨î©|¤£©ú¤F¡A¸ÓÃĪºÀø®Ä¥i¯à¬O³q¹L5-HT1A¨üÅé©M¦h¤ÚÓiD2¨üÅ骺³¡¤À¿E°Ê¾¯¬¡©Ê¡B¦å²M¯À5-HT2A¨üÅ骺«ú§Ü¾¯¬¡©ÊÁp¦X¤¶¾É¡C¦¹¥~¡ARexulti°£¤F¹ï³o¨Ç¨üÅéªí²{¥X°ª¿Ë©M¤O¡]¦¸¯Ç¼¯º¸¡Asubnanomolar¡^¡A°w¹ï¥h¥ÒµÇ¤W¸¢¯À£\1B/2C¨üÅé¤]ªí²{¥X°ª¿Ë©M¤O¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/12/18 ¤U¤È 05:59:32²Ä 466 ½g¦^À³
|
½²±Ð±Â½×¤å¶° Publications by authors named Guochuan Tsai www.pubfacts.com/author/Guochuan+Tsai 1. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. ... 57. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/12/12 ¤U¤È 06:07:21²Ä 465 ½g¦^À³
|
SND-11 , SND-12 , SND-13 , SND-14 ªº¥Î³~±M§Q³£®³¨ì¤F 10,149,845 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical 10,098,861 Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof 10,039,730 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical 9,675,604 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical 9,649,304 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical ³o¥NªíµÛ ·íÃÄÃÒ®³¨ì¥H«á , ¥Îf¥Ò»Ä(ÆQ)¨ÓªvÀø«äı¥¢½Õ¯g ¥¢´¼¯g »´«×»{ª¾»Ùê , ¤ß®®¾Ö¦³±MÄÝÅv , ¥L¼t¤£±o¨Ï¥Î ¦Ó¥B±M½æ´Á¤]¥i¥Ñì¨Óªº 3¦~ 5¦~ ©Î 7¦~ , ¤j´T¸õ¤É¨ì±M§Q´Áº¡(³Ì¤j20¦~,¹ê°È¤W©Î¦³¤Q¨Ó¦~) ³o¹ï¤@ÀÉ·sÃĦӨ¥ , ±M½æ´Á©µªøµ¥©ó¬O¾P°â°ª®p´Áªº©µªø , ¹ï·sÃĤ½¥qªºÀò§Q§U¯q , §ó¦³¦p¸Às¦b¤Ñ¦h¦h¦~ ³o¬OÓ¤Hªº¸ÑŪ , µMY¦³©Ò¿ù»~ , ¤]½Ð¤j®a«ü¾É«ü¥¿ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/12/11 ¤U¤È 05:41:02²Ä 464 ½g¦^À³
|
¹ù¥S¤S¦³·s±M¤åµoªí Frontiers Molecular Biosciences 107¦~11¤ë , ¤wDAAO¬°¥DÃD ¥X¥Z±´°Q liawbf.pixnet.net/blog/post/48719601 ¹ù¥S¨Ã¹ï¨ä´£¥X5ÂI«n«ä¦Ò ÁÂÁ¹ù¥S¤À¨É ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/12/11 ¤U¤È 02:49:38²Ä 463 ½g¦^À³
|
¹ï¤£°_ §ó¥¿³sµ² patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=%22Tsai%3B+Guochuan+Emil%22.INNM.&OS=IN/%22Tsai;+Guochuan+Emil%22&RS=IN/%22Tsai;+Guochuan+Emil%22 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/12/11 ¤U¤È 02:43:02²Ä 462 ½g¦^À³
|
®¥³ß ½²±Ð±ÂèèÀò±of¥Ò»Ä(ÆQ)¥Î©óªvÀø¥¢´¼¯g©Î»´·L»{ª¾»Ùꪺ¬ü°ê±M§Q United States Patent 10,149,845 December 11, 2018 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical Inventors: Tsai; Guochuan Emil (Pasadena, CA) patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=34&f=G&l=50&co1=AND&d=PTXT&s1=Tsai.INNM.&OS=IN/Tsai&RS=IN/Tsai ²q´ú NaBen Áö¤wÀò±oFDA®Öã¶i¦æADªºÁ{§É , µM¿ð¥¼¶i¦æ ©Î³\½²±Ð´N¬O¦bµ¥«Ý®³¨ì³oÓ±M§Q«á , ¤~nµÛ¤â¦¬®×§a?! ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/12/7 ¤U¤È 12:37:07²Ä 461 ½g¦^À³
|
쥻©óApril 26, 2018 ¤½¶}ªº±M§Q¥Ó½Ð °µ¤FY¤z×¥¿ ¤S«·s¤½¶} United States Patent Application 20180346400 December 6, 2018 POLYMORPHIC FORMS OF SODIUM BENZOATE AND USES THEREOF Abstract The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2.theta. of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2.theta. of approximately 3.7, 5.9, and 26.6 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer¡¦s disease). ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/11/15 ¤U¤È 11:36:14²Ä 460 ½g¦^À³
|
ªþ±a説©ú¡G Lurasidone¡]LATUDA¡^ ªvÀø¦¨¤H©M«C¤Ö¦~(13¦Ü17·³)ªº«äı¥¢½Õ¯g¡F²Ä¤@«¬Âù·¥©Ê¯e±w¤§Æ{¯gµo§@(¬°´Á¤»¶g¤§³æ¤@Àøªk©Î°t¦X¾YÆQ©Îvalproate¤§»²§UÀøªk) ³o¤SÅý¤H¹ï SNS¨t¦C±H¤©«p±æ ¦p¦PNRX-101ÂùÃÄÁp¦X¤@¼Ë¡A²£¥Í 1 + 1 ¤j©ó 2 ªºÀø®Ä ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/11/15 ¤U¤È 11:22:59²Ä 459 ½g¦^À³
|
§ÚÌ°Q½×¹LªºNRX-101 FDA±Â¤©²Ä¤@´Ú°w¹ï¦Û±þ©ÊÂù¬Û§íÆ{¯g¤fªAÃĪ«¬ð¯}©ÊÀøªk»{ÃÒ ¨Ó·½¡G°Ê¯ßºô ¡@2018-11-15 §@ªÌ¡GMailman med.sina.com/article_detail_103_2_55953.html NRX-101¬O¤@ºØ¥Ñ©T©w¾¯¶qªºD-Àôµ·®ò»Ä¡]DCS¡^(NMDA«ú§Ü¾¯)¤Îlurasidone²Õ¦¨ªº¤fªAÃĪ«²Õ¦X¡A¨ã¦³5-HT2a¨üÅé«ú§Ü¾¯¬¡©Ê¡C»P¦¹«e§å㪺©Ò¦³§Ü§íÆ{ÃĪ«¬Û¤ñ¡ADCS¯à´£°ª¨âºØ¯«¸g»¼½èªº¤ô¥¡A§Y¨¦®ò»Ä©M¨¦®ò酰Ói¡]Glx¡^ NeuroRx¥Ø«e¥¿¦bSPA¤U¶i¦æ¤@¶µÃöÁ䪺2b/3´ÁÁ{§É¸ÕÅç¡A§Y³q¹L¹ï¤ñ¨C¤é¤fªANRX-101Àøªk»P¼Ð·ÇªvÀø¡]lurasidone¡^¡A¨ÓªvÀø¦b´âÓiପì©léw«áªºÄY«Âù¬Û§íÆ{©M«æ©Ê¦Û±þ·N©À±wªÌ¡C www.neurorxpharma.com/tablet/nrx-100nrx-101-overview.html ·P·Q¡G SNA-1 ÃÄ®ÄÀò±oÃÒ¹ê ¥t¥~¡A¬Û¦Pªº·Qªk¡A³o·|¥[³t«P¦¨J&J esketamine ©M SNG-12 ©Î SNA-1 ªº¦X§@¶Ü¡H §Æ±æ¤ß®®¥[§ÖÁ{§É¸}¨B ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/11/9 ¤W¤È 10:17:26²Ä 458 ½g¦^À³
|
f¥Ò»Ä¾Y f¥Ò»Ä + ¾Y Âù¥\®Ä¶Ü? ±M§Q¤º¤å§i¶D§ÚÌ Finally, lithium benzoate unexpectedly showed better pharmacokinetic features and therapeutic efficacies as compared with sodium benzoate and lithium chloride in combination. »Pf¥Ò»Ä¶u©M´â¤Æ¾Yªº²Õ¦X¬Û¤ñ¡Af¥Ò»Ä¾Y¥X¥G·N®Æ¦aÅã¥Ü¥X§ó¦nªºÃÄ¥N°Ê¤O¾Ç¯S¼x©MªvÀø¥\®Ä¡C ¦CÁ|f¥Ò»Ä¾Y¥\®Ä . Lithium benzoate successfully rescued neuron toxicity induced by 3-nitropropionic acid (3-NP), which is known to induce mitochondria dysfunction, oxidative stress, and reactive oxygen species overproduction . enhanced spare respiratory capacity for mitochondria function, which plays an important role in various CNS disorders; ameliorated disease progression in an amyotrophic lateral sclerosis (ALS) animal model . protected neurons from oxygen and glucose deprivation . reduced cell death and behavior disability from toxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) either alone, or in combination with 3-NP . protected neuron damages caused by amyloid-£] peptides . lithium benzoate was observed unexpectedly to alleviate pain . Finally, lithium benzoate unexpectedly showed better pharmacokinetic features and therapeutic efficacies as compared with sodium benzoate and lithium chloride in combination ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! Y¦³¤£§´ , ·Ð½Ðª©¥D¤j¤j³w¤©§R°£ ÁÂÁÂ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/11/9 ¤W¤È 09:13:35²Ä 457 ½g¦^À³
|
¹ï¤£°_! ¸É¥R¤@¤U±M§Q¥Ó½Ð USE OF LITHIUM BENZOATE FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS November 8, 2018 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/11/9 ¤W¤È 08:58:23²Ä 456 ½g¦^À³
|
f¥Ò»Ä¾Y f¥Ò»Ä + ¾Y Âù¥\®Ä¶Ü? |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/11/8 ¤W¤È 08:58:42²Ä 455 ½g¦^À³
|
¤½¶}¸ê°TÆ[´ú¯¸«¤j°T®§¤½§i (6575)¤ß®®¥»¤½¥q»PSIMPEX PHARMA PRIVATE LIMITEDñqSNA1 505(b)(2)¸z·»¿õ¾¯¤§¥Í²£¤Î¾P°â¨óij 1.¨Æ¹êµo¥Í¤é:107/11/07 2.«´¬ù©Î©Ó¿Õ¬Û¹ï¤H:SIMPEX PHARMA PRIVATE LIMITED 3.»P¤½¥qÃö«Y:µL¡C 4.«´¬ù©Î©Ó¿Õ°_¨´¤é´Á(©Î¸Ñ°£¤é´Á):107/11/07 5.¥Dn¤º®e(¸Ñ°£ªÌ¤£¾A¥Î):¥»¤½¥q©e°USIMPEX PHARMA PRIVATE LIMITED¥Í²£»s³yÃÄ«~¡A¤Î¥¼¨Ó¦L«×¡B¿W¥ß°ê®a°ê¨ó(CIS Countries)¡B«D¬wªk»y¨t°ê®a(Africa Francophone Countries)¡BªF«n¨È°ê¨ó(South East ASEAN Countries)¤§¦X§@¾P°â¡C 6.¨î±ø´Ú( ¸Ñ°£ªÌ¤£¾A¥Î):µL¡C 7.¹ï¤½¥q°]°È¡B·~°È¤§¼vÅT(¸Ñ°£ªÌ¤£¾A¥Î):¹ï¤½¥qªøµu´ÁÀç¹B¨ã¦³¥¿±ªº¼vÅT¡C 8.¨ãÅé¥Øªº(¸Ñ°£ªÌ¤£¾A¥Î): ¥Í²£SNA1Ãøªv«¬««×¼~Æ{¯g(Treatment-Resistant Depression)Á{§É¹êÅç¥ÎÃÄ¡A¤Î©Ý®i¥¼¨Ó¤Wz¦a°Ï¤§®ü¥~¥«³õ¡ASNA1¤]¦P®É¬OªvÀøµ²®Ö¯f¤§¥ÎÃÄ¡C 9.¨ä¥LÀ³±Ô©ú¨Æ¶µ:¥¼«OÃÒ¥¼¨Ó¨ú±oÃÄÃҤξP°â¤@©w¯à¦¨¥\¡A¦¹µ¥§ë¸ê·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/11/7 ¤W¤È 11:02:12²Ä 454 ½g¦^À³
|
^±M®a:§Ü疱¯lÃĹw¨¾ªü¯÷®üÀq¯g ¥xÆW¹êÅçÀòÃÒ©ú 2018-11-07 01:21¤¤¥¡ªÀ °Ò¹ý´µ¯S6¤éºî¦X¥~¹q³ø¾É udn.com/news/story/6812/3465572?from=udn_ch1cate5_pulldownmenu ¤ß®®ÃĪ«ªº¥D¦¨¥÷ f¥Ò»Ä¶u ³æ¹ç»Ä , ³£¦³§Üµß §Ü¯f¬rªº¥\¯à Y hsv ¬° AD ªº¦¨¦]¤§¤@ , ¬O§_¬°f¥Ò»Ä¶u ³æ¹ç»ÄªvÀø AD ´£¨Ñ¥t¤@ªvÀø¾÷Âà ? ¦³½Ð¤j®aµo´§Google¥\¯à , §ä§ä¬Ý¬O§_¦³¦¹¥\®Ä ? Áö¹ù¥S¤wÀ°§Ú̾ã²z¤ß®®ÃĪ«¹ïªvÀøADªº²³¦h¾÷Âà µMY¤ß®®ÃĪ«¹ï¦¹hsv¦³ªvÀø¥\®Ä , °Z¤£¦b¦hºÞ»ô¤U¤¤¤S¼W²K¤@¼Î¬ü¨Æ ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/10/24 ¤U¤È 07:51:50²Ä 453 ½g¦^À³
|
¹ù¥Sªº·s§@ 10710 ¬ã¨s§Ö°T... liawbf.pixnet.net/blog/post/48648474 ÁÂÁ¹ù¥Sªº¤À¨É ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/10/23 ¤U¤È 03:41:54²Ä 452 ½g¦^À³
|
®¥³ß¤ß®® SND-51´I¶°»s³Æ¤èªk ¤µ¤éÀò±o¬ü°ê±M§Q Enrichment methods for preparing tannic acid compositions United States Patent 10,105,378 October 23, 2018 »s³Æ§t³æ¹ç»Äªº²Õ¦Xª«¡]¨Ò¦p¡AÃĪ«²Õ¦Xª«¡AÀç¾i²Õ¦Xª«©ÎÂå¾Ç¹«~²Õ¦Xª«¡^ªº¤èªk¡A¯S§O¬O¨ã¦³Àu²§®Ä¤O¡A¯Â«×©M¦w¥þ©Êªº´I§t³æ¹ç»Ä¸sªº¨º¨Ç¡C¥»¤åÁÙ´£¨Ñ¤F§t¦³³æ¹ç»Äªº²Õ¦Xª«¡A¨ä¥Î©ó§í¨îD-®ò°ò»Ä®ñ¤Æ酶©M/©Î¥Î©óªvÀøCNS¯f¯g©MªÎD¯g¡A¥]¬A¿}§¿¯f¡A°ª¦å¿}¯g¡A°ª¯×¦å¯g©Î°ªÁx©T¾J¦å¯g¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/10/20 ¤W¤È 11:51:28²Ä 451 ½g¦^À³
|
¹ù¥S¥ÑGlobaldata¬ã½Õ³ø§iªºÁÍ¶Õ , ¨Ó½×z SND-14 ( NaBen ) ªvÀø AD ªº¦h±¬Û¾÷Âà liawbf.pixnet.net/blog/post/48640176 ÁÂÁ¹ù¥Sªº¤À¨É ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/10/18 ¤U¤È 03:29:07²Ä 450 ½g¦^À³
|
¹ù¥S¤Sµ¹§ÚÌ SNG-12 ( sarcosine )ªvÀø¾÷Â઺¬ã¨s¦õÃÒ ¹ï¥I¼~Æ{¯g ¬¡¤Æ¾¢Ói»Ä¯à¨t²Î , ¦³«á³]¤§²z liawbf.pixnet.net/blog/post/48639666 ÁÂÁ¹ù¥S ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/10/16 ¤U¤È 07:38:36²Ä 449 ½g¦^À³
|
®¥³ß¤ß®® SAND-12 Clozaben® ¤µ¤éÀò±o¬ü°ê±M§Q United States Patent 10,098,861 October 16, 2018 Inventors: Tsai; Guochuan Emil (Pasadena, CA), Wang; Ching-Cheng (New Taipei, TW) Assignee: SyneuRx International (Taiwan) Corp. (New Taipei, TW) Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=%22TSAI,+Guochuan+Emil%3B%22&OS=%22TSAI,+Guochuan+Emil;%22&RS=%22TSAI,+Guochuan+Emil;%22 . ¥»¤½¶}´£¨Ñ¤FÃĪ«²Õ¦Xª«¡A¨ä¥]§t¦³®Ä¶qªºf¥Ò»Ä¶u¤Æ¦Xª«©M¦³®Ä¶qªº´â´á¥¡C¥»µo©úªºµ²´¹f¥Ò»Ä¶u¡]§Yf¥Ò»Ä¶uªº¦h´¹«¬¡^¤ñµL©w§Î©M¨ä¥L¤wª¾ªº¦h´¹«¬f¥Ò»Ä¶u©Î¨ä²Õ¦X§óéw¡C¥t¥~¡A¥]§t¦b¥»¤å©ÒzÃĪ«²Õ¦Xª«¤¤ªº½á§Î¾¯§ïµ½¤Ff¥Ò»Ä¶u¤Æ¦Xª«©M´â´á¥ªº²Õ¦XªºÃ©w©Ê¡C¥»¤å©ÒzªºÃĪ«²Õ¦Xª«¥i¥Î©ó¹w¨¾¡AªvÀø©M/©Î°§C¨ü¸ÕªÌ¤¤¦UºØ¯e¯f©M¯f¯g¡]¥]¬A¯«¸gºë¯«¯f¯g¡^ªº·ÀI¡C¦]¦¹¡A¥»¤åÁÙ´£¨Ñ¤F¤@ºØ¥Î©ó¹w¨¾ªº¤èªk . ¥t¤@¤è±¡A¥»µo©ú´£¨ÑªvÀø©M/©Î°§C¯«¸gºë¯«¯f¯g·ÀIªº¤èªk¡A¸Ó¤èªk¥]¬Aµ¹»ÝnªvÀøªº¨ü¸ÕªÌ¬I¥Î¦³®Ä¶qªº¥»¤å©Òzªº¥ô¦óÃĪ«²Õ¦Xª«¡C¥Ø¼Ð¯«¸gºë¯«¯e¯f¥]¬A¦ý¤£©óºë¯«¤Àµõ¯g¡Aºë¯«»Ùê¡Aªüº¸¯ý®üÀq¯f¡Aè§b¡AÃBù®¸Ã¨§b¡A»´«×»{ª¾»Ùê¡A¨}©Ê¿ò§Ñ¡A³¬¦X©ÊÀY³¡·l¶Ë¡A¦Û³¬¯gÃШt»Ùê¡Aªü´µ§B®æºî¦X¯g¡Aª`·N¤O¯Ê³´¦h°Ê»Ùê¡A±j¢¯g¡A©â°Ê»Ùê¡A¨àµ£¾Ç²ß»Ùê¡A¸g«eºî¦X¯g¡A§íÆ{¯g¡A¦Û±þ·N©À©M/©Î¦æ¬°¡AÂù¬Û±¡·P»Ùê¡AµJ¼{¯g¡A³Ð¶Ë«áÀ³¿E»Ùê¡AºC©Ê¯kµh¡A¶¼¹¥¢½Õ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/10/14 ¤U¤È 01:03:49²Ä 448 ½g¦^À³
|
ÁÂÁ¹ù¥Sªº«ü¾É ì¨Ó¹ù¥S2017´N¼g¤F½×¤å¯Åªº¤j§@¡A¨Ó±´°Q¼vÅTSND-13 2b+3 ¦¨¥\ªºÃöÁä ¦p¦ó¥Ñ¤G´Á¸ÕÅç¨Ó¼ÒÀÀ»P¹w´Á¤T´ÁÁ{§É¸ÕÅç¡A⋯ liawbf.pixnet.net/blog/post/47642511 Åý¤H·P¨Ø¹ù¥Sªº¥ýª¾¥ýı»Pºë±m²`«×ªº¤ÀªR ¼Ð·Ç®tªº¤j¤p©M¦w¼¢¾¯®ÄÀ³¬O¥ª¥k¤j§½ªºÃöÁä ½²±Ð±Âªº¹BÄw±cØò»P°õ¦æ¡A¦b¦b³£¬O¥H°§C«ez¨âªÌ¬°¨ÌÂk Y¼Ð·Ç®tÅܤp¡A¤À¥¬¦±½u·|¶V°~®k¡A¸ÕÅç²Õ©M¹ï·Ó²Õªº¤À¥¬¦±½u©Ò«Å|ªº³¡¤À±N¶V¤Ö ¦w¼¢¾¯®ÄÀ³¶V§C¡A¸ÕÅç²Õ©M¹ï·Ó²Õªº¤À¥¬¦±½u±NÂ÷¶V»·¡A«Å|³¡¤À¤]¬O¶V¤Ö ·í¨â²Õ¦±½u«Å|³¡¤À¶V¤Ö¡A«hpÈ·|¶V¤p¡ApowerȶV¤j¡A¥Ç«¬£¸¡B«¬¤G¿ù»~´N¶V¤p §ÚÌ´Á±æ¦b½²±Ð±Âªº¥Î¤ß§V¤Oªº³W¹º°õ¦æ¤U SND-13ªº¤T´Áµ²ªG¯à©M¤G´Áªºªí²{£¸¼Ë¥X¦â¡A¬Æ©Î¶W¶V¡A«h¬Æ©¯¤] ÁÂÁ¹ù¥S ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/10/13 ¤U¤È 03:47:42²Ä 447 ½g¦^À³
|
¹ù¥S·s§@ ¼~¼{ µJ¼{ , GG§a?! liawbf.pixnet.net/blog/post/48627621 Tannquilynne ªº¥t¶µªvÀø¥\¯à ?! ÁÂÁ¹ù¥S ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/10/10 ¤U¤È 07:03:18²Ä 446 ½g¦^À³
|
¥@¬Éºë¯«½Ã¥Í¤é¡G§íÆ{¯gÃĪ«ªºµo®i²¥v ¨Ó·½¡G¤õ¥Û³Ð³y ¡@2018-10-10 §@ªÌ¡GWinnie med.sina.com/article_detail_103_2_53834.html 2018¦~10¤ë10¤é¬O²Ä25Ó¥@¬Éºë¯«½Ã¥Í¤é¡C®Ú¾Ú¥@¬É½Ã¥Í²Õ´²Îp¡A¥þ¥@¬É§íÆ{¯g±wªÌ¹F3»õ¥H¤W¡A¦Ó¨ä¤¤¨C¦~¥þ²y¦]§íÆ{¯g¦Û±þ¦º¤`¤H¼Æ¬ù100¸U¡A¹wp¨ì2020¦~¡A§íÆ{¯g¥i¯à¦¨¬°¶È¦¸©ó¤ß¸£¦åºÞ¯fªº¤HÃþ²Ä¤G¤j¯e¯f¡C ¤£¦P©ó¤ß¸£¦åºÞ¯e¯f¦h¨£©ó°ªÄÖ±wªÌ¡A¥b¼Æºë¯«¯e¯f©l©ó14·³¡C´N«C¤Ö¦~ªº¯e¯ft¾á¦Ó¨¥¡A§íÆ{¯g¬O²Ä¤T¤jì¦]¡C¦Û±þ¬O15-29·³¤H¸sªº²Ä¤G¤j¦º¤`ì¦]¡C¬°©IÆ~¤HÌ»{ÃѨìÀ°§U¦~»´¤H±q¤p«Ø¥ß¤ß²z¾AÀ³¤Oªº¥²n©Ê¡A¤µ¦~¥@¬Éºë¯«½Ã¥Í¤é±N¥DÃD³]¬°¡§¤£Â_Åܤƪº¥@¬É¤¤ªº¦~»´¤H©Mºë¯«½Ã¥Í¡¨¡A §Æ±æ¹w¨¾«C¤Ö¦~©M¦~»´¤Hªººë¯«µhW©M¯e¯f¡A¦P®É«P¶iºë¯«¯e¯fªººÞ²z©M±d´_¡C ... |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/10/5 ¤U¤È 04:44:33²Ä 445 ½g¦^À³
|
êɤj¤F! ³oӨƨàÃÒ©ú¦Û¤v¦Ñ¤F ¦h°·§Ñ ¤pªº¥ÎÃöÁä¦r Obesity tannic acid ¬d¸ê®Æ®É , ¬ðµMµoı TA ¤w¸g¦³¤H±¶¨¬¥ýµn¥Ó½Ð±M§Q¤F ¤ßùØ¥¿Ä±ª°ºÃ®É , ÂI¤J¤@¬Ý , «¢! ¬Ý¨ì¤F¼ô±xªº¦r²´ SyneuRx ì¨Ó¬O¤ß®®¥h¦~¦V USPTO ¥Ó½Ðªº [ §t¦³³æ¹ç»Äªº²Õ¦Xª«¤Î¨ä¥Î³~ ] ¥]§t³æ¹ç»Ä¡A¯S§O¬O³æ¹ç»Äªº²Õ¦Xª«¡]¨Ò¦p¡AÃĪ«²Õ¦Xª«¡AÀç¾i²Õ¦Xª«©ÎÂåÃĹ«~²Õ¦Xª«¡^¡A©Òz³æ¹ç»Ä¬O¨ã¦³Àu²§®Ä¤O¡A¯Â«×©M¦w¥þ©ÊªºD-®ò°ò»Ä®ñ¤Æ酶§í¨î¾¯; ¤Î¨ä¥Î©óªvÀøCNS¯e¯f©MªÎD¯gªº¥Î³~¡A¥]¬A¿}§¿¯f¡A°ª¦å¿}¯g¡A°ª¯×¦å¯g©Î°ªÁx©T¾J¦å¯g¡C ½Ð¤j®aì½Ì¤pªº¤â·Æ©M«áª¾«áı ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/10/5 ¤U¤È 04:32:52²Ä 444 ½g¦^À³
|
êɤj¤F! ³oӨƨàÃÒ©ú¦Û¤v¦Ñ¤F ¦h°·§Ñ ¤pªº¥ÎÃöÁä¦r Obesity tannic acid ¬d¸ê®Æ®É , ¬ðµMµoı TA ¤w¸g¦³¤H±¶¨¬¥ýµn¥Ó½Ð±M§Q¤F |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/10/5 ¤U¤È 04:32:51²Ä 443 ½g¦^À³
|
êɤj¤F! ³oӨƨàÃÒ©ú¦Û¤v¦Ñ¤F ¦h°·§Ñ ¤pªº¥ÎÃöÁä¦r Obesity tannic acid ¬d¸ê®Æ®É , ¬ðµMµoı TA ¤w¸g¦³¤H±¶¨¬¥ýµn¥Ó½Ð±M§Q¤F |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/10/5 ¤W¤È 10:33:44²Ä 442 ½g¦^À³
|
±µÄò¬Q¤é TA ªº¸ÜÃD ®Ú¾Ú¬ü°ê«X¥è«X¤j¾Çªº¬ã¨s Tannic Acid Stimulates Glucose Transport and Inhibits Adipocyte Differentiation in 3T3-L1 Cells academic.oup.com/jn/article/135/2/165/4663627 . TA ¥HÃþ¦ü©ó¯Ø®q¯Àªº¯S¼x¨ë¿E¸²µå¿}Âà¹B . TA ³q¹L§í¨î©Î§ïÅܯתեͦ¨¹Lµ{¤¤¯A¤ÎªºÃöÁä°ò¦]ªí¹F¨Ó§í¨î¯×ªÕ²ÓM¤À¤Æ . TA ¤Wz2ºØ¬¡©Êªº²Õ¦X¨Ï¨ä«D±`¾A¦X§@¬°ì«¬¤Æ¦Xª«¶i¦æ¶i¤@¨Bªºµ²ºc©M¥\¯à¬ã¨s¡A¥H¶}µoªvÀø¥NÁ¯gÔ¸s©MT2D(II«¬¿}§¿¯f)ºî¦X¯gª¬ªº·s«¬ÃĪ«¡A¦p°ª¦å¿}¡A°ª¯Ø®q¯À¦å¯g(ºÙ¬°:¯Ø®q¯À§Ü©Ê)©M°ª¥Ìªo¤Tà¦å¯g¡A¥BµL¦ñÀHÅ髼W¥[¬Æ¦Ü´îªÎ¡C¹ï©ó±w¦³¿}§¿¯f¬ÛÃöÅé«°ÝÃD°ª¹F90¢HªºT2D±wªÌ¡A¨ã¦³³oºØ©Ê½è²Õ¦XªºÃĪ«À³¸Ó¬O§ó¦nªº¿ï¾Ü¡C ©Ò¥H¤ß®®SNS¨t¦C ¦n¶Ü ?! §Ú̧Ʊ椽¥q±N (NaBen + tannic acid + ²{¦æÃĪ« ) ªº²Õ¦X°t¤ñ¦³®Ä¾¯¶q¬ã¨s²M·¡ °£¤F±N²Õ¦XÃĪºÀø®Ä¶W¶V²{¦æÃĪ«¥~ , ÁÙ¯à°÷¤@Á|±N²{¦æÃĪ«ªº¥NÁ¯g԰Ƨ@¥Î±±¨î ´î»´©Î®ø°£ ¨º SNS ¨t¦Cªº¼ç¤O¤j¨o«v? ¦³½Ð¤j®a«ü¥¿¤Î¸É¥R ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/10/4 ¤U¤È 05:17:57²Ä 441 ½g¦^À³
|
¦b¬ã¨s NASH ®É , ¬Ý¨ì GA(gallic acid )¥i°TG (¤T»Ä¥Ìªoà)ªº¸ê®Æ Åý¤pªºÁp·Q¨ì TA (tannic acid ) ¬O§_¤]¦æ ? 1992¦~ °ê¥ß·s¥[©Y¤j¾Ç¾ÇªÌ¥H¦Ñ¹«ªº¬ã¨sµ²ªG ½Ð°Ñ Effects of polyphenolic natural products on the lipid profiles of rats fed high fat diets www.ncbi.nlm.nih.gov/pubmed/1522762 Male Wistar rats were fed a high fat diet (HFD) containing 2.5% cholesterol and 16% lard supplemented with polyphenolic natural products namely quercetin, morin or tannic acid (100 mg/rat/day) for 4, 7 and 10 wk. Rats fed HFD without the supplements served as control. The effects of these compounds on blood lipid profiles, enzymes, liver fat and aorta of the rat were studied. In rats fed HFD containing tannic acid, plasma total cholesterol (TC), low density lipoprotein cholesterol (LDLC) and triglyceride (TG) were reduced by 33.3%, 29.6% and 65.1%, respectively, at week 10. High density lipoprotein cholesterol (HDLC) concentration was not altered. Fat deposition was also decreased in the liver of these rats. Plasma alanine aminotransferase, alkaline phosphatase and bilirubin in control and treated groups were not significantly different. However, hepatic lipase activity in rats fed tannic acid was significantly lower. Aortae of all groups of rats showed no abnormalities. The present report indicates that tannic acid and morin are effective in reducing plasma and liver lipids when supplemented with a high fat diet in rats. ¶¯©ÊWistar¤j¹«Áý¹§t¦³2.5¢HÁx©T¾Jªº°ª¯×ªÕ¶¼¹¡]HFD¡^©M16¢H½Þªo¡A¨Ã¸É¥R§t¦³¦h×ôªº¤ÑµM²£ª«¡A§YåÚ¥Ö¯À¡A®á¦â¯À©Î³æ¹ç»Ä¡]100mg /¤j¹«/¤Ñ¡^¡A«ùÄòÁý¹4,7©M10¶g¡C¥B¥H¨S¦³Áý¹¸É¥R¾¯ªºHFD¤j¹«§@¬°¹ï·Ó¡C¬ã¨s³o¨Ç¤Æ¦Xª«¹ï¤j¹«¦å¯×ÃСA酶¡A¨xŦ¯×ªÕ©M¥D°Ê¯ßªº¼vÅT¡C¦bÁý¹§t¦³³æ¹ç»ÄªºHFDªº¤j¹«¤¤¡A¦å¼ßÁ`Áx©T¾J¡]TC¡^¡A§C±K«×Áx©T¾J¡]LDLC¡^©M¤T»Ä¥Ìªoà¡]TG¡^¦b²Ä10¶g¤À§O°§C¤F33.3¢H¡A29.6¢H©M65.1¢H¡C°ª±K«×Áx©T¾J¡] HDLC¡^¿@«×¥¼§ïÅÜ¡C³o¨Ç¤j¹«ªº¨xŦ¤¤¯×ªÕ¨I¿n¤]´î¤Ö¡C ¹ï·Ó²Õ©MªvÀø²ÕªºÆP©ÊÁC»Ä酶©MÁx¬õ¯ÀµLÅãµÛ®t²§¡CµM¦Ó¡AÁý¹³æ¹ç»Äªº¤j¹«ªº¨x¯×酶¬¡©ÊÅãµÛ°§C¡C©Ò¦³²Õ¤j¹«ªº¥D°Ê¯ß§¡¥¼Åã¥Ü²§±`¡C¥»³ø§iªí©ú¡A·í¦b¤j¹«¤¤Áý¹°ª¯×ªÕ¶¼¹®É¡A³æ¹ç»Ä©M®á¦â¯À¥i¦³®Ä´î¤Ö¦å¼ß©M¨xŦªº¯×½è¡C ªþµù: ¨x¯×酶ªº¥Dn¥\¯à¤§¤@¬O±N¤¤±K«×¯×³J¥Õ¡]IDL¡^Âà¤Æ¬°§C±K«×¯×³J¥Õ¡]LDL¡^ ³o¨Çµ²½×Åý§Ú·Q°_¤ß®®ªº SNS ¨t¦C , ¤]´N¬O Naben + Tannic acid + ²{¦æÃĪ« ³o¼Ë¤£´N¬O¶W±jªº²Õ¦X , ¬J¥i¼W±j¨Ã¶W¶V²{¦æÃĪ«ªºÀø®Ä , ¤S¥i(³¡¥÷)¸Ñ¨M¥NÁ¯gÔ¼x¤F¶Ü ? ½²±Ð±Âªº³Ð·N©M³Ð·s , ¤£³×¤Sµ¹§Ṳ́W¤F¤@½Ò ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/10/3 ¤W¤È 10:06:10²Ä 440 ½g¦^À³
|
¹ù¥Sªº·s§@ ¤£K¥L©R , ´Nn§A©R ? liawbf.pixnet.net/blog/post/48612810 ²Ä¤@¥y¸Ü´NÂI¥X«ÂI [ ¤£K°ª¾¯¶q ketamine , ¦Û±þ·N©Àn§A©R ? ] ªº¨âÃø ? ÁÂÁ¹ù¥S ÁÂÁ¤j®a ! |
|
|
·|û¡GYOYO10140343 µoªí®É¶¡:2018/10/1 ¤W¤È 10:20:14²Ä 439 ½g¦^À³
|
¦^À³seniorbbs¤j, ¨ä¹ê°ê¥~Äw¸ê«üªº¬O¤Þ¶i°ê¥~³Ð§ë¸êª÷©Î±ÂÅv,¨âªÌ¬Ò¬O¿ï¶µ,·íµM¤½¥q¤]·Ç³Æ¦n§Q¦h¤~·|¶Ò±o¦n¸êª÷;¦Ó³y¦¨n¦b°ê¥~IPO¤§¬üÄRªº»~·|¬O·í®É¦³°ê¥~IPO¤§°Q½×¼ö¼é,¤]¦³¦P·~¿ï¦¹±ø¸ô,¦³¨ÇªÑªF»~¥H¬°¤ß®®¤]n¤ñ·Ó¿ì²z¦Ó½æ¥X,¬Ý°_¨Ó¤½¥q©Ò¦³°Ê§@³£¬O¥H°ê¤º±¾µP¬°¥D,¤£µM¤£n·d¤@¤j°ï¤l¤½¥q©Î®]¤½¥q,³o»P¥h°ê¥~¤W¥«ªº¹Lµ{¤Ï¦ÓI¹D¦Ó¹£. ²{¦b¬Ý¬Ý¦¨¥æ¶q,¯à³Q¬~¥X¥hªº¦´N¬~¨«¤F,½æÀ£¤£¨£¤F,¤£n¤Ó¦h¸êª÷,«Ü§Ö·|¦^¨ì¤Wªi°ªÂI |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/10/1 ¤W¤È 09:31:26²Ä 438 ½g¦^À³
|
¹ù¥S½×¤å¯Å¤j§@ ¹ï§Ü¤@¥NîǤý , ±z¤µ¤Ñ¦YG¤F¨S ? îǤý·N«ü¥ÒîÇ ( Formaldehyde ) ¦ý³o©M¤ß®®µo®iªºÃĪ«¤S¦³¬Æ»òÃö«Y? ½Ð¤j®a¦n¦n«~À|³o¹D¤jµæ liawbf.pixnet.net/blog/post/48611865 ÁÂÁ¹ù¥S ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/27 ¤U¤È 01:09:24²Ä 437 ½g¦^À³
|
¨Ó¦Û¹ù¥Sªº®ø®§ ¤½¥q¤S¦A¼x¤~ Á{§É¬ã¨sû/°Æ¬ã¨sû (Clinical Coordinator) ¤u§@¤º®e 1. Bachelor or Master degree in Life Science from US University is a must 2. Proficient in English listening, speaking, and writing is also a must 3. More than 1-3 years of exposure to clinical trials strongly preferred 4. Clinical trial project management of new drug development programs 5. Managing and monitoring CRO on all clinical activities 6. Good communication skills and team spirit (Will mostly work in the US) ¾°ÈÃþ§O¡GÂåÃĬãµo¤Hû¡B¯f²zÃIJz¬ã¨s¤Hû¡B¥Íª«¬ì§Þ¬ãµo¤Hû ¤u§@«Ý¹J¡G±Ä³ ¤u§@©Ê½è¡G¥þ¾ ¤W¯Z¦aÂI¡G¬ü¦è¦a°Ï ºÞ²z³d¥ô¡G¤£»Ýt¾áºÞ²z³d¥ô ¥X®t¥~¬£¡G»Ý¥X®t¡A¤@¦~²Ö¿n®É¶¡¥¼©w ¤W¯Z®É¬q¡G¤é¯Z ¥ð°²¨î«×¡G¶g¥ð¤G¤é ¥i¤W¯Z¤é¡G¤£ »Ý¨D¤H¼Æ¡G1 ¤H |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/24 ¤U¤È 04:39:02²Ä 436 ½g¦^À³
|
´XÓúµ|ªº¸ê®Æ , ¦³½Ð¤j®a°Ñ¦Ò ¥x¥_°êµ|§½ ®ü¥~©Ò±o±M°Ï www.ntbt.gov.tw/etwmain/front/ETW118W/CON/1815/7479101553677013505?tagCode= ÃҨ餽·|ªº¥Dn°ê®aÃÒ©Òµ|¤ñ¸û www.tri.org.tw/trinews/doc/1010524_4.pdf ¥xÆW©M·s¥[©Y¤Î»´äµ|°È²³æ¤ñ¸û www.trusty.tw/index.php/en/2014-09-10-20-49-53/2014-09-10-20-50-27/1212-2015-05-11-11-18-15 ¤@¤å·dÀ´¬üªÑªÑ®§¡A¬üªÑ°t®§¤À¬õ«ç»ò°µ www.stockfeel.com.tw/%E4%B8%80%E6%96%87%E6%90%9E%E6%87%82%E7%BE%8E%E8%82%A1%E8%82%A1%E6%81%AF%EF%BC%8C%E7%BE%8E%E8%82%A1%E9%85%8D%E6%81%AF%E5%88%86%E7%B4%85%E6%80%8E%E9%BA%BC%E5%81%9A-2/ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/24 ¤W¤È 10:13:13²Ä 435 ½g¦^À³
|
seniorbbs¤j ±zªº°ÝÃD , ½Ð®¤¤pªº¨S¦³µª®× ½²±Ð±Â«ù¦³¤ß®®ªÑÅv1.9¸U¦h±iªº SyneuRx International Corp. «Y^Äݶ}°Ò¸s®qªº¤½¥q ¤ß®®¥ÍÂå¥s°µ SyneuRx International ( Taiwan ) Corp. ¤ß®®¥ÍÂå¥Ø«e´¦ÅSªº100 % ¤l¤½¥q ¥s°µ SyneuRx International ( SAMOA ) Corp. ©M SyneuRx International ( BVI ) Corp. ¨ä¥Lµù¥U¦b°ê¥~ªº¤½¥q , ¦p SyneuRx neuroscience ; SyneuRx Lifescience ...µ¥¤½¥q , ¤pªº¤£ª¾¨ä³sµ²¤ÎÂkÄÝ ©Ò¥H , ¥H¤pªº²{¦b©Òª¾ªº¸ê®Æ©M¬Q¤éªºµ|ªk¤ÀªR Y½²±Ð±Â¤Ò¤H§â©Ó±µ¤ß®®ªÑÅvªº¤½¥q¿ï¦b°ê¤ºµù¥U , ¥¦©Ò¥Nªíªº·N²[ , ¥i¯à´N¬O¤ß®®¦b°ê¤ºIPOªº¾÷·|ÅÜ¿@¤F¥B¤ß¬ùªº³]¥ß¬O¥H»â¨úªÑ§Q¬°¥D , ²¦³º¦pªG³]¥ßªº¥Øªº¬On³B¤ÀªÑÅv , ´NÀ³³]¦b¥i¥H§Kµ|ªº°ê¥~ ¤£¹L¸Ü¤S»¡¦^¨Ó , n¯à°÷»â¤ß®®ªºªÑ§Q¤£¬OÁÙn¦n¦h®É¶¡¶Ü?!²{¦b´N¥¬§½¤£¬O¤Ó¦¤F¶Ü? °ß¤@¤pªº¯à·Q¨ìªº , ¥i¯à´N¬OS... ½Ð¤j®aì½Ì¤pªº¸Ü¦h ÁٽЧå§P ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡Gseniorbbs10144999 µoªí®É¶¡:2018/9/23 ¤U¤È 11:06:40²Ä 434 ½g¦^À³
|
·Q½Ð±Ð²q·Q¤j¡ASyneuRx neuroscience ¬O¥Ø«e¥xÆW¤ß®®¦Ê¤À¤§¦Ê§ë¸êªº¤½¥q¶Ü¡H ¦pªG¬O¥Nªí·sªº¬O¤ß®®ªº®]¤½¥q.... ¨ì©³¬O¬°¤°»ò©O |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/23 ¤U¤È 08:43:43²Ä 433 ½g¦^À³
|
¤ß¼Ö»P¤ß¬ù , ¦n¦³·N¹Òªº¦W¦r! ¦P®ÉÁÂÁ Cliff ¤j®¦¼wªº¤À¨É , ÁÙ¦³»{¦Pseniorbbs¤jªºµûªR ³o¨â®a¤½¥qªº¾Ô²¤¾Ô³N , ¨s³º«ü¦V¦ó¤è§r? ¤pªº·Q¤F¥b¤Ñ¤S¥b¤Ñ , ¤´¤£±o¨ä¸Ñ ¤ß¼Öµn°OªºÀç·~¶µ¥Ø»P¤ß®®ªº¬Û¦P , ¤ß¬ù«h¬O¤@¯ë§ë¸ê·~ ¨â®aÀ³ÄÝ¿W¸ê¤½¥q ( ¤½¥q¥þ¦W¨S¦³ [ ªÑ¥÷ ] ¨â¦r ) ; ¤ß¼Ö¬°¶}°Ò°Ó SyneuRx neuroscience ©Ò§ë¸ê ; ¤ß¬ù«hµn°O¦b½²±Ð±Â¤Ò¤H¦W¤U ¤ß¼Ö¥ÍÂå , ¤pªº¤£ª¾¨ä¬°¦ó¦Ó³]? ¦æ¾P¥xÆW¶Ü? ¨ú¨äµoµ¬Û¦Pªº©öÃѩʶÜ? ¦Ü©ó¤ß¬ù , À³¬°¸`µ|¦Ò¶q §Ú̬ݨì 8 ¤ë¥÷ , ½²±Ð±Â®a¤HªºªÑÅv ¥Ñ310±i¼W¬°620±i , ©Î¬°¥x¥_´I¨¹»È¦æ¤ß®®¥ÍÂå«H°UªÑÅvªºÂಾ , ¦Ó¤ß¬ù¤S«ê¥©¦b8¤ë6¤é¥Ó¥ß , ©Ò¥H²q´úÀ³¬°©Ó±µ«H°UªÑÅvÂಾ¦Ó³] ¤pªº¬ã¨s°ê¤º©Ò±oµ|ªk¤@Ó¤U¤È º¥ýªì±´¤½¥q³]¦b°ê¤º©Î°ê¥~µ|§O µ|²vªº¤£¦P ¨Ì©Ò±oµ|ªk¨âÓ¼h±¨Ó¤ñ¸û 1. ÃÒ¨é¥æ©ö©Ò±oµ| °ê¥~¤½¥q : §Kµ| °ê¤º¤½¥q : ú¥æ12 % °ò¥»µ| 2. ªÑ§Q©Ò±o °ê¥~¤½¥q : ´N·½¦©Ãº 21 % ªºªÑ§Q©Ò±o °ê¤º¤½¥q : °ò¥»¤W§Kú , ¦ýY¦³¥¼¤À°t¬Õ¾l«hú¥æ5% ©Î10% µ|²v , «YÄݦ^Âk¨ìÓ¤Hºî©Òµ|ú¥æ ºî¤W©Òz Y¥HªÑ²¼¥æ©ö¬°¥D , «hÀ³¥H³]¦b°ê¥~¬°©y µMY¥H»â¨úªÑ§Q¬°¥D , «h¥H³]¦b°ê¤º¬°¨Î ¦Ó¤µ½²±Ð±Â¤Ò¤H¦b°ê¤º³]¥ß¤ß¬ù , ¤S¿Å¤§¬ü°ê¹ï¥~¸ê½Ò¥H30%ªºªÑ§Q©Ò±oµ| ³o¤S¸Ó¦p¦ó¨Ó¤ÀªR? ¤pªº¯à¤Oª¾ÃѦ³ , ¥u¯à²q¨ì³o¸Ì¤F ¤]½Ð¤j®a¦h«ü¥¿»P«ü¾É ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡Gseniorbbs10144999 µoªí®É¶¡:2018/9/23 ¤W¤È 09:46:36²Ä 432 ½g¦^À³
|
¤µ¦~¤½¥qªº°Ê§@¶V¨Ó¶V¦h¡A¬Ý¨Ó¯uªº§Ön¦¬³Îªº®ÉÔ¤F..... |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/9/22 ¤W¤È 10:52:58²Ä 431 ½g¦^À³
|
¤ß¼Ö¥ÍÂ妳¤½¥q¡]twinc.com.tw/#/%E5%BF%83%E6%A8%82%E7%94%9F%E9%86%AB%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8/50858870/ ¡^ ¦¨¥ß¤é´Á¡G2018/08/06 ¸ê¥»ÃB¡G100¸U t³d¤H¡GVIVIAN YALING WU ¤ß¬ù¦³¤½¥q ¡]twinc.com.tw/#/%E5%BF%83%E7%B4%84%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8/50858859/ ¡^ ¦¨¥ß¤é´Á¡G2018/08/06 ¸ê¥»ÃB¡G49¸U t³d¤H¡GVIVIAN YALING WU |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/21 ¤U¤È 04:51:19²Ä 430 ½g¦^À³
|
¡iJAMA¡j·s§Þ³N¶EÂ_ªü¯÷®üÀq¯f·Ç½T«×¶W¹L90%¡I ¨Ó·½¡G±d°··sµø³¥ ¡@2018-09-21 med.sina.com/article_detail_103_1_53100.html ³oºØ·sªºtau-PET¤èªk¨ã¦³«Ü°ªªº±Ó·P©Ê©M¯S²§©Ê¡C ¤wª¾¾ý¯»¼Ë³J¥Õ£]¡]a£]¡^©Mtau³J¥Õ³o¨âºØ³J¥Õ½èªº¥\¯à»Ùê»PADµo®i¦³Ãö¡C¦b°·±dªº¤j¸£¤¤¡Aa£]·|³Q°¸Ñ©M®ø°£¡A¦ý¬O¦bAD¤¤¡Aa£]ªº¥¢½Õ·|¾ÉP¯«¸g¤¸¤§¶¡§Î¦¨´³¶ô¡Ctau³J¥Õ¤]¬O¥¿±`¤H¤j¸£¤¤±`¨£ªº³J¥Õ¡A¯àºû«ù²ÓMªºÃ©w¡CµM¦Ó¦b¯fÅܪº¤j¸£¤¤¡A¿ù»~§éÅ|ªºtau³J¥Õ·|²§±`¿n»E¡A¾ÉP¯«¸gìÅÖºûÄñµ²©M²ÓM¦º¤`¡A³o¨ÇÅܤƷ|¾ÉP¤j¸£¥\¯à¨ü·l¡C¦b±wªÌ¥X²{¯e¯f¸ñ¶H¤§«e¼Æ¤Q¦~¡Aa£]´N¤w¸g¦b¾ãÓ¤j¸£¤¤¶Ç¼½¡A¦Ótau³J¥Õ«h¬O¦b¯e¯f«á´Á¶}©l½¯©µ¡A±qù®¸¨ì¤j¸£ªº¨ä¥L³¡¤À¡C ³o¶µ¬ã¨s©Û¶Ò¤F¤C¦Ê¦h¦W±wªÌ¡A¥L̨Ӧ۷ç¨å¶©¼w¡B¬ü°êª÷¤s©MÁú°êºº¸ªº°O¾Ð¶E©Ò¡C¬ã¨sªÌ§Q¥ÎPET±½´y»öÀˬd¤F±wªÌ¤j¸£¤¤tau³J¥Õªº±¡ªp¡Cµ²ªGªí©ú¡A³oºØ·sªºtau-PET¤èªk¨ã¦³«Ü°ªªº±Ó·P©Ê©M¯S²§©Ê¡G¥¦ÀË´ú¨ì¤F90 - 95¢HªºAD±wªÌ¡A¨Ã¥B¦]¬°¨ä¥L¯e¯f¤Þ°_ªº°²¶§©Êµ²ªG«Ü¤Ö¡C»P¥Ø«e±`¥Îªº¨ä¥L¨âºØ¤èªk¬Û¤ñ¡Atau-PET¤èªk¤ñºÏ¦@®¶¦¨¹³¡]MRI¡^¨ã¦³§ó¨Îªº¶EÂ_·Ç½T©Ê¡A¨Ã¥B¤ña£]-PET¨ã¦³§ó¤Öªº°²¶§©Êµ²ªG¡C¦]¦¹¡A¤@¥¹¸Ó¤èªk³Q§åã¥Î©óÁ{§É¡Atau-PET¦³±æ¦b°O¾Ð°ÝÃD¬ã¨s»â°ì¤j¦³§@¬°¡C¦P®É¡Atau-PET¦b°w¹ïADªº·sÃĪ«¸ÕÅ礤¤]«Ü¦³»ùÈ¡A¦]¬°¥¦¥i¥HÅã¥Ü·sÃĬO§_¦¨¥\¹w¨¾¤F¤j¸£¤¤tau³J¥ÕªºÂX´²¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/19 ¤U¤È 05:07:21²Ä 429 ½g¦^À³
|
¦¹ÃĦ³¬r¡H¦ãº¸«Ø ( Allergan ) ©M Sosei ¼È°±ªüº¸¯ý®üÀq·sÃÄÁ{§É¸ÕÅç ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-09-19 ·s®öÂåÃĽsĶ/newborn med.sina.com/article_detail_103_2_52947.html ¤é¥»¥Íª«»sÃĤ½¥qSosei¶°¹Î»P¦X§@¹Ù¦ñ¦ãº¸«Øªñ¤éÁp¦X«Å¥¬¡A¤w¨M©w¦ÛÄ@¼È°±¹êÅç©ÊÃĪ«HTL0018318ªºÁ{§É¶}µo¬¡°Ê¡CÂù¤èªí¥Ü¡A¦¹¦¸¼È°±¨Ã«D°ò©ó¥ô¦ó¤HÃþ¬ã¨sµo²{¡A¦Ó¬O¥Ñ©ó¦b¤@¶µ«D¤HÆFªøÃþ°Êª«¬ã¨s¤¤µo¥Íªº·N·Q¤£¨ìªº¡§²§±`¼W´Þªº¡B¨u¨£ªº¸~½F¡¨¬r²z¾Çµo²{¡C ¥Ñ©ó³o¤@¬r²z¾Çµo²{©MÀH«áªº½Õ¬d¡AHTL0018318¦bAD©MDLB±wªÌ¤¤¤wp¹ºªºII´ÁÁ{§É¬ã¨s¹wp±N³Q±À¿ð¦Ü¤Ö6Ó¤ë¡A¨Ã¦]¦¹Sosei¤½¥q¦b2019¦~ªº¦¬¤J±N·|²£¥Í¼vÅT¡C¸Ó¤½¥q¹wp2019¦~·|±q¦ãº¸«ØÀò±o¦¹ÃĪ«¦X§@¶µ¥Ø¶i®i¬ÛÃöªº«¤j¨½µ{¸O¥I´Ú¡C(Ãø©Ç¤µ¤éSoseiªÑ»ù¤U¶^ªñ 22 % , ªÑ»ù¡G 4565 (TYO) ¥1,424 -400.00 (-21.93%)) 2016¦~4¤ë¡A¦ãº¸«Ø»PSoseiºX¤U¤½¥qHeptareñ¸p¤F¤@¶µÁ`ÃB°ª¹F33»õ¬ü¤¸ªº¥þ²y¬ãµo©M°Ó·~¤Æ¨óij¡C®Ú¾Ú¨óij±ø´Ú¡A¦ãº¸«Ø±N¤ä¥I¤@µ§1.25»õ¬ü¤¸ªº¹w¥I´Ú¡A°ª¹F6.6»õ¬ü¤¸ªº¬ãµo¨½µ{¸Oª÷¡A¥H¤Î°ª¹F25»õ¬ü¤¸ªº°Ó·~¤Æ¨½µ{¸Oª÷¡C¦¹¥~¡A¦ãº¸«ØÁÙ±N¬°¦X§@¶µ¥Ø´£¨Ñ5000¸U¬ü¤¸¸ê§U¬ÛÃö¤Æ¦Xª«§¹¦¨II´ÁÁ{§É¡A¤§«á¦ãº¸«Ø±N¿W¦Ût³dIIb´Á¤Î¤§«áªºÁ{§É¶}µo¬¡°Ê¡C¦X§@ªº¶µ¥Ø¬°¹v¦V¤j¸£¬r¿¸ÆPM1©MM4¨üÅ骺¤p¤À¤l¿E°Ê¾¯¡A¥]¬A¨âÓM1¿E°Ê¾¯¡]HTL0018318©MHTL9936¡^¦®¦bªvÀøAD¬ÛÃö»{ª¾¥\¯àªº¤U°¡F¦ÓM4¿E°Ê¾¯«h³q¹L¤@ºØ¤£¦Pªº¾÷¨îªvÀø¯«¸g¦æ¬°¯gª¬¡C¨Ó¦ÛI´ÁÁ{§É¬ã¨sªº¼Æ¾ÚÅã¥Ü¡A³o¨Ç¤Æ¦Xª«¦b¤¤¼Ï¯«¸g¨t²Î¤¤¨ã¦³¨}¦nªº@¨ü©Ê¨Ã´£¨Ñ¤F¹v¦ì°Ñ»PªºÃÒ¾Ú¡C ªñ¤é¡A¿ÕµØ©M¦w¶iµo¥¬¤F¥þ²y³Ì¤j³W¼ÒªºAD½Õ¬d³ø§i¡C¸Ó³ø§i¯A¤Î¶W¹L1¸U¦W¦¨¦~¤H¡A½Õ¬dÅã¥Ü¡A62%ªº¤H¾á¤ß¥LÌ¥i¯à·|±w¤WAD¡A¦Ó91%ªº¤H¬Û«H¸Ñ¨M¸Ó¯e¯fªº¤èªk¦b©óÂå¾Ç¬ã¨s¡A79%ªº¤HÄ@·N°Ñ»PÂå¾Ç¬ã¨s¡A¦ý75%ªº¤H¤£ª¾¹D¦p¦ó°Ñ»P¡C¦¹¥~¡A¦³60%ªº¤H¬Û«H¦b¨ä¦³¥Í¤§¦~·|¦³¤@ºØªv·U©ÊÀøªkÀò§å¤W¥«¡C¡]·s®öÂåÃĽsĶ/newborn¡^ «z!³o»òÈ¿ú 016¦~4¤ë¡A¦ãº¸«Ø»PSoseiºX¤U¤½¥qHeptareñ¸p¤F¤@¶µÁ`ÃB°ª¹F33»õ¬ü¤¸ªº¥þ²y¬ãµo©M°Ó·~¤Æ¨óij¡C®Ú¾Ú¨óij±ø´Ú¡A¦ãº¸«Ø±N¤ä¥I¤@µ§1.25»õ¬ü¤¸ªº¹w¥I´Ú¡A°ª¹F6.6»õ¬ü¤¸ªº¬ãµo¨½µ{¸Oª÷¡A¥H¤Î°ª¹F25»õ¬ü¤¸ªº°Ó·~¤Æ¨½µ{¸Oª÷¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/18 ¤U¤È 07:57:26²Ä 428 ½g¦^À³
|
¹ï¤£°_!«e¤å¦³Ó¦a¤è»~´Ó¤F . Áp¦X°ê³¹¤Î¹A·~²Õ´¡]FAO¡^©M¥@¬É½Ã¥Í²Õ´¡]WHO¡^Áp¦X©eû·|«Øij¥Ø«e¥i±µ¨üªº¨C¤éÄá¤J¶q¬° 0.5 ²@§J/¤½¤çÅé« À³§ï¬° . Áp¦X°ê³¹¤Î¹A·~²Õ´¡]FAO¡^©M¥@¬É½Ã¥Í²Õ´¡]WHO¡^Áp¦X©eû·|«Øij¥Ø«e¥i±µ¨üªº¨C¤éÄá¤J¶q¬° 5 ²@§J/¤½¤çÅé« ©Ò¥H , ¥H70¤½¤ç¦¨¤Hpºâ, ¨C¤é¥i±µ¨üªºÄá¤J¶q¬° 350 ²@§J ½Ð°Ñ www.who.int/ipcs/publications/cicad/cicad26_rev_1.pdf BENZOIC ACID AND SODIUM BENZOATE World Health Organization Geneva, 2000 Published under the joint sponsorship of the United Nations Environment Programme, the International Labour Organization, and the World Health Organization, and produced within the framework of the Inter-Organization Programme for the Sound Management of Chemicals. P.29 11.1.2 Criteria for setting tolerable intakes or guidance values for benzoic acid and sodium benzoate As given in section 11.1.1, the database is insufficient for deriving NO(A)EL values for oral uptake. If the provisional NO(A)EL of about 500 mg/kg body weight per day is applied, and by incorporating an uncertainty factor of 100 (10 for uncertainty of the database, 10 for interspecies variation), a provisional tolerable intake would be 5 mg/kg body weight per day. Applying this tolerable intake, one has to keep in mind that benzoates at lower doses can cause nonimmunological contact reactions (pseudoallergy) in sensitive persons. ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/18 ¤U¤È 05:28:10²Ä 427 ½g¦^À³
|
¹ù¥S¤µ¦©Ò¤Þ¥Îªº¿D¬wÂå¾Ç±M®a Alex Ryan, Andrea Baker, Frances Dark, Sharon Foley, Anne Gordon, Sean Hatherill, Stephen Stathis, Sukanta Saha, George Bruxner, Martin Beckman, Drew Richardson, Michael Berk, Olivia Dean,John McGrath, Cadence Working Group, and James Scottµ¥¾ÇªÌªº¬ã¨s¤è®× The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial www.ncbi.nlm.nih.gov/pmc/articles/PMC5383965/ ¨ä¤¤¦³±M¸`»¡©úf¥Ò»Ä¶uªº¦w¥þ©Ê , ºKĶ¦p¤U .¤fªAf¥Ò»Ä¶u¦b¤HÅ餤ªº«æ©Ê¬r©Ê«Ü§C .¦b¤HÃþ¤¤¨Ï¥Îf¥Ò»Ä¶u¥Î©óªvÀøºë¯«¯e¯f¬O²{¥Nªº¹Lµ{¡A¦ý±q70¦~¥N±ß´Á¶}©l¤w¸g¥Î©óªvÀø§¿¯À´`Àôenzymopathies±wªÌ¤Þ°_ªº°ª®ò¦å¯g¡C¥Î©óªvÀø°ª®ò¦å¯gªºªvÀø¾¯¶q¦b¼Æ¦~¤º¬° 250-500 mg / kgÅé«/¤Ñ¡A¬Û·í©ó¨C¤Ñ17-35 g (Åé«70kg)¡Cȱoª`·Nªº¬O¡A¦b¸Ó¾¯¶q¤ô¥¤U¡A¬r©ÊªºÁ{§É¯gª¬«Ü¤Ö¡A¨Ã¥B¶È©ó¹½¹©M¹Ã¦R¡A¤×¨ä¬O¦b¨ã¦³100¢H¥Íª«§Q¥Î«×ªº¤j¶qÀR¯ßª`®g«á¡C .¬ü°ê¹«~©MÃÄ«~ºÞ²z§½¡]FDA¡^ÂkÃþf¥Ò»Ä¶u¬°¡§¤@¯ë»{¬°¦w¥þ¡¨(¡§Generally Recognized As Safe¡¨) , ¨Ã±Nf¥Ò»Ä¶uªº¿@«×(¥H«¶qp)ºÞ¨î¦b1¢H(ÃĪ«)©M0.1¢H (¹«~) .Áp¦X°ê³¹¤Î¹A·~²Õ´¡]FAO¡^©M¥@¬É½Ã¥Í²Õ´¡]WHO¡^Áp¦X©eû·|«Øij¥Ø«e¥i±µ¨üªº¨C¤éÄá¤J¶q¬°0.5²@§J/¤½¤çÅé«¡Cȱoª`·Nªº¬O¡A´XÓ°ê®aªºÄá¤J¶q¥§¡¦ôpȬ° 0.18-2.3²@§J/¤d§JÅé« ; µM¦Ó¡A¤¤°ê¨C¤Ñ¶È±q¶¼¹¤¤Äá¨ú°ª¹F14²@§J/¤½¤çÅé«¡]§Y¨C¤HÅé«70¤½¤ç¡A¨C¤Ñ980²@§J¡^¡C .°ê»Ú¤Æ¾Ç«~¦w¥þ¤è®×¡]IPCS¡^©ó2000¦~µoªí¤FÃö©óf¥Ò»Ä¶u¡]¤Î¬ÛÃö¤Æ¦Xª«¡Af¥Ò»Ä¡^ªº³ø§i¡A¸Ô²Ó´yz¤Ff¥Ò»Ä¶u¦b°Êª«¬ã¨s¤¤ªº¼ç¦b°·±d¼vÅT¡C ..¦bø¥¾¦°Êª«¤¤¶i¦æªº´ú¸ÕÅã¥Ü¥X§C¬r©Ê¡A¥§¡P¦º¾¯¶q¡]LD50¡^È> 1,940 mg / kgÅé«¡C ..±qø¥¾¦°Êª«ªº¨â¶µªø´Á¬ã¨s¡]12-16Ó¤ë¡^¤¤±o¥XÃÒ¾Ú¡A¨S¦³ÃÒ¾Úªí©úf¥Ò»Ä¶u¨ã¦³PÀù©Ê¡C¦P¼Ë¡A¹ïf¥Ò»Ä«eÅé - ¤A»ÄËyà¡Af¥Ò¾J©Mf¥ÒîǪº¬ã¨sªí©ú¡Af¥Ò»Ä¶u¤£¤Ó¥i¯à²£¥ÍPÀù§@¥Î¡C ..¦bIPCS³ø§i¤¤¡A¿ò¶Ç¬r©Ê¬¡°Êªºµ²ªG©|µL©w½×¡A¨Ã¥B°ò©óAmes¸ÕÅç¨S¦³¤@Pªº²§±`µo²{¡C°ò©ó¤HÃþ²O¤Ú¥À²ÓM¨tªºÅé¥~¬ã¨s¡A .f¥Ò»Ä¶u½T¹ê¨ã¦³FL¬r©Ê©ML¨à¬r©Ê§@¥Î; µM¦Ó¡A³o¨Ç¶È¦b¾¯¶q°ª¨ì¨¬¥H¤Þ°_ÄY«ªº¥ÀÅé¬r©Ê®É¤~©úÅã¡C«Ø¥ß¤F¹ïø¥¾¦°Êª«P·î§@¥Î¬ù1,310 mg / kgÅ髵L¥iÆ[¹î¨ìªº¤£¨}¤ÏÀ³¤ô¥¡]NOAEL¡^ ÁÂÁ¿D¬wÂå¾Ç±M®aªºÂç²M ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/18 ¤W¤È 09:41:50²Ä 426 ½g¦^À³
|
ÁÂÁ¹ù¥Sªº¸É¥R»P«ü¾É ¹ù¥S¹ïf¥Ò»Ä¶u©Mºû¥Í¯ÀC¤ÏÀ³ªº°ÝÃD , ¥H¬ì¾ÇªºÆ[ÂI¨ÓÄÄzÅ餺±ø¥ón²£¥Íf´XµL¥i¯à ¨ÃÁ|^°êFSA ¤Î¬ü°ê FDAªºÀË´ú¥«±¶¼®Æ¼Æ¾Ú , ¨Ó»¡©ú¨ä¿@«×§¡»·§C©óWHO¶¼¥Î¤ô§tfªº¼Ð·Ç ¤]¤Þ¥Î¿D¬wÂå¾Ç±M®a¾ÇªÌI®Ñ»{¬°f¥Ò»Ä¶u¤£¨ãPÀù©Ê ¹ù¥S³Ì«áµ²½× f¥Ò»Ä¶u©Mºû¥Í¯ÀC¤ÏÀ³²£¥Ífªº°ÝÃD¬°³¯¦~°²Ä³ÃD , µL±e¦Aij liawbf.pixnet.net/blog/post/48505422 ÁÂÁ¹ù¥Sµ¹§Ú̪º±Ð¾É ¤]§Æ±æ¤½¥q¦h¹ï¥Á²³«Å¾É , ¤×¨ä¬O±wªÌ ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/17 ¤U¤È 04:39:19²Ä 425 ½g¦^À³
|
¹ï¤£°_ ! ¸É¥R¤@¤U ¤pªº§Ñ¤F´£ SND-13 °Ñ»PÁ{§É¸ÕÅ窺º§å±wªÌ , ©Î¤w§¹¦¨¤@¦~¤S¤TÓ¥b¤ëªº¸ÕÅç ¥L(¦o)̹ï©ó¦w¥þ©Êªº¤ÏÀ³ , ©Î¦bªk¥O³\¥i¤U , ¥ç½Ð¤½¥q¤@¨Ö´£¨Ñµ¹«á¨Ó¥[¤JªºÁ{§É¸ÕÅçªÌ°Ñ¦Ò ¤£¦¨¼ôªº«Øij , ½Ð®ü²[ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/17 ¤U¤È 03:51:44²Ä 424 ½g¦^À³
|
¹ï¤ß®® SND-1¨t¦C¦¬®×ªº«ä¦Ò ½t°_¡G ºô¸ôSZ±wªÌ¹ïf¥Ò»Ä¶uªvÀøSZªº°Q½× , ½Í¤Îf¥Ò»Ä¶u¸g¤Æ¾Ç¤ÏÀ³¦³¥Í¦¨fªº¥i¯à©Ê , §Î¦¨³¡¤À±wªÌªººÃ¼{ µM¦Ó³oºØ¥i¯à©Ê©Î¬O¯S©w±ø¥ó¤Uªº¤ÏÀ³µ²ªG ¥Ø«e¤Ö¼Æªº¨Ò¤l¬O²GÅéÀô¹Ò®É , ¦pªG¦P®É§t¦³f¥Ò»Ä©Mºû¥Í¯ÀC¡A¦bÅKÂ÷¤l©Î¤G»ù»ÉÂ÷¤lªº¶Ê¤Æ¤U¡A¦b°ª·Å°ª»Ä¤U , f¥Ò»Ä¦³¾÷·|³Qºû¥Í¯ÀC ÁÙ즨f¡]Gardner & Lawrence, 1993¡^¡C §tºû¥Í¯ÀC¶¼®Æ + f¥Ò»Ä ¦b¹B°e¹Lµ{©Î¨ü¶§¥ú·Ó®g , è¦n§Î¦¨¦b¯S©w±ø¥ó¤U¦Ó¥Í¦¨·L¶qªºf , µM¯Ê¤@±ø¥ó«KµLªk²£¥Íf ¤@¯ë´CÅé¦ü¥G³£¬O°w¹ï¦¹¤@¯S®í±¡ªp¤Uªº³ø¾É , ¦Ó³y¦¨¥Á²³ªº»~¸Ñ , ¥H¬°¦Y¤Uf¥Ò»Ä¶u´N·|²£¥Íf ¨Æ¹ê¤W , ¤H̨C¤Ñ©Ò§l¤Jªº¨T¾÷¨®¼o®ð§tfªº¶q ¥ç¤£¤Ö§r ! ¦æ¬F°|Àô«O¸p ¬rª«¤Î¤Æ¾Çª«½è§½ 107-02-13 ªº¤å³¹ f¥Ò»Ä¡G°®³fÌÂ\²æ¤£¤Fªº¨¾»G¾¯? www.tcsb.gov.tw/cp-263-2726-2530f-1.html ¤Î f¥Ò»Ä¶u¬O§_¦³¬r 2014/08/11 ¨Ó·½¡G¯à·½ºô ì¤åºô§}¡Gread01.com/AMG5y.html#.W585B84zapo ³£¦³©Ò±´°Q ¤pµ²«Øij : «Øij¤½¥q¦b¥i¦æªº±¡ªp¤U , °Ñ¦Ò¦U¶µ¤åÄm°µ¦¨Â²¼äªº»¡©« , ¨Ó®ø°£ÀÀ°Ñ¥[Á{§É±wªÌ¤Î¤j²³ªº»~¸Ñ©MºÃ¼{ , ¶i¦Ó¥[§Ö¦¬®×¶i«× µMY¤½¥q¤w¦³Ãþ¦ü°µªk , «hÁÂÁ¤½¥q¹Î¶¤ªº§V¤O ÁÂÁ±zÌ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/13 ¤U¤È 05:12:04²Ä 423 ½g¦^À³
|
¹L¥h20¦~ªüº¸¯ý®üÀq¯f¬ãµo³ø§i¡G146ºØÃĪ«¥¢±Ñ¶È4ºØ¤W¥« ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-09-13 ·s®öÂåÃĽsĶ/newborn med.sina.com/article_detail_103_2_52598.html ¬ü°êÃÄ«~¬ã¨s»P»s³y°Ó¨ó·|¡]PhRMA¡^ªñ¤éµo¥¬³ø§i«ü¥X¡A¾¨ºÞ¤w¥I¥X¤F¥¨¤jªº¬ì¾Ç§V¤O¡AºI¦Ü¥Ø«e¶È¦³6ºØªüº¸¯ý®üÀq¯f¡]AD¡^ÃĪ«Àò¬ü°êFDA§åã¤W¥«¡]¤À§O¬°¡G1993¦~§åã¥L§JªL¡F1996¦~§åã¦h©`哌»ô¡F2000¦~§åã¥d¤Ú©Ô¥Å¡F2001¦~§åã¥[Äõ¥L±Ó¡F2003¦~§åãÆQ»Ä¬üª÷è¡F2014¦~§åã¬üª÷è/¦h©`哌»ô½Æ¤è»s¾¯¡^¡A©Ò¦³³o¨ÇÃĪ«³£¥u¬O¹ï¯gªvÀø¡A¨S¦³¤@ºØ¯à°÷ªý¤î©ÎªÌ©µ½wAD¯f±¡ªº¶i®i¡C 2014¦~§åã¬üª÷è/¦h©`哌»ô½Æ¤è»s¾¯: SNS¨t¦C ¬O§_´N¬Onµo®i ( SND1 + SND5 + ¬J¦³¤W¥«ÃĪ« ) ¨âºØ¾÷¨îÁp¦Xªº½Æ¤è? |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/13 ¤W¤È 08:43:38²Ä 422 ½g¦^À³
|
¹ù¥S¹ï¤ß®®µo®iSNS¨t¦Cªº·P·Q ½Ð°Ñ liawbf.pixnet.net/blog/post/48455244 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/12 ¤U¤È 05:09:03²Ä 421 ½g¦^À³
|
¤j®a¦pªG¬Ý¤F±M§Q¤º¤å , ´N§ó©ö©ú¥Õ³oÓ²Õ¦X¦p¦óÀ³¥Î?! [ Claims ] 1. A composition, comprising a benzoate compound and an excipient, wherein the excipient comprises tannic acid, or a pharmaceutically acceptable salt thereof, wherein the benzoate compound and the tannic acid are at a ratio of 100:1 to 1:100 by weight in the composition, and wherein the composition comprises about 100 mg to about 1,200 mg of the benzoate compound and about 2.0 to about 1,200 mg of the tannic acid. ... 7. The composition of claim 1, further comprising an additional therapeutic agent for a central nervous system (CNS) disorder. 8. The composition of claim 7, wherein the additional therapeutic agent for the CNS disorder is selected from the group consisting of cariprazine, brexpiprazole, butyrophenone, phenothiazine, fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine, mesoridazine, promazine, triflupromazine, promethazine, thioxanthene, chlorprothixene, flupenthixol, thiothixene, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, amisulpride, asenapine, paliperidone, aripiprazole, lamotrigine, droperidol, pimozide, butaperazine, carphenazine, eemoxipride, piperacetazine, sulpiride, acamprosate, tetrabenazine, vilazodone, levomilnacipran, fluoxetine, paroxetine, escitalopram, citalopram, sertraline, fluvoxamine, venlafaxine, milnacipram, duloxetine, mirtazapine, mianserin, reboxetine, bupropion, amitriptyline, nortriptiline, protriptyline, desipramine, trimipramine, amoxapine, clomipramine, doxepin, tranylcypromine, selegiline, trazodone, nefazodone, phenelzine, lamatrogine, lithium salts, topiramate, gabapentin, carbamazepine, oxacarbazepine, valporate, maprotiline, mirtazapine, brofaromine, moclobemide, isoniazid, iproniazid, amphetamine, mixed salts amphetamine, modafinil, desoxyn, methamphetamine, cocaine, arecoline, dexmethylphenidate, dextroamphetamine, methylphenidate, lisdexamfetamine dimesylate, atomoxetine, clonidine, guanfacine, arecoline, pemoline, donepezil, tacrine, rivastigmine, memantine, physostigmine, arecoline, selegiline, riluzole, tannic acid, and Ginkgo Biloba extract. Åv§Qn¨D¶µ1.¬O·§¬Aªº¼gªk Åv§Qn¨D¶µ7. 8.¬O¦A¤@¦¸½T«OÅv§Qªº¥¿±ªí¦C , ³o¬O·íÅv§Qn¨D¶µ1.ªº·§¬A¼gªk³Q§ð¯}¦ÓµLªk«O»Ù®É , ¦Ü¤Ö¥Õ¯È¶Â¦rªº¥¿±ªí¦C¶µ¥Ø¥i¥H½T«O ¤S¤º¤åªº»¡©ú¸Ì , ¹ï©ó¦p¦ó²Õ¦XÀ³¥Î´N§ó¥[²M·¡¤F ÃĪ«²Õ¦Xª«: .¦b¤@¨Ç¹ê¬I¤è®×¤¤¡A¥]§tf¥Ò»Äà¤Æ¦Xª«©M³æ¹ç»Äªº¥ô¦óÃĪ«²Õ¦Xª«¥i¥H¶i¤@¨B¥]§t°ò©ó²Õ¦Xª«ªº¹w´ÁªvÀø¥Î³~ªº¥t¥~ªºªvÀø¾¯¡C .¦b¤@¨Ç¹ê¨Ò¤¤¡A¥t¥~ªºªvÀø¾¯¬O¥Î©óªvÀøCNS¯e¯f/¯f¯gªºÃľ¯¡C³oºØªvÀø¾¯¥i¥H¬O§Üºë¯«¯fÃÄ¡C ¥Ü¨Ò©Ê§Üºë¯«¯fÃÄ¥]¬A¦ý¤£©ó¤B酰f¡]¨Ò¦p¡A¬t哌Ôr¾J¡]HALDOL TM¡^¡A§h噻嗪¡]¨Ò¦p¡A´â¤þ嗪¡]THORAZINE TM¡^¡^¡A¬t¾Ä¤DÀR¡]PROLIXIN TM¡^¡A¾Ä¤DÀR¡]TRILAFON TM¡^¡A¤þ´â©Ô嗪¡]COMPAZINE TM¡^¡A²¸§Q¹F嗪¡]MELLARIL™¡^¡A¤T¬t©Ô嗪¡]STELAZINE™¡^¡A¬ü¯Á¹F嗪¡A¤þ嗪¡A¤T¬t¤þ嗪¡]VESPRIN™¡^¡A¥ª±Û¤þ嗪¡]NOZINAN™¡^¡A²§¤þ嗪¡]PHENERGAN™¡^¡A噻¾·¡]¨Ò¦p´â噻§h¡A¬t哌噻¾J¡]DEPIXOL™¡AFLUANXOL™¡^¡A²¸¥N噻§h¡] NAVANE™¡Azuclopenthixol¡]CLOPIXOL™¡AACUPHASE™¡^¡A´â´á¥¡]CLOZARIL™¡^¡A¶ø´á¥¡]ZYPREXA™¡^¡A§Q°öଡ]RISPERDAL™¡ARISPERDAL CONSTA™¡^¡A喹²¸¥¡]SEROQUEL™¡^¡A»ô©Ô¦èଡ]GEODON™¡^¡A®òÁD¥²§Q¡]SOLIAN¡^ ™¡^ .¥t¥~ªºªvÀø¾¯¥i¥H¬O§Ü§íÆ{¾¯©M/©Î±¡ºüéw¾¯¡C ¦b¬Y¨Ç¹ê¬I¤è®×¤¤¡A§Ü§íÆ{ÃÄ¥]§t³æÓi®ñ¤Æ酶§í»s¾¯¡]MAOI¡^¡A¤TÀô§Ü§íÆ{ÃÄ¡]TCA¡A¦pIMIPRAMINE TM¡^¡A¥|ÀôÃþ§Ü§íÆ{ÃÄ¡]TeCA¡^¡A¿ï¾Ü©Ê5-ßm¦âÓi¦AÄá¨ú§í»s¾¯¡]SSRI¡^¡A¥h¥ÒµÇ¤W¸¢¯À¯à©M¯S²§©Ê5-ßm¦âÓi¯à§Ü§íÆ{ÃÄ¡]NASSA¡^¡C ¡A¥h¥ÒµÇ¤W¸¢¯À¡]¥h¥ÒµÇ¤W¸¢¯À¡^¦AÄá¨ú§í»s¾¯¡A¥h¥ÒµÇ¤W¸¢¯À - ¦h¤ÚÓi¦AÄá¨ú§í»s¾¯©M/©Î5-ßm¦âÓi - ¥h¥ÒµÇ¤W¸¢¯À¦AÄá¨ú§í»s¾¯¡]SNRI¡^¡C¥Ü¨Ò©ÊSSRI¥]¬A¬t¦è¥Å¡]PROZAC TM¡^¡A©¬Ã¹¦è¥Å¡]PAXIL TM¡ASEROXAT TM¡A¨Ì¥L´¶±[¡]LEXAPRO TM¡AESIPRAM TM¡^¡A¦è酞´¶Äõ¡]CELEXA TM¡^¡AªÙ¦±ªL¡]ZOLOFT TM¡^¡A¬t¥ñ¨F©ú¡]LUVOX TM¡^¡^¡C¥Ü¨Ò©ÊSNRI¥]¬A¤å©Ôªk¨¯¡]EFFEXOR TM¡^¡A¦Ì¨º´¶±[©M«×¬¥¦è¥Å¡]CYMBALTA TM¡^¡C .¦b¨ä¥L¹ê¨Ò¤¤¡A¥t¥~ªºªvÀø¾¯¥i¥H¬O¥Î©óªvÀøADD©M/©ÎADHDªºÃľ¯¡C ¦X¾AªºADHDÃĪ«¥]¬A¦ý¤£©ó¥L¥ÅÃþ¡A¦w«D¥L©ú¡A²ö¹F«D¥§¡ADesoxyn¡A¥Ò°òf¤þÓi¡A¥i¥d¦]¡AÂb·}ÆP¡ADexmethylphenidate¡]Focalin¡AFocalin XR¡^¡A¥k±Û¦w«D¥L©ú¡]Dexedrine¡ADexedrine Spansules¡ADextroamphetamine ER¡ADextrostat¡^¡A哌¥Òà¡]Concerta¡ADaytrana¡^ ¡AMetadate CD¡AMetadate ER¡AMethylin¡AMethylin ER¡ARitalin¡ARitalin-LA¡ARitalin-SR¡^¡Alisdexamfetamine dimesylate¡]Vyvanse¡^¡A²V¦XÆQ¦w«D¥L©ú¡]Adderall¡AAdderall XR¡^¡AAtomoxetine¡]Strattera¡^¡AÆQ»Ä¥i¼Ö©w¡]Catapres¡^¡AÆQ»ÄÐgªk¨¯¡]Tenex¡^¡AÂb·}ÆP©M¤Ç²öªL¡C .¦¹¥~¡A¥t¥~ªºªvÀø¾¯¥i¥H¬O¥Î©óªvÀø»{ª¾»ÙêªºÃľ¯¡A©M/©Î¥H¯«¸gÅܩʬ°¯S¼xªº¯f¯g¡]¨Ò¦p¡Aªüº¸¯ý®üÀq¤ó¯f©Î©¬ª÷´Ë¯f¡^¡C ¦¹ÃþªvÀø¾¯¥]¬A¦ý¤£©óDonepezil¡]Aricept TM¡^¡A¥L§JªL¡ARivastigmine¡A¬üª÷è¡]AXURA TM¡AAKATINOL TM¡ANAMENDA TM¡AEBIXA TM¡AABIXA TM¡^¡A¬r«ó¨§ÆP¡A¥§¥j¤B¡AÂb·}ÆP¡A¥Û§üÆP¥Ò¡A¥q¨Ó¦NÄõ¡ARilutek TM¡]§Q¾|Ðü¡^¡Aºû¥Í¯ÀC¡Aºû¥Í¯ÀE¡AÃþJÅÚ½³¯À¡A»È§ö¸´£¨úª«µ¥¡C .¥»¤åÁÙ´£¨Ñ¤F¨Ï¥Î¥]§t¥»¤å©Òzªºf¥Ò»Äà¤Æ¦Xª«©M³æ¹ç»Äªº¥ô¦ó²Õ¦Xª«©M¥t¥~ªºªvÀø¾¯¡]¨Ò¦p¥»¤å©Òzªº¨º¨Ç¡^ªº²Õ¦XÀøªk¡C...µ¹ÃĤ覡¡A¥]¬A¦ý¤£©ó¤fªA³~®|¡AÀR¯ß³~®|¡A¦Ù¦×¤º¡A¥Ö¤U³~®|¡A©Î³q¹LÖß½¤²Õ´ª½±µ§l¦¬¡C¥i¥H³q¹L¬Û¦P³~®|©Î³q¹L¤£¦P³~®|¬I¥ÎÃľ¯¡C¨Ò¦p¡A¥i¥H¤fªA¬I¥Î²Ä¤@Ãľ¯¡]¨Ò¦p¡A¥]§tf¥Ò»ÄÆQ¤Æ¦Xª«©M³æ¹ç»Äªº²Õ¦Xª«¡^¡A¨Ã¥B¥i¥HÀR¯ß¤º¬I¥Î¥t¥~ªºÃľ¯¡]¨Ò¦p¡A§ÜCNS¾¯¡^¡C (Google½Ķ»Pì¤å©Î¦³¥X¤J , ½Ð°Ñ¾\ì¤å ) Âø¶Ã¤§³B ½Ð®ü²[ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! ( Y¦³»Ý«O±K«OÅ@±M§Qªº¦a¤è , ½Ð³w¤©§R°£ , ÁÂÁÂ! ) |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/12 ¤W¤È 10:35:41²Ä 420 ½g¦^À³
|
ÁÂÁ Cliff ¤j®¦¼wªº¸É¥R«ü¾É , Åý¶W¯Å¾Ç¦WÃĪºÀu¶Õ§ó¥[²M´· .¾¨ºÞ¶}µo¦¨¥»¤ñ¼Ð·Ç¾Ç¦WÃÄ©ù¶Q¡A¶}µo¶W¯Å¾Ç¦WÃĪº§ë¸ê¸û¦³ ¦ý»P³Ð·s¤À¤l¬Û¤ñ , ¶W¯Å¾Ç¦WÃĨ㦳 .¥¢±Ñªº·ÀI§C .µo®i®É¶¡ªí¸ûµu .°Ó·~¤Æªº¹D¸ô¬Û¹ï¨S¨º»ò½ÆÂø .¦³¤@©wªº±Æ¥L©Ê ¤j®a¥i¬Ý¬Ýf¥Ò»Ä¶u¦b«äı¥¢½Õ ¥¢´¼ ¼~Æ{¤T¤j¯gª¬ªºªvÀø®ÄªG ¦p¤µ³oÓ±M§Q---³æ¹ç»Ä¥i°§Cf¥Ò»Ä¶uªº¾¯¶q , ¦Ó¤£´î¨äÀø®Ä ¬Æ©Î¶W¶V ³oӳгy §C¾¯¶qNMDAR½Õ¸`¾¯ ¥[¤W ¬J¦³ÃĪ« 1+1¤j©ó2 ªºÀø®Ä ( ·s»D½Z¤]»¡:³z¹L§ÚÌ¿W¦³ªº§Þ³N§ïµ½ÃĪ«µ²ºc¤Î²Õ¦X,¦Ó§ó¦³§Q©óÃĪ«ªº§l¦¬©MÀø®Ä ) ³oºØ¼s²[»\©Ê , ¤S¨ã¦³§C·ÀI §C¦¨¥» §C¶}µo®É¶¡ , ÁÙ¦³°ªÀø®Ä ; ÂX®i¤F¤ß®®¦¨¥\ªº°ò¦ , ¤]¤j¤j´£°ª¤F§ë¸ê¤ß®®ªº¦w¥þ©Ê ©Î¦A¤]¤£¥ÎÀH®É´£µÛ¤ß¦QµÛÁxªºµ¥«Ý·sÃĪºÁ{§Éµ²ªG , ²¦³º¦³³oÓ¶W¯Å¾Ç¦WÃÄ·í©³¤F ¥H«e¤£ª¾³oÓ±M§Qªº«n©Ê ²{¦b¤~ª¾¹D½²±Ð±Â¥¬§½ªº²`¼s¥©§® ³Ì«á , §ÚÌn·PÁ¤߮®¤½¥qªº§V¤O , ÁÙ¦³±N«n¬ãµo¦¨ªG¶gª¾¤À¨É§ë¸ê¤j²³ªº¬ü·N ÁÂÁ½²±Ð±Â¹Î¶¤ ÁÂÁÂCliff ¤j®¦¼w ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/9/12 ¤W¤È 08:24:42²Ä 419 ½g¦^À³
|
¡uFrom Generics to Supergenerics¡v ¡]www.pharmtech.com/generics-supergenerics¡^ ¡uUnlike the copycat version of the branded product with established bioequivalence, supergenerics offer a therapeutic advantage with product differentiation achieved through improved pharmacokinetics, such as with novel controlled release delivery, combination formulations, modified dosage strengths, or different routes of administration. The development of supergenerics requires limited financial investment despite being more expensive to develop than standard generics. The risk of failure, however, is low compared to innovative molecules; development timelines are shorter; the route to commercialization is far less complex; and there is some scope for exclusivity.¡v |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/12 ¤W¤È 08:17:28²Ä 418 ½g¦^À³
|
³o¤]¤Ó¼F®`¤F¡I ÁÂÁ³¯ÀR¤j¤@»y¹D¯}SNS¨t¦C²£«~ªº²Õ¦XÀu¶Õ¡AÅý¤pªº¬íÀ´¥¦ÌªººëµØ ¡u ¤ß®®¥ÍÂå°£¤F«ùÄò±q¤W¦ì®Ú·½©ÊªºNMDA¾÷Âà¶}µo¼s®Äªº³Ð·sªvÀø¥~¡A¥tµo²{SND5¨ã¦³¼W±jSND1ªº®ÄªG¡A§Y¦P®É¬I¤©§C¾¯¶qªºSND1»PSND5«K¥i¹F¨ì©Î¶W¶V°ª¾¯¶qSND1ªº®ÄªG¡A ¹EµÛ¤â¬ãµo¬J¦³¤¤¼Ï¯«¸gÃĪ«»PSND1¡BSND5¶i¦æ²Õ¦Xªº¥i¦æ©Ê¡C¡v ¡u ºë¯«¤Àµõ¯g¡Bªü¯÷®üÀq¥¢´¼¯g¡B««×¼~Æ{¯g¬O¤¤¼Ï¯«¸gÃĪ«¥«³õ¤T¤jªvÀø»â°ì¡A¤ß®®¤w¦b¦¹¤T¤j»â°ì¿ï©w¦X¾A·sÃĪ«»PSNS1-7¶i¦æ¶}µo¡C ¡v ì¨Ó¦p¦¹ ¬O¤@ºØ¡u ¬J¦³¤¤¼Ï¯«¸gÃĪ«»PSND1¡BSND5¶i¦æ²Õ¦X ¡vªº NME ÃĪ« ¦A¦¸·PÁ³¯ÀR¤jªº«ü¾É ¤]ÁÂÁ¤j®a ¡I |
|
|
·|û¡G³¯ÀR10141886 µoªí®É¶¡:2018/9/12 ¤W¤È 06:55:24²Ä 417 ½g¦^À³
|
SNS ¤°»òßÓª«²Õ¦X¡H ¤u¨ã½cªº·§©À¡B¨¬¥H¶W¶V(super)¥ô¦ó²{¦³ÃĪ«¡A¤S¦³¾Ç¦WÃĬÛ対²³æ§Ö³tªº¬ãµo¹Lµ{ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/11 ¤U¤È 08:04:29²Ä 416 ½g¦^À³
|
¤ß®®2018-09-10 ªº·s»D½Z °£¤FSND, SNG, SNA¡A¤ß®®¥ÍÂåSNS ¨t¦C²£«~Àò¤¤µØ¥Á°ê¡B¬ü°ê±M§Q®Öã www.syneurx.com/2018/09/10/article13/ ¬Ý¤F¦n´X¹M¡A¤]·Q¤F¦n´X¦^ ÁÙ¬O¨S¦³¿ìªk²z¥XSNS¨t¦CNME ( New Molecular Entities )ªº²Õ¦X¼Ë»ª ¤pªº¦¤Wªº²q·Q¡A¦n¹³Â÷¨Æ¹êº¡»·ªº ©Ò¥H¡A·Q½Ð±Ð¤j®a ¡A³oSNS¨t¦C¨ì©³¬O¨º¨ÇÃĪ«ªº²Õ¦X¡H ÁÂÁ¤j®a ¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/11 ¤W¤È 08:28:49²Ä 415 ½g¦^À³
|
¤Ó«Ó¤F! ÁÂÁ Cliff ¤j®¦¼w ªº°T®§©M¸Ñ»¡ , Åý§Ṳ́F¸ÑSNS¨t¦Cªº¥\¤O ¬Ý¨ìSNS¨t¦C , Åý¤pªº·Q¨ì¤ß®®©M½²±Ð±Âªº¨ä¥L±M§Q ªvÀø SZ ªº±M§Q¤¤¦³ 1. 9,675,604 June 13, 2017 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical ³oÓ¬ONaBen©M²{¦æSZÃĪ« , «e«áªA¥Îªº±M§Q 2. 10,039,730 August 7, 2018 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical ³o¬O¤@Ópharmaceutical composition ¦³¨âÓ¬¡©Ê¦¨¤À , ¤]´N¬ONaBen©M²{¦æSZÃĪ«ªº²Õ¦X ¤£¾å±o³o¨Ç²Õ¦X¬O©M clozapine ¤@¼Ë »s¦¨Clozaben , ÁÙ¬OÀ³¥Î¥t¤@Ó½²±Ð±Â¦´N³W¹º¦nªº±M§Q 9,724,279 August 8, 2017 Core-shell particles, preparation process thereof, and composition containing the same §Q¥Îmultilayer core-shell particle ¨Ó§@¬°¤@ºØ²Õ¦XÃĪ« ³o¨Ç¤pªºªF«÷¦è´êªº²q·Q , ¦³½Ð¤j®a«ü¥¿ ³o«h¤½¥q¥D°Êµo¥¬ªº·s»D , ¬O§_¥NªíµÛ¤½¥q¤ßºAªº§ïÅÜ ? ¦³«Ý¨Ó¤é¦LÃÒ ¦A¦¸·PÁÂCliff ¤j®¦¼w ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/9/11 ¤W¤È 01:10:18²Ä 414 ½g¦^À³
|
¦£¤¤¥²¦³¿ù ¤W¶K¤å¦r¡G ¡uNaben 200mg/kg¡]SND-1¡^+ Tannic acid 60mg/kg¡]SND-5¡^¦¨¬°¤@¿õ¡]¾¯¡^¡A¦b¤p¹«¦æ¬°¸ÕÅ礤µo²{¤ñ³æ¤@¦¨¤ÀªºNaben 1000mg/kg¡]SND-1¡^Àø®Ä§ó¨Î¡C¤]´N¬O»¡¡A¥[¤JTannic acid¡]SND-5¡^«á¡A¥iÅýNaben¡]SND-1¡^ªº¾¯¶q¦³®Ä¦a°§C¡A¥BÀò±o§ó¨ÎªºÀø®Ä¡C¡v §ó¥¿¬°¡G ¡uNaben 200mg/kg¡]SND-1¡^+ Tannic acid 60mg/kg¡]SND-5¡^¦¨¬°¤@¿õ¡]¾¯¡^¡A¦b¤p¹«¦æ¬°¸ÕÅ礤µo²{¥iÀò±o±µªñ³æ¤@¦¨¤ÀªºNaben 1000mg/kg¡]SND-1¡^ªºÀø®Ä¡C¤]´N¬O»¡¡A¥[¤JTannic acid¡]SND-5¡^«á¡A¥iÅýNaben¡]SND-1¡^ªº¾¯¶q¦³®Ä¦a°§C¡C¡v ¨ä¾l²Ó¸`¦³ªÅ¦A½Í¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/9/11 ¤W¤È 12:24:25²Ä 413 ½g¦^À³
|
Supergenerics¡]¶W¯Å¾Ç¦WÃÄ¡^¬O¬Æ»ò¡H¦³¬Æ»òÀu¶Õ¡H ¡]www.slideshare.net/anthonycrasto64/what-are-supergenerics¡^ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/9/11 ¤W¤È 12:05:42²Ä 412 ½g¦^À³
|
2018/9/10 ¡u¤ß®®¥ÍÂåSNS¨t¦C²£«~ Àò¥x¡B¬ü±M§Q®Öã¡v¡]m.ctee.com.tw/livenews/aj/20180910003470-260410¡^ ¡u¤ß®®SNS¨t¦C²£«~Àò¬ü¡B¥x±M§Q®Öã¡v¡]www.idn.com.tw/news/news_content.php?catid=3&catsid=1&catdid=0&artid=20180910kofang014 ¡^ Naben 200mg/kg¡]SND-1¡^+ Tannic acid 60mg/kg¡]SND-5¡^¦¨¬°¤@¿õ¡]¾¯¡^(?)¡A¦b¤p¹«¦æ¬°¸ÕÅ礤µo²{¤ñ³æ¤@¦¨¤ÀªºNaben 1000mg/kg¡]SND-1¡^Àø®Ä§ó¨Î¡C¤]´N¬O»¡¡A¥[¤JTannic acid¡]SND-5¡^«á¡A¥iÅýNaben¡]SND-1¡^ªº¾¯¶q¦³®Ä¦a°§C¡A¥BÀò±o§ó¨ÎªºÀø®Ä¡C ³o¼Ëªº·s²Õ¦X²£¥Í¤F¤ß®®ªº·s²£«~¡A¦W¤§¬°SNS¨t¦C¡A²Ä¤GÓS²q´ú¬OSupergeneric¡]¶W¯Å¾Ç¦WÃÄ¡^ªºÁY¼g¡A¦ý¥Ø«e¦¹²q´ú©|«ÝÃÒ¹ê¡C ¤§«eŪ¨ìTannic acidªº±M§Q¤å¥ó®É¡A¤£À´¨âºØ¦¨¤À¤@°_¯Ç¤J±M§Q¬O«ç»ò¦^¨Æ¡A²{¦b¤ñ¹ï´CÅé³ø¾É¤ñ¸û¬ÝÀ´¤F¤@ÂIÂI¡A¤´¦³¦h³BºÃ°Ý©|«Ý¸Ñµª¡C¥H¤W¤º®eY¦³¿ù»~½Ð´f¤©«ü¥¿¡C Is the SNS series , after phase I study, the new candidate for next BTD of SyneuRx in the future¡H |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/8 ¤U¤È 07:15:11²Ä 411 ½g¦^À³
|
¹ù¥S´X¤Ñ«eªº¤j§@---Benzoate ®í³~¦PÂkªºªvÀøÀ³¥Î( liawbf.pixnet.net/blog/post/48400287 ) »¡©ú Benzoate ªººØºØÀ³¥Î ¤µ¤Ñ¤p§Ì¬Ý¨ì¤@ÓªiÄõÂå¾Ç³Õ¤hªº³¡¸¨®æ ¼gªº¬O¤@Ó±w¦³¦Û³¬¯g¤p«Ä¤÷¿Ë¹ï¦Û³¬¯gªº¬ã¨sªº¨ä¤¤¤@½g¤å³¹---Sodium Benzoate and GABRA5 - Raising Cognitive Function in Autism ( ¤ß®®©xºôÅã¥Ü¤UÓÁ{§ÉªºªvÀø»â°ì ´N¬O¦Û³¬¯g ) epiphanyasd.blogspot.com/2017/10/sodium-benzoate-and-gabra5.html ¥L¤]¤Þ¥Î RUSH ¤j¾Ç Pahan ±Ð±Âªº¬ã¨s °£¤F¹ù¥S©Ò¤ÞzªÌ¥~ ³o¦ì¥S¥x¤]´£¤Î .¤@ºØ®ÄÀ³¯A¤ÎºÙ¬°DJ-1ªº³J¥Õ½è¡A¨ä¥Ñ©¬ª÷´Ë¤ó°ò¦]¡]PARK7¡^²£¥Í¡C·íNrf2¿E¬¡«á¨Åé¸Õ¹Ï¥´¶}¨ä§Ü®ñ¤Æ°ò¦]®É¡A¦pªG¨S¦³¨¬°÷ªºDJ-1¡A³oÓ¹Lµ{´NµLªk¶i¦æ¡CCOPD±wªÌ¥i¯à±q§ó¦hªºDJ-1¤¤¨ü¯q¡C COPD¬O¤@ºØÄY«ªºý³Ý¡A¦ñ¦³ÄY«ªº®ñ¤ÆÀ³¿E¡A®ñ¤ÆÀ³¿E¨Ï¼Ð·Çªºý³ÝÃÄ°±¤î¤u§@¡A³o´N¬O¬°¤°»ò³o»ò¦h¤H¦º©óCOPDªºì¦]¡C®ñ¤ÆÀ³¿E¬O¤j¦h¼Æ¦Û³¬¯gªº¤@ÓÃöÁä¯S¼x¡C ¬°¤F»s§@§ó¦hDJ-1¡A¥i¥H¨Ï¥Îf¥Ò»Ä¶u¡]NaB¡^ .®ü°¨Åé¬O¤j¸£¤¤²£¥Í¡A²Õ´©MÀx¦s°O¾Ðªººc³y¡C¬ã¨s¤Hûµo²{¡A»P¦nªº¾Ç²ßªÌ¬Û¤ñ¡A®tªº¾Ç²ßªÌªº®ü°¨Åé¨ã¦³¸û¤ÖªºCREB¡]¤@ºØ°Ñ»P°O¾Ð©M¾Ç²ßªº³J¥Õ½è¡^©M§ó¦hªº£\5¨È°òGABAA¨üÅé©ÎGABRA5¡]¤@ºØ¦b¤j¸£¤¤²£¥Í§í¨î¶Ç¾Éªº³J¥Õ½è¡^¡C ¬ã¨s¤¤ªº¤p¹«±µ¨ü¤F¦×®Û¯»ªº¤fªAÁý¾i¡A¥¦Ìªº¨Åé¥NÁ¦¨f¥Ò»Ä¶u¡A³o¬O¤@ºØ¥Î§@¸£·l¶ËÃĪ«ªvÀøªº¤Æ¾Çª«½è¡C·íf¥Ò»Ä¶u¶i¤J¤p¹«ªº¤j¸£®É¡A¥¦¼W¥[¤FCREB¡A°§C¤FGABRA5¡A¨Ã¨ë¿E¤F®ü°¨¯«¸g¤¸ªº¥i¶ì©Ê¡]§ïÅܯà¤O¡^¡C ( ºK¦Û www.rush.edu/news/cinnamon-may-aid-learning-ability ) f¥Ò»Ä¶u¬J¼W¥[NMDA¥\¯à , ¨Ã´î¤ÖGABRA5ªºªí¹F , ÂùºÞ»ô¤U´î§C»{ª¾¯Ê·l Roche ªº Basmisanil ¬O¤@ºØ GABRA5 negative allosteric modulator (NAM) tÅܺc½Õ¸`¾¯( ¥\¯àÃþ¦ü§í¨î¾¯ ) Basmisanil ¹ïð¤óºî¦X¯g¡]DS¡^ªºÁ{§É¤w¤¤¤î , ²{ÁÙ¦b¶i¦æSZ»{ª¾¯Ê·l¤G´ÁÁ{§Éªº©Û¶Ò .¬ã¨s¤HûÁÙÀˬd¤F±q¤p¹«¨¤W¨ú±oªº¸£²ÓM¡C¥L̵o²{f¥Ò»Ä¶u¼W±j¤F²ÓMµ²ºcªº§¹¾ã©Ê - ´N¬O¦b¾ð¬ð(¤@ºØ¯«¸g¤¸ªº¾ðª¬©µ¦ù, ¨Ï¥¦Ì¯à°÷»P¨ä¥L¸£²ÓM³q«H)¡C f¥Ò»Ä¶u¹ï¤HÅ骺¦h¥\¯à§@¥Î , µÛ¹ê¶W¥G¤p§Ìªº·Q¹³ ¤×¨ä¬O¥i¥H¼W¥[NMDA¥\¯à , ¤S¥i´î¤ÖGABRA5ªºªí¹F , ÂùºÞ»ô¤U´î§C»{ª¾¯Ê·l , §ó¬O¤p§Ì¤µ¤Ñªº·sª¾ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/5 ¤U¤È 02:43:43²Ä 410 ½g¦^À³
|
·¨´Ë¤½¥q»¼¥æ·sÃÄ¥Ó½Ð50¦~¨ÓºÓ§íÆ{¯g·sÃÄ 50¦~ªº³oÓ¼ÐÃD¤Ó¹LÅ宪 £¸¨¥¹DºÉCNS»â°ì·sÃĬãµoªº·É®á ¤]»¡©ú¤FCNS»â°ì·s¾÷Âà·sÃĪºÃø³V §ó¥YÅã¤FCNS»â°ìÃĪ«ªºªø¹Ø¡A°Ê«h´X¬B¦~pºâ ¤p¤ü§i¶D¹L§Ú¡A²{¦³CNS»â°ìªvÀøªºÃĪ«¡A 4±iA4¯È¼g¤£§¹ §Y¨Ï¦b³o»ò¤í¯ÊÃĪ«ªº¥«³õ¡A½²±Ð±Â¤´³£¿ï¾Ü¥¼³Qº¡¨¬»â°ìªº·s¾÷Âà·sÃĨӬãµo ¦p½²±Ð±Â©Ò´£¥Ü¡A¥¼³Qº¡¨¬ªº»â°ì´N¬O¤@¤W¥«´N¥i¥Hº¡¨¬±wªÌªº»Ý¨D¡A§Ö³t¦û¦³¥«³õ §Æ±æ¤ß®®¥[§Ö¸}¨B¡AÁ{§É¶¶§Q¡B¦¨¥\ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/5 ¤U¤È 02:08:19²Ä 409 ½g¦^À³
|
·¨´Ë¤½¥q»¼¥æ·sÃÄ¥Ó½Ð50¦~¨ÓºÓ§íÆ{¯g·sÃÄ ¨Ó·½¡GÃÄ©ú±d¼w¡@2018-09-05 med.sina.com/article_detail_103_2_52066.html 9¤ë5¸¹¡A±j¥Í¤½¥q¡]J&J¡^ºX¤Uªº·¨´Ë¤½¥q¡]Janssen¡^«Å¥¬¦V¬ü°êFDA»¼¥æ¤Fesketamine»ó¼QÃú¾¯ªº·sÃĤW¥«¥Ó½Ð¡C¸ÓÃĪ«¥Î©óªvÀø¦¨¦~ªvÀø©è§Ü©Ê§íÆ{¯g¡]treatment-resistant depression¡^±wªÌ¡C¦pªGÀò±o§åã¡A¸ÓÃĪ«±N¦¨¬°ªñ50¦~¨ÓªvÀøÃøªv©ÊÄY«§íÆ{¯gªº²Ä¤@Ó·sÃÄ¡C ÄY«§íÆ{¯g¦b¥þ²y½d³ò¤º§xÂZ±µªñ3»õ¤Hªº¥Í¬¡¡A¥¦¬O¥@¬É¤W¾ÉP´Ý¯eªººnì¦]¤§¤@¡C§íÆ{¯g¹ï±wªÌ¥Í¬¡ªº¤è¤è±±³£·|²£¥ÍÄY«ªºt±¼vÅT¡A¥]¬A¥Í¬¡½è¶q©M¤é±`¯à¤O¡CÁöµM¥Ø«e¤w¦³ªº§Ü§íÆ{ÃĪ«¹ï«Ü¦h±wªÌ¦³®Ä¡A¦ý¬O±µªñ¤T¤À¤§¤@ªº±wªÌ¹ï¤w¦³Àøªk¨S¦³¤ÏÀ³¡C¦b§íÆ{µo§@®É´Á¹ï¦Ü¤Ö¨âºØ¤£¦Pªº§Ü§íÆ{Àøªk¤ÏÀ³¤£¨}ªº±wªÌ³QºÙ¬°ªvÀø©è§Ü©Ê§íÆ{¯g±wªÌ¡C Esketamine¬O¤@ºØ¨£®Ä¨³³tªº§Ü§íÆ{ÃÄ¡A¥¦ªº§@¥Î¤è¦¡»P¥Ø«eªvÀøÄY«§íÆ{¯gªºÃĪ«¤£¦P¡C³q¹L½Õ¸`¨¦®ò»Ä¨üÅ鬡©Ê¡Aesketamine¯à°÷½Õ¸`©è§Ü©Ê§íÆ{¯g±wªÌ¤j¸£²ÓM¤§¶¡ªº¯«¸g¬ðIJªº¥i¶ì©Ê¡A±q¦Ó¨³³t¨Ã¥B«ù¤[¦a§ïµ½±wªÌ¯gª¬¡C¨Ï¥Î»ó¼QÃú¾¯ªºµ¹ÃĤ覡¡Aesketamine¥i¥H¦b±M·~ÂåÅ@¤HûªººÊ·þ¤U¡A¥Ñ±wªÌ¦Û¤v¨Ï¥Î¡C¸ÓÃĪ«¤w¸gÀò±o¬ü°êFDA±Â¤©ªº¬ð¯}©ÊÀøªk»{©w¡C ªø´Á¦w¥þ©Ê¬ã¨sªí©ú¡Aesketamineªí²{¥X¨}¦nªº@¨ü©Ê¡A¦bªø¹F52¶gªº¨Ï¥Î¹Lµ{¤¤¨S¦³¥X²{·sªº¦w¥þ©Ê°ÝÃD¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/4 ¤U¤È 07:17:50²Ä 408 ½g¦^À³
|
®¥³ß ¤ß®®¤µ¤é¨ú±o¬ü°ê±M§Q United States Patent 10,064,833 September 4, 2018 Compositions containing benzoate compound and tannic acid for treating central nervous system disorders Abstract : Compositions (e.g., pharmaceutical compositions or nutraceutical compositions) comprising a benzoate compound and an excipient, wherein the excipient is tannic acid, and uses thereof for treating central nervous system disorders. Inventors: Tsai; Guochuan Emil (Pasadena, CA), Huang; Ching-Hsun (Taipei, TW), Wang; Ching-Cheng (New Taipei, TW), Hsieh; Tien-Lan (New Taipei, TW) Applicant: SyneuRx International (Taiwan) Corp. New Taipei TW Assignee: SyneuRx International (Taiwan) Corp. (New Taipei, TW) ¸Ô²Ó [ Claims ]¤º¤å , ½Ð°Ñ¾\ USPTO ¤½§i ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/2 ¤U¤È 02:35:59²Ä 407 ½g¦^À³
|
ÁÂÁ¹ù¥S¤S¥X¦n¤å Benzoate ®í³~¦PÂkªºªvÀøÀ³¥Î liawbf.pixnet.net/blog/post/48400287 Cliff ¤j®¦¼w ±z¤Ó«È®ð¤F ¤pªº¥u¯à°l´M , ¶ÇÄÀ¤§¨Æ(ª¾ÃÑ)·ß«Ý¦p±z¤§¯à¤H§r ½Ð¾A®Éµ¹¤©«ü¾É , µeÀsÂI·ú¤§®Ä¨ôº¸ ÁÂÁ±z ! ÁÂÁ¤j®a! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/9/1 ¤U¤È 11:19:31²Ä 406 ½g¦^À³
|
²q·Q¤j¤j¡A ¤p§Ì¸Ó·PÁ±z¤£®É´£¨ÑÄ_¶Q¸ê®Æ»P°T®§¤~¹ï¡C ÁÙ¦³¹ù¥Sªº³¡¸¨®æ¤]¬O«nªº¸ê°T¨Ó·½¡C ¤p§Ì¤£¤~¡A©ó®É¶¡¡B¯à¤O¡A¯à´£¨Ñªº¤º®e«Ü¦³¡A ½Ð±z¡B¹ù¥S¤Î½Ñ¦ì¤j¤j¦h¦hÀ°¦£¡C ·PÁ¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/9/1 ¤W¤È 09:06:50²Ä 405 ½g¦^À³
|
ÁÂÁ Cliff ¤j®¦¼w¬°¤pªººë±m¸Ô²Óªº»¡©ú©M«ü¾É ¤Ó«Ó¤F! Åý¤pªº¤F¸Ñ¸Ó¬q³X°ÝªºI´º¤º²[ , ¦P®É¤]©ú¥Õ¬°¦óSAGE CEO ¦b¤µ¦~6¤ë±µ¨üCNBC³X°Ý®É , ¹ïSAGE-217©Ò§@ªº¸àÄÀ Sage CEO Jeff Jonas »¡ , SAGE-217 ªvÀø MDD ·|¹³¨â¶gÀøµ{ªº§Ü¥Í¯À¤@¼Ë , µM«á¤@³Ò¥Ã¶h ½Ð°Ñ A pharma CEO says a new depression drug could have lasting effects after one short course, like antibiotics ¡X here¡¦s what experts think Erin Brodwin Jun. 25, 2018, 5:58 PM www.businessinsider.com/sage-depression-drug-problem-2018-6 ¤pªº·Q , ³oӨ̾ڥi¯à¨Ó¦Û©ó¸Ó¤½¥qµoªíªºÃÄ®Ä--®É¶¡¹Ï www.google.com.tw/search?tbm=isch&q=sage-217&chips=q:sage+217,online_chips:sage+therapeutics&sa=X&ved=0ahUKEwiykpySx5jdAhVVBIgKHYelClsQ4lYIJigB&biw=1396&bih=663&dpr=1.38#imgrc=dKhpPgaBl1ONRM: µM¦ÓCEOªº³oÓ»¡ªk , ¥t¤@¤è±©Î³\¤]¦b¾á¤ß SAGE-217 ªø¤[¨Ï¥Î·|¤£·|¹³f¤G´á¥ÃþÃĪ«¡]Benzodiazepines¡^ªº²ßºD°ÝÃD SAGE CEO ¤]¥O¤H¨ØªA , ¯à°÷§âSAGEªº¥«È«O«ù¦b70´X»õ¬ü¤¸ , ³o«Ü¤£Â²³æ ·PÁ Cliff ¤j®¦¼w ¦Ñ¥v¤j¤jê©ó¨¤À , µLªk¦AÀ°§Ṳ́W½Ò ¥u³Ñ liaw6575¤j¤j¦b±Ð¨|§ÚÌ Y Cliff ¤j®¦¼w ¤]¯à©âªÅÀ°§ÚÌ«ü¾É«ü¾É ¨º§Ṳ́j®aªºª¾ÃѱN¯qµoªø¶i ÁÂÁ¤j®a! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/9/1 ¤W¤È 12:08:17²Ä 404 ½g¦^À³
|
Call Leader: No problem, but I was wondering, there¡¦s a bit of an argument about these drugs. I know you haven¡¦t necessarily researched them too deeply. Some people think they are neuroactive steroids and others just think of them as maybe even better Benzodiazepines. Doctor: That is possible, but we¡¦ll learn about that if that¡¦s true and there¡¦s nothing wrong if that¡¦s the case. We just have to sort this out and work around it. If they are Benzodiazepine-like, but they¡¦re non habit forming, there¡¦s no problem with that. °Ý¡G ¨S°ÝÃD¡A¦ý§Ú·Qª¾¹D¡A³o¨ÇÃĦs¦bµÛ¤@¨Çª§Ä³¡C §Úª¾¹D§Aı±o¨S¦³¥²n¹ï³o¨ÇÃĬã¨s±o¤Ó²`¡C ¦³¨Ç¤H»{¬°¥¦Ì¬O¯àÅý¯«¸g¬¡¤Æªº¬ü°ê¥P¤¦(Ãþ©T¾J)¡AµM¦Ó¦³¨Ç¤H«o»{¬°¥¦Ì¥i¯à¥u¤ñf¤G´á¥Ãþ¦n¤@ÂI¦Ó¤w¡C µª¡G ¦³¥i¯à¡A¦ý¬O¦pªG¯uªº¬O³o¼Ë¡A¨º§Ú̱N·|¥h¾Ç²ß¥¦¡A¦pªG³o¼Ë°µªº¸Ü¡A¨º´N¨S¦³¿ù¤F¡C §ÚÌ¥u»Ýn§â³oÓ°ÝÃD¤ÀÂ÷¥X¨ÓµM«á¸Ñ¨M±¼¡C °²³]¥¦ÌÃþ¦üf¤G´á¥¡A«o¤S¤£§Î¦¨²ßºD©Ê¡A¨º´N¤£¦¨°ÝÃD¡C ¥@»¡·s»y¡G f¤G´á¥ÃþÃĪ«¡]Benzodiazepines¡^¦b¹L¥h¼Æ¤Q¦~¨Ó³Q¼sªx¥Î¦bºë¯«¬ì¯e¯f¡A¦]¬°¥¦³q±`§t¦³¥|ºØ¤ñ¨Ò¤£¤@ªº¥\¯à¡G¦w¯v¡B§ÜµJ¼{¡B§Üµj癴¤Î¦Ù¦×ÃP¦¢¡C¾Ö¦³¸û¦h¦w¯v¥\¯àªºf¤G´á¥±`±`³Q¥Î¨Ó·í§@¦w¯vÃÄ¡F¾Ö¦³¸û¦h§ÜµJ¼{¥\¯àªºf¤G´á¥±`±`³Q¥Î¨Ó·í§@§ÜµJ¼{ÃĪ«¡F¾Ö¦³¸û¦h¦Ù¦×ÃP¦¢¥\¯àªºf¤G´á¥«h±`³Q®³¨Ó§ïµ½©]¶¡¤£¹ç»L¡]Restless leg¡^¡F¨ä¾lÃþ±À¡C f¤G´á¥ÃþÃĪ«ªº¯ÊÂI¬O¡A¸g¹Lªø®É¶¡¥ÎÃÄ«á¡A®e©ö²£¥Í®Ä¥Î»¼´î¡]Áû¼Æ·U¦Y·U¦h¡^¡BÆJµM°±ÃĮɷ|¦³¤Ï¼u®ÄÀ³¡]¨Ì¿à©Ê¡^¡B¥H¤Îªø´ÁªA¥Î¥i¯à¼W¥[°O¾Ð³à¥¢¡B¿©±w¥¢´¼ªº·ÀIµ¥¡C ¥D«ù¤H´£¨ì¤H̹ï¡]¨º¤T¶µ¬ãµo¤¤·sÃÄ¡^ªºµû»ù¨â·¥¤Æ¡F¦³¨Ç¤H»{¬°¥¦ÌµL©Ò¤£¯à¡A¦n¹³¬ü°ê¥P¤¦¤@¯ë¡A«ç»ò¥Î´N«ç»ò¦³®Ä¡A¹³¬O¯àÅý¯«¸g¬¡¤Æ¤@¯ë¡C¤]¦³¤Hı±o¡]¨º¨Ç¬ãµo¤¤·sÃÄ¡^¥u¤£¹L¤ñ¥Rº¡¯ÊÂIªºf¤G´á¥ÃþÃĪ«¦n¤@ÂI¦Ó¤w¡C ¨ü³XªºÂå®v¦^µª¡A¥un¨£©Û©î©Û¡A¥X²{¬Æ»ò¯ÊÂI´N³]ªk¸Ñ¨M±¼´N¦n¡C¡]°ÝÃD¬O¡G«ç»ò¸Ñ¨M¡H¡^¡C ¥Lı±o´Nºâ¸òf¤G´á¥ÃþÃĪ««Ü¹³¡A¦ý¬O¥un¤£·|¹³f¤G´á¥¤@¼Ë¾ÉP²ßºD©Ê´N¨S¦³»ò°ÝÃD¡C ³¥¤HÄmÃn¡A²¨º|Ãø§K¡A¤Á¤ÅºÉ«H¡A¬Ý©x½Ð¦Û¦æ·r°u¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/31 ¤U¤È 04:09:17²Ä 403 ½g¦^À³
|
¬Q¤Ñ¬Ý¨ì¤@«h³X°Ý½Z An Expert¡¦s View On New CNS Drugs Including Esketamine, SAGE-547, And SAGE-217 In PPD And MDD Call Date/Time: 05/11/2017 at 3pm ET. seekingalpha.com/article/4072727-experts-view-new-cns-drugs-including-esketamine-sageminus-547-sageminus-217-ppd-mdd?page=3 ¬O¥Ñ NYU ªº Psychiatrist Dr. Michael Thase µûªR¦bMDD»â°ìÀò±oBTD ªº¤TÓ¬ãµo¤¤·sÃÄ J&J ªºEsketamine AllerganªºRapastinel SAGE ªº SAGE-217 ³o¦ì±M®a¹ïEsketamineªºµû½× ±qªø»·¨Ó¬Ý¡A§Ú»{¬°Esketamine±N¬O¿é®a¡A©Î³\¥u¯à±Mª`¦bÃøªv«¬±wªÌ¨¤W¡CµM«á±N¨ä¥L´À¥NÀøªk§@¬°ªø´Á¿ï¾Ü¡C ¹ïRapastinelªºµû½× . ¦bMDDªºªvÀø , IVµ¹ÃĵLªk¨ü¨ì«C·ý ; ±N¥¦§ï¬°¤fªAªº¾¯«¬¥s°µApimostinel (NRX-1074)¤]¦bµo®i¤¤,¤@´Á¤fªA 2015§¹¦¨ , ¤G´Á¤fªA©|¥¼¶i¦æ ; ¦ýAllergan 2018/05¤S±qAptinyx¤½¥q¨ú±oÀò FDA Fast Track Designation ªº AGN-241751 (©ó2018¦~7¤ë¶i¦æÁ{§É¤G´Á ) , Apimostinel (NRX-1074)¬O§_¤´nÄ~ÄòÁ{§É , ¤£±o¦Óª¾ . Rapastinel¡]GLYX-13¡^¬O¨ã¦³¥Ì®ò»Ä¦ìÂI³¡¤À¿E°Ê¾¯¯S©ÊªºNMDA¨üÅé½Õ¸`¾¯ , ¦b¦Ñ¹«ªº¸ÕÅç¥i¥H¼W±j»{ª¾ , ©Ò¥H±M®a»{¬°Y§ï¬°¤fªA¤S¥i¦b¤HÃþ¼W±j»{ª¾ , ±N·|«Ü¦³¥¼¨Ó ¹ïSAGE-217ªºµû½× ¤pªº¦³³¡¤À¬Ý¤£À´ , µLªkºKn ¦ý¬O³X½ÍªÌ¦³´£¤Î SAGE-217ªº¾÷Âà¬OÃþ¦üBenzo Benzo ¬Of¤G´á¨ôÃþÃĪ« , ¥i¼W±j¯«¸g»¼½è £^-®ò°ò¤B»Ä¡]GABA¡^¹ïGABA A¨üÅ骺§@¥Î¡A±q¦Ó²£¥ÍÂíÀR¡A¶Ê¯v¡]ºÎ¯v»¤¾É¡^¡A§ÜµJ¼{¡]§ÜµJ¼{¡^¡A§ÜÅå³Ö©M¦Ù¦×ÃP¦¢¯S©Ê¡C f¤G´á¨ôÃþÃĪ«³q±`³Q»{¬°µu´Á¨Ï¥Î¬O¦w¥þ¦³®Äªº¡A°¸º¸·|µo¥Í»{ª¾»Ùê¡Cf¤G´á¨ôÃþÃĪ«¤]»P¦Û±þ·ÀI¼W¥[¦³Ãö¡Cªø´Á¨Ï¥Î¬O¦³ª§Ä³ªº¡A¦]¬°¾á¤ß®ÄªG°§C¡A¨Åé¨Ì¿à¡A§ÙÂ_©Mè§b·ÀI¼W¥[¡C°±¥Îf¤G´á¨ôÃþÃĪ«³q±`¥i¥H§ïµ½¨¤ß°·±d¡C¦Ñ¦~¤H¬O³B¦bªøµu´Á°Æ§@¥Î³£¦³¼W¥[ªº·ÀI¤¤¡A¦]¦¹¡A©Ò¦³ªºf¤G´á¨ôÃþ³£¦C¦b¤ñº¸´µ¦Cªíªº¤£¾A¥Î¦Ñ¦~¤HªºÃĪ«¸Ì¡CÃö©ó¥¥´Áf¤G´á¨ôÃþÃĪ«ªº¦w¥þ©Ê¦s¦bª§Ä³¡CÁöµM¥¦Ì¤£¬O¥DnªºP·îª«¡A¦ý¬O¥¦Ì¬O§_·|¦b¤Ö¼ÆÀ¦¨à¤¤¤Þ°_腭µõ¥H¤Î¬O§_¥Ñ©ó²£«e¼ÉÅS¦Óµo¥Í¯«¸g¦æ¬°¼vÅT¤´¦s¦b¤£½T©w©Ê¡C²³©Ò©Pª¾¡A¥LÌ·|³y¦¨³oºØ±¡ªp·s¥Í¨à§ÙÂ_¯gª¬¡C f¤G´á¨ôÃþÃĪ«ªA¥Î¹L¶q¡A¥i¾ÉP¦MÀIªº²`¼h©ü°g¡CµM¦Ó¡A¥¦Ìªº¬r©Ê§C©ó¥¦Ìªº«e½ú---¤Ú¤ñ§´ÃþÃĪ«¡A¨Ã¥B·íf¤G´á¨ôÃþÃĪ«¬O°ß¤@ªA¥ÎªºÃĪ«®É«Ü¤Ö·|¾ÉP¦º¤`¡C·í»P¨ä¥L¤¤¼Ï¯«¸g¨t²Î¡]CNS¡^§í¨î¾¯¡]¦p°sºë¶¼®Æ©M¾~¤ùÃþÃĪ«¡^Áp¦X¨Ï¥Î®É¡A¬r©Ê©MP©R¹L¶qªº¥i¯à©Ê·|¼W¥[¡Cf¤G´á¨ôÃþÃĪ«±`³Q»~¥Î¡A¨Ã»P¨ä¥LÀÝ¥ÎÃĪ«Áp¦X¨Ï¥Î Google ºKĶ¦Û en.wikipedia.org/wiki/Benzodiazepine (³oÓ½g´T«Üªø , f¤G´á¨ôÃþÃĪ«ªº°Æ§@¥Î , ¥i¯à»P¦³Ãþ¦ü¾÷Â઺SAGE-217ªº°Æ§@¥Î©Î¦³¬ÛÃö , ½Ð¤j®a@¤ß°Ñ¾\) ¤]¦]¦¹ SAGE-217ªºÁ{§É , ³£¦³ÀË´ú¦Û±þ·ÀIªº«ü¼Ð ©Ò¥H¤pªº²q SAGE-217 À³¸Ó¨S¦³ÓV½w¦Û±þ·N©ÀªºÀø®Ä ¦Ó¥B¬JµM·|³y¦¨»{ª¾»Ùê , SAGE-217À³¤]¤£·|¼W±j»{ª¾ ÁÙ¦³¤W¦¸§ÚÌ»¡ªº , ¥¦ªº³Ì¤j@¨ü¾¯¶qMTD¡]Maximum tolerated dose¡^¬O¥ÎÂíÀRªºÄY«©Ê¨Ó±±¨îªº , ³o¥i¯à¬O¦]¬°f¤G´á¨ôÃþÃĪ«ªA¥Î¹L¶q¡A¥i¾ÉP¦MÀIªº²`¼h©ü°gªº«e¨®¤§Å²§a! ¥t¤W¦¸§Ṳ́]²q SAGE-217Á{§É¥u¥ÎÃÄ14¤Ñ , ¥i¯à¦³ªø´Á¨Ï¥Îªº°ÝÃD ³oÓºû°ò¦Ê¬ì§i¶D§ÚÌ f¤G´á¨ôÃþÃĪ«ªø´Á¨Ï¥Î¬O¦³ª§Ä³ªº¡K ¤pªºì¥»¥H¬°¶W±jªºSAGE-217 ©Î³\¨S·Q¹³¤¤ªº¦n ( °§C¦Û±þ·N©À©M¼W±j»{ª¾³£¨SÀø®Ä , ¬Æ©Î¦³®` ) ˬOAllerganªºApimostinel (NRX-1074)©MAGN-241751 ¥i¥H°lÂÜ ¦A¦^¨ì¤ß®®ªº SNG-12 ¤fªA ; ½w¸Ñ§íÆ{ ; °§C¦Û±þ·N©À ; »{ª¾¼W±j SNG-12 ªºÄvª§¤O¦p¦ó?! ¤pªºª¾ÃÑ°ò¦¯Ê¥F , ¹ï©ó¸ê®Æªº¸ÑŪ©ö¥Í»~¸Ñ , ¥B¬y©ó¬ïÆwªþ·| ¦³½Ð¤j®a¦h«ü¥¿ «ü¾É¤Î¸É¥R ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! ¤S ¤pªº¹ï©ó¸Ó³X½Íªº³o¬q¹ï¸Ü , ¨ì©³±M®a©Ò«ü¬°¦ó? ¦³½Ð¤j®a¶}ÄÀ ÁÂÁ¤j®a! Call Leader: No problem, but I was wondering, there¡¦s a bit of an argument about these drugs. I know you haven¡¦t necessarily researched them too deeply. Some people think they are neuroactive steroids and others just think of them as maybe even better Benzodiazepines. Doctor: That is possible, but we¡¦ll learn about that if that¡¦s true and there¡¦s nothing wrong if that¡¦s the case. We just have to sort this out and work around it. If they are Benzodiazepine-like, but they¡¦re non habit forming, there¡¦s no problem with that. ( ºK¦Û seekingalpha.com/article/4072727-experts-view-new-cns-drugs-including-esketamine-sageminus-547-sageminus-217-ppd-mdd?page=3 ) |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/26 ¤U¤È 09:54:41²Ä 402 ½g¦^À³
|
The Lancet Psychiatry 2016 COMMENT| VOLUME 3, ISSUE 5, P392-393, MAY 01, 2016 Treating cognitive impairment in depression: an unmet need Richard S E Keefe ( Duke University Medical Center ) www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(16)00095-X/abstract?code=lancet-site#%20 Cognitive impairment is a substantial unmet need in patients with major depressive disorder. ÁaµM¦b¼~Æ{¯gª¬¤w§¹¥þ½w¸Ñªº±wªÌ , ¦bªvÀø«áªº»{ª¾ªí²{¤´¤ñ¹ï·Ó²Õ®t »¡©ú¤F§¹¥þ½w¸Ñ¼~Æ{¯gª¬ , »{ª¾¯Ê·l¤´µM¦s¦b EMA ©M FDA ªº±M®a¤p²Õ¥çµ²½×:««×§íÆ{¯gªº»{ª¾¯Ê·l¬O¤@Ó legitimate treatment target SNG-12 ¤]¥i´£¤É»{ª¾¥\¯à , ¬O§_¦³¦¹¯à@¶i§ð³o»â°ì ? Y©Î¨S¦³ , ©Î³\¦bªvÀøMDD®É , °£¤F¼~Æ{¯gª¬ ¦Û±þ·N©À¥~ , ¤]¥iÅý±wªÌªº»{ª¾¥\¯à§ïµ½ , ¹F¤@¾¯¤T®Ä¤§¥\ «¢! ¤pªº¦Ñ¬O¤Ñ°¨¦æªÅ , ¦³½Ð¤j®a¸É¥R «ü¾É©M«ü¥¿ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/24 ¤W¤È 07:30:10²Ä 401 ½g¦^À³
|
»´¤¤«×¥¢´¼¯g¦X¨Öºë¯«¥¢±`¤§ªvÀø²{ªp liawbf.pixnet.net/blog/post/48209793 ³o¬Oliaw6575¤j¤j¬Q¤Ñ²`©]爲§Ú̼¶¼gªº¤j¤å åªR³oÓ©|¥¼³Qº¡¨¬»â°ìªºªvÀø²{ªp ÁÙ¦³Tannquilynne ( SND-5 )ªº¾÷·| ½²±Ð±Âªº¬ãµo¡A³£¿ï¾Ü¦b©|¥¼³Qº¡¨¬ªºÂÅ®ü»â°ì¡AÄ´¦p¡G«äı¥¢½Õªºt©Ê¯gª¬¡B»{ª¾¯Ê·l¡AÁÙ¦³¦Û±þ«äºûµ¥ ÁöµM°ê»ÚÃļt¤]²`ª¾³o¨Ç»â°ìªº¥«³õ¼ç¤O¡A¦ý¤]±o¦³¬ÛÀ³Àø®ÄªºÃĪ«¤~¯à¦³¥\¡A³o¬O¤ß®®·í«eªº§Q°ò©Ò¦b §Æ±æ¤ß®®Á{§É¶¶§Q ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/21 ¤U¤È 12:24:49²Ä 400 ½g¦^À³
|
¸É¥R: °²¦p±z¬Ý¤FTable 1 ªº¹ï·Óªí , À³·|§ó¥[¤@¥Ø¤FµM Table 1. Treatment options and their mechanisms for the aminergic, GABAergic and NMDA drugs. ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/21 ¤W¤È 11:59:53²Ä 399 ½g¦^À³
|
½²±Ð±Â¦b 2014 µoªíªº¤@½g¤å³¹ Editorial (Thematic Issue: Regulating the CNS Grand Regulator; N-methyl-D-aspartate Receptor-Mediated Neurotransmission) Author(s): Guochuan Emil Tsai. Journal Name: Current Pharmaceutical Design Volume 20 , Issue 32 , 2014 www.eurekaselect.com/120179/article ³o½g½²±Ð±Âªº¤j¤å ¥i¥H»¡¬O¥L¦h¦~¨ÓÅÞ¿è«ä¦Ò ¬ãµo¾úµ{ªºÁ`µ² ¤pªº¬Ý¤F¨ü¯q¨}¦h , ´X¥G§â¤pªº¹L¥h¹s´²ªº»{ÃÑ°µ¤F¾ã¦X , ¦¨¤F¨t²Î ¤×¨ä½²±Ð±Â§â¯«¸gªvÀø´X¤Q¦~¨Óªºµo®i , ±q¹L¥hªºaminergic(Ói¯à) ©M GABAergic( GABA¯à)ªvÀø , ÁÙ¦³¥i¯à¥¼¨Ó¦¨¬°²Ä¤T¥Nªº NMDA , °µ¤F¤@µfÄÄz ½²±Ð±Â¬O³o¼Ë»¡ªº ...... ¦b¦^ÅUÓi¯à©MGABA¯àªvÀøªºµo®i®É¡A§Ú¬Ý¨ì¹L¥h¤G¤T¤Q¦~µo®i°_¨Óªº¨¦®ò»Ä¯àªvÀøªº¾ú¥v ¥i¥HªuµÛÃþ¦üªº¸ô®|«e¶i¡C©Ò¦³¤TºØªvÀø¤èªk³£¯A¤Î¯«¸g»¼½è¤Î¨ä«eÅé¡]´â¥N®ñ¤Æª«¡A¦â®ò»Ä¡^¡A¿E°Ê¾¯/«ú§Ü¾¯¡]¥ª±Û¦h¤Ú¡A´â¤þ嗪¡^¡AÄá¨úªýº¢¾¯¡]¤þ«}嗪¡A¬t¦è¥Å¡A¦w«D¥Lଡ^¡A¤À¸Ñ¥NÁ§í¨î¾¯¡]²§¤þ嗪¡A¥q¨Ó¦NÄõ¡^¡]ªí1¡^¡C»PÓi¯à©MGABA¯àªvÀø¬Û¦ü¡A§Ú¬Ý¨ì¤FNMDA¯Ê¥¢ªºªvÀø¿ï¾Ü¡Gº¥ý¡AGlyT-1§í¨î¾¯¹ï¯«¸g»¼½èªºÄá¨ú§í¨î§@¥Î; ²Ä¤G¡ANMDAR«ú§Ü¾¯; ²Ä¤T¡A§í¨îD-®ò°ò»Ä®ñ¤Æ酶¡]DAAO¡^¡A¥¦¥NÁÂD-µ·®ò»Ä[30]¡CDAAO§í¨îªºªvÀøÃþ¦ü©ó³æÓi®ñ¤Æ酶§í¨î¾¯¡]MAOI¡^¡A¨ä§í¨î³æÓi¹ïCNS¯e¯f¦p§íÆ{¯g©M©¬ª÷´Ë¯fªº§í¨î¡C´«¥y¸Ü»¡¡A³q¹L§í¨î¤À¸Ñ¥NÁÂ酶¡ADAAO§í¨î¾¯¦b´£°ª·P¿³½ìªº¯«¸g»¼½èªº°ò½Õ¤è±Ãþ¦ü©óMAOI¡C ...... ¤ß®®¦b°µ¬Æ»ò¬ãµo , ©Î³\³o½g¤å³¹´N»¡©ú¤F¤j³¡¤À Y±zÁÙ¤£¬Æ¤F¸Ñªº¸Ü ±ÀÂ˵¹±z ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/18 ¤U¤È 04:55:23²Ä 398 ½g¦^À³
|
½²±Ð±Â ¦b BIT¡¦s 16th Annual Congress of International Drug Discovery Science and Technology-2018 ºtÁ¿ªº Title: Facilitating NMDA System Balance to Address CNS Disorders Abstract & Biography Dr. Guochuan Emil Tsai CEO, SyneuRx Professor, David Geffen School of Medicine, UCLA USA ½Ð°Ñ: www.iddst.com/iddst2018/IDDST-Proceeding.pdf P.193 ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/16 ¤U¤È 08:09:01²Ä 397 ½g¦^À³
|
¯u¬O¦½ÃC ¤pªº¤µ¤Ñ¤~ª¾¹D ,SND-13 ©Ò add-on ªºÃĪ« , ¤£¥u¬O¤fªAÃĪ« , ¤]¥]¬Aªø®Ä«¬ªº°w¾¯ ¨º¤£¬O¥þ³¡¥]¬A¦b¤ºªº·N«ä¶Ü?! ½Ð°ÑSND-13¸ÕÅ窺¤J¿ï¼Ð·Ç 7.An unchanged antipsychotic medication regimen for at least eight (8) weeks prior to screening into the study and expected to remain unchanged during the study (longer for depot or long-acting antipsychotics: ten (10) months for Aripiprazole and Paliperidone; six (6) months for Olanzapine pamoate monohydrate; and at least 6 times duration of the reported half life or minimum four (4) months for other depot or long-acting antipsychotics) clinicaltrials.gov/ct2/show/NCT02261519?term=SyneuRx&rank=2 ¨º Janssen ªº INVEGA SUSTENNA® INVEGA TRINZA® ¥i¥H¶Ü?! ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/16 ¤U¤È 03:38:23²Ä 396 ½g¦^À³
|
¤µ¤Ñ¤½§Gªº¨âÓ¬ü°ê±M§Q¥Ó½Ð . 20180228753 ( August 16, 2018 ) CO-CRYSTALS OF SUBSTITUTED GLYCINE AND USES THEREOF . 20180228754 ( August 16, 2018 ) CO-CRYSTALS OF SUBSTITUTED GLYCINE AND USES THEREOF ¹w´Á¨ú¥Nªº¥Ì®ò»Ä¦@´¹Åã¥Ü¥X¦³§Qªº©Ê½è¡A¥]¬A§ïµ½ªº§lÀã©Ê¡A·»¸Ñ©Ê¡A·»¸Ñ³t²v¡Aª«²zéw©Ê¡A¤Æ¾Çéw©Ê¡A¥Íª«§Q¥Î«×¡A¥i¥[¤u©Ê©MÀu²§ªºÃÄ¥N°Ê¤O¾Ç©ÎªvÀø©Ê½è¡C ³Ì¤p¤ÆªºÃĪ«§lÀã©Ê¥i¯à¬OÃĪ«¶}µo©M»s³y¤¤³Ì¨ã¬D¾Ô©Êªº¥ô°È¤§¤@¡C ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/7 ¤U¤È 08:15:33²Ä 395 ½g¦^À³
|
Åý§Ų́Ӭݬݤµ¤Ñ¨ú±o±M§Qªº¨âÓ¥Ü¨Ò patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=%22TSAI,+Guochuan+Emil%22&OS=%22TSAI,+Guochuan+Emil%22&RS=%22TSAI,+Guochuan+Emil%22 ¥Ü¨Ò1 (¤p¹«) »¡©ú³¡¤À½Ð°Ñ¦Òì¤å µ²ªG §Ú̵o²{¦b¦U²Õ¤¤°ò½u®Éªº¾AÀ³©Ê¡]·í¨S¦³¬I¥ÎÃĪ«®É¡^¨S¦³®t²§¡]¹Ï1¡A¥ª²Õ¡^¡C¦ý¬OÁp¦XªvÀø¤ñ³æ¿Wªºf¥Ò»ÄÆQ©Î¦Ù®ò»ÄªvÀø»¤¾É§ó±jªº¾AÀ³©Ê§@¥Î¡]¹Ï1¡A¤¤²Õ¡^¡CµM¦Ó¡Af¥Ò»ÄÆQªº®ÄªG±µªñ©ó²Õ¦X³B²z¡C·í¬I¥Îf¤þÓi¨Ã¯}Ãa¾AÀ³®É¡A¬Û¦Pªº¾AÀ³ÁͶա]²Õ¦XªvÀø > f¥Ò»ÄÆQ > ¦Ù®ò»Ä¡^¬O©úÅ㪺¡]¹Ï1¡A¥k²Õ¡^¡C¸Ó²Õ¦X¦b¼W±j¾AÀ³©Ê¤è±Àu©óÓÅéªvÀø¡]¹Ï1¡A¤¤¶¡¡^¡CÁp¦XªvÀø±Nf¤þÓi»¤¾Éªº¾AÀ³©Ê¯}Ãa«ì´_¨ì¥¿±`ª¬ºA¡A¦ÓNMG©Îf¥Ò»ÄÆQªº³æ¦¸ªvÀø³¡¤À¦aªÈ¥¿¤F¯Ê³´¡]¹Ï1¡A¥k²Õ¡^¡C ¹ï©óPPI¡A§Ú̵o²{³q±`§ó±jªº«e¯ß½Ä§í¨î¯ß½ÄÅTÀ³§ó¦h¡]§í¨î525Hz> 487Hz> 468Hz¡^¡]¹Ï2¡^¡C¦w«D¥L©ú¯}Ãa¤F©Ò¦³ªvÀø¤¤ªº§í»s§@¥Î¡Cf¤þÓiªº³oºØ¯}Ãa¦b¸üÅé³B²zªº¤p¹«¡]¥ªÄæ¡^¤¤³Ì©úÅã¡A³q¹L¦Ù®ò»Ä¡]NMG¡^©Îf¥Ò»ÄÆQ¡]¤¤¶¡2¦C¡^³¡¤À®Õ¥¿¡A¨Ã¥B³Ì¦n³q¹L²Õ¦X³B²z¡]¥kÄæ¡^®Õ¥¿¡C ¹Ï 1. ¹Ï2. ¹Ï3. patentscope.wipo.int/search/en/detail.jsf?docId=US199606500&recNum=13&tab=Drawings&maxRec=28&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28TSAI%2C+Guochuan+Emil%29 ( ¥i¥HÂI¥ªÁä©ñ¤j ) ¨Ò2 (¤HÃþ) »¡©ú³¡¤À½Ð°Ñ¦Òì¤å µ²ªG ¦b³o¶µ¸ÕÅç¡A¦w¼¢¾¯¹ï·Ó¡AÀH¾÷¡AÂùª¼¸ÕÅç¡]©|¥¼¤½§G¡^¤¤¡A©M¦w¼¢¾¯¡]n = 18¡^¬Û¤ñ¡A§Ú̵o²{1000 mg /¤Ñf¥Ò»Ä¶u»²§UªvÀø¡]n = 18¡^¥i¥HÅãµÛ§ïµ½ºë¯«¤Àµõ¯g±wªÌªº¥¿±©Mt±¯gª¬©M¥Í¬¡½è¶q¡]¹Ï3¡^¡Cf¥Ò»ÄÆQ¤]¨ã¦³¨}¦nªº¦w¥þ©Ê©M@¨ü©Ê¡Cf¥Ò»ÄÆQ©M¦w¼¢¾¯²Õ¤§¶¡ªºªvÀø¤Þ°_ªº°Æ§@¥Î¤]¬Û¦ü¡C³o¨Ç°Æ§@¥Î³£¬O»´·Lªº¡Aµu¼Èªº¡A¨Ã¥B¤£»ÝnÂåÀø¡C §Ú̦A¦¸½T»{§Q°öଡ]ris¡^ - f¥Ò»ÄÆQ²Õ¦X¡]RBC¡^ªº¥\®Ä©M¦w¥þ©Ê¨ÓÀu¤Æºë¯«¤Àµõ¯gªºªvÀø¡C§Ú̵o²{RBC¦b©Ò¦³Á{§É»â°ì³£Àu©ó§Q°öଡ]ris¡^¡]¦w¼¢¾¯²K¥[¡^¡A¥]¬A»{ª¾¥\¯à©M¥Í¬¡½è¶q¡A¨ä¦w¥þ©Êµ¥©óris¡]¦w¼¢¾¯²K¥[¾¯¡^ªvÀø¡C³oºØ¦³¯qªºµ²ªG±N¬°ºë¯«¤Àµõ¯g´£¨Ñ·sªºªvÀø¤èªk¡A¨ÃÅãµÛ°§C³oºØÄY«ºë¯«¯e¯fªºªÀ·|¦¨¥»¡C ³o»¡©ú¤F²Õ¦XªvÀø ¤ñ°_ ³æ¾¯ªºÀø®Ä§ó¦n Àø®Ä§ó¦n´N¬O¤@ºØ¬ð¯} , ¤£¬O¶Ü? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/7 ¤U¤È 04:47:47²Ä 394 ½g¦^À³
|
¥Ø«e½²±Ð±Â Àò±o¤TÓ¬ü°ê¦³Ãö Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical ªº±M§Q ¨ä { Claims }±ø¦C¦p¤U , ¨ì©³®t¦bþ¸Ì? 9649304 2017¦~5¤ë16¤é Åv§Qn¨D¡G 1.¤@ºØÃĪ«²Õ¦Xª«¡A¯à°÷´î»´¦Ü¤Ö¤@ºØ¯gª¬»Pºë¯«¤Àµõ¯g¦³Ãöªº¡A¥]¬A¡G500²@§J¦Ü10§Jªº²Ä¤@¬¡©Ê¦¨¤À¡A¨ä¬Of¥Ò»Ä©Îf¥Ò»ÄÆQ; ©M¦³®Ä¶qªº²Ä¤G¬¡©Ê¦¨¤À¡A§Y§Q°öଡA¨ä¤¤²Ä¤@¬¡©Ê¦¨¤À»P²Ä¤G¬¡©Ê¦¨¤Àªº¤ñ¨Ò¤j©ó10¡G1¡A¨Ã¥B¨ä¤¤ÃĪ«²Õ¦Xª«¬O©TÅ龯«¬¡C 2.®Ú¾ÚÅv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤@ºØ¬¡©Ê¦¨¤À¬Of¥Ò»Ä¡C 3.®Ú¾ÚÅv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤@ºØ¬¡©Ê¦¨¤À¿ï¦Ûf¥Ò»Ä¡Af¥Ò»Ä¶u¡Af¥Ò»Ä¹[¡Af¥Ò»Ä¶t©Mf¥Ò»Ä¾Y¡C 4.®Ú¾ÚÅv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤@¬¡©Ê¦¨¤À»P²Ä¤G¬¡©Ê¦¨¤Àªº¤ñ¨Ò¤j©ó15¡G1¡C 5.®Ú¾ÚÅv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤@¬¡©Ê¦¨¤À»P²Ä¤G¬¡©Ê¦¨¤Àªº¤ñ¨Ò¤j©ó20¡G1¡C 6.®Ú¾ÚÅv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤@¬¡©Ê¦¨¤À¬Of¥Ò»ÄÆQ¡A¨ä¿ï¦Ûf¥Ò»Ä¶u¡Af¥Ò»Ä¹[¡Af¥Ò»Ä¶t©Mf¥Ò»Ä¾Y¡C 7.®Ú¾ÚÅv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤@ºØ¬¡©Ê¦¨¤À¬Of¥Ò»Ä¶u©Îf¥Ò»Ä¾Y¡C 9,675,604 2017¦~6¤ë13¤é Åv§Qn¨D¡G 1.¤@ºØ¥Î©ó¦b¦³¦¹»Ýnªº¨ü¸ÕªÌ¤¤ªvÀøºë¯«¤Àµõ¯gªº¡A©Òz¤èªk¥]¬A¥H¤U¨BÆJ¡G¦b500²@§Jªº¶qµ¹©Òz¨ü¸ÕªÌ¬I¥Î¤@Ód®ò°ò»Ä®ñ¤Æ酶¡]DAAO¡^§í»s¾¯¨C¤Ñ10§J¡A¨ä¤¤DAAO§í»s¾¯¬Of¥Ò»Ä©Îf¥Ò»ÄÆQ¡A¨Ã¥B¨ä¤¤¨ü¸ÕªÌ¤w¸g¥Î¯«¸gÃĪ«ªvÀø¡A©Òz¯«¸gÃĪ«¿ï¦Û¶ø´á¥¡A§Q°öଡAªü¥ß哌Ðü¡A´â´á¥¡A®òÁD¥²§Q¡A´â¤þ嗪¡A¬t哌噻嗪¡A¬t哌Ôr¾J¡A´I°¨»Ä喹²¸¥¡C ¡AµÎ¥²§Q¡A»ô©Ô¦è଩Mzotepine¡C 2.®Ú¾ÚÅv§Qn¨D1ªº¤èªk¡A¨ä¤¤DAAO§í»s¾¯ªº¶q¬°¨C¤Ñ1§J¡C 3.®Ú¾ÚÅv§Qn¨D1ªº¤èªk¡A¨ä¤¤DAO§í»s¾¯¬Of¥Ò»Ä¡C 4.®Ú¾ÚÅv§Qn¨D1ªº¤èªk¡A¨ä¤¤DAAO§í»s¾¯¬Of¥Ò»ÄÆQ¡A¨ä¬Of¥Ò»Ä¶u¡Af¥Ò»Ä¹[¡Af¥Ò»Ä¶t©Îf¥Ò»Ä¾Y¡C 5.®Ú¾ÚÅv§Qn¨D4ªº¤èªk¡A¨ä¤¤DAAO§í»s¾¯¬Of¥Ò»Ä¶u¡C 6.¤@ºØªvÀø¦³¦¹»Ýnªº¨ü¸ÕªÌªººë¯«¤Àµõ¯gªº¤èªk¡A¸Ó¤èªk¥]¬A¡G¡]a¡^µ¹¨ü¸ÕªÌ¬I¥Î¯«¸gÃĪ«; ¡]b¡^¦V¨ü¸ÕªÌ¬I¥ÎDAAO§í»s¾¯¡A¨ä¶q¬°¨C¤Ñ500mg¦Ü10g; ¨ä¤¤DAAO§í»s¾¯¬Of¥Ò»Ä©Îf¥Ò»ÄÆQ; ¨ä¤¤©Òz¯«¸gÃĪ«¿ï¦Û¶ø´á¥¡A§Q°öଡAªü¥ß哌Ðü¡A´â´á¥¡A®òÁD¥²§Q¡A´â¤þ嗪¡A¬t哌噻嗪¡A¬t哌Ôr¾J¡A´I°¨»Ä喹²¸¥¡AµÎ¥²§Q¡A»ô©Ô¦è଩Mzotepine¡C 7.®Ú¾ÚÅv§Qn¨D6ªº¤èªk¡A¨ä¤¤DAAO§í»s¾¯ªº¶q¬°¨C¤Ñ1§J¡C 8.®Ú¾ÚÅv§Qn¨D6ªº¤èªk¡A¨ä¤¤DAAO§í»s¾¯¬Of¥Ò»Ä¡C 9.®Ú¾ÚÅv§Qn¨D6ªº¤èªk¡A¨ä¤¤DAAO§í»s¾¯¬Of¥Ò»ÄÆQ¡A¨ä¬Of¥Ò»Ä¶u¡Af¥Ò»Ä¹[¡Af¥Ò»Ä¶t©Îf¥Ò»Ä¾Y¡C 10.®Ú¾ÚÅv§Qn¨D9ªº¤èªk¡A¨ä¤¤DAAO§í»s¾¯¬Of¥Ò»Ä¶u¡C 11.®Ú¾ÚÅv§Qn¨D6ªº¤èªk¡A¨ä¤¤DAAO§í»s¾¯¦b¯«¸gÃĪ«µ¹ÃĤ§«e¡A¦P®É©Î¤§«áµ¹ÃÄ¡C 12.®Ú¾ÚÅv§Qn¨D11©Òzªº¤èªk¡A¨ä¤¤©ÒzDAAO§í»s¾¯©M©Òz¯«¸gÃĪ«¦b³æ¤@»s¾¯¤¤¤@°_¬I¥Î¡C 10039730 2018¦~8¤ë7¤é Åv§Qn¨D¡G 1.¤@ºØ¥Î©ó´î»´»Pºë¯«¤Àµõ¯g¦³Ãöªº¯gª¬¡A¥]¬A¤@ºØÃĪ«²Õ¦Xª«¡G500²@§J¦Ü10§Jªº²Ä¤@¬¡©Ê¦¨¤À¡A¨ä¬Of¥Ò»Ä¡A©Î¨äÃľǤW¥i±µ¨üªºÆQ; ©M¦³®Ä¶qªº²Ä¤G¬¡©Ê¦¨¤À¡A¿ï¦Û¶ø´á¥¡Aªü¥ß哌Ðü¡A´â´á¥¡A®òÁD¥²§Q¡A´â¤þ嗪¡A¬t哌噻嗪¡A¬t哌Ôr¾J¡A喹²¸¥¡AµÎ¥²§Q¡A»ô©Ô¦è଩Mzotepine¡C 2.Åv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤@¬¡©Ê¦¨¤À»P²Ä¤G¬¡©Ê¦¨¤Àªº¤ñ¨Ò¤j©ó2¡G1¡]w / w¡^¡C 3.Åv§Qn¨D2ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤@¬¡©Ê¦¨¤À»P²Ä¤G¬¡©Ê¦¨¤Àªº¤ñ¨Ò¤j©ó10¡G1¡]w / w¡^¡C 4.®Ú¾ÚÅv§Qn¨D3ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤@¬¡©Ê¦¨¤À»P²Ä¤G¬¡©Ê¦¨¤Àªº¤ñ¨Ò¤j©ó20¡G1¡]w / w¡^¡C 5.Åv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä°t»s¦¨©TÅ龯«¬¡C 6.Åv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤@ºØ¬¡©Ê¦¨¤À¬Of¥Ò»Ä¡C 7.Åv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤@ºØ¬¡©Ê¦¨¤À¬Of¥Ò»ÄªºÃľǤW¥i±µ¨üªºÆQ¡A¨ä¿ï¦Ûf¥Ò»Ä¶u¡Af¥Ò»Ä¹[¡Af¥Ò»Ä¶t©Mf¥Ò»Ä¾Y¡C 8.Åv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤GºØ¬¡©Ê¦¨¤À¬O´â´á¥¡C 9.Åv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤@ºØ¬¡©Ê¦¨¤À¬Of¥Ò»Ä¶u¡C 10.Åv§Qn¨D9ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤GºØ¬¡©Ê¦¨¤À¬O´â´á¥¡C 11.Åv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤GºØ¬¡©Ê¦¨¤À¬O¶ø´á¥¡C 12.Åv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤GºØ¬¡©Ê¦¨¤À¬Oªü¥ß哌Ðü¡C 13.Åv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤GºØ¬¡©Ê¦¨¤À¬O®òÁD¥²§Q¡C 14.Åv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤GºØ¬¡©Ê¦¨¤À¬O´â¤þ嗪¡C 15.Åv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤GºØ¬¡©Ê¦¨¤À¬Oflupenthixol¡C 16.Åv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤GºØ¬¡©Ê¦¨¤À¬O¬t哌Ôr¾J¡C 17.Åv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤GºØ¬¡©Ê¦¨¤À¬O喹²¸¥¡C 18.Åv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤GºØ¬¡©Ê¦¨¤À¬OµÎ¥²§Q¡C 19.Åv§Qn¨D1ªºÃĪ«²Õ¦Xª«¡A¨ä¤¤²Ä¤GºØ¬¡©Ê¦¨¤À¬O»ô©Ô¦èଡC |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/7 ¤U¤È 03:07:57²Ä 393 ½g¦^À³
|
¬Q¤Ñ»¡n¥ð®§ , ¤µ¤Ñ USPTO ´N¬£¤F¤u§@ ®¥³ß½²±Ð±Â ¤µ¤éÀò±o±M§Q 10,039,730 Tsai August 7, 2018 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical ¤s±ù»Ä©Mf¥Ò»Ä¤Î¨äl¥Íª«¼W±j¯«¸gÃĪ«ªº¬¡©Ê patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=%22TSAI,+Guochuan+Emil%22&OS=%22TSAI,+Guochuan+Emil%22&RS=%22TSAI,+Guochuan+Emil%22 Abstract Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent. ´£¨Ñ¤F¥Î©óªvÀø¯«¸gºë¯«¯f¯g¦pºë¯«¤Àµõ¯g¡A§íÆ{¯g¡Aª`·N¤O¯Ê³´»Ùê¡A»´«×»{ª¾»Ùê¡Aè§b©MÂù¬Û±¡·P»Ùꪺ¤èªk©M²Õ¦Xª«¡C¸Ó¤èªk»Ýnµ¹¤©¶EÂ_¬°±w¦³¯«¸gºë¯«¯f¯g¡]¨Ò¦p¡Aºë¯«¤Àµõ¯g¡A§íÆ{¯g¡Aª`·N¤O¯Ê³´»Ùê¡A»´«×»{ª¾»Ùê¡Aè§bÂù¬Û±¡·P»Ùêµ¥¡^ªº±wªÌ©Î¨ã¦³¯«¸gºë¯«»Ùê·ÀIªºf¥Ò»Ä¡Af¥Ò»ÄÆQ¡C ¡A©M/©Îf¥Ò»Äl¥Íª«¡A©M/©Î¤s±ù»Ä¡A¤s±ù»ÄÆQ©M/©Î¤s±ù»Äl¥Íª«¡A»P¯«¸gÃIJz¾ÇÃľ¯¡]¨Ò¦p§Üºë¯«¯fÃÄ¡A§Ü§íÆ{ÃÄ¡Aª`·N¤O¯Ê³´©M¦h°Ê»ÙêÃĪ«¡A»{ª¾ÃĪ«¡^Áp¦X¨Ï¥Î·l¶Ë¡A©Îè§bµ¥ (Google¤jôĶ) ÁÂÁ¤j®aªº¹ªÀy ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/6 ¤U¤È 08:37:09²Ä 392 ½g¦^À³
|
¥ß½×ºë±m·¥¤F! ¤£¦A½Æ²ß´N¥i±¤¤F liaw6575¤j¤jªº¤j¤å ªvÀøºë¯«¤Àµõ¯g , ¬°¦óº«§ïµ½t©Ê¯gª¬»P»{ª¾¥\¯à---SEM ¨Ó¤F liawbf.pixnet.net/blog/post/47604381 ³o¥i¯à´N¬O J&J ¹ï¦¹¤è±ªºªvÀø¦³µê¦ì¥H«Ý¤§·N ? ¦Ü©ó¬Ý¤¤¨º®a? ®É¶¡±N·|§i¶D§ÚÌ ! ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/6 ¤U¤È 01:07:09²Ä 391 ½g¦^À³
|
Ãö©ó¤pªº«e«h¶K¤å ½Ð¤j®a°Ñ¦Ò liaw6575¤j¤jªº¤j¤å ºë¯«¤Àµõ¯gªºªvÀø ¬°¦ó¥²¶·º«©ó§ïµ½»{ª¾¯Ê·l¤Ît©Ê¯gª¬ liawbf.pixnet.net/blog/post/48017646 ¨ä¤¤ªºªþ¹Ï ------ ºë¯«¤Àµõ¯gªº¯fµ{µo®i¥Ü·N¹Ï §ÚÌ¬Ý¨ì ¥¿©Ê¯gª¬---¥Ñ«C¬K´Á°ªÄY««×¡AÀHµÛ¦~ÄÖ¼Wªøº¥¦¸´î»´ ¦ý¬O »{ª¾¯Ê·l¤Ît©Ê¯gª¬---«h¬OÀHµÛ¦~ÄÖ , ¦Ó³vº¥´c¤Æ¥[« ©Ò¥H¦b¦¨¦~¥H«á , ´X¥G´N¬O¥H»{ª¾¯Ê·l¤Ît©Ê¯gª¬¬°ªvÀø¥Ø¼Ð ¤]¦]¦¹²q´ú J&J ¦b³oªvÀø»{ª¾¯Ê·l¤Ît©Ê¯gª¬»â°ìªº«æ¢©Ê J&J ¦b¨ä©xºô ªí©ú¨ä¦bºë¯«¤Àµõ¦XÌ©»â°ìªº·N¦V ¤£ºÞ J&J ³Ì«á¬O©M½Ö¦X§@ ³o¦ü¥G¤]»¡©ú¤F NaBen ¦bºë¯«¤Àµõ»â°ìµ¦²¤ªº¥¿½T , Àò¨âÓBTD¦Û¤£«Ý¨¥ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/6 ¤U¤È 12:04:21²Ä 390 ½g¦^À³
|
½ÃºÖ³¡¤½¥¬ªº «äı¥¢½Õ¯g¶i¤J°·«O³Ì·s¤Q¤j¯e¯fµ¹¥Iº]³æ ³oÅý¤p§Ì·Q°_ J&J ¬O¥Hºë¯«¯«¸gªvÀøÃĪ«°_®aªº ²{¦b¦b«äı¥¢½Õ»â°ì , ¦~½æ¶W¹L 3B ¬ü¤¸ ªº J&J ªø®Ä«¬°w¾¯ INVEGA TRINZA® INVEGA SUSTENNA® ÁöµM¦p¦¹ ¦ý J&J ¯Êªº¬O : ªvÀøt©Ê¯gª¬¤Î»{ª¾¯Ê·l ³o¤@¶ô ¤µ¤Ñ , ¤p§Ì¦b³} J&J ©xºô®É , °¸µM¬Ý¨ì³oÓ¶± www.janssen.com/neuroscience/schizophrenia Schizophrenia Our Areas of Interest for Collaboration ¶µ¥Ø: Novel Therapies in Phase 2b or Later for Symptomatic Treatment of the Underlying Symptoms of Schizophrenia with Special Emphasis on Treatment of Cognitive Impairment and Negative Symptoms. ¦ü´¿¬ÛÃѪº·Pı ¦ý¶µ¥Ø»¡©úÄæ«oªÅ¥Õ ½Ð¤j®aì½Ì¤pªº¤Ñ°¨¦æªÅ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/5 ¤U¤È 06:39:16²Ä 389 ½g¦^À³
|
°·«O³Ì·s¤Q¤j¯e¯f¥XÄl «äı¥¢½Õ¯gº¶iº] 2018-08-05 17:57Áp¦X³ø °OªÌ¾H®Ûªâ¢¬§Y®É³ø¾É udn.com/news/story/7266/3291941 ½ÃºÖ³¡¤½¥¬³Ì·s°·«Oªá¶O«e10¤j¯e¯f±Æ¦W¡A¥h¦~¥þ¥x«æºC©ÊµÇ¯f±wªÌ¦@ªá±¼°·«O¬ù503»õ¤¸¡A«ùÄòÁI³s³Ìªá¿úªº°ê¯fº¦ì¡C¯S§Oªº¬O¡A«äı¥¢½Õ¯g¤]º«×¤Jº]¡A¦~ªá°·«O127»õ¤¸¡C°·«O¸p¤ÀªR¡A¥i¯à©M°ê¤H§ó»{ÃѺ믫¯e¯f¦³Ãö¡A¥B·sÃİƧ@¥Î°§C¨ÏªAÃĶ¶±q©Ê°ª¡A¦³§Uéw¯f±¡¡B¦^ÂkªÀ·|¡C ¹ï©ó«äı¥¢½Õ¯gº¤Jº]¡A½²²Q¬Â¤ÀªR¡A¹L¥h°ê¤H¹ïºë¯«¯e¯f¤£»{ÃÑ¡B´NÂå¤Ö¡A¥[¤W¹L¥hÃĪ«°Æ§@¥Î°ª¡AªAÃĶ¶±q©Ê¸û§C¡A¨Ï±o°·«Oªá¶O¤£°ª¡C ¤£¹L¡A²{¦b°ê¤H¸û»{ÃѺ믫¯e¯f¡A·|¤Î¦´NÂåªvÀø¡AªÀ°Ï¨¤ß¬ì¶E©Ò¤]·U¶}·U¦h¡C¥t¥~¡A·sªºªø®ÄÃĪ«°Æ§@¥Î§C¡AÅý¯f¤HªAÃĶ¶±q©Ê°ª¡A¥B·sÃijæ»ù¸û©ù¶Q¡A¤~¨Ï¾ãÅé°·«Oªá¶OÀH¤§´£°ª¡C ¡u°·«Oªá¶O¼W¦h¤£¥Nªíªá±o¤£¾A·í¡C¡v¥xÆWºë¯«Âå¾Ç·|²z¨Æªø¿à¼w¤¯»¡¡A©M10¦~«e¬Û¤ñ¡Aºë¯«¯e¯f¦í°|²v¬ù°¤T¦¨¡A¥Nªí¥´ªø®Ä°wÃĪ«¦³§U¯e¯féw©Ê´£°ª¡A¯f¤H¥i¦^ÂkªÀ·|¤u§@¡B°§C®a®xt¾á¡A¤]¯àÅýªÀ·|¦w¥þºô§ó¨c©T¡A¬O¦n¨Æ¡C ¿à¼w¤¯»¡¡Aºë¯«ÂåÀø¬OéwªÀ·|ªº«n¤O¶q¡A¦ý¦nªººë¯«¯e¯f·ÓÅU¤£¥u¬OÂåÀø¡A§ón§â¯f¤HÂà»Î¦ÜªÀ°Ï¡A¨Ò¦p¼W¥[ªÀ°Ï´_°·¤¤¤ß©Î±d´_¤§®a¼Æ¶q¡A´£¨ÑӮ׺޲z¨î«×¡AÅý±wªÌ¿n·¥¦^ÂkªÀ·|»P®a®x¡C¥i±¤¬F©²¸g¶O§ë¤J¤Ó§C¡A©IÆ~½ÃºÖ³¡«µø¡C |
|
|
·|û¡GµLµß®ñ10021927 µoªí®É¶¡:2018/8/5 ¤U¤È 12:27:27²Ä 388 ½g¦^À³
|
www.biodiscover.com/news/industry/177459.html ¦¨¹³¬¡脑¬ðàD±K«×开ûD脑³¡¯e¯fªv疗·s¥@¬Éªº¤j门 2016/07/22 来·½¡G¥Íª«±´¯Á C鲁¤j学领导ªº¤@个¬ã¨s¤p组¤_7¤ë20¤é¦bScience Translational Medicine¤W发ªí¤F¤@Ïú¤j脑¦¨¹³ªº·s¤èªk¡A该¤èªk¥i¥H观¹î¤@¨ÇÉO±`见脑³¡¯e¯f¦³关ªº¬ðàD变¤Æ¡C这项§Þ术¥i¯à为癫痫©Mªüûدý®üÀq¯fµ¥¤@¨t¦C脑³¡¯e¯f´£¨Ñ诊断©Mªv疗¤è®×¡C ¬ðàD§@为¤j脑¯«经细M¤§间ªº连±µ³¡¤À¡A¥¦ªº¬Y¨Ç变¤ÆÉO脑³¡¯e¯f±K¤Á¬Û关¡C¦ý¥Ø«e¬ã¨s¤H员¥u¯à¦b¤r检¤¤观¹î¬ðàD变¤Æ¡C¦b该¬ã¨s¤¤¡A¬ã¨s¤H员发©ú¤F¤@Ïú检测¬¡脑内¬ðàD数¶q¤Î¬ðàD±K«×ªº¤èªk¡C为¤F©w¶q¥þ脑¬ðàD¡A©ñ®g¤Î¥Íª«医学¦¨¹³±Ð±ÂRichard Carson¤Î¥Lªº¦P¨Æ将PET¦¨¹³§Þ术ÉO¥Í¤Æ结¦X°_来¡C¥L们发©ú¤F¤@Ïú©ñ®g©Ê¥Ü踪剂[11C]UCB-J¡Aª`®g¨ìÊ^内ªº¥Ü踪剂将ÉO¤@Ïú关键³J¥Õ¡X¡X¬ðàDªw¿}³J¥Õ2A¡]SV2A¡^结¦X¡A这Ïú³J¥Õ¤À¥¬¦b脑内©Ò¦³¬ðàD¤W¡C±µ¤U来¥ÎPET¦¨¹³观¹î¥Ü踪剂¡A¦A应¥Î数学¤u¨ã处²z«K¥i¶q¤Æ¬ðàD±K«×¡C ¬ã¨sªÌ将¦¨¹³§Þ术应¥Î¤_ÍaÍaÉO¤H类¡C¥L们ÚÌ«H这个·s¤èªkÚÌ实¥i¥H¦¨为¤Ï¬M¬ðàD±K«×ªº标§Óª«¡C实验还显¥Ü¡AÉO°·±d个Ê^¬Û¤ñ¡A¤T¦ì癫痫±wªÌ¥X现¬ðàD丢¥¢ªº现¶H¡C ¡§这¬O§Ú们²Ä¤@¦¸¯àû{¦b¬¡¤HÊ^内测©w¬ðàD±K«×¡C¡¨该论¤åªº¥Dn§@ªÌCarson说¡C ¡§¨ì¥Ø«e为¤î¥ô¦ó¬ðàD±K«×ªº测©w³£¬O¦b¤r检¤¤§¹¦¨ªº¡C¡¨ 这¤@发现¦³¤L个ýͦbªº应¥Î¡Cº¥ý¡A³q过这ÏúÆÓ创¤èªk¡A¬ã¨sªÌ¥i¥H³q过检测¬ðàD±K«×ªº变¤Æ来观¹î癫痫©Mªüûدý®üÀq¯fµ¥脑³¡¯e¯fªº¯fµ{¡C¥t¤@个应¥Î¥i¯à¬O评¦ô药ª«¦p¦óú£缓¯«经¤¸ªº丢¥¢¡C¡§这项§Þ术为¬ã¨s°I¦Ñ过µ{¤¤¬ðàDªº¦ÛµMºt¤Æ¥H¤Î药ª«¦p¦ó§ï变¬ðàD¤Î¬ðàD§Î¦¨开¹@ªº·sªº¹D¸ô¡C¡¨ Carson©M¥Lªº¦P¨Æ计¦E§Q¥ÎPET¦¨¹³¬ðàD来¬ã¨s¤@¨t¦C脑³¡¯e¯f¡A¥]¬A癫痫¡Bªüûدý®üÀq¯f¡Bºë¯«¤Àµõ¯g¡B§í§¯g¡B©¬ª÷´Ë¯fµ¥¡C¡§这¨ä¤¤¦³许¦h³£¬O¯«经°h¦æ©Ê¯e¯f¡C¡¨Carson补¥R¹D¡C 备ª`¡G¥»¤å编译¦ÛmedicalxpressÊI¯¸¡Aì标题¡G¡§Scientists apply new imaging tool to common brain disorders¡¨¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/5 ¤W¤È 11:19:46²Ä 387 ½g¦^À³
|
«·s«ôŪ liaw6575 ¤j¤j¤j¤å¦³·P SND-14 , ¯u¥¿¦³·N«ä ( 2a ¸ÕÅç¬ã¨sºKn ) liawbf.pixnet.net/blog/post/47570421 FDA 2018¦~2¤ëµo¥¬ ¦´ÁADÃĪ«¬ãµo¤§·~¬É«ü¤Þ ( ¯ó½Z ) liawbf.pixnet.net/blog/post/47895075 liaw6575 ¤j¤j À°§Ú̾ã²z AD µo¯f¹Lµ{ªº¥Í²z¼x¥ü , ÁÙ¦³ SND-14 ªºªvÀøµ²ªGºKn ³o©Î³\´N¤w¦^µª¤pªº¦b¥»ª©385¸¹¶K¤å°ÝÃDªº¤j³¡¤À C¾|¤j¾Ç SV2A PET ¹ï¦³Ãö¦´Á¥¢´¼¯g ( ©Î AD )±wªÌªº¬ðIJ¥á¥¢¬ã¨s ¬O¥HCDRȬ° 0.5 ¤Î 1.0 ±wªÌ¬°¹ï¶H , ¦A©M´X¥G¦PÄÖªº°·±d±Ú¸s°µ¤ñ¸û µ²ªG§Ú̬ݨì¤F , ±wªÌªº¬ðIJ±K«×¥§¡¤ñ°·±dªÌ¤Ö¤F 41% ¦AªÌ FDA ¹ï AD Á{§É¸ÕÅç outcome Æ[¹î«ü¼ÐªºÅܲ ·íµM , Æ[¹î«ü¼Ðªº§ïÅÜ , ©Î³\ÁÙnFDA´M¨D¾Ç¬É·~¬Éªº¦@ÃÑ ¦ýC¾|¤j¾Çªº³Ð·s , ¤]³\ȱo®³¨Ó·íÃĪ«¬ãµoªº°Ñ¦Ò ¤pªº´N·Q¨ì¤F SND-51 ªº¤G´ÁÁ{§É¸ÕÅç , ¬O§_¥i¥H¦b±wªÌ¬IÃÄ«e©M§¹¦¨®É(¨Ò¦p24¶g)°µ¬ðIJ±K«×ªºÀË´ú , ¨Ó¤ñ¸û¬ðIJ±K«×ªºÅÜ¤Æ ·íµMªá¶O«Ü¤j¬O¯ÊÂI , µMY·í§Ú̵o²{¬ðIJ±K«×½T¦p©Ò¹w´Á¦a¦³©Ò¦^´_ , ¬Æ©Î¦^¨ì¥¿±`¤Hªº¤ô·Ç ³oºØ°²»¡²q´úªº¹ê¨Ò¦LÃÒ , ªá¶O©Î¤w¤£¬O«ÂI , Tanquilynne®ªº³ÐÁ|©Î±N§l·ú·~¬É , ¬Æ¦Ü FDA ¥~·¸®ÄªG¦Û¤£«Ý¨¥? °Ú«¢!³oºØÃþ¦üè¤H»¡¹Úªº±¡¹Ò , ¦³¥i¯à¹ê²{¶Ü? ¤pªº·Q C¾|¤j¾Ç SV2A PET ¹ï¦³Ãö¦´Á¥¢´¼¯g ( ©Î AD )±wªÌ¬ðIJ¥á¥¢¬ã¨sªºÀ³¥Î Y¤£µo¥Í¦b Tanquilynne® ¤W , ¤]·|µo¥Í¦b¨ä¥L¤j¼t·sÃĪº¨¤W °²»¡ªºÀò±o¦LÃÒ , ©Î±N¬O¸£¯«¸g¬ì¾Ç¬Éªº¤j¨Æ J«ä¶Ã·Q¤§¨¥ , ¦³½Ð¤j®a¦h¦h«ü¥¿ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¤p©¯¹B10141538 µoªí®É¶¡:2018/8/3 ¤U¤È 07:49:44²Ä 386 ½g¦^À³
|
·PÁ²q·Q¤j..Cliff¤j..¤Îª©¤W¦U¤j¤j̤@ª½«ùÄò´£¨Ñ¬ÛÃö¸ê®Æ... ±y¬¡ªº¤é¤l...¬Ý¬Ý®Ñ...¨ì³B¨«¨«...¥H¥ÀR¤Î³ß¼Öªº¤ßµ¥«Ý... |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/2 ¤U¤È 09:21:55²Ä 385 ½g¦^À³
|
èè¬Ý¨ì¤@½g¤å³¹ , ¬O¥Ñ Rich Haridy ¥ý¥Í©ó2018¦~7¤ë16¤é©Ò¼¶¼g newatlas.com/pet-scan-alzheimers-disease-diagnose-yale/55472/ ¤j·N¸`¿ý¦p¤U: C¾|¤j¾Ç¥O¤H¿³¾Äªº·s¬ã¨s´¦¥Ü¤F¤@ºØ·s¤èªk¡A¥i¥H³q¹L«D«I¤J©ÊPET±½´y¡A«ÈÆ[¦a¶EÂ_¤@Ó¤H¬O§_±w¦³ªüº¸¯ý®üÀq¯fªº¦´Á¶¥¬q¡C C¾|¤j¾Ç³Ð·s¨Ï¥ÎPET¦¨¹³§Þ³N³q¹L¦³®Ä¦a´ú¶q±wªÌ¤j¸£¤¤µo¥Íªº¬ðIJ·l¥¢©Î°¸Ñ¨Óµû¦ô»{ª¾¤U°¡C¬°¤F¶q¤Æ¤@Ó¤Hªº¡§¬ðIJ±K«×¡¨¡A¬ã¨s¤Hû¬ã¨s¤F¤@ºØ¦W¬°SV2Aªº³J¥Õ½è¡C³oºØ³J¥Õ½è´X¥G¦s¦b©ó©Ò¦³°·±dªº¬ðIJ¤¤¡A¦ýÀHµÛ³o¨Ç³s±µªº°¸Ñ¡ASV2Aªº¦s¦b¤]·|°§C¡C ¨Ï¥Î»PSV2Aµ²¦X¨Ö·Ó«GSV2Aªº¯S©w©ñ®g©Ê¤Æ¾Çª«½è¡A¬ã¨s¤Hû¯à°÷³Ð«ØPET±½´y¡A¥i¥H«ÈÆ[¦a´ú¶q¦UºØ¤£¦P¸£°Ïªº¬ðIJ±K«×¡C»P°·±d¹ï·Ó²Õ¬Û¤ñ¡A¨Ï¥Î¸Ó¤èªkªºªì¨B´ú¸ÕÅã¥Ü¡A±w¦³¦´Áªüº¸¯ý®üÀq¯fªº±wªÌ¦b»P°O¾Ð¬ÛÃöªº¸£°Ï°ì¤¤SV2A¼Ð°Oª«´î¤Ö¤F41¢H¡C( AD±wªÌ CDR ¦b 0.5~1.0 ¶¡) ¡§§Ú̵o²{¡A¦b¦´Áªüº¸¯ý®üÀq¯f¤¤¡A®ü°¨°Ï°ìªº¬ðIJ±K«×¤w¸g³à¥¢¡A¡¨·sµoªíªº¬ã¨sªº²Ä¤@§@ªÌ³¯©ú³Í»¡¡C¡§³q¹L³oºØ·sªº¥Íª«¼Ð»xª«¡A¥Î©óSV2AªºPET¦¨¹³¡A§ÚÌ¥i¥H´ú¶q¬¡¤H¸£¤¤ªº¬ðIJ±K«×¡C¡¨ ¡§ªüº¸¯ý®üÀq¤ó¯g¬ã¨sªº¤@ÓÃöÁä»Ùê¬OµLªk´ú¶q¬¡ÅéÓÅ骺¬ðIJ±K«×¡A¡¨C¾|ªüº¸¯ý®üÀq¯f¬ã¨s³¡¥D¥ôChristopher Van Dyck»¡¡C¡§¹ï©ó§Ú̳o¨Çªüº¸¯ý®üÀq¤ó¯g»â°ìªº¤H¨Ó»¡¡A¬ðIJ±K«×ªºÅ餺µû¦ô¥i¯à·|§ïÅܧÚÌ°l踪¦´Áªüº¸¯ý®üÀq¤ó¯gµo¯f¾÷¨î©MªvÀø¤ÏÀ³ªº¯à¤O¡C¡¨ ¸Ó¬ã¨sªº¤U¤@¨B¬OÅçÃÒ¸Ó¤èªk¹ï§ó¤jªº±wªÌ¶¤¦Cªº·Ç½T©Ê¡C¬ã¨s¤p²ÕÁÙ«Øij¡A³oºØ¤èªkÀ³¾A¥Î©ó¯A¤Î¬ðIJ¥á¥¢ªº¦UºØ¯e¯f¡A¥]¬A©¬ª÷´Ë¯f©MÅöíw¡A¬Æ¦Ü§íÆ{¯g©Îºë¯«¤Àµõ¯g¡C ******* ½×¤å¦b³o¸Ì Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging Ming-Kai Chen, MD, PhD1; Adam P. Mecca, MD, PhD2; Mika Naganawa, PhD1; et al July 16, 2018 jamanetwork.com/journals/jamaneurology/article-abstract/2687472 ¤pªºª¾ÃѦ³ , ©Ò¥H ·Q½Ð±Ð¤j®a ¦]¬°½×¤å§@ªÌ¼g¹D Importance : Synaptic loss is well established as the major structural correlate of cognitive impairment in Alzheimer disease (AD). The ability to measure synaptic density in vivo could accelerate the development of disease-modifying treatments for AD. ¬ðIJªº¥á¥¢©MADªº»{ª¾¨ü·l¬ÛÃö ©Ò¥H¦bADªº¦´Á¶¥¬q , ¬O§_´N¥i¥H¨Ï¥Î¼W±j»{ª¾¯à¤OªºÃĪ« ? ¨ÓÅý¬ðIJ¥i¶ì©Ê¼W¥[ , ¨Ï¬ðIJ¼Æ¶q¦^´_¨ì°·±d¤Hªº¤ô·Ç? ³oÅý¤pªº·Q¨ì SND-14 , SND-51 ³£¬ONMDARP®Ä¾¯ , ¥i¨Ï¬ðIJ¥i¶ì©Ê¼W¥[ , »{ª¾¯à¤O¼W±j ¬O¥H , ³o¹ï¦´ÁAD¬O¹ï¯g¤UÃÄ¶Ü ? ªp¥B SND-14 , SND-51 ÁÙ¦³§Üª¢ §Ü®ñ¤Æ §Ü¦Û¥Ñ°ò...µ¥¥i¥H¦hºÞ¹D¦h¼ÐªºªvÀøAD ¦]¦¹ , ½²±Ð±Â¹ï SND-51 ¦³ single pivotal study ªº«H¤ß©M´Á³\ ? ¬O³o¼Ë¶Ü? ½Ð±Ð¤j®a! ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/2 ¤W¤È 11:24:51²Ä 384 ½g¦^À³
|
D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review www.ncbi.nlm.nih.gov/pmc/articles/PMC4851259/ ¼w°ê¾ÇªÌ³o½g¨t²Îµû»ù , ÄÄzD-Àôµ·®ò»Ä¹ïªvÀø¯«¸gºë¯«¯e¯fªº¼ç¤Oµû¦ô Åý§Ú̪¾¹D D-Àôµ·®ò»Ä ³º¦³³o»ò¦hªº¥Î³~ , ¥u¬OÀø®Ä¤£¤@ ³o¨Ç¯«¸g©Mºë¯«¯e¯f¥]¬A : ªü¯÷®üÀq¯g¡Aºë¯«¤Àµõ¯g¡A§íÆ{¯g , ¦Û³¬¯g©MµJ¼{¯g...µ¥¡C µM¦Ó , ½²±Ð±Â¥Ø«e¥u¬D¿ï°ª¾¯¶qªº D-Àôµ·®ò»Ä ¥Î¥HªvÀøÃøªv«¬§íÆ{¯g¨ÓÁ{§É¸ÕÅç ©Î¥Ñ¦¹±À½×ÅѪ¾ , ²{¦b¤ß®®±À¥Xªº²£«~½u©M¾AÀ³¯g , À³¬O½²±Ð±Â¦Ò¶q¦hºØ¦]¯À«áªºÅv¿Å ¬°½²±Ð±Â¦Û¦~»´¥H¨ÓªºÁ{§É©M¬ã¨s¤ß¦åµ²´¹ , ¤@®É¤§¿ï¦Û¤£¦b¸Ü¤U ¥B½²±Ð±Â¤£«æ©óµ²§ô¦¬®× , ¦Ó¬Oºë¬D²Ó¿ï±ý¥[¤Jªº±wªÌ ¬D¿ï¦X¥G¯f²z , ¬D¿ï¦YÃĨ̱q©Ê°ªªº±wªÌ , ±q¦UºØ¦³¥i¯àÅý¸ÕÅ禨¥\ªº²Ó¸`µÛ¤â ¹çÄ@ºC¤@ÂI , ¤]¤£Ä@¶]§Ö¶^Ë , ²¦³º¤@¶^Ë´N¬O©µ¿ð¤T~¤¦~°_¸õ §Ú̪¾¹D½²±Ð±Âªº¥Î¤ß , ´NÅý§Ú̥ΥÀR³ß¼Öªº¤ßµ¥«Ý ·PÁ½²±Ð±Âªº¨¯W ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/8/2 ¤W¤È 07:16:53²Ä 383 ½g¦^À³
|
¥ý¥ÎKetamine , Ä~¤§¥Hd-Cycloserine ¨ÓªvÀø depression ¦´N¦³¾ÇªÌ·Q¨ì¤F! ¤@Ó¶W¤p¼Ë¥»ªºÁ{§É , ¬O§_·|¶}±Ò J&J ªº«µø©Mµû¦ô? Single-Dose Ketamine Followed by Daily d-Cycloserine in Treatment-Resistant Bipolar Depression www.psychiatrist.com/jcp/article/Pages/2015/v76n06/v76n0609.aspx d-Cycloserine is a US Food and Drug Administration (FDA)¡Vapproved antituberculosis drug that acts as an NMDAR antagonist when used at high doses (> 750 mg). d-Cycloserine targets the glycine coreceptor of the NMDAR and may have improved safety relative to ketamine . A large, between-group, large effect-size (d = 0.91, P = .005) difference was seen in unipolar depression, corresponding to a mean 48% reduction in symptoms. We report the first study of acute ketamine followed by daily d-cycloserine in bipolar depression Follow-up paired t test analysis suggested significant improvement from baseline at all rating points except at 2 weeks, with a large effect size seen at day 1 (Cohen d = 2.0 SD) and 8 weeks (Cohen d = 1.1 SD) ¤S¸É¥R¤W«h¶K¤å---Á{§Éµ²ªG»¡©ú Interestingly, a subset analysis limited to participants with baseline serum glycinelevels xceeding 300mM demonstrated an especially robust treatment effect, reducing depressive symptoms per the 21-item HAM-D (13.6-point versus 0.1 point reduction, p,0.001). ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/31 ¤U¤È 05:17:25²Ä 382 ½g¦^À³
|
«×¹Lµ¥«Ý´Á³Ì¦nªº¤è¦¡´N¬O¬ã¨s°ò¥»± ------ Ãøªv«¬§íÆ{¯g J&J ¦b¤µ¦~ 5¤ë¶¡ ¤½¥¬ Esketamine »ó¤º¼Q¾¯ªº¤T´ÁÁ{§Éµ²ªG . New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression www.janssen.com/new-phase-3-data-show-esketamine-nasal-spray-demonstrated-rapid-improvements-depressive-symptoms May 05, 2018 . Long-Term Phase 3 Study Shows Esketamine Nasal Spray Plus an Oral Antidepressant Delayed Time to Relapse in Patients with Treatment-Resistant Depression www.prnewswire.com/news-releases/long-term-phase-3-study-shows-esketamine-nasal-spray-plus-an-oral-antidepressant-delayed-time-to-relapse-in-patients-with-treatment-resistant-depression-300657458.html May 31, 2018, 12:31 ET J&J°w¹ïÃøªv«¬§íÆ{¯gªº¤Ó3´ÁÁ{§É , ©|¥¼¦³½×¤å³ø§i ©Ò¥H , ´N¥Î2´Áªº³ø§i¨Ó·§²¤¤F¸Ñ¥¦ªºÀø®Ä Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression Ella J. Daly, MD1; Jaskaran B. Singh, MD2; Maggie Fedgchin, PharmD1; et al jamanetwork.com/journals/jamapsychiatry/fullarticle/2666767 In period 1, participants were randomized (3:1:1:1) to placebo (n = 33), esketamine 28 mg (n = 11), 56 mg (n = 11), or 84 mg (n = 12) twice weekly. During the open-label phase, dosing frequency was reduced from twice weekly to weekly, and then to every 2 weeks. Change (least squares mean [SE] difference vs placebo) in MADRS total score (both periods combined) in all 3 esketamine groups was superior to placebo (esketamine 28 mg: −4.2 [2.09], P = .02; 56 mg: −6.3 [2.07], P = .001; 84 mg: −9.0 [2.13], P < .001), with a significant ascending dose-response relationship (P < .001). Improvement in depressive symptoms appeared to be sustained (−7.2 [1.84]) despite reduced dosing frequency in the open-label phase. ¤ß®® ¥Ø«e°w¹ïÃøªv«¬§íÆ{¯gªº¸ÕÅç·sÃÄ ------ Synserine® Phase 2 Data Shows Statically Significant HAMD Responses in Refractory Depression ¥¦ªº slide ¦b www.bplifescience.com/SyneuRxPresentationApril2018.pdf P.43 ¦³¨âÓ«GÂI • Antagonism of the NMDA receptor through Synserine® resulted in robust responses (≥ 50% reduction in HAMD score from baseline) in patients with refractory depression • Patients with plasma glycine ≥300µM (n=7 of 13) showed marked improvement in depression (HAMD reduction by 13.6 points) when treated with Synserine®. À³¬O½²±Ð±Â¦X§@¹Î¶¤ªº³ø§i Heresco-Levy et al et al; International Journal of Neuropsychopharmacology: 2013, 16, 501-506 liaw6575¤j¤j ¥h¦~¼g±o§ó¸ÔºÉ ¥~¥[µû½×¤Î¤ß±o ½Ð°Ñ liawbf.pixnet.net/blog/post/47593383 Ãļt¶¡ªº¬ãµo , ³£¦b´M§ä¥«³õªº°Ï¹j ´M¨D¥D»â°ì¤Uªº¦¸»â°ì¹è¦û ¨Ò¦p¥»¨Ò Esketamine ¦bÃøªv«¬§íÆ{¯gªº©µ½w´_µo ¤ß®® SNG-12 ¦b MDD ¦Û±þ·N©Àªº®ø«Ú°§C µM´N Ãøªv«¬§íÆ{¯g ©M MDD ªº»â°ì , ©Î³\ SNA-11 . SNG-12 ¥H«á¦¨¬° J&J ¦X§@¹ï¶H¤]»¡¤£©w? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/31 ¤U¤È 03:54:48²Ä 381 ½g¦^À³
|
¨C¤ë¤@¦¸§Q°öଽwÄÀ²GÀò¬üFDA§åãªvÀøºë¯«¤Àµõ¯g ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-07-31 med.sina.com/article_detail_103_2_49733.html ^°ê»sÃĤ½¥qIndivior PLCªñ¤é«Å¥¬¡A¬ü°ê¹«~©MÃÄ«~ºÊ·þºÞ²z§½¡]FDA¡^¤w§åãPerseris¥Î©óºë¯«¤Àµõ¯g¦¨¤H±wªÌªºªvÀø¡C¦¹¦¸§åã¡A¨ÏPerseris¦¨¬°ºÓ¨C¤ë¤@¦¸¥Ö¤Uª`®gµ¹ÃĪº§Q°öଡ]risperidone¡^ªø®Äª`®g²G¡]LAI¡^¡C ¦¹¦¸§åã¡A¬O°ò©óÃöÁä©ÊIII´ÁÁ{§É¬ã¨s¡]NCT02109562¡^ªº¼Æ¾Ú¡C¸Ó¬ã¨s¬O¤@¶µÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¡B8¶g¬ã¨s¡A¤J²Õ¤F354¨Òºë¯«¤Àµõ¯g¦¨¤H±wªÌ¡C¬ã¨sµ²ªGÅã¥Ü¡A¦bªvÀø²Ä57¤Ñ¡A»P¦w¼¢¾¯²Õ¬Û¤ñ¡APerserisªvÀø²Õ¦b¶§©Ê©M³±©Ê¯gª¬¶qªí¡]PANSS¡^Á`¤À¤è±ªí²{¥XÅãµÛ§ïµ½¡A¹F¨ì¤F¬ã¨sªº¥Dn²×ÂI¡C¦¹¥~¡A¦bªvÀø²Ä57¤Ñ¡APerserisªvÀø²Õ¦bÁ{§É¾ãÅé¦L¶H¯e¯fÄY«µ{«×¡]CGI-S¡^¶qªí¤è±¤]ªí²{¥X²Îp¾Ç·N¸qªºÅãµÛ§ïµ½¡C Perserisªº¨t²Î©Ê¦w¥þÄÝ©Ê»P¤fªA§Q°öତwª¾ªº¦w¥þ©Ê¤@P¡C ºë¯«¤Àµõ¯g¬O¤@ºØºC©Ê¡BÄY«¡BP´Ýªº¸£³¡¯e¯f¡A³q±`ªí²{¬°¿n·¥¯gª¬¡]¤Ûı©M¦k·Q¡^¡B®ø·¥¯gª¬¡]§íÆ{¡B±¡ºü¿ð¶w©MªÀ¥æ°hÁY¡^©MµL§Ç«äºû¡C¾Ú¦ôp¡A¬ü°ê¬ù¦³240¸U¦¨¦~¤H±w¦³ºë¯«¤Àµõ¯g¡A¨k©Ê©M¤k©Ê±w¯f²v¬Û¦P¡C¹ï©ó³o¨Ç±wªÌ¨Ó»¡¡A«O«ùªAÃÄ©MÅ@²zªº³sÄò©Ê«Ü¨ã¦³¬D¾Ô¡A«æ»Ý¤@´Ú¦³®ÄÀøªk¨Ó´£°ªÃĪ«¨Ì±q©Ê¡C ½Ð¤j®a°O±o SND - 13 ¬O¤@´Ú add-on ¸ÕÅ礤ªº·sÃÄ ®³¨ì BTD ©M¥»´Úè®Ö㪺ªø®Ä·sÃÄ À³µL½Ä¬ð ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/31 ¤U¤È 03:37:42²Ä 380 ½g¦^À³
|
ÁÂÁ liaw6575¤j¤j ¬°§Ú̧ä¨Ó±Ð¾ÇµøÀW Schizophrenia and NMDA Receptors www.youtube.com/watch?v=iKMhrfSEZ2Q ¦P®É ¤]ªþ¤W ºë¯«Âå¾Ç±Ð¬ì®Ñ¸t¸gªº§@ªÌ ¼C¾ô±Ð±Â Dr Stephen Stahl ªº³X½Í The Future of Antipsychotic Medication - Conversations with Dr Stephen Stahl ( ¦³¦r¹õ ) www.youtube.com/watch?v=6TUQ7nMP6Q4&t=1500s Á¿¨ì ¥¼¨Ó§Üºë¯«¯fÃĪ« ªº¤è¦V 1. ¾¢Ói»Ä ( ¨¦®ò»Ä Glutamic acid ) ¨ú¦VªºÃĪ« 2. »{ª¾¼W±j¾¯ªº»Ý¨D 3. Schizophrenia ªº NMDAR ¥\¯à§C¤U°²»¡ ¬Ý¨Ó¥Lªº±M®a·N¨£§¹¥þ§k¦X ¤ß®® SND -1 ªº¬ãµo¤è¦V , Ãø©Ç¤½¥q°ª¼h»{¬° ¥Ø«e¬O»â¥ý¥þ²y ( liaw6575¤j¤jµûªR , ¤pªºì¤å·Ó§Û ) ÁÂÁ liaw6575¤j¤j ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/30 ¤W¤È 08:05:47²Ä 379 ½g¦^À³
|
¹ï¤£°_ ! ¹ï¤W«h¶K¤åªº¸É¥R»¡©ú °²¦p±z¤£²ßºD^¤å , ¥i¥HÂI·Æ¹«¥kÁä , ½Ð GOOGLE ¥ý¥Í½Ķ ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/30 ¤W¤È 07:55:31²Ä 378 ½g¦^À³
|
¤ß®® Ô¿ï·sÃľã²z ( ¨Ó·½:2018/4 ²³ø ) www.bplifescience.com/SyneuRxPresentationApril2018.pdf . R&D team has generated more than 15 IPs since 2013 . Approach 1 ¡V D-amino acid oxidase (DAAO) Inhibition .. NaBen® for Adolescent Schizophrenia (SND 11) .. ClozaBen® for Refractory Schizophrenia (SND 12) .. NaBen® for Adult Schizophrenia (SND 13) .. NaBen® for Early Dementia (SND 14) .. Tanquilynne® for Dementia & Psychosis (SND 51) .. NaBen® is a proprietary formulation of an FDA approved molecule (Sodium Benzoate) with well established safety ..FDA designated as a ¡§generally recognized as safe¡¨ (GRAS) .. 505b2 filing strategy and the Breakthrough Therapy Designation for NaBen® .. Tanquilynne® enable single pivotal study registration process . Approach 2 ¡V Gly-T1 Inhibition ( Increases Free Synaptic Glycine to Upregulate NMDAr ) .. Synapsine® for Depression & Suicidality ( SNG 12 ) .. Synapsine® is a proprietary co-crystalized and stable formulation of a known naturally occurring amino acid derivative . Approach 3 ¡V Dual Role by Concentration of Agonist/Antagonist .. Synserine® for Refractory Depression ( SNA 11 ) .. D-cycloserine (DCS) acts on the glycine/D-serine-binding site of the NMDAr located on the NR1 subunit of the receptor .. Synserine® is the Company¡¦s proprietary novel salt form of DCS with enteric coated/stable formulation ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/28 ¤U¤È 12:21:40²Ä 377 ½g¦^À³
|
ÁÂÁ booli ¤j ´£¨Ñ¸ê®Æ¤Î«ü¾É ì¨Ó¬OÂI¦r°ê»yª`µªº { ¤ß®® } «¢! ¤Ó¼F®`¤F!¤]¤Ó¥©¤F! ¤pªº¦A«ç»ò¬Ý³£«Ü¹³ { ¸Às¦b¤Ñ }( ¦ñ¤õ¯] ) ªº¹Ï¹³ ½Ð¤j®a¬Ý³o´T¹Ï i.epochtimes.com/assets/uploads/2011/10/1110122306232357-600x400.jpg ¤j®a®T¼Ö¤@¤U ÁÂÁ¤j®a! |
|
|
·|û¡Gbooli10146418 µoªí®É¶¡:2018/7/28 ¤W¤È 11:45:26²Ä 376 ½g¦^À³
|
ÂI¦r www.blind.org.tw/braile.htm |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/28 ¤W¤È 11:10:22²Ä 375 ½g¦^À³
|
¤TÓ¥Nªí¤ß®®¤½¥qªº°Ó¼Ð www.trademarkia.com/ctm/syneurx-017889089.htm www.trademarkia.com/ctm/logo-017889083.htm www.trademarkia.com/ctm/logo-017889093.htm ¨ä¤¤ www.trademarkia.com/ctm/logo-017889093.htm ³o¬O¦³¤¤¤å¨ã¶Hªº { ¤ß } ¦r¶Ü ? ¦³¨S¦³¥Nªí { Às } ªº·N¶H ? ÁÙ¬O¥t¦³§t·N ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/27 ¤U¤È 09:08:57²Ä 374 ½g¦^À³
|
¦b SYNAPSINAE TANNQUILYNNE CLOZABEN ¤§«á ¤ß®®¤S¥Ó½Ð¤TӰӼРSYNSERIN ¡] Therapeutic pharmaceutical for the treatment of neuropsychiatric disorders¡Famino acids for medical purposes ¡^ NEUSERINE ¡] ¦P ¤W ¡^ SYNXYRIN ¡] ¦P ¤W ¡^ ³o¬O¨º¨Ç®ò°ò»Ä©O¡H ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/27 ¤U¤È 01:34:52²Ä 373 ½g¦^À³
|
³sÄò¨â¤Ñ¥h¤F¸ÑÄvª§¹ï¤â ¦ý¤µ¤Ñ¬d¬Ý2018/4ªº¸ôºt¸ê®Æ®É ©¿¦bP. 6 µo²{ÁÙ¦³´X¶µ¦b·§©À¤WªºªÅ¥Õ www.bplifescience.com/SyneuRxPresentationApril2018.pdf ¦b¤F¸Ñ±o·í¤U , ·Q¥²ÁÙ¦³¤j¤j¬O¸ò¤pªº¤@¼Ë , ¤£²M·¡¬Y¨Ç·§©À·N²[ ÂÔ¦b¦¹³¥¤HÄmÃn , »P¤j®a¤@¶ô¤À¨É ½²±Ð±Â¹ï¤ß®®²£«~½uªººë¤ß³W¹º ¤ß®®²£«~½uªº¥«³õ©w¦ì©M²£«~®t²§¤Æ ¥«³õ©w¦ì¤è± : ( ¹Ï ) µo®iªº²£«~¬Ò¦b¥¼³Qº¡¨¬°Ï°ì , ¥B Dementia > Schizophrenia > Depression ¥ç¦³±j¯Pªº¥«³õ°Ï¹j ²£«~®t²§¤Æ¤è± : ( ªí ) Schizophrenia : • First in class • First ¡§negative¡¨ & ¡§cognitive¡¨ symptom Rx • Add-on to all drugs Dementia : • First in class • First disease-modifying Rx • First psychosis symptom Rx Depression : • First in class • First ¡§suicidality¡¨ Rx • First refractory depression Rx .. ªvÀø«äı¥¢½Õªºt©Ê¯gª¬©M»{ª¾¬O¤ß®®©Ò¼Ðº]ªº , ¥B»P²{¦³ÃĪ«¦X¥Î¥H±j¤Æ¥¿t©Ê¯gª¬ªºªvÀø , ¬ð¥XªºÃÄ®Ä ¦]¦Ó®³¨ì FDA ªº BTD .. ¬Æ»ò¬Odisease-modifying ? ¦h°ê¾ÇªÌSalvatore Salomone , Filippo Caraci , Gian Marco Leggio , Julia Fedotova & Filippo Drago ªº³o½g½×¤å , Áö¦³¨Ç¹L®É , ¦ýÀ³¤]¥i±o¨ì·§©À©Êªº»{ÃÑ New pharmacological strategies for treatment of Alzheimer¡¦s disease: focus on disease modifying drugs Published Online : 28 October 2011 bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2125.2011.04134.x Current approved drug treatments for Alzheimer disease (AD) include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist memantine. These drugs provide symptomatic relief but poorly affect the progression of the disease. Drug discovery has been directed, in the last 10 years, to develop ¡¥disease modifying drugs¡¦ hopefully able to counteract the progression of AD. Because in a chronic, slow progressing pathological process, such as AD, an early start of treatment enhances the chance of success, it is crucial to have biomarkers for early detection of AD-related brain dysfunction, usable before clinical onset. ¡K¡K A disease modifying drug is an agent that slows the progression of structural damage, such that its effect is persistent and can be detected even after stopping the treatment, because the cumulative pathological changes would be less severe in the treated group as compared with the control (placebo) group. In contrast, the definition ¡¥symptomatic drug¡¦ refers to an agent that does not alter the progression of the disease, but only decreases (palliates) the severity of symptoms. The symptomatic effect is usually reversible, such that, if the treatment is interrupted, the treated group might be indistinguishable from the control (placebo) group. .. ¬Æ»ò¤S¬Opsychosis symptom ªø©°Âå°T ³¯©É§gÂå®v±M¤å www.cgmh.org.tw/cgmn/category.asp?id_seq=1607129#.W1p45NUzapo °£¤F°O¾Ð»P»{ª¾¥\¯à¤U°¤§¥~¡A¦³¶W¹L¤@¥bªº¥¢´¼¯g¯f¤H·|¦ñÀHºë¯«¯gª¬¡A¨Ò¦p¼~Æ{¡B¦k·Q¡B¿ù»{¡B¤Ûı¡BºzµM¡BºÎ¯v»Ùê¡B§ðÀ»¦æ¬°¡B°g¸ô¡B¤£¾A·í¦æ¬°¡B«½Æ²{¶H¡Bº©¹C¡B³g¹¦æ¬°µ¥¯gª¬¡C³o¨Ç¯«¸gºë¯«¯gª¬«Ü±`¨£¡A¨Ã¥B¤ñ°O¾Ð¤U°¹ï¤é±`¥\¯àªº¼vÅT§ó¤j¡A¤]±`±`¬O¯f¤H³Q±a¨ìÂå°|´N¶Eªºì¦]¡C ¥t¥~ÁÙ¦³ Can we end damaging dementia psychosis cycle? Date: October 2, 2017 Source: University of Exeter www.sciencedaily.com/releases/2017/10/171002092252.htm ¦h¹F¤T¤À¤§¤G±w¦³ªüº¸¯ý®üÀq¯gªº¤H·|¸g¾úºë¯«¯gª¬µo§@¡A³oºØ¥O¤HµhWªº¯gª¬¤´¥¼³Q¼sªx¤F¸Ñ»{¥i, ¥BÃø¥HªvÀø¡C¥Ø«eªº§Üºë¯«¯fªvÀø¹ï½w¸Ñ¯gª¬´X¥G¨S¦³¼vÅT¡A¦ý«o¥i¯à¨ã¦³¯}Ãa©Êªº°Æ§@¥Î¡A¨C¦~¾ÉP^°ê¦³1,660¦¸¤£¥²nªº¤¤·©M1,800¦¸¤£¥²nªº¦º¤`¡C ºë¯«¯f¯gª¬»P»{ª¾¥\¯à§ó§Ö³tªº¤U° ¤Î ¥[³tªº¦º¤`²v ¬ÛÃö¡C ºë¯«¯f¯gª¬©MªvÀøÃĪ«°Æ§@¥Î¦b¨ä¥LÃþ«¬ªºÃ¨§b¯g¤¤§ó¬°·¥ºÝ¡A¥]¬A©¬ª÷´Ë¯fè§b©M¸ô©öÅéè§b¡C¦b³o¨Ç¤H¤¤¡A±`¥Îªº§Üºë¯«¯fÃÄ¥i¯à¯S§O¨ã¦³¯}Ãa©Ê¡A¤¤·©M¦º¤`ªº·ÀI½¤F¥|¿¡C Suicidality : ¦Û±þ·N©À , §ÚÌ»¡«Ü¦h¤F ½Ð¤j®a¦A½Æ²ß¤@¦¸ ®Ú¾Ú mentalhealth.gov ºô¯¸ªº¸ê®Æ On average, 122 Americans die by suicide each day. Suicide is the second leading cause of death among 15-24 year olds and more than 9.4 million adults in the United States had serious thoughts of suicide within t |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/26 ¤U¤È 02:39:29²Ä 372 ½g¦^À³
|
ì¨Ó ½Ã§÷ ©M Biogen ªº BAN2401 ªvÀø AD ªº¤G´ÁÁ{§É¦b AAIC µoªí³o¼Ëªº¦¨ÁZ³æ µM¥X¦â¶Ü?! Eisai, Biogen outline a 30% and 47% advantage for their Alzheimer¡¦s drug BAN2401 endpts.com/eisai-biogen-outline-an-impressive-30-and-47-advantage-for-their-alzheimers-drug-ban2401/ ¬Ý¬Ý³o±i ADAS-Cog »P®É¶¡ªºÁÍ¶Õ¹Ï ( ½Ðª`·NÁa®y¼Ð , ¹s¶b¥H¤Wªí¥Ü¤ñ°ò´Á§ïµ½ , ¹s¶b¥H¤Uªí¥Ü¤ñ°ò´Á°h¤Æ ) www.google.com.tw/search?q=diagram&tbm=isch&tbs=simg:CAQSlwEJEObPxuJ3GWQaiwELEKjU2AQaBAgVCAoMCxCwjKcIGmIKYAgDEii_1E7sTuBPAE8ET9h-CE7oT7ge2E_1A_10T_1UNu4_1oT6vPq0-0j-jPqQ-GjBhjLovto34U_1FN3B8hfsgyFAF5I1Ai-QN3qwfzUI4IduLj1vsc3amPSvYaG4Ivo4ogBAwLEI6u_1ggaCgoICAESBObk1OUM&sa=X&ved=0ahUKEwi05tGEh7zcAhUTZt4KHRQdA80Qwg4IIygA&biw=1536&bih=734#imgrc=b89lYZg5vnQt4M: Y»P SND-14 2a ¤ñ¸û liawbf.pixnet.net/blog/post/47570421 (¡@Dementia ) ±z»{¬°¦óªÌ±j§r? SND-14 ( CDR 1 ²Õ ) ¬O²Ä 8 ¶g´N¦³§ïµ½ ( ADAS-Cog »{ª¾¤À¼Æ¥Ñ 17.1 °¦Ü 13 ) ; ²Ä 16 ¶g«ùÄò§ïµ½¦Ü 10.6 ¤À ; 24 ¶g 9.9 ; ²×µ²¶g 10 ¤À BAN2401 ©O? ¤W¹Ïªí§i¶D§ÚÌ ²Ä 6 Ó¤ëµy¦³§ïµ½( ´X»P°ò½u«ù¥ ) , ²Ä 12 , 18 Ó¤ë´NÂର«ùÄò°h¤Æ ©Î³\¤W¦C¼Æ¾Ú , ¦³¤H·|»{¬°¤£¥i¤ñ¸û ¦]¬°ÀH³Xªº®É¶¡¤£¦P , ¤S¬°°h¤Æ©Ê¯e¯f , Æ[¹î®É¶¡¶V¤[ , ¶V¦³¥i¯à°h¤Æ§ó¦h ¦AªÌ , ±wªÌ°ò´Á±¡ªp¥¼ª¾ ÁöµM¦p¦¹ , ¦ý®³¨âªÌªº¤@Ó¬Û¦PÀH³X®É¶¡ÂIªºÃÄ®Ä ( ´N¬O¦b²Ä 6Ó¤ë ) ©Î³\´N¯à²¤²¤¬Ý¥X¤@ÓºÝÙ ·q½Ð«ü¥¿ ¸É¥R ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/26 ¤U¤È 12:13:40²Ä 371 ½g¦^À³
|
§ó¦hÃö©óTrigriluzole ªº¸ê®Æ Trigriluzole ¬O Riluzole ( ¤fªA ALS ¥ÎÃÄ ) ªº¦Þ¤U»s¾¯ ¦³¨âÓ¦n³B : ¨Ï¥Î¾¯¶q¸û¤fªAªÌ´î¤Ö , §l¦¬¥ç¸û§Ö ¥i¯à¦]¬°¾¯¶qªº¨Ï¥Î´î¤Ö , ³s±a¨Ï°Æ§@¥Î°§C ¦b¨ä±M§Q¤å¥ó¤¤ ¥u´£¤Î¨â¼Ë : ´î¤Ö¤fµÄ³Â¤ì , ¦b¤Ö©ó30¤ÀÄÁ¤º®ø¥¢ ; ÁÙ¦³¨x¥\¯à²§±`ªº°Æ§@¥Î´î®z ¦ý¨Ìºû°ò¦Ê¬ì©Òz , Riluzoleªº°Æ§@¥Î¦³ en.wikipedia.org/wiki/Riluzole . «D±`±`¨£¡]> 10¢HÀW²v¡^¡G äú¤ß ; µê®z ; ªÍ¥\¯à¤U° . ±`¨£¡]1-10¢HÀW²v¡^¡GÀYµh; ÀY·w; ºÎ·N; ¹Ã¦R; ¸¡µh; ¤É°ª®ò°òÂಾ酶 ( ¤É°ªªº®ò°òÂಾ酶 , ¨ä¦s¦b¥i¥H¬O¨xŦ©M¤ßŦ·l¶Ëªº«ü¼Ð¡C¨âºØ«nªºÂà®ò酶¬O¤Ñ¥V®ò»ÄÂà®ò酶¡]AST¡^¡A¤]ºÙ¬°¦å²M½\®ò»Ä¯ó酰¤A»ÄÂà®ò酶¡]SGOT¡^; ©M¤þ®ò»ÄÂà®ò酶¡]ALT¡^¡A¤]ºÙ¦å²M½\®ò»Ä - ¤þ଻ÄÂà®ò酶¡]SGPT¡^¡@¡A¬O¨xŦ°·±d«ü¼Ð) . ¨u¨£¡]0.1-1¢HÀW²v¡^: ¯Ø¸¢ª¢ ; ¶¡½è©ÊªÍ¯f . ¨u¨£¡]<0.1¢HÀW²v¡^ : ¤¤©Ê²É²ÓM´î¤Ö¯g ; ¹L±Ó¤ÏÀ³¡]¥]¬A¦åºÞ¯«¸g©Ê¤ô¸~¡A¹L±Ó¤ÏÀ³¡^ Riluzole ¬J¬° ALS ¥ÎÃÄ ¦Ó Trigriluzole ¤SÀu¤Æ¦Û Riluzole , ¨ä¬ÛÃöÃIJz¾÷¨î , À³©M Trigriluzole ¬Û¥h¤£»· ¥B Biohaven ¥ý¶i¦æªº¤HÅé¸ÕÅç¤S¬°±j¢¯g©M¯áÅè¤p¸£¦@ÀÙ¥¢½Õ¯g ©Ò¥H , ¤pªº»{¬° Trigriluzole ¹ï AD ªºªvÀø®ÄªG , ©Î«ÝÆ[¹î ·íµM©M SND-14 , SND-51 ÃĮĩM°Æ§@¥Îªº¤ñ¸û , ¤]¥u¯à¥H«á¦A½Í¤F. ¦³½Ð¤j®a¦h¸É¥R¡A¦h«ü¥¿ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/26 ¤W¤È 07:11:32²Ä 370 ½g¦^À³
|
¹ï¤£°_¡I §Ñ¤F¶K¤W³sµ² www.marketwatch.com/investing/stock/bhvn ¸Ó¤½¥qªº·s»D¡A¤]½Ð°Ñ¦Ò ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/26 ¤W¤È 06:58:32²Ä 369 ½g¦^À³
|
¦¤W¿ô¨Ó Biohaven³o¤¤ÑªºªÑ»ù¨«¶Õ¡A¨ÃµL¤j´Tªi°Ê ¦¬¦b 35.6 ¬ü¤¸¡AÁ`¥«È 14 »õ¬ü¤¸ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/25 ¤U¤È 08:06:55²Ä 368 ½g¦^À³
|
Daniel Javitt ¤j®v ¬°§Ú̶}ÄÀºë¯«¤Àµõªº¦¨¦]------ NMDAR ¥\¯à§C¤U ÁöµM¤p§Ì¦³Å¥¨S¦³À´ ¦ý¬Ý¨ì¤j®v¥Î¨º»ò¦h¹Ïªí¨ÓÄÄÄÀ , ´N·Q·íµM¦Õ¦a»{¬° NaBen ªº¹ï¯g¤UÃÄ , Àò±oºë¯«¤Àµõ»â°ìªº¨â±i BTD , ¦ÛÄݨä¨Ó¦³¦Û , ¤]´N¤£¨¬¬°©_¤F ?! ¤£¬O¶Ü ?! ½Ð®¤¤p§Ì¦h¸Ü ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/25 ¤U¤È 07:30:48²Ä 367 ½g¦^À³
|
liaw6575 ¤j¤j À°§Ṳ́¶²Ð¨â³¡±Ð¾Ç¼v¤ù 1. ¨¦®ò»Ä¨t²Îªº AMPA and NMDA receptors www.youtube.com/watch?v=4-DuvwoH2zQ 2. Daniel Javitt - NMDAR dysfunction in schizophrenia Implications for pathophysiology and basic neuro www.youtube.com/watch?v=2841I0tdcx8&list=1876s Daniel Javitt ¬O¬ã¨s DSC ¹ïºë¯«¤Àµõ¯gªº¤j®v ȱo°Ñ¾\ ·Q·Q¤j®v³£³o»ò¤ä«ùºë¯«¤Àµõ¯g¬O¦]¬° NMDAR ¥\¯à§C¤U , §ÚÌ°Z¯à¤£¤ä«ù ? ! ( liaw6575 ¤j¤jì¤å ¤p§Ì·Ó§Û ) ÁÂÁ liaw6575 ¤j¤j ÁÂÁ¤j®a ! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/25 ¤U¤È 04:32:36²Ä 366 ½g¦^À³
|
Ävª§¹ï¤â---¬Q¤é MDD , ¤µ¤é AD liaw6575¤j¤jªº±M¤å---¤À¨É Biohaven ·sÃĤ½¥q¸ê®Æ liawbf.pixnet.net/blog/post/48040266 ´X¤p®É«eªº·s»D Biohaven Receives FDA May Proceed Letter And Initiates Phase 2/3 Clinical Trial Of Trigriluzole (BHV-4157) In Alzheimer¡¦s Disease www.prnewswire.com/news-releases/biohaven-receives-fda-may-proceed-letter-and-initiates-phase-23-clinical-trial-of-trigriluzole-bhv-4157-in-alzheimers-disease-300685314.html NEW HAVEN, Conn., July 24, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (Biohaven or the Company) announced today that it initiated a Phase 2/3 clinical trial of trigriluzole (BHV-4157), a novel glutamate modulator, in patients with mild-to-moderate Alzheimer¡¦s disease (AD). Biohaven ªº©xºô¸Ì , ¬O³o¼Ë¤¶²Ð Trigriluzole ªº biohavenpharma.com/glutamates-role-in-the-brain/ BHV-0223 and trigriluzole increase the activity of the EAATs to increase the clearance of glutamate and decrease glutamate release from the pre-synaptic neuron. Trigriluzole and BHV-0223 also inhibit presynaptic ion channels that may inhibit the release of glutamate from presynaptic neurons. ( BHV-0223©Mtrigriluzole¼W¥[EAATsªº¬¡©Ê¡A¼W¥[¨¦®ò»Äªº²M°£²v¡A´î¤Ö«e¬ðIJ¯«¸g¤¸¨¦®ò»ÄªºÄÀ©ñ¡CTrigriluzole©MBHV-0223¤]§í¨î«e¬ðIJÂ÷¤l³q¹D¡A¥i§í¨î«e¬ðIJ¯«¸g¤¸ÄÀ©ñ¨¦®ò»Ä ) ³ø¾É¤]»¡±o«Ü¯« Some potential targets related to trigriluzole¡¦s mechanism of action include (1) reducing presynaptic glutamate release through actions at the voltage-gated ion channels, (2) facilitating glutamate uptake via EAATs located on glial cells, (3) enhancing transmission through synaptic AMPA receptors, (4) altering GABAergic neurotransmission, and (5) effecting neurotrophic agents such as BDNF. ¦³³o»ò¦h§@¥Î , ¦ý¤]©|¥¼¶i¤J¤HÅé¸ÕÅç , ¥¼¨Ó´NÅý§Ú̬ݬݦb¤HÅ骺¸ÕÅçµ²ªG¦p¦ó? ¥Ø«e¥¦°µªº¬O§Oªº¾AÀ³¯g clinicaltrials.gov/ct2/results?cond=&term=BHV-4157&cntry=&state=&city=&dist= . BHV-4157 in Adult Subjects With Obsessive Compulsive Disorder . Trial in Adult Subjects With Spinocerebellar Ataxia . Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma ²{¦b¤~n±Ò°Ê AD ªºÁ{§É ¤S Biohaven ¤½¥q¦W¤Uªº±M§Q©M¥Ó½Ð¤½¶}¤å¥ó ±M§Q : Prodrugs of riluzole and their method of use patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=Biohaven&OS=Biohaven&RS=Biohaven ¥Ó½Ð¤½¶}¤å¥ó : appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Biohaven&FIELD1=&co1=AND&TERM2=&FIELD2=&d=PG01 --PUB. APP. NO.--------Title 1. 20180153862 SUBLINGUAL ADMINISTRATION OF RILUZOLE 2. 20180153794 SUBLINGUAL FORMATION OF RILUZOLE 3. 20180037557 PRODRUGS RILUZOLE AND THEIR METHOD OF USE 4. 20180036290 RILUZOLE PRODRUGS AND THEIR USE 5. 20170334870 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE ¤pªº·Pı¬O ³oÓtrigriluzole ¬Ý¨ä©xºôªº±Ôz trigriluzole ¬OÀu¤Æ¦Û²{¦sªº ALS ÃĪ« Riluzole , ¦ü¥G¬OÃþ¦ü§Ü«ú¾¯¥\¯àªº¤@ºØ¤Æ¦Xª« ©M SND-14 , SND-5 DAAO§í¨î¾¯ªº¥\¯à«ê«ê¬Û¤Ï ¦ý¤ß®®¦Ü¤Ö¦³¤@Ó SND-14 ªº¤HÅéÁ{§Éµ²ªG ¥BSND-14 , SND-5 ³£¬°¼sªx¦s¦b¦ÛµM¬Éªº¤Æ¦Xª« , ©Î¦³ºØºØªþ¥[¥\¯à , ¦p§Ü®ñ¤Æ , §Üª¢©Êµ¥ ¤HÅ骺¹B§@ , ¨s¬°¦p¦ó ? ´NÅý¤HÅé¸ÕÅç¨ÓÃÒ©ú§a ¦³½Ð¤j®a¦h¸É¥R , ¦h«ü¥¿ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/25 ¤U¤È 03:12:29²Ä 365 ½g¦^À³
|
ÁÂÁ Cliff ¤j®¦¼w µ¹¤F³o»ò¦h¥d«nªº¸ê®Æ ¥]¬A 5.6»õ¬ü¤¸ªº«eª÷ + development and commercial milestones¡AÁÙ¦³ ( ÃÄ®Ä--®É¶¡ ) ¦±½u¹Ï ¤p§Ì¬d¤FÁ{§É©xºôªº¸ê®Æ ©Î¥i±ÀÂ_ AGN-241751 ´N¬ONRX-1074 ªº¤fªA¾¯«¬ Allergan MDD ²£«~½u Rapastinel : ( ¥þ³¡ÀR¯ßµ¹ÃÄ ) clinicaltrials.gov/ct2/results?cond=&term=rapastinel&cntry=&state=&city=&dist= ¨ä¤¤ ²Ä 3 ¶µ ´N¬O¬Q¤é·s»D©Ò¿×ªº [¦ãº¸«Ø¤]¦b¶}®i¤@¶µII´ÁÁ{§É¬ã¨sµû¦ôrapastinelªvÀø¦s¦b¢¦b¬Ü·û¦Û±þ·ÀIªºMDD±wªÌ¡C ] . Recruiting . ( ÀR¯ßµ¹ÃÄ ) A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder ( Actual Study Start Date : December 5, 2017 ) Apimostinel : Á{§É©xºô¨S¦³¸ê®Æ NRX-1074 : clinicaltrials.gov/ct2/results?cond=&term=NRX-1074&cntry=&state=&city=&dist= .Completed . ( ¤fªAµ¹ÃÄ ) ( Phase 1 ) Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers . Withdrawn . ( ÀR¯ßµ¹ÃÄ ) NRX-1074 in Early Course Schizophrenia .Completed . ( ÀR¯ßµ¹ÃÄ ) ( Phase II ) Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder . Completed . ( ÀR¯ßµ¹ÃÄ ) Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers AGN-241751 : . Recruiting . ( ¤fªAµ¹ÃÄ ) ( Phase II ) AGN-241751 in the Treatment of Major Depressive Disorder ( Actual Study Start Date : June 13, 2018 ) Allergan ¥ý±À¥XÀR¯ßª`®gªºRapastinel , Ä~¤§¥H¤fªAªºAGN-241751 Allergan¦³³oÓÅÞ¿è , ¦Ó¥¼«Bº÷Á[¶R¤FNRX-1074 ³o¦ü¥G¥i¥HÅý J&J ¥h«ä¦Ò¥¦µo®iªº esketamine ªº«áÄò¥ÎÃÄ n«ç»ò±µÄò ²¦³º , esketamine¦³¤£¥i¤[¥Îªº°Æ§@¥Î ¥i¥H¦Ò¶q·í¤µ±j®ÄªºÔ¿ïÃĪ« , ¼Æ¼Æ¬Ý , ÁÙ¦³½Ö§r? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/7/25 ¤W¤È 01:01:21²Ä 364 ½g¦^À³
|
ÃhºÃAGN-241751¬O«eNaurexÃļtªºNRX-1074¡C 2018¦~5¤ëAllergan¨ÖÁÊAptinyx®É¡A¤]³s¦P§â¥¦ºX¤Uªºl¥Í¤½¥qNaurexªº³o´Ú¬ãµo¤¤·sÃÄ¡]NRX-1074¡^¯Ç¤JAllergan¾£¤U²£«~½u¡A¨Ã³Wµe¬°Rapastinelªº¤fªA¸É¥R¾¯¡]oral complement¡^¡C ¡uALLERGAN TO ACQUIRE NAUREX¡v ¡]phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUxOTk4MjZ8Q2hpbGRJRD01ODgxNTg=¡^ Page 6 Naurex Compounds: *Bind to a unique site(s) on NMDA receptor *Allosterically modulate receptor activity, acting like glycine-site partial agonists *Differentiated antidepressant efficacy and well-tolerated Page 7 NRX-1074 *Administration: IV and Oral *Stage: Phase 2 IV formulation; Phase I oral formulation *Clinical Data: Well tolerated with rapid & substantial antidepressant effects in subjects with major depressive disorder (MDD) *Regulatory: Monotherapy for MDD patients 2015/01/27 NRX-1074 Phase II³ø§iªº´CÅé³ø¾É ¡uNaurex¡¦s First Orally Active Molecule, NRX-1074, Demonstrates Statistically Significant Improvement in Depression Scores within 24 Hours in Phase 2 Study for Major Depressive Disorder¡v ¡]www.prnewswire.com/news-releases/naurexs-first-orally-active-molecule-nrx-1074-demonstrates-statistically-significant-improvement-in-depression-scores-within-24-hours-in-phase-2-study-for-major-depressive-disorder-300025943.html¡^ Apimostinel en.wikipedia.org/wiki/Apimostinel AGN-241751 en.wikipedia.org/wiki/AGN-241751 |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/24 ¤U¤È 05:33:00²Ä 363 ½g¦^À³
|
¦ãº¸«Ø¹v¦VNMDARªº««×§íÆ{¯g·sÃÄ Àò¬ü°êFDA§Ö³t³q¹D¦a¦ì ¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-07-24 med.sina.com/article_detail_103_2_49334.html ·Rº¸Äõ»sÃİӦ㺸«Ø¡]Allergan¡^ªñ¤é«Å¥¬¡A¬ü°ê¹«~ÃÄ«~ºÊ·þºÞ²z§½¡]FDA¡^¤w±Â¤©¹êÅç©ÊÃĪ«AGN-241751§Ö³t³q¹D¦a¦ì¡A³o¬O¤@ºØ·s«¬¡B¤fªA¡B§Ö³t°_®Äªº§Ü§íÆ{ÃĪ«¡A¥Ø«e¥¿³B©óII´ÁÁ{§É¶}µo¡A¥Î©ó««×§íÆ{¯g¡]MDD¡^ªºªvÀø¡C ¦ãº¸«Øº®u¬ãµo©xDavid Nicholsonªí¥Ü¡AFDA±Â¤©AGN-241751§Ö³t³q¹D¦a¦ì¡A¬O¹ï§Ú̶}µo·sªº¡B°ª«×³Ð·sªº§Ü§íÆ{ÃĪ«©Ò¥I½Ñ§V¤OªºªÖ©w¡A³o¬O¤@ÓÂåÀø»Ý¨DÅãµÛ¥¼º¡¨¬ªº»â°ì¡C §Ú̬۫HAGN-241751±N¦¨¬°¤½¥q¥t¤@´Ú³t®Ä§Ü§íÆ{ÃÄrapastinel«nªº¤fªA¸É¥R¾¯ ; AGN-241751¡Brapastinel»P±j¥Í³Æ¨üÆf¥Øªº§Ü§íÆ{ÃÄesketamine§@¥Î¾÷¨î¬Û¦P¡A§¡¹v¦VN-¥Ò°ò-D¤Ñ¥V®ò»Ä¨üÅé¡]NMDAR¡^¡A³o¬O§íÆ{¯gªº¤@ºØ·s¾÷¨î¡C ¦ãº¸«Ø¤]¦b¶}®i¤@¶µII´ÁÁ{§É¬ã¨sµû¦ôrapastinelªvÀø¦s¦b¢¦b¬Ü·û¦Û±þ·ÀIªºMDD±wªÌ¡C¦¹«e¤½§GªºII´Á¬ã¨sÅã¥Ü¡A¦b¹ï¤@ºØ©Î¦hºØ§Ü§íÆ{ÃĤÏÀ³¤£¨¬ªºMDD±wªÌ¤¤¡Arapastinel³æ¾¯¶qµ¹ÃÄ«á¤@¤Ñ´NÅã²{¥X¤F¦³®Äªº§Ü§íÆ{§@¥Î¡C AGN-241751§@¬°¤@ºØ·s«¬¤fªA¥i¥Íª«§Q¥ÎªºNMDAR½Õ¸`¾¯¡A³Ìªì¥Ñ¦ãº¸«Ø»PAptinyx¤½¥q¦X§@¶}µo¡C¤µ¦~5¤ë¡A¦ãº¸«Ø¦æ¨Ï¿ï¾ÜÅv¡A±NAGN-241751§¹¥þ¦¬ÁÊ¡C ¹ï¶Ç²Îªº³æÓi¹v¦VÀøªk§e¤£§¹¥þÀ³µªªº±wªÌ¥i¯àÄ~Äò¸g¾úÅãµÛªº§íÆ{¯gª¬¡A¥]¬A¥i¯à¦bÄY«¡B´_µo©ÎºC©Ê§íÆ{¯g±wªÌ²£¥Í¦Û±þªº·N©À¡C¸Ó»â°ì¹ï¨ã¦³·s§@¥Î¾÷¨îªº·s«¬ÃĪ«¦s¦bµÛ¢¤ÁªºÂåÀø»Ý¨D¡C¡]·s®öÂåÃĽsĶ/newborn¡^ 2017¦~Informa Pharma Intelligence³ø§iÅã¥Ü¡ANMDAÃĪ«¥i¨Ï¬ü°ê§Ü§íÆ{ÃĪº¾P°âÃB±q2016¦~ªº¨C¦~¬ù46»õ¬ü¤¸¼W¥[¨ì2024¦~ªº70¦h»õ¬ü¤¸¡C ¬JµM¬°Ävª§¹ï¤â Allergan ªºrapastinel»P±j¥Íªº§Ü§íÆ{ÃÄesketamine , SAGEªº SAGE-217 ¥H«e¤j®a¤w¦h©Ò°Q½× ¤µ¤Ñªº AGN-241751 ¤p§Ì©|¥¼査¨ìÁ{§Éµ²ªGªº³ø§i ¨Ì©¹¨Ò ¦A¨Ó¬Ý§Ú̪º SNG-12 .¤fªA , ¤£¹³rapastinelªºÀR¯ßª`®g .½²±Ð±Â»¡ SNG-12 ¨â¤Ñ°_®Ä .¾AÀ³¯g: ««×§íÆ{¯g¡]MDD¡^+ ¦Û±þ·N©À¡C ³ø¾É¤]»¡ ¹ï¶Ç²Îªº³æÓi¹v¦VÀøªk§e¤£§¹¥þÀ³µªªº±wªÌ¥i¯àÄ~Äò¸g¾úÅãµÛªº§íÆ{¯gª¬¡A¥]¬A¥i¯à¦bÄY«¡B´_µo©ÎºC©Ê§íÆ{¯g±wªÌ²£¥Í¦Û±þªº·N©À¡C¸Ó»â°ì¹ï¨ã¦³·s§@¥Î¾÷¨îªº·s«¬ÃĪ«¦s¦bµÛ¢¤ÁªºÂåÀø»Ý¨D¡C ¤j®aÁÙ°O±o¶Ü? ®Ú¾Ú mentalhealth.gov ºô¯¸ªº¸ê®Æ On average, 122 Americans die by suicide each day. Suicide is the second leading cause of death among 15-24 year olds and more than 9.4 million adults in the United States had serious thoughts of suicide within the past 12 months. ¦b¬ü°ê¡A¹L¥h12Ó¤ë , ¶W¹L 940 ¸U¤H¦³ÄY«ªº¦Û±þ«äºû SNG-12 ¦³ÃÄ®Ä , ¥«³õ¤S¦³°Ï¹j §ÚÌÁÙ»Ýn¦k¦ÛµáÁ¡¶Ü ? ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/23 ¤U¤È 05:46:43²Ä 362 ½g¦^À³
|
ÁÂÁ³¯ÀR¤jªº¸É¥R ¤pªº´ýµM§Ñ¤FSND-5 ( TA )°£¤F¦³ BACE1 §í¨î¾¯ , ¯}Ãa A£] éw, ªý¤îtau »E¦X ªº¤TºØ¾÷¨î¤Î«Ü±jªº §Ü®ñ¤Æ ©M §Üª¢©Ê §@¥Î ¥~ ÁÙ¬O DAAO §í¨î¾¯ , ¦b¼W¶i»{ª¾¤è±°µ¥X°^Äm Ä~Äò¬Q¤éªº¸ÜÃD TA ¦b¦Ñ¹«Å餺ªº¥NÁ ºK¦Û ¤é¥»¾ÇªÌ Yumiko Nakamura, Sumiko Tsuji, and Yasuhide Tonogai Method for Analysis of Tannic Acid and Its Metabolites in Biological Samples: Application to Tannic Acid Metabolism in the Rat pubs.acs.org/doi/full/10.1021/jf020847%2B In conclusion, 66.12% of administered TA was excreted as TA and its metabolites into feces and urine: 62.74% as TA and 0.97% as TA metabolites into feces and 2.41% as TA metabolites into urine, when TA was administered to the rat as a single dose at 1.0 g/kg to the rat. Nondetection of 33.78% of the administered TA might be accounted for in two ways. One might be further degradation of GA in the intestinal tract, entry into the TCA cycle, and finally expiration as CO2; another might be the difficulty of extracting bound TA in feces. These explanations do not rule out other possibilities. ... ¦ý©_©Çªº¬O , ¦b¦å²M¤¤ , «o¨S¦³°»´ú¨ì TA ( In our study, no EA or TA was detected from serum ) ³Ì«á , ¾ÇªÌ¤]´£¨ì ª«ºØªº¥NÁ¤£ºÉ¬Û¦P , ©Î¤£¯àª½±µÀ³¥Î©ó¤HÃþ , ¤´«ÝÂç²M Y¤j¤j̦³¤HÅé TA ªº¥NÁ¸ê®Æ , ½Ð¤À¨É¤§ , ÁÂÁ°Õ! ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G³¯ÀR10141886 µoªí®É¶¡:2018/7/22 ¤U¤È 08:27:28²Ä 361 ½g¦^À³
|
¦³½ì, SND5¾÷Âà¤è±,¦³Âù«ªº§@¥Î,¤@¤è±¬ODAAO§í¨î§@¥Î,«P¶iNMDA¥\¯à, ¤S¦³¤@¯ë±`¨£ªº§í¨îA£]»E¿n§@¥Î,¤@½bÂùÀJ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/22 ¤U¤È 05:49:57²Ä 360 ½g¦^À³
|
Biophenols: Impacts and Prospects in Anti-Alzheimer Drug Discovery www.sciencedirect.com/science/article/pii/B9780128095935000045?via%3Dihub ´¦¥Ü Gallic Acid . GA significantly protects (IC50: 42£gM) the hippocampal cells from A£]35-induced toxicity. . To attempt tau filament inhibition, GA inhibited their assembly with an IC50 of 92£gM . AChE inhibition by GA was also reported with an IC50 value of 16.8£gM ( AChE : ¤A酰ÁxÆPà酶 , ¨ä§í¨î¾¯¦p Donepezil ¥Î©ó§ïµ½ªüº¸¯ý®üÀq¤ó¯g±wªÌªº»{ª¾©M¦æ¬°¡A¦ý¤£·|´î½w¯e¯fªº¶i®i©Îªv¡¯e¯f¡C) Tannic Acid : . showed significant inhibition of both A£]40 (IC50: 0.012£gM) and A£]42 (IC50: 0.022£gM) fibrils . TA was involved in tau pathology and inhibited its polymerization significantly with an IC50 of 3.5£gM . TA, however, has little effect on AChE activity ¥Ñ¦¹¬Ý¥X , ½²±Ð±Âªº¹BÄw±cØò ( ½Ð¤j®a¦Û¦æ°Ñ¾\±M§Q¥Ó½Ð¤å¥ó ) ¦A°Ñ¦Ò³o½g½×¤å(§K¶O¥þ¤å) , ¹ï¤F¸Ñ AD ¦³©ÒÀ°§U The protective role of plant biophenols in mechanisms of Alzheimer¡¦s disease www.sciencedirect.com/science/article/pii/S0955286316307343?via%3Dihub ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/22 ¤U¤È 01:00:17²Ä 359 ½g¦^À³
|
Cliff ¤j®¦¼w ±zW¤ßÁÓÂàÀò¦¹½×¤å©M²`¨sªº¤ß , Y«D¾ÇªÌ , ¤]¬O¾ÇªÌ·½d [ ¤O¦³¤£¶e ]¡A[ ¹N½×¤ß±o ] , §ó¬OÁ¾Á¾§g¤l±¡Ãh ÁÂÁ±zªº«ü¾É , ÁÙ¦³¥´¤F¨º»ò¦h¦r¤À¨É [ ¦¸¼ÐÃD ] , ¨Ãµû»ù¤TÓ [ Ãø ] ¦r ¤pªº¤]¥u¯à¾ÌµÛ¦¸¼ÐÃD©M·Q¹³ , ²q·Q¬O«ç»òªº¤@Ó±¡ªp ±qFig.(2). Interaction of TA with tau , ¤pªº§ä¨ìÃþ¦ü½×¤å ¤W®ü¦PÀÙ¤j¾Ç¾ÇªÌ Junliang Yao, Xing Gao, Wenliang Sun, Tianming Yao, Shuo Shi, and Liangnian Ji ªº Molecular Hairpin: A Possible Model for Inhibition of Tau Aggregation by Tannic Acid pubs.acs.org/doi/abs/10.1021/bi400240c?journalCode=bichaw ¥H¤pªºµ{«× , ¸Óµ¥²z½×¤§²` , ¦ó¥u¤TÓÃø¦r ¤pªº¤]¥u¯àºK¨úÃþ¦üµ²½× , ¨Ó²áªí¦Û¤v¨ì¦¹¤@¹C µ¹Figure 2. Effects of TA and GA on the kinetics of R3 aggregation. ©M Figure 8. Binding of tannic acid to the R3 peptide. T »P Figure 10. Parallel-growth model of the R3 peptide ÁÙ¦³ [ §Ú̵o²{ TA Åã¥Ü¥X¹ï TAU肽R3 ªºÅãµÛ¿Ë©M¤O ; ¦ý GA «h¤£ ( ³o¬O¥Ñ©ó¤À¤lµ²ºcªº¤£¦P ) ³oºØTA ¹ï R3 ªº±j¯P¸j©w , ¯à°÷À£§íTAUÅÖºû§Î¦¨ªººc¶HÂàÅÜ ©Ò¥H , ¤]´N¥i¥H¥´¯}tau−tau ¶¡ªº¬Û¤¬§@¥Î ©M §í¨îR3 ªº¦Û§Ú»E¦X ] ¦³³o¼Ë , ¤pªº´Nº¡¨¬¤F ¨Ì¦¹ ¿D¬w¾ÇªÌ´£¥Xªº 9.The need for newer drug delivery system of TA ¡]Tannic acid¡^ ©Î³\´N¬O¦b»¡(¤pªº²q´ú) , ¦p¦ó¦bÅ餺«O«ùTAªº¤À¤lµ²ºc , ¦Ó¤£Åý¥¦ÂনGA ( gallic acid ) ¨ÃÅý TA ³q¹L BBB §a ! ? ¤]³\¤j®a¥i¥H¦A°Ñ¦Ò±M§Q¤å¥óªº¤½¶}»¡©ú Cliff ¤j®¦¼w ¤pªº¥H¤@¤¶¶m¶¡»À¤Ò ±o±z¦p¦¹¬Û«Ý , ¯u¬O»Ê·P¤¤º ÁÂÁ±z! TA ©M TAU ³¡¤À ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/7/21 ¤U¤È 08:42:39²Ä 358 ½g¦^À³
|
²q·Q¤j¡A ³o¤@½g¤å³¹¹M´M°ê¤ºªºÀ]»Ú¦X§@¤´¤£¥i±o¡A¤WÓ¤ëªá¤F¤E¤Ñ¶¹D±q°ê¥~À]»Ú¦X§@¤~¨ú±oì¤å¡Aªá¶O450²{¤j¬v¡A¦Ó¥BÁÙ¬O¯È¥»ªº¡A¤£´£¨Ñ¹q¤lª©¥»¡A©Ò¥HµLªk»P±z¦@½à¡C ³o¤@½g¤º®e¬O°w¹ï¤À¤l¼h¦¸ªºTannic acid ªº±´°Q¡A¯S¦â¦³¤T¡A¤@¬O¡uÃø¡v¡A¤G¬O¡uÃø¡v¡A¤T¤´¬O¡K¡K¡C ¤p§Ì¤O¦³¤£¶e¡AÃø¥H±Ôz¤º®e¡A§ó¹N½×¤ß±o¡F¦ý¥i¥H´N¡u¦¸¼ÐÃD¡v»P±z¤À¨É¡C 1.Introduction 2.Chemistry of Tannic acid and related Tannins 3.Pathobiolody of AD¡]Alzheimer¡¦s disease¡^ 4.BACE1 as a therapeutic target for AD 5.BACE1 inhibitiors¡XA summary 6.Tannic acid as a natural inhibitor of BACE1 7.Inhibitory activity of Tannic acid on AB aggregation ¡]AB = Amyloid beta¡^ 8.Tannic acid¡XA pharmacophore for inhibition of Tau aggregation 9.The need for newer drug delivery system of TA ¡]Tannic acid¡^ 10.Conclusion and future prospects Fig.(1). The binding site of BACE1 inhibitors(OM series) Fig.(2). Interaction of TA with tau Å¥»¡±z´¿¥X®u¤µ¦~ªÑªF·|¡H¨S¯à·í±»P±z¤Á½R¡A´Ý©À¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/21 ¤U¤È 07:48:20²Ä 357 ½g¦^À³
|
¸òµÛliaw6575¤j¤jªº¸}¨B ¨Ó¬Ý TA ¹ï AD ªº§@¥Î ¤Þ¦Û ¿D¬w¾ÇªÌ Braidy N, Jugder BE, Poljak A, Jayasena T, Nabavi SM, Sachdev P, Grant R.µ¥ ¤§ Molecular Targets of Tannic Acid in Alzheimer¡¦s Disease ªº [ Abstract ] www.ncbi.nlm.nih.gov/pubmed/28176625 . Á{§É¤W¡ATA ¨ã¦³«Ü±jªº§Ü®ñ¤Æ/²M°£¦Û¥Ñ°ò¡A§Üª¢¡A§Ü¯f¬r/²Óµß©M§ÜÀùªº¯S©Ê¡C . TA ªº´XºØÅé¥~©MÅ餺¼Ò«¬¤wÅã¥Ü TA ¹ï AD ªº¯«¸g«OÅ@§@¥Î¡C .. °£¤F¨ä±j¤jªº§Ü®ñ¤Æ©M§Üª¢§@¥Î¥~¡A¦³ÃÒ¾Úªí©ú TA ¤]¬O £]-¤Àªc酶¡]BACE1¡^¬¡©Ê©M³J¥Õ½èªí¹Fªº¤ÑµM§í¨î¾¯¡CBACE1¬Ot³d A£]肽 ²£¥Í©M¨H¿nªº¥Dn酶¡C .. TA ÁÙ¦bÅé¥~¨Ï¯«¸g¬r©Ê¾ý¯»¼Ë³J¥Õ£]¡]A£]¡^ìÅÖºû¤£Ã©w¡C .. TA ¤]¥i¥H§í¨î tau肽 ªºÅé¥~»E¶°¡Atau肽 ¬O²ÓM¤º¯«¸gìÅÖºûÄñµ²¡]NFT¡^ªº®Ö¤ß¦¨¤À¡C ¸ÓºîzÁÙÁ`µ²¤F TA ©M TA¬ÛÃö´Óª«´£¨úª«¡]³æ¹ç¡^¦b AD µo¯f¾÷¨î¤Î¨ä酶¹v¼Ð¤¤ªº¬ÛÃö©Ê¡C¤]±j½Õ¤FTA§@¬°§ÜAD«nªº¥ý¾É¤Æ¦Xª«ªº«n©Ê¡C ¥i±¤ªº¬O , µLªk¬Ý¨ì¸Óºîzªº¸Ô²Ó¤º¤å , §_«h , À³§ó¯à±aµ¹§Ú̶i¤@¨Bªº»{ÃÑ ³o½gºîz§â TA ¥Ø«e©Òª¾¹ï AD ªºªvÀø¾÷¨î°µ¤@ÓÁ`µ² ²{¦b¦U¤jÃļtÁ{§É·sÃĪº¾÷¨î , ´X¥G¶°¤¤¦b A£] , tau , BACE1 , ¥B¦h¬°³æ¤@¾÷¨î SND-5 ( TA ) ¶° A£] , tau , BACE1 §í¨î¾¯ ªº¤TºØ¾÷¨î©ó¤@¨ ¤S¦³ , «Ü±jªº §Ü®ñ¤Æ ©M §Üª¢©Ê §@¥Î µ¥¦h¥\¯à²Õ¦X°_¨Ó , ©è§Ü©Î®ø°£³o¨Ç AD ¥i¯àªº§Î¦¨¦]¯À©Î¸ñ¶H §Æ±æ SND-14 , SND-5 ¦¤é±Ò°ÊÁ{§É, Åý§Ṳ́@¿s¥¦¹ï¦¤¤´Á AD ªºÁ{§ÉÀø®Ä ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡Gbooli10146418 µoªí®É¶¡:2018/7/18 ¤W¤È 12:09:54²Ä 356 ½g¦^À³
|
¤p¼g |
|
|
·|û¡Gyuki10141394 µoªí®É¶¡:2018/7/17 ¤U¤È 11:26:29²Ä 355 ½g¦^À³
|
²q·Q¤j¤j¡Aliawbf.pixnet.net/blog/post/48029790 ªº±K½X¬O³oӶܡHTANNQUILYNNE «ô°U±z¤F |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/17 ¤U¤È 04:33:16²Ä 354 ½g¦^À³
|
liaw6575¤j¤j¤SÀ°§Ú̺ݥX ¤ß®®ªº¤@¹Dº¡º~¥þ®u Tannic Acid ¹ï¦Ü AD ªì±´ ( ¤ß®®°Ó«~¦W TANNQUILYNNE ) liawbf.pixnet.net/blog/post/48029790 ÁÂÁÂliaw6575¤j¤j ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/1 ¤W¤È 07:20:34²Ä 353 ½g¦^À³
|
ÁÂÁª©¥D¤j¤j µ¹¤j®a²K³Â·Ðªº¦a¤è¡A²`·Pºp·N¡A½Ð¨£½Ì ÁÂÁ¤j®a¡I |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2018/7/1 ¤W¤È 05:40:17²Ä 352 ½g¦^À³
|
²q·Q¤j ¦b·«BÄÆ·nªº´Á¶¡¡A±z¤´¤£Â_ªºpo¸ê®Æ¹ªÀy¤j®a¡A¯u¤ß·PÁ ¤]´Á¬ß½²±Ð±Â¬Ý¨ìÅ¥¨ì |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/6/30 ¤U¤È 08:34:51²Ä 351 ½g¦^À³
|
ÁÂÁ¤j®aªº´£¿ô ¤pªº®¥·q¤£¦p±q©R ¤£ºÞ¦bþ¸Ì¤W¥« , ¤pªº§¡µL·N¨£ ¥u§Æ±æ½²±Ð±Â¯à§â³o¨Ç¤£¦bÅv¤O®Ö¤ßªºªÑªFªºªÑ²¼ ¤@°_¤W¥« ³o¨ÇªÑªF¦h¬O©Ó¨ü¤F³¡¤Àì©lªÑªFªºÀò§Q½æÀ£ , °í¦u¨ì²{¦b , ´Á¶¡¾úµ{ªº¨¯W , «D·í¨Æ¤HµL¥HÅé·| ©Ò¥H¤£n¹³¬Y¤½¥qªº°µªk , ¤@Ó»ù®æ´N§âªÑ²¼±j¨î¦¬¦^ , Åý¦³¤ß§ë¸ê¤ß®®ªºªÑªF±o¤£¨ì»P¤½¥q¤@°_¦¨ªøªº¾÷·| ¤pªº¥u¦³³oÓ¤p¤p½Ð¨D §Æ±æ½²±Ð±ÂÅé½Ì¤Î«OÅ@³o¨Ç¤ä«ù¤½¥qªÑªFªºÅv¯q ÁÂÁ½²±Ð±Â ÁÂÁ¤j®a! |
|
|
·|û¡G¤p·ç10140606 µoªí®É¶¡:2018/6/30 ¤U¤È 07:55:30²Ä 350 ½g¦^À³
|
ÃÙ¦P³¯ÀR¤jªº´£¿ô¡A·í¤Ñ±Ð±Â¤]§Æ±æ¤j®a¤Å¦bºô¸ô¤W°Q½×¡A ¤×¨ä²{¦b¬Fªv´c°««ÜÄY«¡A¦~©³¤Sn¿ïÁ|¡A ©ú©úµLÃö¬Fªvªº¨Æ±¡³£·|³Q¬Fªv§ä¤W¡A ¤p§Ìı±o¯E¹©¥u¬OÂźñ´c°«¤UªºÞ»î½}¤F¡A «Øij¤j®a¤Å¦b°w¹ïªÑªF·|¤º®e°µ°Q½×¡A ¥H§K¦¨¬°¯E¹©²Ä¤G¡A ªñ´Á ³s¹qºX¤U ¦X°· n¦b¹ï©¤¤W¥«¡A¬Q¤Ñ´N³Q¬Y´CÅé°µ¬°ºô¶·s»DÀYª©³B²z¡A ÁÙµo¦h½g±M¤å±´°Q¡A³o«Ü©úÅã´N¬O·Q¥Í¬O«D¡A §â³o®a¤½¥q¶Ò¸ê³W¹º·í§@¬FÄÒ°«ª§ªºÃD§÷©MÄw½X¡A «Øij¤j®a¦pªG·RÅ@¤ß®®¡A´N§O¦A°Q½×ªÑªF·|ªº¤º®e¤F~ ¥H¤W¤p§Ì²L¨£~~ ÁٽЮü²[~~ |
|
|
|